

## СПИСЪК С ЦИТИРАНИЯ НА ПУБЛИКАЦИИТЕ НА ПРОФ. Д-Р ДИМИТЪР МАСЛАРОВ, ДМН

### 1997

Hadjiivanova Chr., V. Petkov, **D. Maslarov**, A. Totev, Y. Panova, I. Belcheva. Effect of Dotarizine on K<sup>+</sup>-stimulated [3H]-Serotonin and [3H]-Acetylcholine release from rat hippocampus. // *General pharmacology*, 28, 1997, № 1, p. 129-132. ISSN 0306-3623.

#### Cited by:

1. **Kim, D. K., S. O. Lee, K. Y. Jung** et al. Effects of NMDA, AMPA and Kainate on the Release of Acetylcholine in Rat Hippocampal and Striatal Slices. // *The Korean Journal of Physiology and Pharmacology*, 8, 2004, № 6, p. 301-305. ISSN 1226-4512.
2. **Torregrosa, G., M. D. Barberaá, M. Ortí** et al. Cerebrovascular Effects of Dotarizine, a Piperazine Derivative, in the Goat. // *Arzneimittelforschung*, 49, 1999, № 8, p. 668-672. ISSN 0004-4172.

### 2008

Gabrovski, N., Vanev, P., Krüstev, E., Uzunov, **K., Maslarov, D.**, Gabrovski, S. Quality of life assessment in patients with malignant glial tumors. // *Khirurgiia*, 2008, № 1-2, p. 24-29. ISSN 0450-2167.

#### Cited by:

3. **Berkowitz, O., K. Jones, L.D. Lunsford** et al. Determining the elements of procedural quality. // *Journal of Neurosurgery*, 119, 2013, № 2, p. 373-380. ISSN 0022-3085.

### 2009

Kolev, P., N. Mihnev, **D. Maslarov**, and M. Markov. Medial temporal lobe epilepsy with severe pain sensation. // *American Journal of Neuroprotection and Neuroregeneration*, 2009, № 1, p. 1-5. ISSN 1947-296X.

#### Cited by:

4. **Pazarcı, N., N. Bebek, B. Baykan** et al. Reappraisal of epileptic pain as a rare symptom of seizures. // *Epilepsy & Behavior*, 55, 2016, p. 101-107. ISSN 1525-5050.

Dimitrova S., Stoilova I., Georgieva K., Taseva T., Jordanova M., **Maslarov D.** Solar and Geomagnetic Activity and Acute Myocardial Infarction Morbidity and Mortality, Fundamental Space Research. *Heliobiology*, Suppl. of **Comptes Rend. Acad. Bulg. Sci.**, Sofia, Bulgaria. ISBN 987-954-322-409-8, 2009, p. 161-165.

**Cited by:**

5. **Kiznys, D., J. Vencloviene, I. Milvidaitė.** The associations of geomagnetic storms, fast solar wind, and stream interaction regions with cardiovascular characteristic in patients with acute coronary syndrome. // *Life sciences in space research*, 25, 2020, p. 1-8. ISSN 2214-5524.
6. **Kiznys, D., J. Vencloviene.** Geomagnetinio aktyvumo bei saulės vėjo sąsajos su ligonių, susirgusių ūmiai koronariniiais sindromais, sveikatos būklės rodikliais. // *Žmogaus ir gamtos sauga*, 2014, p. 21-24. ISSN 1822-1823. Достъпно на: [https://zua.vdu.lt/wp-content/uploads/2019/02/21-24\\_Kiznys\\_II\\_10\\_po\\_rec.pdf](https://zua.vdu.lt/wp-content/uploads/2019/02/21-24_Kiznys_II_10_po_rec.pdf)
7. **Stienen, M. N., N. R. Smoll, M. Battaglia** et al. Intracranial aneurysm rupture is predicted by measures of solar activity. // *World neurosurgery*, 83, 2015, № 4, p. 588-595. ISSN 1878-8750.
8. **Styro, D., A. Usovaite.** On connection of variations between hard cosmic ray flux, temperature and cardiovascular diseases in vilnius and sunspot number during 2001–2012. // *Journal of Environmental Engineering and Landscape Management*, 23, 2015, № 2, p. 113-120. ISSN 1648-6897. Достъпно на: <https://www.tandfonline.com/doi/ref/10.3846/16486897.2015.1009078?scroll=top>
9. **Vega, V. M., M. J. M. Campello, P. S. Figueredo** et al. Mortalidad por infarto agudo del miocardio y su relación con las tormentas solares y geomagnéticas en la provincia Guantánamo. // *Revista Cubana de Cardiología y Cirugía Cardiovascular*, 20, 2014, № 2, p. 78-83. ISSN 1561-2937. Достъпно на: <https://www.medigraphic.com/pdfs/cubcar/ccc-2014/ccc142b.pdf>
10. **Vencloviene, J., A. Raulonytė, J. Stašionytė** et al. Heliofizikinių sąlygų ir skubios stacionarizacijos dėl ūmių koronarinių sindromų ryšys skirtingose Saulės aktyvumo fazėse. // *Žmogaus ir gamtos sauga*, 542, 2013, № 49, 5 p. ISSN 1822-1823. Достъпно на: [http://sauga.asu.lt/wp-content/uploads/sites/8/2016/01/152-155\\_Vencloviene\\_66.pdf](http://sauga.asu.lt/wp-content/uploads/sites/8/2016/01/152-155_Vencloviene_66.pdf)
11. **Vencloviene, J., J. Antanaitiene, R. Babarskiene.** The association between space weather conditions and emergency hospital admissions for myocardial

- infarction during different stages of solar activity. // *Journal of Atmospheric and Solar-Terrestrial Physics*, 149, 2016, p. 52-58. ISSN 1364-6826. Достъпно на: [https://www.researchgate.net/profile/Jone-Vencloviene/publication/310447512\\_ATP\\_galutinis/links/582d68bd08aef19cb8118945/ATP-galutinis.pdf](https://www.researchgate.net/profile/Jone-Vencloviene/publication/310447512_ATP_galutinis/links/582d68bd08aef19cb8118945/ATP-galutinis.pdf)
12. **Vencloviene, J., R. Babarskiene, I. Milvidaite** et al. The effect of solar-geomagnetic activity during and after admission on survival in patients with acute coronary syndromes. // *International journal of biometeorology*, 58, 2014, № 6, p. 1295-1303. ISSN 0020-7128. Достъпно на: <https://link.springer.com/article/10.1007/s00484-013-0725-0>
  13. **Vencloviene, J., R. Babarskiene, I. Milvidaite** et al. The effect of solar-geomagnetic activity during hospital admission on coronary events within 1 year in patients with acute coronary syndromes. // *Advances in space research*, 52, 2013, № 12, p. 2192-2198. ISSN 0273-1177.
  14. **Vencloviene, J., R. Babarskiene, R. Slapikas** et al. The association between phenomena on the sun, geomagnetic activity, meteorological variables, and cardiovascular characteristic of patients with myocardial infarction. // *International journal of biometeorology*, 57, 2013, № 5, p. 797-804. ISSN 0020-7128. Достъпно на: [https://www.researchgate.net/profile/Jone-Vencloviene/publication/233769346\\_The\\_association\\_between\\_phenomena\\_on\\_the\\_Sun\\_geomagnetic\\_activity\\_meteorological\\_variables\\_and\\_cardiovascular\\_characteristic\\_of\\_patients\\_with\\_myocardial\\_infarction/links/571f0bf308aead26e71a93ad/The-association-between-phenomena-on-the-Sun-geomagnetic-activity-meteorological-variables-and-cardiovascular-characteristic-of-patients-with-myocardial-infarction.pdf](https://www.researchgate.net/profile/Jone-Vencloviene/publication/233769346_The_association_between_phenomena_on_the_Sun_geomagnetic_activity_meteorological_variables_and_cardiovascular_characteristic_of_patients_with_myocardial_infarction/links/571f0bf308aead26e71a93ad/The-association-between-phenomena-on-the-Sun-geomagnetic-activity-meteorological-variables-and-cardiovascular-characteristic-of-patients-with-myocardial-infarction.pdf)
  15. **Vencloviene, J., R. Babarskiene, R. Slapikas**. The association between solar particle events, geomagnetic storms, and hospital admissions for myocardial infarction. // *Natural hazards*, 65, 2013, № 1, p. 1-12. ISSN 0921-030X. Достъпно на: [https://www.researchgate.net/profile/Jone-Vencloviene/publication/257633115\\_The\\_association\\_between\\_solar\\_particle\\_events\\_geomagnetic\\_storms\\_and\\_hospital\\_admissions\\_for\\_myocardial\\_infarction/links/571f0c3808aeaced7889ec79/The-association-between-solar-particle-events-geomagnetic-storms-and-hospital-admissions-for-myocardial-infarction.pdf](https://www.researchgate.net/profile/Jone-Vencloviene/publication/257633115_The_association_between_solar_particle_events_geomagnetic_storms_and_hospital_admissions_for_myocardial_infarction/links/571f0c3808aeaced7889ec79/The-association-between-solar-particle-events-geomagnetic-storms-and-hospital-admissions-for-myocardial-infarction.pdf)
  16. **Vencloviene, J., R. M. Babarskiene, D. Kiznys**. A possible association between space weather conditions and the risk of acute coronary syndrome in patients with diabetes and the metabolic syndrome. // *International journal of biometeorology*, 61, 2017, № 1, p. 159-167. ISSN 0020-7128. Достъпно на: <https://link.springer.com/article/10.1007%2Fs00484-016-1200-5>
  17. **Vencloviene, J., R. Radisauskas, V. Vaiciulis** et al. Associations between Quasi-biennial Oscillation phase, solar wind, geomagnetic activity, and the

incidence of acute myocardial infarction. // *International journal of biometeorology*, 64, 2020, № 7, p. 1207-1220. ISSN 0020-7128. Достъпно на: <https://link.springer.com/article/10.1007/s00484-020-01895-z>

18. **Zenchenko, T. A.** Solar wind density variations and the development of heliobiological effects during magnetic storms. // *Izvestiya, Atmospheric and Oceanic Physics*, 47, 2011, № 7, p. 795-804. ISSN 0001-4338. Достъпно на: <https://link.springer.com/article/10.1134/S0001433811070085>
19. **Zenchenko, T. A., T. K. Breus.** The Possible Effect of Space Weather Factors on Various Physiological Systems of the Human Organism. // *Atmosphere*, 12, 2021, № 3, art. no. 346. ISSN 2073-4433. Достъпно на: <https://www.mdpi.com/2073-4433/12/3/346/html>
20. **Ziubryte, G., G. Jarusevicius, M. Landauskas et al.** Cardiovascular System Interactions With The Local Earth Magnetic Field Fluctuations: A Cohort Study. // *Research square*, 2021. ISSN 2693-5015. Достъпно на: <https://assets.researchsquare.com/files/rs-250922/v1/657ce93f-7f0c-46b7-8e3d-2fa47a17d43e.pdf>

## **2011**

Kappos L., D. Li, P. Calabresi, P. O'Connor, A. Bar-Or, F. Barkhof, M. Yin, D. Leppert, R. Glanzman, J. Tinberger, S. Hauser. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicenter trial. Supplementary webappendix, p. 2, **D. Maslarov.** // *The Lancet*, 378, 2011, Issue 9805, № 19, p. 1779-1787. ISSN 0140-6736.

## **Cited by:**

21. **Abushouk, A.I., H. Ahmed, A. Ismail et al.** Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis. // *Rheumatology International*, 37, 2017, № 7, p. 1053-1064. ISSN 0172-8172.
22. **Adiele, R.C., C.A. Adiele.** Metabolic defects in multiple sclerosis. // *Mitochondrion*, 44, 2019, p. 7-14. ISSN 1567-7249.
23. **Adis Medical Writers.** Be aware that the benefits of biological drugs in multiple sclerosis may be offset by their capacity to cause immunological complications. // *Drugs and Therapy Perspectives*, 36, 2020, № 2, p. 63-66. ISSN 1172-0360.
24. **Agahozo, M.C., L. Peferoen, D. Baker et al.** CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis – Targeting T or B cells? // *Multiple Sclerosis and Related Disorders*, 9, 2016, p. 110-117. ISSN 2211-0348.

25. **Agius, M.A., G. Klodowska-Duda, M. Maciejowski** et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. // *Multiple Sclerosis Journal*, 25, 2019, № 2, p. 235-245. ISSN 1352-4585.
26. **Ahlgren, C., A. Odén, T. Bergström** et al. Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome. // *Journal of Neuroimmunology*, 247, 2012, № 1/2, p. 70-74. ISSN 0165-5728.
27. **Airas, L., M. Nylund, I. Mannonen** et al. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. // *Multiple Sclerosis and Related Disorders*, 40, 2020, art. no. 101980. ISSN 2211-0348.
28. **Alexopoulos, H., A. Biba, M.C. Dalakas**. Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. // *Neurotherapeutics*, 13, 2016, № 1, p. 20-33. ISSN 1933-7213.
29. **Ali, R., R.S.J., Nicholas, P.A. Muraro**. Drugs in development for relapsing multiple sclerosis. // *Drugs*, 73, 2013, № 7, p. 625-650. ISSN 0012-6667.
30. **Ali, Z.K., D.E. Baker**. Formulary drug review: Ocrelizumab. // *Hospital Pharmacy*, 52, 2017, № 9, p. 599-606. ISSN 0018-5787.
31. **Alonso-Moreno, M., M. Ladrón-Guevara, P. Ciudad-Gutiérrez**. Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis [Revisión sistemática sobre el sesgo de género en los ensayos clínicos de anticuerpos monoclonales para el tratamiento de la esclerosis múltiple]. // *Neurologia*, 2021. ISSN 0213-4853.
32. **Ancau, M., A. Berthele, B. Hemmer**. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. // *Expert Opinion on Biological Therapy*, 19, 2019, № 8, p. 829-843. ISSN 1471-2598.
33. **Aqel, S.I., M.C. Granitto, P.K. Nuro-Gyina** et al. Distinct roles for Blimp-1 in autoreactive CD4 T cells during priming and effector phase of autoimmune encephalomyelitis. // *Journal of Neuroimmunology*, 325, 2018, p. 20-28. ISSN 0165-5728.
34. **Arneth, B.M.** Impact of B cells to the pathophysiology of multiple sclerosis. // *Journal of Neuroinflammation*, 16, 2019, № 1, art. no. 128. ISSN 1742-2094.
35. **Aung, L.L., K.E. Balashov**. Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis. // *Multiple Sclerosis*, 21, 2015, № 9, p. 1131-1138. ISSN 1352-4585.
36. **Aung, L.L., M.M. Mouradian, S. Dhib-Jalbut** et al. MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated

- by microRNA-320a. // *Journal of Neuroimmunology*, 27, 2015, № 8, p. 185-189. ISSN 0165-5728.
37. **Bakaeva, T., S. Prasad.** For Massachusetts Eye and Ear Special Issue: Updates on Therapies for Multiple Sclerosis for the Ophthalmologist. // *Seminars in Ophthalmology*, 34, 2019, № 4, p. 270-278. ISSN 0882-0538.
  38. **Baker, D., B.M. Jacobs, S. Gnanapavan et al.** Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 35, 2019, p. 19-25. ISSN 2211-0348.
  39. **Baker, D., G. Pryce, L.K. James et al.** The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 44, 2020, art. no. 102279. ISSN 2211-0348.
  40. **Baker, D., G. Pryce, S. Amor et al.** Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. // *Brain*, 141, 2018, № 10, p. 2834-2847. ISSN 0006-8950.
  41. **Baker, D., M. Marta, G. Pryce et al.** Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. // *EBioMedicine*, 16, 2017, p. 41-50. ISSN 2352-3964.
  42. **Baker, D., S.S. Herrod, C. Alvarez-Gonzalez et al.** Both cladribine and alemtuzumab may effect MS via B-cell depletion. // *Neurology: Neuroimmunology and NeuroInflammation*, 4, 2017, № 4. ISSN 2332-7812.
  43. **Baker, D., S.S. Herrod, C. Alvarez-Gonzalez et al.** Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. // *JAMA Neurology*, 74, 2017, № 8, p. 961-969. ISSN 2168-6149.
  44. **Bakhuraysah, M.M., P. Theotokis, J.Y. Lee et al.** B-cells expressing NgR1 and NgR3 are localized to EAE-induced inflammatory infiltrates and are stimulated by BAFF. // *Scientific Reports*, 11, 2021, № 1, art. no. 2890. ISSN 2045-2322.
  45. **Baldassari, L.E., R.J. Fox.** Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. // *Drugs*, 78, 2018, № 15, p. 1549-1566. ISSN 0012-6667.
  46. **Beary, J.M., Y. Li.** Novel therapeutic frontiers for new improvements of myasthenia gravis. – In: *Novel Challenges in Myasthenia Gravis*, 2015, p. 541-557. ISBN 9781634830003; 9781634829779.

47. **Becher, B., S. Tugues, M. Greter.** GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. // *Immunity*, 45, 2016, № 5, p. 963-973. ISSN 1074-7613.
48. **Bellavista, E., A. Santoro, D. Galimberti et al.** Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis. // *Autoimmune Diseases*, 2014, 2014, art. no. 739705. ISSN 2090-0430.
49. **Berenguer-Ruiz, L., A.P. Sempere, J. Gimenez-Martinez et al.** Rescue therapy using rituximab for multiple sclerosis. // *Clinical Neuropharmacology*, 39, 2016, № 4, p. 178-181. ISSN 0362-5664.
50. **Bevan, C.J., B.A. Cree.** Fulminant Demyelinating Diseases of the Central Nervous System. // *Seminars in Neurology*, 35, 2015, № 6, p. 656-666. ISSN 0271-8235.
51. **Bigaut, K., J. De Seze, N. Collongues.** Ocrelizumab for the treatment of multiple sclerosis. // *Expert Review of Neurotherapeutics*, 19, 2019, № 2, p. 97-108. ISSN 1473-7175.
52. **Binks, S., R. Dobson.** Established, new and future disease modifying therapies for MS. // *Progress in Neurology and Psychiatry*, 19, 2015, № 5, p. 27-35. ISSN 1367-7543.
53. **Bittner, S., T. Ruck, H. Wiendl et al.** Targeting B cells in relapsing-remitting multiple sclerosis: From pathophysiology to optimal clinical management. // *Therapeutic Advances in Neurological Disorders*, 10, 2017, № 1, p. 51-66. ISSN 1756-2856.
54. **Bjarnadóttir, K., M. Benkhoucha, D. Merkler et al.** B cell-derived transforming growth factor- $\beta$ 1 expression limits the induction phase of autoimmune neuroinflammation. // *Scientific Reports*, 6, 2016, art. no. 34594. ISSN 2045-2322.
55. **Blauth, K., G.P. Owens, J.L. Bennett.** The ins and outs of B cells in multiple sclerosis. // *Frontiers in Immunology*, 6, 2015, art. no. 565. ISSN 1664-3224.
56. **Blinkenberg, M., P. Soelberg Sørensen.** Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents. // *CNS Drugs*, 31, 2017, № 5, p. 357-371. ISSN 1172-7047.
57. **Blüml, S., K. McKeever, R. Ettinger et al.** B-cell targeted therapeutics in clinical development. // *Arthritis Research and Therapy*, 15, 2013, Suppl.1, art. no. S4. ISSN 1478-6354.

58. **Boehm, T.** Evolution of vertebrate immunity. // *Current Biology*, 22, 2012, № 17, p. R722-R732. ISSN 0960-9822.
59. **Bourdette, D.** Rituximab for treating multiple sclerosis. // *Neurology*, 87, 2016, № 20, p. 2070-2071. ISSN 0028-3878.
60. **Boyko, A.N., N.Yu. Lashch, M.E. Guseva.** New drugs for anti-B-cell therapy of multiple sclerosis. // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 10, 2018, № 1, p. 70-73. ISSN 2074-2711.
61. **Braley, T.J., B.M. Segal.** B-cell targeting agents in the treatment of multiple sclerosis. // *Current Treatment Options in Neurology*, 15, 2013, № 3, p. 259-269. ISSN 1092-8480.
62. **Brandes, D.W., P. Rieckmann.** The manifold economic impact of multiple sclerosis - Indirect and direct costs of managing patients. // *European Neurological Review*, 7, 2012, Suppl. 2, p. 17-23. ISSN 1758-3837.
63. **Brenton, J.N., B.L. Banwell.** Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. // *Neurotherapeutics*, 13, 2016, № 1, p. 84-95. ISSN 1933-7213.
64. **Bridel, C., P.H. Lalive.** Update on multiple sclerosis treatments. // *Swiss Medical Weekly*, 144, 2014, art. no. w14012. ISSN 1424-7860.
65. **Broadley, S.A., M.H. Barnett, M. Boggild et al.** Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. // *Journal of Clinical Neuroscience*, 21, 2014, № 11, p. 1847-1856. ISSN 0967-5868.
66. **Brodie, T., K. Rothaeusler, M. Sospedra.** OMIP-033: A comprehensive single step staining protocol for human T- and B-cell subsets. // *Cytometry Part A*, 89, 2016, № 7, p. 629-632. ISSN 1552-4922.
67. **Bross, M., M. Hackett, E. Bernitsas.** Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis. // *International Journal of Molecular Sciences*, 21, 2020, № 12, art. no. 4312, p. 1-15. ISSN 1661-6596.
68. **Broux, B., P. Stinissen, N. Hellings.** Which immune cells matter? The immunopathogenesis of multiple sclerosis. // *Critical Reviews in Immunology*, 33, 2013, № 4, p. 283-306. ISSN 1040-8401.
69. **Brück, W., R. Gold, B.T. Lund et al.** Therapeutic decisions in multiple sclerosis moving beyond efficacy. // *JAMA Neurology*, 70, 2013, № 10, p. 1315-1324. ISSN 2168-6149.



70. **Buck, D., E., Albrecht, M. Aslam** et al. Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis. // *Annals of Neurology*, 73, 2013, № 1, p. 86-94. ISSN 0364-5134.
71. **Buzzard, K.A., S.A. Broadley, H. Butzkueven**. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? // *International Journal of Molecular Sciences*, 13, 2012, № 10, p. 12665-12709. ISSN 1661-6596.
72. **Bykova, O.V., Y.A., Klimov, S.V. Tikhonov** et al. Clinical observation experience of a pediatric patient with primary progressive multiple sclerosis in the moscow office for the treatment of children and adolescents with multiple sclerosis. // *Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova*, 120, 2020, № 10, p. 45-50. ISSN 1997-7298.
73. **Calabrese, M., A. Gajofatto, M.D. Benedetti**. Therapeutic strategies for relapsing-remitting multiple sclerosis: A special focus on reduction of grey matter damage as measured by brain atrophy. // *Expert Review of Neurotherapeutics*, 14, 2014, № 12, p. 1417-1428. ISSN 1473-7175.
74. **Caldito, N.G., A. Shirani, A. Salter** et al. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. // *Multiple Sclerosis Journal*, 2020. ISSN 1352-4585.
75. **Cantor, J.M.** CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis. // *Journal of Neuroimmunology*, 274, 2014, № 1-2, p. 230-233. ISSN 0165-5728.
76. **Cao, Y., I. Tabansky, J.J. Pan** et al. Bridging the gap between the bench and the clinic. – In: *Nanomedicine for Inflammatory Diseases*, 2017, p. 207-216. ISBN 9781498749800; 9781498749787.
77. **Carstensen, M., T. Christensen, M. Stilund** et al. Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis. // *Immunology and Cell Biology*, 98, 2020, № 7, p. 549-562. ISSN 0818-9641.
78. **Castro Borrero, W., D. Graves, T.C. Frohman** et al. Current and emerging therapies in multiple sclerosis: A systematic review. // *Therapeutic Advances in Neurological Disorders*, 5, 2012, № 4, p. 205-220. ISSN 1756-2856.
79. **Chan, A., A.J. Schutte**. B-cell function modulation in multiple sclerosis: A new therapeutic paradigm. // *Future Neurology*, 9, 2014, № 1, p. 23-26. ISSN 1479-6708.
80. **Chan, A., A.J. Schutte**. Interview: Experiences targeting B cells for the treatment of multiple sclerosis. // *Immunotherapy*, 6, 2014, № 2, p. 127-130. ISSN 1750-743X.

81. **Chan, A.C., P. Brunetta, P. Chin.** Ocrelizumab: A new generation of anti-CD20 mAb for treatment of multiple sclerosis. – In: *Successful Drug Discovery*, 4, 2019, p. 169-199. ISBN 9783527814695; 9783527344680.
82. **Charabati, M., S.J. Donkers, M.C. Kirkland et al.** A critical analysis of helminth immunotherapy in multiple sclerosis. // *Multiple Sclerosis Journal*, 26, 2020, № 12, p. 1448-1458. ISSN 1352-4585.
83. **Chataway, J., D.H. Miller.** Multiple sclerosis - Quenching the flames of inflammation. // *The Lancet*, 378, 2011, № 9805, p. 1759-1760. ISSN 0140-6736.
84. **Chaudhuri, A.** Ocrelizumab in multiple sclerosis: Risks and benefits. // *The Lancet*, 379, 2012, № 9822, p. 1196-1197. ISSN 0140-6736.
85. **Cheng, Y., L. Sun, Z. Xie et al.** Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications. // *Journal of Neuroscience Research*, 95, 2017, № 10, p. 1973-1983. ISSN 0360-4012.
86. **Christopher, M.A., S.N. Johnson, J.D. Griffin et al.** Autoantigen Tetramer Silences Autoreactive B Cell Populations. // *Molecular Pharmaceutics*, 17, 2020, № 11, p. 4201-4211. ISSN 1543-8384.
87. **Claes, N., J. Fraussen, P. Stinissen et al.** B cells are multifunctional players in multiple sclerosis pathogenesis: Insights from therapeutic interventions. // *Frontiers in Immunology*, 6, 2015, art. no. 642. ISSN 1664-3224.
88. **Coclitu, C., C.S. Constantinescu, R. Tanasescu.** The future of multiple sclerosis treatments. // *Expert Review of Neurotherapeutics*, 16, 2016, № 12, p. 1341-1356. ISSN 1473-7175.
89. **Cohan, S.** Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. // *Biologics: Targets and Therapy*, 10, 2016, p. 119-138. ISSN 1177-5475.
90. **Cohan, S.L., E.B. Lucassen, M.C. Romba et al.** Daclizumab: Mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis. // *Biomedicines*, 7, 2019, № 1, art. no. 18. ISSN 2227-9059.
91. **Collongues, N., J. De Seze.** An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. // *Therapeutic Advances in Neurological Disorders*, 9, 2016, № 3, p. 180-188. ISSN 1756-2856.
92. **Collongues, N., L. Michel, J. de Seze.** Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications. // *Current Treatment Options in Neurology*, 19, 2017, № 5, art. no. 19. ISSN 1092-8480.

93. **Conte, W.L., N. Arndt, V.P. Cipriani** et al. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. // *Multiple Sclerosis and Related Disorders*, 27, 2019, p. 397-399. ISSN 2211-0348.
94. **Corboy, J.R.** Changing Paradigms in MS therapies. // *Journal of Managed Care Medicine*, 17, 2014, № 1, p. 16-21. ISSN 1094-1525.
95. **Cortese, I., A. Nath.** Immunomodulatory therapy for multiple sclerosis. – In: *Neuroimmune Pharmacology*, 2016, p. 713-736. ISBN 9783319440224; 9783319440200.
96. **Costa-Frossard, L., I. Moreno-Torres, V. Meca-Lallana** et al. EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic. // *Revista de Neurologia*, 70, 2020, № 9, p. 329-340. ISSN 0210-0010.
97. **Cotchetti, K.R., B.N. Dittel, A.Z. Obeidat.** Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis. // *Multiple Sclerosis and Related Disorders*, 49, 2021, art. no. 102787. ISSN 2211-0348.
98. **Craddock, J., S. Markovic-Plese.** Immunomodulatory therapies for relapsing-remitting multiple sclerosis: Monoclonal antibodies, currently approved and in testing. // *Expert Review of Clinical Pharmacology*, 8, 2015, № 3, p. 283-296. ISSN 1751-2433.
99. **Cree, B.A.C., J.L. Bennett, M. Sheehan** et al. Placebo-controlled study in neuromyelitis optica - Ethical and design considerations. // *Multiple Sclerosis*, 22, 2016, № 7, p. 862-872. ISSN 1352-4585.
100. **Cross, A.H., R.S. Klein, L. Piccio.** Rituximab combination therapy in relapsing multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 5, 2012, № 6, p. 311-319. ISSN 1756-2856.
101. **Cross, A.H., R.T. Naismith.** Established and novel disease-modifying treatments in multiple sclerosis. // *Journal of Internal Medicine*, 275, 2014, № 4, p. 350-363. ISSN 0954-6820.
102. **Cuevas-García, C.F., N.H. Segura-Méndez, D.A. Herrera-Sánchez.** Updates in the immunopathology of multiple sclerosis = Actualidades en la inmunopatología de la esclerosis múltiple. // *Gaceta Medica de Mexico*, 154, 2018, № 5, p. 588-597. ISSN 0016-3813.
103. **Curtin, F., H.-P. Hartung.** Novel therapeutic options for multiple sclerosis. // *Expert Review of Clinical Pharmacology*, 7, 2014, № 1, p. 91-104. ISSN 1751-2433.

104. **D'Amico, E., A. Zanghi, F. Patti.** Personalized therapy in multiple sclerosis: state of art and future perspectives. // *Expert Review of Precision Medicine and Drug Development*, 1, 2016, № 4, p. 353-360. ISSN 2380-8993.
105. **da Silva, J.G., M.F. Pezzini, J. Poeta.** Advances in the treatment of multiple sclerosis through monoclonal antibody Ocrelizumab. // *Medicina (Brazil)*, 53, 2020, № 1, p. 35-41. ISSN 0076-6046.
106. **Damal, K., E. Stoker, J.F. Foley.** Optimizing therapeutics in the management of patients with multiple sclerosis: A review of drug efficacy, dosing, and mechanisms of action. // *Biologics: Targets and Therapy*, 7, 2013, № 1, p. 247-258. ISSN 1177-5475.
107. **D'Amico, E., A. Zanghi, M. Gastaldi et al.** Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. // *Autoimmunity Reviews*, 18, 2019, № 7, p. 665-672. ISSN 1568-9972.
108. **D'amico, E., C. Caserta, F. Patti.** Monoclonal antibody therapy in multiple sclerosis: Critical appraisal and new perspectives. // *Expert Review of Neurotherapeutics*, 15, 2015, № 3, p. 251-268. ISSN 1473-7175.
109. **D'Amico, E., S. Messina, C. Caserta et al.** A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. // *Expert Opinion on Drug Safety*, 14, 2015, № 7, p. 1157-1168. ISSN 1474-0338.
110. **Dargahi, N., M. Katsara, T. Tselios et al.** Multiple sclerosis: Immunopathology and treatment update. // *Brain Sciences*, 7, 2017, № 7, art. no. 78. ISSN 2076-3425.
111. **Davis, J.S., D. Ferreira, E. Paige et al.** Infectious complications of biological and small molecule targeted immunomodulatory therapies. // *Clinical Microbiology Reviews*, 33, 2020, № 3, art. no. e00035-19, p. 1-117. ISSN 0893-8512.
112. **De Flon, P., M. Gunnarsson, K. Laurell et al.** Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. // *Neurology*, 87, 2016, № 2, p. 141-147. ISSN 0028-3878.
113. **De Giglio, L., A.E. Grimaldi, F. Fubelli et al.** Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis. // *Expert Review of Neurotherapeutics*, 19, 2019, № 5, p. 417-429. ISSN 1473-7175.
114. **Deiß, A., I. Brecht, A. Haarmann et al.** Treating multiple sclerosis with monoclonal antibodies: A 2013 update. // *Expert Review of Neurotherapeutics*, 13, 2013, № 3, p. 313-335. ISSN 1473-7175.
115. **Demir, S., M.M. Atmaca, R.E. Togrol.** The first cure experience of a clinic: Approach to the patient to start ocrelizumab [Bir Kliniğin İlk Kür Tecrübesi: Okrelizumab Başlanacak Hastaya Yaklaşım]. // *Noropsikiyatri Arsivi*, 58, 2021, № 1, p. 52-56. ISSN 1300-0667.

116. **Dendrou, C.A., L. Fugger, M.A. Friese.** Immunopathology of multiple sclerosis. // *Nature Reviews Immunology*, 15, 2015, № 9, p. 545-558. ISSN 1474-1733.
117. **Deng, C.-L., J. Zou, H.-F. Song.** Advances in the research of anti-CD20 therapeutic monoclonal antibodies. // *Yaoxue Xuebao*, 48, 2013, № 10, p. 1515-1520. ISSN 0513-4870.
118. **Depaz, R., J. Aboab, O. Gout.** Update on diagnosis and treatment of multiple sclerosis. // *Revue de Medecine Interne*, 34, 2013, № 10, p. 628-635. ISSN 0248-8663.
119. **Derwenskus, J., F.D. Lublin.** Future treatment approaches to multiple sclerosis. // *Handbook of Clinical Neurology*, 122, 2014, p. 563-577. ISSN 0072-9752.
120. **Didonna, A.** Preclinical models of multiple sclerosis: Advantages and limitations towards better therapies. // *Current Medicinal Chemistry*, 23, 2016, № 14, p. 1442-1459. ISSN 0929-8673.
121. **Dirks, P., V. Zingler, J. Leemhuis et al.** Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - The CONFIDENCE study protocol. // *BMC Neurology*, 20, 2020, № 1, art. no. 95. ISSN: 14712377.
122. **Disanto, G., G.K. Sandve, A.J. Berlanga-Taylor et al.** Vitamin d receptor binding, chromatin states and association with multiple sclerosis. // *Human Molecular Genetics*, 21, 2012, № 16, p. 3575-3586. ISSN 0964-6906.
123. **Disanto, G., G.K. Sandve, V.A.G. Ricigliano et al.** DNase hypersensitive sites and association with multiple sclerosis. // *Human Molecular Genetics*, 23, 2014, № 4, p. 942-948. ISSN 0964-6906.
124. **Donzé, C., C. Papeix, C. Lebrun-Frenay et al.** Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. // *Revue Neurologique*, 176, 2020, № 10, p. 804-822. ISSN 0035-3787.
125. **Dörr, J., F. Paul.** The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. // *Current Treatment Options in Neurology*, 17, 2015, № 6, 12 p. ISSN 1092-8480.
126. **Du Pasquier, R.A., D.D. Pinschewer, D. Merkler.** Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. // *CNS Drugs*, 28, 2014, № 6, p. 535-558. ISSN 1172-7047.
127. **Du, F.H., E.A. Mills, Y. Mao-Draayer.** Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. // *Autoimmunity Highlights*, 8, 2017, № 1, art. no. 12. ISSN 2038-0305.

128. **Dubessy, A.-L., B. Stankoff.** Role for plasma exchange in multiple sclerosis and optica spectrum disorders = Place des échanges plasmatiques dans la sclérose en plaques et la neuromyéélite optique. // *Pratique Neurologique - FMC*, 10, 2019, № 4, p. 250-259. ISSN 1878-7762.
129. **Dubey, D., B.C. Kieseier, H.P. Hartung et al.** Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: Approved therapies and emerging candidates. // *Expert Review of Clinical Immunology*, 11, 2014, № 1, p. 93-108. ISSN 1744-666X.
130. **Dubey, D., T. Forsthuber, E.P. Flanagan et al.** B-cell-Targeted therapies in relapsing forms of MS. // *Neurology: Neuroimmunology and NeuroInflammation*, 4, 2017, № 6, art. no. e405. ISSN 2332-7812.
131. **Duffy, S.S., J.G. Lees, C.J. Perera et al.** Managing neuropathic pain in multiple sclerosis: Pharmacological interventions. // *Medicinal Chemistry*, 14, 2018, № 2, p. 106-119. ISSN 1573-4064.
132. **Durozard, P., A. Maarouf, C. Boutiere et al.** Efficacy of rituximab in refractory RRMS. // *Multiple Sclerosis Journal*, 25, 2019, № 6, p. 828-836. ISSN 1352-4585.
133. **Durso-Finley, J., D.L. Arnold, T. Arbel.** Saliency based deep neural network for automatic detection of gadolinium-enhancing multiple sclerosis lesions in brain MRI. // *Lecture Notes in Computer Science* (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), 11992 LNCS, 2020, p. 108-118. ISSN 0302-9743. ISBN 9783030466398.
134. **Dyer, M.J.S.** Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. // *Therapeutic Advances in Hematology*, 3, 2012, № 4, p. 199-207. ISSN 2040-6207.
135. **Eagle, T., F. Stuart, A.S. Chua et al.** Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 18, 2017, p. 196-201. ISSN 2211-0348.
136. **Elangovan, R.I., G. Disanto, A.J. Berlanga-Taylor et al.** Regulatory genomic regions active in immune cell types explain a large proportion of the genetic risk of multiple sclerosis. // *Journal of Human Genetics*, 59, 2014, № 4, p. 211-215. ISSN 1434-5161.
137. **Ellwardt, E., F. Zipp.** Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. // *Experimental Neurology*, 262, 2014, Part A, p. 8-17. ISSN 0014-4886.
138. **Emery, P., W. Rigby, P.P. Tak et al.** Safety with ocrelizumab in rheumatoid arthritis: Results from the ocrelizumab phase III program. // *PLoS ONE*, 9, 2014, № 2, art. no. e87379. ISSN 1932-6203.

139. **Evonuk, K.S., C.E. Moseley, R.E. Doyle et al.** Determining immune system suppression versus CNS protection for pharmacological interventions in autoimmune demyelination. // *Journal of Visualized Experiments*, 2016, 2016, № 115, art. no. e54348. ISSN 1940-087X.
140. **Farber, R.S., A. Harel, F. Lublin.** Novel agents for relapsing forms of multiple sclerosis. // *Annual Review of Medicine*, 67, 2016, p. 309-321. ISSN 0066-4219.
141. **Ferl, G.Z., A. Reyes, L.L. Sun et al.** A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. // *Clinical and Translational Science*, 11, 2018, № 3, p. 296-304. ISSN 1752-8054.
142. **Fernandez, O.** Alemtuzumab in the treatment of multiple sclerosis. // *Journal of Inflammation Research*, 7, 2014, № 1, p. 19-27. ISSN 1178-7031.
143. **Fernández, O., V.E. Fernández, M. Guerrero.** Multiple sclerosis treatment = Tratamiento de la esclerosis múltiple. // *Medicine (Spain)*, 11, 2015, № 77, p. 4622-4633. ISSN 0304-5412.
144. **Fernández-Menéndez, S., M. Fernández-Morán, I. Fernández-Vega et al.** Epstein-Barr virus and multiple sclerosis. from evidence to therapeutic strategies. // *Journal of the Neurological Sciences*, 361, 2016, p. 213-219. ISSN 0022-510X.
145. **Filippini, G., C. Del Giovane, M. Clerico et al.** Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. // *Cochrane Database of Systematic Reviews*, 2017, 2017, № 4, art. no. CD012200. ISSN 1469-493X.
146. **Filippini, G., M. Clerico, O. Beiki et al.** Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. // *Cochrane Database of Systematic Reviews*, 2016, 2016, № 5, art. no. CD012200. ISSN 1469-493X.
147. **Fillatreau, S.** B cells and their cytokine activities implications in human diseases. // *Clinical Immunology*, 186, 2018. p. 26-31. ISSN 1521-6616.
148. **Findling, O., J. Sellner.** Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors? // *Drug Discovery Today*, 26, 2021, № 2, p. 416-428. ISSN 1359-6446.
149. **Finkelsztejn, A., A. Finkelsztejn.** Multiple sclerosis: Overview of Disease-Modifying agents. // *Perspectives in Medicinal Chemistry*, 6, 2014, p. 65-72. ISSN 1177-391X.

150. **Fletcher, J.M., K.H. Mills.** Immunology of MS. – In: *The Biology of Multiple Sclerosis*, 2009, p. 62-89. ISBN 9780511979088; 9780521196802.
151. **Florou, D., M. Katsara, J. Feehan et al.** Anti-cd20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab. // *Brain Sciences*, 10, 2020, № 10, art. no. 758, p. 1-13. ISSN 2076-3425.
152. **Fogarty, E., S. Schmitz, N. Tubridy et al.** Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. // *Multiple Sclerosis and Related Disorders*, 9, 2016, p. 23-30. ISSN 2211-0348.
153. **Förster, M., P. Küry, O. Aktas et al.** Managing Risks with Immune Therapies in Multiple Sclerosis. // *Drug Safety*, 42, 2019, № 5, p. 633-647. ISSN 0114-5916.
154. **Forsthuber, T.G., D.M. Cimbora, J.N. Ratchford et al.** B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. // *Therapeutic Advances in Neurological Disorders*, 11, 2018. ISSN 1756-2856.
155. **Forsthuber, T.G., O. Stuve.** Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium? // *Neurology: Neuroimmunology and NeuroInflammation*, 3, 2016, № 5, art. no. e283. ISSN 2332-7812.
156. **Fox, E., A.E. Lovett-Racke, M. Gormley et al.** A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. // *Multiple Sclerosis Journal*, 27, 2021, № 3, p. 420-429. ISSN 1352-4585.
157. **Fox, E.J., E. Havrdova.** Breakthrough disease in multiple sclerosis - The problem and treatment options. // *European Neurological Review*, 7, 2012, Suppl. 2, p. 24-31. ISSN 1758-3837.
158. **Frampton, J.E.** Ocrelizumab: First Global Approval. // *Drugs*, 77, 2017, № 9, p. 1035-1041. ISSN 0012-6667.
159. **Frau, J., G. Coghe, L. Lorefice et al.** New horizons for multiple sclerosis therapeutics: Milestones in the development of ocrelizumab. // *Neuropsychiatric Disease and Treatment*, 14, 2018, p. 1093-1099. ISSN 1176-6328.
160. **Freedman, M.S.** Emerging Therapies for Multiple Sclerosis. – In: *Translational Neuroimmunology in Multiple Sclerosis: From Disease Mechanisms to Clinical Applications*, 2016, p. 285-304. ISBN 9780128020074; 9780128019146.
161. **Freedman, M.S.** Present and emerging therapies for multiple sclerosis. // *Continuum Lifelong Learning in Neurology*, 19, 2013, № 4, p. 968-991. ISSN 1080-2371.



162. **Freedman, M.S., C.A. Rush.** Severe, Highly Active, or Aggressive Multiple Sclerosis. // *CONTINUUM Lifelong Learning in Neurology*, 22, 2016, № 3, p. 761-784. ISSN 1080-2371.
163. **Freskgård, P.-O., E. Urich.** Antibody therapies in CNS diseases. // *Neuropharmacology*, 120, 2017, p. 38-55. ISSN 0028-3908.
164. **Frisch, E.S., R. Pretzsch, M.S. Weber.** A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues. // *Neurotherapeutics*, 2021. ISSN 1933-7213.
165. **Galicía, G., B. Boulianne, N. Pikor et al.** Secondary B Cell Receptor Diversification Is Necessary for T Cell Mediated Neuro-Inflammation during Experimental Autoimmune Encephalomyelitis. // *PLoS ONE*, 8, 2013, № 4, art. no. e61478. ISSN 1932-6203.
166. **García-Ruiz, A.J., G. Izquierdo-Ayuso, G. Navarro-Mascarell et al.** Efficacy of the treatments used in multiple sclerosis: From meta-analysis to number needed to treat. // *Clinical Neuropharmacology*, 40, 2017, № 1, p. 37-42. ISSN 0362-5664.
167. **Gasparini, C., S. Haggiag, S. Ruggieri.** Drugs in clinical development for multiple sclerosis: Focusing on anti-CD20 antibodies. // *Expert Opinion on Investigational Drugs*, 22, 2013, № 10, p. 1243-1253. ISSN 1354-3784.
168. **Gharibi, T., Z. Babaloo, A. Hosseini et al.** The role of B cells in the immunopathogenesis of multiple sclerosis. // *Immunology*, 160, 2020, № 4, p. 325-335. ISSN 00192805.
169. **Gholamzad, M., M. Ebtekar, M.S. Ardestani et al.** A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. // *Inflammation Research*, 68, 2019, № 1, p. 25-38. ISSN 1023-3830.
170. **Gilli, F., L. Li, S.J. Campbell et al.** The effect of B-cell depletion in the Theiler's model of multiple sclerosis. // *Journal of the Neurological Sciences*, 359, 2015, № 1-2, p. 40-47. ISSN 0022-510X.
171. **Gingele, S., T. Skripuletz, R. Jacobs.** Role of CD20+ T cells in multiple sclerosis: Implications for treatment with ocrelizumab. // *Neural Regeneration Research*, 15, 2020, № 4, p. 663-664. ISSN 1673-5374.
172. **Giovannoni, G.** Efficacy and safety of existing and emerging monoclonal antibody therapies for multiple sclerosis. // *European Neurological Review*, 11, 2016, № 2, p. 96-100. ISSN 1758-3837.
173. **Giovannoni, G., C. Hawkes, M. Levy et al.** Editors' Welcome. // *Multiple Sclerosis and Related Disorders*, 19, 2018, p. A1-A2. ISSN 2211-0348.

174. **Gjelstrup, M.C., M. Stilund, T. Petersen** et al. Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis. // *Immunology and Cell Biology*, 96, 2018, № 2, p. 160-174. ISSN 0818-9641.
175. **Glatigny, S., B. Höllbacher, S.J. Motley** et al. Abatacept targets T follicular helper and regulatory T cells, disrupting molecular pathways that regulate their proliferation and maintenance. // *Journal of Immunology*, 202, 2019, № 5, p. 1373-1382. ISSN 0022-1767.
176. **Goldenberg, M.M.** Multiple sclerosis review. // *P and T*, 37, 2012, № 3, p. 175-184. ISSN 1052-1372.
177. **Goodman, A.D., T. Gyang, A.D. Smith** et al. Ibudilast for the treatment of multiple sclerosis. // *Expert Opinion on Investigational Drugs*, 25, 2016, № 10, p. 1231-1237. ISSN 1354-3784.
178. **Goudarzi, M.H., M.J. Eadie, S.A. Hollingworth.** Disease modifying therapies for relapsing-remitting multiple sclerosis: Use and costs in Australia (1996-2019). // *Multiple Sclerosis and Related Disorders*, 50, 2021, art. no. 102835. ISSN 2211-0348.
179. **Graetz, C., S. Groppa, F. Zipp** et al. Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies? // *Expert Review of Neurotherapeutics*, 18, 2018, № 3, p. 203-219. ISSN 1473-7175.
180. **Graf, J., O. Aktas, K. Rejdak** et al. Monoclonal Antibodies for Multiple Sclerosis: An Update. // *BioDrugs*, 33, 2019, № 1, p. 61-78. ISSN 1173-8804.
181. **Graf, J., P. Albrecht, N. Goebels** et al. Ocrelizumab for treatment of multiple sclerosis [Ocrelizumab zur Behandlung der Multiplen Sklerose]. // *Nervenarzt*, 91, 2020, № 8, p. 722-734. ISSN 0028-2804.
182. **Greenlee, J.E.** Treatment of paraneoplastic cerebellar degeneration. // *Current Treatment Options in Neurology*, 15, 2013, № 2, p. 185-200. ISSN 1092-8480.
183. **Grigoriadis, N., V. van Pesch.** A basic overview of multiple sclerosis immunopathology. // *European Journal of Neurology*, 22, 2015, p. 3-13. ISSN 1351-5101.
184. **Grzegorski, T., J. Losy.** Multiple sclerosis-the remarkable story of a baffling disease. // *Reviews in the Neurosciences*, 30, 2019, № 5, p. 511-526. ISSN 0334-1763.
185. **Guerrier, T., M. Labalette, D. Launay** et al. Proinflammatory B-cell profile in the early phases of MS predicts an active disease. // *Neurology: Neuroimmunology and NeuroInflammation*, 5, 2018, № 2, art. no. e431. ISSN 2332-7812.

186. **Gysling, E.** Ocrelizumab. // *Pharma-Kritik*, 40, 2018, № 3, p. 9-11. ISSN 1010-5409.
187. **Haase, S., R.A. Linker.** Inflammation in multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 14, 2021. ISSN 1756-2856.
188. **Haghikia, A., R. Gold.** Current and future treatments of multiple sclerosis. – In: *Multiple Sclerosis Immunology: A Foundation for Current and Future Treatments*, 2013, p. 357-384. ISBN 9781461479536; 1461479525; 9781461479529.
189. **Haghikia, A., R. Hohlfeld, R. Gold et al.** Therapies for multiple sclerosis: Translational achievements and outstanding needs. // *Trends in Molecular Medicine*, 19, 2013, № 5, p. 309-319. ISSN 1471-4914.
190. **Häusler, D., K. Akgün, L. Stork et al.** CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study. // *Brain Pathology*, 2021. ISSN 1015-6305.
191. **Häusler, D., S. Häusser-Kinzel, L. Feldmann et al.** Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 115, 2018, № 39, p. 9773-9778. ISSN 0027-8424.
192. **Häusler, D., S. Nessler, N. Kruse et al.** Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model. // *Neuropathology and Applied Neurobiology*, 41, 2015, № 6, p. 814-831. ISSN 0305-1846.
193. **Heliopoulos, I., A. Patousi.** Therapeutic monoclonal antibodies and multiple sclerosis: The essentials. // *Medicinal Chemistry*, 14, 2018, № 2, p. 144-154. ISSN 1573-4064.
194. **Høglund, R.A., J. Polak, F. Vartdal et al.** B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate. // *Multiple Sclerosis and Related Disorders*, 26, 2018, p. 90-95. ISSN 2211-0348.
195. **Huang, H., K. Ito, F. Dangond et al.** Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation. // *Journal of Neuroimmunology*, 258, 2013, № 1/2, p. 27-31. ISSN 0165-5728.
196. **Huber, A.K., P.C. Duncker, D.N. Irani.** The conundrum of interferon- $\beta$  non-responsiveness in relapsing-remitting multiple sclerosis. // *Cytokine*, 74, 2015, № 2, p. 228-236. ISSN 1043-4666.
197. **Hutchinson, M., D.P.J. Hunt.** Trials of licenced RRMS DMTs in progressive MS. – In: *Progressive Multiple Sclerosis: Second Edition*, 2017, p. 207-232. ISBN 9783319659213; 9783319659206.

198. **Ireland, S.J., A.A. Guzman, E.M. Frohman** et al. B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses. // *Journal of Neuroimmunology*, 291, 2016, p. 46-53. ISSN 0165-5728.
199. **Ireland, S.J., M. Blazek, C.T. Harp** et al. Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity. // *Autoimmunity*, 45, 2012, № 5, p. 400-414. ISSN 0891-6934.
200. **Jakimovski, D., B. Weinstock-Guttman, M. Ramanathan** et al. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. // *Expert Opinion on Biological Therapy*, 17, 2017, № 9, p. 1163-1172. ISSN 1471-2598.
201. **Jones, D.E., M.D. Goldman.** Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: A review of its clinical pharmacology, efficacy and safety. // *Expert Review of Clinical Immunology*, 10, 2014, № 10, p. 1281-1291. ISSN 1744-666X.
202. **Jones, J.L., A.J. Coles.** Mode of action and clinical studies with alemtuzumab. // *Experimental Neurology*, 262, 2014, Part A, p. 37-43. ISSN 0014-4886.
203. **Jones, J.L., S.A.J. Thompson, P. Loh** et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 110, 2013, № 50, p. 20200-20205. ISSN 0027-8424.
204. **Juanatey, A., L. Blanco-García, N. Téllez.** Ocrelizumab: Its efficacy and safety in multiple sclerosis = Ocrelizumab: Eficacia y seguridad en la esclerosis múltiple. // *Revista de Neurologia*, 66, 2018, 12, p. 423-433. ISSN 0210-0010.
205. **Juto, A., K. Fink, F. Al Nimer** et al. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. // *Multiple Sclerosis and Related Disorders*, 37, 2020, art. no. 101468. ISSN 2211-0348.
206. **Karmon, Y., N. Gadoth.** Present drug therapy of demyelinating disorders. // *Current Drug Therapy*, 13, 2018, № 1, p. 25-42. ISSN 1574-8855.
207. **Karussis, D.** Immunotherapy of multiple sclerosis: The state of the art. // *BioDrugs*, 27, 2013, № 2, p. 113-148. ISSN 1173-8804.
208. **Karussis, D.** Multiple Sclerosis. – In: *International Encyclopedia of Public Health*, 2016, p. 145-179. ISBN 9780128037089; 9780128036785.
209. **Kasper, L.H., A.T. Reder.** Immunomodulatory activity of interferon-beta. // *Annals of Clinical and Translational Neurology*, 1, 2014, № 8, p. 622-631. ISSN 2328-9503.

210. **Kattah, A.G., F.C. Fervenza.** Rituximab: Emerging treatment strategies of immune-mediated glomerular disease. // *Expert Review of Clinical Immunology*, 8, 2012, № 5, p. 413-421. ISSN 1744-666X.
211. **Katz Sand, I.B., S. Krieger.** Emerging strategies for the treatment of multiple sclerosis. // *Future Neurology*, 7, 2012, № 2, p. 193-207. ISSN 1479-6708.
212. **Kaunzner, U.W., M. Al-Kawaz, S.A. Gauthier.** Defining Disease Activity and Response to Therapy in MS. // *Current Treatment Options in Neurology*, 19, 2017, № 5, art. no. 20. ISSN 1092-8480.
213. **Kim, W., H.J. Kim.** Monoclonal antibody therapies for multiple sclerosis and neuromyelitis optica spectrum disorder. // *Journal of Clinical Neurology (Korea)*, 16, 2020, № 3, p. 355-368. ISSN 1738-6586.
214. **Kinzel, S., K. Lehmann-Horn, S. Torke et al.** Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. // *Acta Neuropathologica*, 132, 2016, № 1, p. 43-58. ISSN 0001-6322.
215. **Kinzel, S., M.S. Weber.** B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence. // *CNS Drugs*, 30, 2016, № 12, p. 1137-1148. ISSN 1172-7047.
216. **Klineova, S., N. Mitiku, A.E. Miller.** Disease-modifying therapy for multiple sclerosis. // *Future Neurology*, 10, 2015, № 3, p. 253-279. ISSN 1479-6708.
217. **Klineova, S., S. Krieger.** Emerging therapies in multiple sclerosis. – In: *Handbook of Relapsing-Remitting Multiple Sclerosis*, 2017, p. 99-113. ISBN 9783319406282; 9783319406268.
218. **Klotz, L., H. Wiendl.** Monoclonal antibodies in neuroinflammatory diseases. // *Expert Opinion on Biological Therapy*, 13, 2013, № 6, p. 831-846. ISSN 1471-2598.
219. **Klotz, L., H. Wiendl.** Multiple sclerosis update = Was gibt es Neues bei der Multiplen Sklerose? // *Aktuelle Neurologie*, 39, 2012, № 3, p. 116-126. ISSN 0302-4350.
220. **Knier, B., B. Hemmer, T. Korn.** Novel monoclonal antibodies for therapy of multiple sclerosis. // *Expert Opinion on Biological Therapy*, 14, 2014, № 4, p. 503-513. ISSN 1471-2598.
221. **Koch, M.W., L.M. Metz, S.M. Agrawal et al.** Environmental factors and their regulation of immunity in multiple sclerosis. // *Journal of the Neurological Sciences*, 324, 2013, № 1-2, p. 10-16. ISSN 0022-510X.

222. **Kowarik, M.C., D. Astling, G. Lepennetier et al.** Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. // *Neurotherapeutics*, 18, 2021, № 1, p. 364-377. ISSN 1933-7213.
223. **Kretzschmar, B., K. Hein, Z. Moinfar et al.** Treatment with atacicept enhances neuronal cell death in a rat model of optic neuritis. // *Journal of Neuroimmunology*, 268, 2014, № 1-2, p. 58-63. ISSN 0165-5728.
224. **Krumbholz, M., E. Meinl.** B cells in MS and NMO: Pathogenesis and therapy. // *Seminars in Immunopathology*, 36, 2014, № 3, p. 339-350. ISSN 1863-2297.
225. **Krumbholz, M., T. Derfuss, R. Hohlfeld et al.** B cells and antibodies in multiple sclerosis pathogenesis and therapy. // *Nature Reviews Neurology*, 8, 2012, № 11, p. 613-623. ISSN 1759-4758.
226. **Laureys, G., B. Willekens, L., Vanopdenbosch et al.** A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis. // *Acta Neurologica Belgica*, 118, 2018, № 2, p. 161-168. ISSN 0300-9009.
227. **Lehmann Horn, K., H.C. Kronsbein, M.S. Weber.** Targeting B cells in the treatment of multiple sclerosis: Recent advances and remaining challenges. // *Therapeutic Advances in Neurological Disorders*, 6, 2013, № 3, p. 161-173. ISSN 1756-2856.
228. **Lehmann-Horn, K., S. Kinzel, L. Feldmann et al.** Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity. // *Annals of Clinical and Translational Neurology*, 1, 2014, № 7, p. 490-496. ISSN 2328-9503.
229. **Lehmann-Horn, K., S. Kinzel, M.S. Weber.** Deciphering the role of B cells in multiple sclerosis-towards specific targeting of pathogenic function. // *International Journal of Molecular Sciences*, 18, 2017, № 10, art. no. 2048. ISSN 1661-6596.
230. **Lehmann-Horn, K., S.A. Sagan, R.C. Winger et al.** CNS accumulation of regulatory B cells is VLA-4-dependent. // *Neurology: Neuroimmunology and NeuroInflammation*, 3, 2016, № 2, art. no. e212. ISSN 2332-7812.
231. **Levin, M.C., S. Lee, L.A. Gardner et al.** Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered 'ribostasis' and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis. // *Journal of Neuroimmunology*, 304, 2017, p. 56-62. ISSN 0165-5728.
232. **Levin, S.N., T.B. Kaplan.** Infectious Complications of Novel Multiple Sclerosis Therapies. // *Current Infectious Disease Reports*, 19, 2017, № 2, art. no. 7. ISSN 1523-3847.

233. **Lewin, A., S. Hamilton, A. Witkover** et al. Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. // *Wellcome Open Research*, 1, 2017, art. no. 10. ISSN 2398-502X.
234. **Lewin, A., S. Hamilton, C.R.M. Bangham** et al. Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. // *Wellcome Open Research*, 1, 2016, art. no. 10. ISSN 2398-502X.
235. **Lin, M., S. Shi, J. Zhang** et al. Ocrelizumab for multiple sclerosis. // *Cochrane Database of Systematic Reviews*, 2019, № 1, art. no. CD013247. ISSN 14694-93X.
236. **Lindén, M., M. Khademi, I. Lima Bomfim** et al. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13. // *Multiple Sclerosis Journal*, 19, 2013, № 7, p. 863-870. ISSN 1352-4585.
237. **Linker, R.** Ocrelizumab for the treatment of multiple sclerosis = Ocrelizumab in der Therapie der multiplen Sklerose. // *Psychopharmakotherapie*, 25, 2018, № 5, p. 234-239. ISSN 0944-6877.
238. **Lisak, M., V. Bašić Kes.** Monoclonal antibodies in the treatment of multiple sclerosis = Monoklonska antitijela u liječenju multiple skleroze. // *Acta Medica Croatica*, 72, 2018, № 3, p. 399-408. ISSN 1330-0164.
239. **Loebermann, M., A. Winkelmann, H.-P. Hartung** et al. Vaccination against infection in patients with multiple sclerosis. // *Nature Reviews Neurology*, 8, 2012, № 3, p. 143-151. ISSN 1759-4758.
240. **Loleit, V., V. Biberacher, B. Hemmer.** Current and future therapies targeting the immune system in multiple sclerosis. // *Current Pharmaceutical Biotechnology*, 15, 2014, № 3, p. 276-296. ISSN 1389-2010.
241. **Longbrake, E.E., B.J. Parks, A.H. Cross.** Monoclonal antibodies as disease modifying therapy in multiple sclerosis. // *Current Neurology and Neuroscience Reports*, 13, 2013, № 11, art. no. 390. ISSN 1528-4042.
242. **LoPresti, P.** Silent free fall at disease onset: A perspective on therapeutics for progressive multiple sclerosis. // *Frontiers in Neurology*, 9, 2018, art. no. 973. ISSN 1664-2295.
243. **Lorefice, L., G. Fenu, J. Frau** et al. Monoclonal antibodies: A target therapy for multiple sclerosis. // *Inflammation and Allergy - Drug Targets*, 13, 2014, № 2, p. 134-143. ISSN 1871-5281.
244. **Louapre, C., E. Maillart, C. Papeix** et al. New and emerging treatments for multiple sclerosis=Nouveautés thérapeutiques et stratégies émergentes dans la

- sclérose en plaques. // *Medecine/Sciences*, 29, 2013, № 12, p. 1105-1110. ISSN 0767-0974.
245. **Lovett-Racke, A.E., M. Gormley, Y. Liu et al.** B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. // *Journal of Neuroimmunology*, 332, 2019, p. 187-197. ISSN 0165-5728.
  246. **Lu, Y., J. Zhao, Q. Zhan.** Effect of interferon- $\beta$ 1 $\alpha$  therapy on multiple sclerosis based on gadolinium-enhancing or active T2 magnetic resonance imaging outcomes: a meta-analysis. // *Neurological Research*, 38, 2016, № 10, p. 909-915. ISSN 0161-6412.
  247. **Lubetzki, C., B. Stankoff.** Demyelination in multiple sclerosis. // *Handbook of Clinical Neurology*, 122, 2014, p. 89-99. ISSN 0072-9752.
  248. **Lugaresi, A., M. di Ioia, D. Travaglini et al.** Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. // *Neuropsychiatric Disease and Treatment*, 9, 2013, p. 893-914. ISSN 1176-6328.
  249. **Lühder, F., R. Gold.** Trial and error in clinical studies: Lessons from ATAMS. // *The Lancet Neurology*, 13, 2014, № 4, p. 340-341. ISSN 1474-4422.
  250. **Lulu, S., E. Waubant.** Humoral-Targeted Immunotherapies in Multiple Sclerosis. // *Neurotherapeutics*, 10, 2013, № 1, p. 34-43. ISSN 1933-7213.
  251. **Lycke, J.** Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: Differentiating mechanisms and clinical outcomes. // *Therapeutic Advances in Neurological Disorders*, 8, 2015, № 6, p. 274-293. ISSN 1756-2856.
  252. **Lyons, J.A., M.M. Riter, A.M., Almatrook et al.** Amelioration of EAE by a cryptic epitope of myelin oligodendrocyte glycoprotein. // *Journal of Neuroimmunology*, 300, 2016, p. 66-73. ISSN 0165-5728.
  253. **Ma, L.-H., M.-J. Sun, B.-Y. Yuan et al.** Ocrelizumab in the treatment of relapsing multiple sclerosis: a Meta-analysis. // *Chinese Journal of New Drugs*, 28, 2019, № 11, p. 1397-1403. ISSN 1003-3734.
  254. **Maarouf, A., C. Boutière, A. Rico et al.** How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update. // *Revue Neurologique*, 174, 2018, № 6, p. 429-440. ISSN 0035-3787.
  255. **MacMillan, E.L., J.J. Schubert, I.M. Vavasour et al.** Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a. // *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, 5, 2019, № 4. ISSN 2055-2173.



256. **Magliozzi, R., O.W. Howell, R. Nicholas** et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. // *Annals of Neurology*, 83, 2018, № 4, p. 739-755. ISSN 0364-5134.
257. **Malpass, K.** Disease mechanisms in MS: Cell adhesion molecule MCAM on pathogenic T cells-a green light for CNS entry in multiple sclerosis. // *Nature Reviews Neurology*, 8, 2012, № 11, p. 592. ISSN 1759-4758.
258. **Maltby, V.E., R.A. Lea, M.C. Graves** et al. Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients. // *Scientific Reports*, 8, 2018, № 1, art. no. 17418. ISSN 2045-2322.
259. **Maria, Z., E. Turner, A. Agasing** et al. Pertussis toxin inhibits encephalitogenic t-cell infiltration and promotes a b-cell-driven disease during th17-eae. // *International Journal of Molecular Sciences*, 22, 2021, № 6, art. no. 2924, p. 1-14. ISSN 1661-6596.
260. **Márquez, A.C., M.S. Horwitz.** The role of latently infected B cells in CNS autoimmunity. // *Frontiers in Immunology*, 6, 2015, art. no. 544. ISSN 1664-3224.
261. **Marta, M., G. Giovannoni.** Disease modifying drugs in multiple sclerosis: Mechanisms of action and new drugs in the Horizon. // *CNS and Neurological Disorders - Drug Targets*, 11, 2012, № 5, p. 610-623. ISSN 1871-5273.
262. **Martinez-Pasamar, S., E. Abad, B. Moreno** et al. Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity. // *BMC Systems Biology*, 7, 2013, art. no. 34. ISSN 1752-0509.
263. **Marziniak, M.** Multiple sclerosis: New treatment options=Multiple Sklerose: Neue therapieoptionen. // *MMW-Fortschritte der Medizin*, 156, 2014, № 23, p. 69-76. ISSN 1438-3276.
264. **Mathias, A., G. Perriard, M. Canales** et al. Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. // *Multiple Sclerosis*, 23, 2017, № 6, p. 802-809. ISSN 1352-4585.
265. **Matveeva, O., J.F.J. Bogie, J.J.A. Hendriks** et al. Western lifestyle and immunopathology of multiple sclerosis. // *Annals of the New York Academy of Sciences*, 1417, 2018, № 1, p. 71-86. ISSN 0077-8923.
266. **Mazdeh, M., M. Khamseh, M. Taheri** et al. Effect of Rituximab on Expanded Disability Status Scale and Relapse Rate in Multiple Sclerosis Patients. // *Journal of Molecular Neuroscience*, 70, 2020, № 8, p. 1165-1168. ISSN 0895-8696.
267. **McCormack, P.L.** Natalizumab: A review of its use in the management of relapsing-remitting multiple sclerosis. // *Drugs*, 73, 2013, № 13, p. 1463-1481. ISSN 0012-6667.

268. **McGinley, M.P., B.P. Moss, J.A. Cohen.** Safety of monoclonal antibodies for the treatment of multiple sclerosis. // *Expert Opinion on Drug Safety*, 16, 2017, № 1, p. 89-100. ISSN 1474-0338.
269. **McKay, F.C., P.N. Gatt, N. Fewings et al.** The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies. // *Clinical Immunology*, 163, 2016, p. 96-107. ISSN 1521-6616.
270. **McNamara, C., G. Sugrue, B. Murray et al.** Current and emerging therapies in multiple sclerosis: Implications for the radiologist, part 1-mechanisms, efficacy, and safety. // *American Journal of Neuroradiology*, 38, 2017, № 9, p. 1664-1671. ISSN 0195-6108.
271. **Melbye, P., A. Olsson, T.H. Hansen et al.** Short-chain fatty acids and gut microbiota in multiple sclerosis. // *Acta Neurologica Scandinavica*, 139, 2019, № 3, p. 208-219. ISSN 0001-6314.
272. **Melendez-Torres, G.J., P. Auguste, X. Armoiry et al.** Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: Systematic review and economic evaluation. // *Health Technology Assessment*, 21, 2017, № 52, 396 p. ISSN 1366-5278.
273. **Melendez-Torres, G.J., X. Armoiry, R. Court et al.** Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: Systematic review and network meta-analysis of trials including recommended dosages. // *BMC Neurology*, 18, 2018, № 1, art. no. 162. ISSN 1471-2377.
274. **Melzer, N., S.G. Meuth.** Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: Common and divergent current and future strategies. // *Clinical and Experimental Immunology*, 175, 2014, № 3, p. 359-372. ISSN 0009-9104.
275. **Memon, A.B., A. Javed, C. Caon et al.** Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. // *PLoS ONE*, 13, 2018, № 1, art. no. e0190425. ISSN 1932-6203.
276. **Menezes, S.M., D. Decanine, D. Brassat et al.** CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. // *Journal of Neuroinflammation*, 11, 2014, art. no. 18. ISSN 1742-2094.
277. **Menge, T., D. Dubey, C. Warnke et al.** Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. // *Expert Review of Neurotherapeutics*, 16, 2016, № 10, p. 1131-1139. ISSN 1473-7175.

278. **Michel, L.** Immunological mechanisms of treatments in multiple sclerosis=Mécanismes immunologiques des traitements de fond de la sclérose en plaques. // *Pratique Neurologique - FMC*, 7, 2016, № 2, p. 159-165. ISSN 1878-7762.
279. **Michel, L.** Therapeutic news in multiple sclerosis = Actualités thérapeutiques dans la sclérose en plaques. // *Pratique Neurologique - FMC*, 10, 2019, № 3, p. 183-186. ISSN 1878-7762.
280. **Michel, L., C. Larochelle, A. Prat.** Update on treatments in multiple sclerosis. // *Presse Medicale*, 44, 2015, № 4, p. e137-e151. ISSN 0755-4982.
281. **Michel, L., M. Chesneau, P. Manceau et al.** Unaltered regulatory B-cell frequency and function in patients with multiple sclerosis. // *Clinical Immunology*, 155, 2014, № 2, p. 198-208. ISSN 1521-6616.
282. **Midaglia, L., L. Mora, P. Mulero et al.** Rituximab: Its efficacy, effectiveness and safety in the treatment of multiple sclerosis = Rituximab: Eficacia, efectividad y seguridad en el tratamiento de la esclerosis múltiple. // *Revista de Neurologia*, 66, 2018, № 1, p. 25-32. ISSN 0210-0010.
283. **Miller, A.E.** Teriflunomide for the treatment of relapsing-remitting multiple sclerosis. // *Expert Review of Clinical Immunology*, 11, 2015, № 2, p. 181-194. ISSN 1744-666X.
284. **Milo, R.** The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 7, 2014, № 1, p. 7-21. ISSN 1756-2856.
285. **Mimpen, M., J. Smolders, R. Hupperts et al.** Natural killer cells in multiple sclerosis: A review. // *Immunology Letters*, 222, 2020, p. 1-11. ISSN 0165-2478.
286. **Miyazaki, Y., M. Niino, T. Fukazawa et al.** Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. // *Clinical Immunology*, 151, 2014, № 2, p. 127-135. ISSN 1521-6616.
287. **Miyazaki, Y., M. Niino.** Molecular targeted therapy against B cells in multiple sclerosis. // *Clinical and Experimental Neuroimmunology*, 5, 2014, № s1, p. 16-27. ISSN 1759-1961.
288. **Moiola, L., V. Barcella, S. Benatti et al.** The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. // *Multiple Sclerosis Journal*, 27, 2021, № 3, p. 331-346. ISSN 1352-4585.

289. **Molnarfi, N., K. Bjarnadóttir, M. Benkhoucha et al.** Activation of human B cells negatively regulates TGF- $\beta$ 1 production. // *Journal of Neuroinflammation*, 14, 2017, № 1, art. no. 13. ISSN 1742-2094.
290. **Molnarfi, N., U., Schulze-Topphoff, M.S. Weber et al.** MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. // *Journal of Experimental Medicine*, 210, 2013, № 13, p. 2921-2937. ISSN 0022-1007.
291. **Montalban, X., D.L. Arnold, M.S. Weber.** Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. // *New England Journal of Medicine*, 380, 2019, № 25, p. 2406-2417. ISSN 0028-4793.
292. **Monteiro, S., J. Cerqueira.** Fingolimod mode of action=Modo de ação do fingolimod. // *Sinapse*, 12, 2012, № 2, Suppl. 1, p. 23-29. ISSN 1645-281X.
293. **Moreno Torres, I., A. García-Merino.** Anti-CD20 monoclonal antibodies in multiple sclerosis. // *Expert Review of Neurotherapeutics*, 17, 2017, № 4, p. 359-371. ISSN 1473-7175.
294. **Mouyis, M., C. Ciurtin, D.A. Isenberg.** Biologic therapies for systemic lupus erythematosus. – In: *Biologics in Rheumatology: New Developments, Clinical Uses and Health Implication*, 2016, p. 3-31. ISBN 9781634853026; 9781634852746.
295. **Mulero, P., L. Midaglia, X. Montalban et al.** Ocrelizumab: a new milestone in multiple sclerosis therapy. // *Therapeutic Advances in Neurological Disorders*, 11, 2018. ISSN 1756-2856.
296. **Muller, I., C. Moran, B. Lecumberri et al.** 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. // *European Thyroid Journal*, 8, 2019, № 4, p. 173-185. ISSN 2235-0640.
297. **Mütze, T., F. Konietzschke, A. Munk et al.** A studentized permutation test for three-arm trials in the ‘gold standard’ design. // *Statistics in Medicine*, 36, 2017, № 6, p. 883-898. ISSN 0277-6715.
298. **Myhr, K.-M., Ø. Torkildsen, A. Lossius et al.** B cell depletion in the treatment of multiple sclerosis. // *Expert Opinion on Biological Therapy*, 19, 2019, № 3, p. 261-271. ISSN 1471-2598.
299. **Mysler, E.F., A.J. Spindler, R. Guzman et al.** Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. // *Arthritis and Rheumatism*, 65, 2013, № 9, p. 2368-2379. ISSN 0004-3591.

300. **Nakashima, I.** Molecular targeted therapy for neuroimmunological diseases. // *Brain and Nerve*, 65, 2013, № 11, p. 1353-1361. ISSN 1881-6096.
301. **Napier, J., L. Rose, O. Adeoye** et al. Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis. // *Immunopharmacology and Immunotoxicology*, 41, 2019, № 1, p. 7-15. ISSN 0892-3973.
302. **Naser Moghadasi, A., A. Darki, P. Masoumi** et al. Evaluating the efficacy and safety of Zytux<sup>TM</sup> (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. // *Multiple Sclerosis and Related Disorders*, 36, 2019, art. no. 101419. ISSN 2211-0348.
303. **Negron, A., R.R. Robinson, O. Stüve** et al. The role of B cells in multiple sclerosis: Current and future therapies. // *Cellular Immunology*, 339, 2019, p. 10-23. ISSN 0008-8749.
304. **Ng, H.S., C.L. Rosenbult, H. Tremlett.** Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. // *Expert Opinion on Drug Safety*, 19, 2020, № 9, p. 1069-1094. ISSN 1474-0338.
305. **Nguyen, A.-L., M. Gresle, T. Marshall** et al. Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. // *British Journal of Pharmacology*, 174, 2017, № 13, p. 1895-1907. ISSN 0007-1188.
306. **Nicholas, J.A., A.L. Boster, M.K. Racke.** Multiple sclerosis Five new things. // *Neurology: Clinical Practice*, 3, 2013, № 5, p. 404-412. ISSN 2163-0402.
307. **Nielsen, C.H., L. Börnsen, F. Sellebjerg** et al. Myelin basic protein-induced production of tumor necrosis factor- $\alpha$  and interleukin-6, and presentation of the immunodominant peptide MBP85-99 by B cells from patients with relapsing-remitting multiple sclerosis. // *PLoS ONE*, 11, 2016, № 1, art. no. e0146971. ISSN 1932-6203.
308. **Nosadini, M., S. Sartori, S. Sharma** et al. Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. // *Seminars in Pediatric Neurology*, 24, 2017, № 3, p. 214-228. ISSN 1071-9091.
309. **Ochi, H.** B-cell-targeted therapy in multiple sclerosis. // *Clinical and Experimental Neuroimmunology*, 7, 2016, № 3, p. 260-271. ISSN 1759-1961.
310. **Ochi, H.** Revisiting the role of B cells in multiple sclerosis: Regulatory B cell function and defects in peripheral B cell tolerance. // *Clinical and Experimental Neuroimmunology*, 4, 2013, № 3, p. 251-252. ISSN 1759-1961.
311. **Okada, Y., H. Ochi, C. Fujii** et al. Signaling via toll-like receptor 4 and CD40 in B cells plays a regulatory role in the pathogenesis of multiple sclerosis through

- interleukin-10 production. // *Journal of Autoimmunity*, 88, 2018, p. 103-113. ISSN 0896-8411.
312. **Oldham, R.J., K.L.S. Cleary, M.S. Cragg.** CD20 and its antibodies: Past, present, and future. // *Forum on Immunopathological Diseases and Therapeutics*, 5, 2014, № 1-2, p. 7-23. ISSN 2151-8017.
  313. **Olsson, T., F. Piehl.** The Immunobiology of Multiple Sclerosis. – In: *Encyclopedia of Immunobiology*, 5, 2016, p. 180-191. ISBN 9780080921525.
  314. **Önder, H.** Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis. // *Türk Noroloji Dergisi*, 25, 2019, № 2, p. 105-106. ISSN 1301-062X.
  315. **Ozakbas, S., B.P. Cinar, T. Kahraman et al.** The 20-year history: Change of multiple sclerosis patient profile over 20 years. // *Multiple Sclerosis and Related Disorders*, 33, 2019, p. 1-4. ISSN 2211-0348.
  316. **Palavra, F.** Monoclonal antibodies for multiple sclerosis treatment = Anticorpos Monoclonais para Tratamento da Esclerose Múltipla. // *Acta Medica Portuguesa*, 28, 2015, № 5, p. 640-651. ISSN 08703-99X.
  317. **Palmer, A.M.** New and emerging immune-targeted drugs for the treatment of multiple sclerosis. // *British Journal of Clinical Pharmacology*, 78, 2014, № 1, p. 33-43. ISSN 0306-5251.
  318. **Palmer, A.M.** Pharmacotherapeutic options for the treatment of Multiple sclerosis. // *Clinical Medicine Insights: Therapeutics*, 4, 2012, p. 145-168. ISSN 1179-559X.
  319. **Parnell, G.P., P.N. Gatt, M. Krupa et al.** The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. // *Clinical Immunology*, 151, 2014, № 1, p. 16-24. ISSN 1521-6616.
  320. **Patel, S.Y., J. Carbone, S. Jolles.** The expanding field of secondary antibody deficiency: Causes, diagnosis, and management. // *Frontiers in Immunology*, 10, 2019, art. no. 33. ISSN 1664-3224.
  321. **Pawate, S., F. Bagnato.** Newer agents in the treatment of multiple sclerosis. // *Neurologist*, 19, № 2015, № 4, p. 104-117. ISSN 1074-7931.
  322. **Payandeh, Z., A.A. Bahrami, R. Hoseinpoor et al.** The applications of anti-CD20 antibodies to treat various B cells disorders. // *Biomedicine and Pharmacotherapy*, 109, 2019, p. 2415-2426. ISSN 0753-3322.

323. **Pelletier, J.** Multiple sclerosis: Treatments of future = [Sclérose en plaques : les traitements d'avenir. // *Pratique Neurologique - FMC*, 3, 2012, № 2, p. 101-105. ISSN 1878-7762.
324. **Perumal, J., O. Khan.** Emerging disease-modifying therapies in multiple sclerosis. // *Current Treatment Options in Neurology*, 14, 2012, № 3, p. 256-263. ISSN 1092-8480.
325. **Pfeuffer, S., T. Ruck, C. Kleinschnitz et al.** Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010–2015. // *Expert Review of Neurotherapeutics*, 16, 2016, № 6, p. 689-700. ISSN 1473-7175.
326. **Piancone, F., M. Saresella, I. Marventano et al.** B lymphocytes in multiple sclerosis: Bregs and BTLA/CD272 expressing-CD19+ lymphocytes modulate disease severity. // *Scientific Reports*, 6, 2016, art. no. 29699. ISSN 2045-2322.
327. **Piehl, F.** A changing treatment landscape for multiple sclerosis: Challenges and opportunities. // *Journal of Internal Medicine*, 275, 2014, № 4, p. 364-381. ISSN 0954-6820.
328. **Piehl, F., J. Hillert.** Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes. // *Multiple Sclerosis Journal*, 24, 2018, № 9, p. 1157-1159. ISSN 1352-4585.
329. **Pikor, N., J.L. Gommerman.** B cells in MS: Why, where and how? // *Multiple Sclerosis and Related Disorders*, 1, 2012, № 3, p. 123-130. ISSN 2211-0348.
330. **Pires, L.R., F. Marques, J.C. Sousa et al.** Nano- and micro-based systems for immunotolerance induction in multiple sclerosis. // *Human Vaccines and Immunotherapeutics*, 12, 2016, № 7, p. 1886-1890. ISSN 2164-5515.
331. **Pitřha, J.** Treatment targeted for B lymphocytes – significant progress in the treatment of multiple sclerosis = Léčba cílená na B lymfocyty – významný pokrok v léčbě roztroušené sklerózy. // *Ceska a Slovenska Neurologie a Neurochirurgie*, 81, 2018, № 4, p. 395-402. ISSN 1210-7859.
332. **Podkowa, A., R.J. Miller, R. Motl et al.** Focused Ultrasound Treatment of Cervical Lymph Nodes in Rats with EAE: A Pilot Study. // *Ultrasound in Medicine and Biology*, 42, 2016, № 12, p. 2957-2964. ISSN 0301-5629.
333. **Pröbstel, A.-K., N.S. R. Sanderson, T. Derfuss.** B cells and autoantibodies in multiple sclerosis. // *International Journal of Molecular Sciences*, 16, 2015, № 7, p. 16576-16592. ISSN 1661-6596.
334. **Prockl, V., F.T. Nickel, K.S. Utz et al.** Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients. // *Journal of the Neurological Sciences*, 415, 2020, art. no. 116973. ISSN 0022-510X.

335. **Quinn, J.L., G. Kumar, A. Agasing** et al. Role of TFH cells in promoting T Helper 17-induced neuroinflammation. // *Frontiers in Immunology*, 9, 2018, art. no. 382. ISSN 1664-3224.
336. **Quinn, J.L., R.C. Axtell**. Emerging role of follicular T helper cells in multiple sclerosis and experimental autoimmune encephalomyelitis. // *International Journal of Molecular Sciences*, 19, 2018, № 10, art. no. 3233. ISSN 1661-6596.
337. **Radick, L., S.R. Mehr**. The latest innovations in the drug pipeline for multiple sclerosis. // *American Health and Drug Benefits*, 8, 2015, № 8, p. 448-453. ISSN 1942-2962.
338. **Rahmanzadeh, R., M.S. Weber, W. Brück** et al. B cells in multiple sclerosis therapy - A comprehensive review. // *Acta Neurologica Scandinavica*, 137, 2018, № 6, p. 544-556. ISSN 0001-6314.
339. **Rahmanzadeh, R., W. Brück, A. Minagar** et al. Multiple sclerosis pathogenesis: Missing pieces of an old puzzle. // *Reviews in the Neurosciences*, 30, 2019, № 1, p. 67-83. ISSN 0334-1763.
340. **Rajić Džolić, Z., S. Šipicki, I. Perković**. Therapy of multiple sclerosis - Of conventional therapy and monoclonal antibodies to cannabinoids=Terapija multiple skleroze - Od konvencionalnih lijekova i monoklonskih protutijela do kanabinoida. // *Farmaceutski Glasnik*, 73, 2017, № 3, p. 177-190. ISSN 0014-8202.
341. **Ramaglia, V., O. Rojas, I. Naouar** et al. The Ins and Outs of Central Nervous System Inflammation mdash Lessons Learned from Multiple Sclerosis. // *Annual Review of Immunology*, 39, 2021, p. 199-226. ISSN 0732-0582.
342. **Ransohoff, R.M., D.A. Hafler, C.F. Lucchinetti**. Multiple sclerosis - A quiet revolution. // *Nature Reviews Neurology*, 11, 2015, № 3, p. 134-142. ISSN 1759-4758.
343. **Rasenack, M., T. Derfuss**. Disease activity return after natalizumab cessation in multiple sclerosis. // *Expert Review of Neurotherapeutics*, 16, 2016, № 5, p. 587-594. ISSN 1473-7175.
344. **Ratzer, R., H.B. Söndergaard, J.R. Christensen** et al. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. // *Multiple Sclerosis Journal*, 19, 2013, № 14, p. 1841-1848. ISSN 1352-4585.
345. **Reddy, V., D. Jayne, D. Close** et al. B-cell depletion in SLE: Clinical and trial experience with rituximab and ocrelizumab and implications for study design. // *Arthritis Research and Therapy*, 15, 2013, Suppl.1, art. no. S2. ISSN 1478-6354.



346. **Remick, A.K., M.L. Pershing, T.L. Papenfuss** et al. Immunopathology of the nervous system. // *Molecular and Integrative Toxicology*, 2017, p. 123-219. ISSN 2168-4219.
347. **Ribeill, Y.J.** Discovery of New Medicines. – In: *The Textbook of Pharmaceutical Medicine*, 2013, p. 1-31. ISBN 9780470659878.
348. **Rivas, J.R., S.J. Ireland, R. Chkheidze.** Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. // *Acta Neuropathologica*, 133, 2017, № 1, p. 43-60. ISSN 0001-6322.
349. **Roach, C.A., A.H. Cross.** Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis. // *Frontiers in Neurology*, 11, 2021 art. no. 595547. ISSN 1664-2295.
350. **Robinson, A.P., C.T. Harp, A. Noronha** et al. The experimental autoimmune encephalomyelitis (EAE) model of MS. utility for understanding disease pathophysiology and treatment. // *Handbook of Clinical Neurology*, 122, 2014, p. 173-189. ISSN 0072-9752.
351. **Rolf, L., A.-H. Muris, R. Hupperts** et al. Illuminating vitamin D effects on B cells - the multiple sclerosis perspective. // *Immunology*, 147, 2016, № 3, p. 275-284. ISSN 0019-2805.
352. **Roman, C., K. Menning.** Treatment and disease management of multiple sclerosis patients: A review for nurse practitioners. // *Journal of the American Association of Nurse Practitioners*, 29, 2017, № 10, p. 629-638. ISSN 2327-6886.
353. **Rommer, P.S., A. Dudesek, O. Stüve** et al. Monoclonal antibodies in treatment of multiple sclerosis. // *Clinical and Experimental Immunology*, 175, 2014, № 3, p. 373-384. ISSN 0009-9104.
354. **Rommer, P.S., R. Milo, M.H. Han** et al. Immunological aspects of approved MS therapeutics. // *Frontiers in Immunology*, 10, 2019, art. no. 1564. ISSN 1664-3224.
355. **Rommer, P.S., R. Patejdl, U.K. Zettl.** Monoclonal antibodies in the treatment of neuroimmunological diseases. // *Current Pharmaceutical Design*, 18, 2012, № 29, p. 4498-4507. ISSN 1381-6128.
356. **Roostaei, T., P.L. De Jager.** Epidemiology and Genetics. // *Current Clinical Neurology*, 2020, p. 71-87. ISSN 1559-0585.
357. **Rossmann, I.T., J.A. Cohen.** Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis? // *Expert Review of Clinical Immunology*, 12, 2016, № 5, p. 489-491. ISSN 1744-666X.

358. **Rounds, W.H., E.A. Salinas, T.B. Wilks et al.** MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. // *Gene*, 572, 2015, № 2, p. 191-197. ISSN 0378-1119.
359. **Rubin, S.J.S., M.S. Bloom, W.H. Robinson.** B cell checkpoints in autoimmune rheumatic diseases. // *Nature Reviews Rheumatology*, 15, 2019, № 5, p. 303-315. ISSN 1759-4790.
360. **Sacco, K.A., R.S. Abraham.** Consequences of B-cell-depleting therapy: Hypogammaglobulinemia and impaired B-cell reconstitution. // *Immunotherapy*, 10, 2018, № 8, p. 713-728. ISSN 1750-743X.
361. **Salhofer-Polanyi, S., F. Leutmezer.** Contemporary treatment options for relapsing-remitting multiple sclerosis. // *Drugs of Today*, 50, 2014, № 5, p. 365-383. ISSN 1699-3993.
362. **Salmen, A., R. Gold, A. Chan.** Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. // *Clinical and Experimental Immunology*, 176, 2014, № 2, p. 135-148. ISSN 0009-9104.
363. **Salzer, J., R. Svenningsson, P. Alpinget et al.** Rituximab in multiple sclerosis. // *Neurology*, 87, 2016, № 20, p. 2074-2081. ISSN 0028-3878.
364. **Samjoo, I.A., E. Worthington, A. Haltner et al.** The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. // *Current Medical Research and Opinion*, 36, 2020, № 7, p. 1145-1156. ISSN 0300-7995.
365. **Schaeffer, J., C. Cossetti, G. Mallucci et al.** Multiple Sclerosis. – In: *Neurobiology of Brain Disorders: Biological Basis of Neurological and Psychiatric Disorders*, 2015, p. 497-520. ISBN 9780123982803; 9780123982704.
366. **Schafflick, D., B.C. Kieseier, H. Wiendl et al.** Novel pathomechanisms in inflammatory neuropathies. // *Journal of Neuroinflammation*, 14, 2017, № 1, art. no. 232. ISSN 1742-2094.
367. **Schirmer, L., R. Srivastava, B. Hemmer.** To look for a needle in a haystack: The search for autoantibodies in multiple sclerosis. // *Multiple Sclerosis Journal*, 20, 2014, № 3, p. 271-279. ISSN 1352-4585.
368. **Schreiner, B., B. Becher.** Perspectives on cytokine-directed therapies in multiple sclerosis. // *Swiss Medical Weekly*, 145, 2015, art. no. w14199. ISSN 1424-7860.
369. **Schuh, E., K. Berer, M. Mulazzani et al.** Features of human CD3<sup>+</sup>CD20<sup>+</sup> T cells. // *Journal of Immunology*, 197, 2016, № 4, p. 1111-1117. ISSN 0022-1767.

370. **Scott, T.F., N. Bertha.** The impact of multiple sclerosis relapses on worsening over the long term; insights in the treatment era. // *Journal of the Neurological Sciences*, 413, 2020, art. no. 116773. ISSN 0022-510X.
371. **Scotto, R., A. Reia, A.R. Buonomo et al.** Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. // *Expert Opinion on Drug Safety*, 2021. ISSN 1474-0338.
372. **Seifert-Held, T.** Update: Treatment of multiple sclerosis - Oral therapies and new biologicals = Update - Behandlung der multiplen sklerose: Orale therapien und neue biologika. // *Journal fur Neurologie, Neurochirurgie und Psychiatrie*, 15, 2014, № 2, p. 76-80. ISSN 1608-1587.
373. **Sellebjerg, F., M. Blinkenberg, P.S. Sorensen.** Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. // *CNS Drugs*, 34, 2020, № 3, p. 269-280. ISSN 1172-7047.
374. **Sellebjerg, F., P.S. Sorensen.** Therapeutic interference with leukocyte recirculation in multiple sclerosis. // *European Journal of Neurology*, 22, 2015, № 3, p. 434-442. ISSN 1351-5101.
375. **Sellner, J., P.S. Rommer.** Multiple sclerosis and SARS-CoV-2 vaccination: Considerations for immune-depleting therapies. // *Vaccines*, 9, 2021, № 2, art. no. 99, p. 1-12. ISSN 2076-393X.
376. **Seraji-Bozorgzad, N., O. Khan, B.A.C. Cree et al.** Cerebral Gray Matter Atrophy Is Associated with the CSF IgG index in African American with Multiple Sclerosis. // *Journal of Neuroimaging*, 27, 2017, № 5, p. 476-480. ISSN 1051-2284.
377. **Sica, F., D. Centonze, F. Buttari.** Fingolimod Immune Effects Beyond Its Sequestration Ability. // *Neurology and Therapy*, 8, 2019, № 2, p. 231-240. ISSN 2193-8253.
378. **Siddiqui, M.K., I.S. Khurana, S. Budhia et al.** Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. // *Current Medical Research and Opinion*, 34, 2018, № 8, p. 1361-1371. ISSN 0300-7995.
379. **Singer, B.A.** Fingolimod for the treatment of relapsing multiple sclerosis. // *Expert Review of Neurotherapeutics*, 13, 2013, № 6, p. 589-602. ISSN 1473-7175.
380. **Singer, B.A.** Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies. // *Seminars in Neurology*, 36, 2016, № 2, p. 140-147. ISSN 0271-8235.

381. **Soelberg Sorensen, P.** Safety concerns and risk management of multiple sclerosis therapies. // *Acta Neurologica Scandinavica*, 136, 2017, № 3, p. 168-186. ISSN 0001-6314.
382. **Sola-Valls, N., M. Sepúlveda, Y. Blanco et al.** Current Role of Chemotherapy and Bone Marrow Transplantation in Multiple Sclerosis. // *Current Treatment Options in Neurology*, 17, 2015, № 1, p. 1-20. ISSN 1092-8480.
383. **Soldan, S.S., S. Jacobson.** Virus-induced demyelination: The case for virus(es) in multiple sclerosis. – In: *Neurotropic Viral Infections: Volume 2: Neurotropic Retroviruses, DNA Viruses, Immunity and Transmission*, 2016, p. 175-220. ISBN 9783319331898; 9783319331881.
384. **Soleimani, B., K. Murray, D. Hunt.** Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. // *Drug Safety*, 42, 2019, № 8, p. 941-956. ISSN 0114-5916.
385. **Sorensen, P.S.** New management algorithms in multiple sclerosis. // *Current Opinion in Neurology*, 27, 2014, № 3, p. 246-259. ISSN 1350-7540.
386. **Sorensen, P.S., M. Blinkenberg.** The potential role for ocrelizumab in the treatment of multiple sclerosis: Current evidence and future prospects. // *Therapeutic Advances in Neurological Disorders*, 9, 2016, № 1, p. 44-52. ISSN 1756-2856.
387. **Sorensen, P.S., S. Lisby, R. Grove et al.** Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study. // *Neurology*, 82, 2014, № 7, p. 573-581. ISSN 0028-3878.
388. **Sormani, M.P., P. Bruzzi.** MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. // *The Lancet Neurology*, 12, 2013, № 7, p. 669-676. ISSN 1474-4422.
389. **Sospedra, M.** B cells in multiple sclerosis. // *Current Opinion in Neurology*, 31, 2018, № 3, p. 256-262. ISSN 1350-7540.
390. **Spelman, T., T. Frisell, F. Piehl et al.** Comparative effectiveness of rituximab relative to IFN- $\beta$  or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. // *Multiple Sclerosis Journal*, 24, 2018, № 8, p. 1087-1095. ISSN 1352-4585.
391. **Stahnke, A.M., K.M. Holt.** Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis. // *Annals of Pharmacotherapy*, 52, 2018, № 5, p. 473-483. ISSN 1060-0280.
392. **Staun-Ram, E., A. Miller.** Effector and regulatory B cells in Multiple Sclerosis. // *Clinical Immunology*, 184, 2017, p. 11-25. ISSN 1521-6616.

393. **Steinman, L.** Immunology of relapse and remission in multiple sclerosis. // *Annual Review of Immunology*, 32, 2014, p. 257-281. ISSN 0732-0582.
394. **Steinman, L.** The road not taken: Antigen-specific therapy and neuroinflammatory disease. // *JAMA Neurology*, 70, 2013, № 9, p. 1100-1101. ISSN 2168-6149.
395. **Steinman, L., R.C. Axtell, D. Barbieri et al.** Piet Mondrian's trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011. // *Multiple Sclerosis Journal*, 19, 2013, № 1, p. 5-14. ISSN 1352-4585.
396. **Steinman, L., S.S. Zamvil.** Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica. // *Annals of Neurology*, 71, 2012, № 3, p. 287-288. ISSN 0364-5134.
397. **Stellmann, J.-P., K.H. Stürner, K.L. Young et al.** Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts - Is there a place for baseline-to-treatment studies in MS? // *PLoS ONE*, 10, 2015, № 2, art. no. e0116559. ISSN 1932-6203.
398. **Stepanov, A., Y. Lomakin, A. Gabibov et al.** Peptides against autoimmune neurodegeneration. // *Current Medicinal Chemistry*, 24, 2017, № 17, p. 1761-1771. ISSN 0929-8673.
399. **Steri, M., V. Orru, M.L. Idda et al.** Overexpression of the cytokine BAFF and autoimmunity risk. // *New England Journal of Medicine*, 376, 2017, № 17, p. 1615-1626. ISSN 0028-4793.
400. **Streicher, K., C.A. Morehouse, C.J. Groves et al.** The plasma cell signature in autoimmune disease. // *Arthritis and Rheumatology*, 66, 2014, № 1, p. 173-184. ISSN 2326-5191.
401. **Stüve, O., C. Warnke, K. Deason et al.** CD19 as a molecular target in CNS autoimmunity. // *Acta Neuropathologica*, 128, 2014, № 2, p. 177-190. ISSN 0001-6322.
402. **Syed, Y.Y.** Ocrelizumab: A Review in Multiple Sclerosis. // *CNS Drugs*, 32, 2018, № 9, p. 883-890. ISSN 1172-7047.
403. **Tanasescu, R., C. Ionete, I.-J. Chou et al.** Advances in the treatment of relapsing - Remitting multiple sclerosis. // *Biomedical Journal*, 37, 2014, № 2, p. 41-49. ISSN 2319-4170.
404. **Tas, S.W., D.L. Baeten.** Recent advances in the treatment of immune-mediated inflammatory diseases. // *Methods in Molecular Biology*, 1371, 2016, p. 143-155. ISSN 1064-3745.

405. **Tenembaum, S.N.** Ethical challenges in paediatric clinical trials in multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 5, 2012, № 3, p. 139-146. ISSN 1756-2856.
406. **Tramacere, I., C. Del Giovane, G. Salanti et al.** Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis. // *Cochrane Database of Systematic Reviews*, 2015, 2015, № 9, art. no. CD011381. ISSN 1469-493X.
407. **Tramacere, I., M.D. Benedetti, M. Capobussi et al.** Adverse effects of immunotherapies for multiple sclerosis: A network meta-analysis. // *Cochrane Database of Systematic Reviews*, 2016, № 5, art. no. CD012186. ISSN 1469-493X.
408. **Traub, J., S. Traffehn, J. Ochs et al.** Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis. // *Brain Pathology*, 29, 2019, № 5, p. 640-657. ISSN 1015-6305.
409. **Triantis, C., K. Chatzimichail, P. Theodosios-Nobelos et al.** New pharmaceutical approaches to the treatment of multiple sclerosis. // *Archives of Hellenic Medicine*, 37, 2020, № 5, p. 602-611. ISSN 1105-3992.
410. **Trojano, M., C. Avolio.** Environmental Factors and Their Regulation of Immunity in Multiple Sclerosis. – In: *Translational Neuroimmunology in Multiple Sclerosis: From Disease Mechanisms to Clinical Applications*, 2016, p. 100-111. ISBN: 9780128020074; 9780128019146.
411. **Varrin-Doyer, M., K.L. Pekarek, C.M. Spencer et al.** Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. // *Neurology: Neuroimmunology and NeuroInflammation*, 3, 2016, № 5, art. no. e272. ISSN 2332-7812.
412. **Viala, M., M. Vinches, M. Alexandre et al.** Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: Tested doses and rationale for dose selection. // *British Journal of Cancer*, 118, 2018, № 5, p. 679-697. ISSN 0007-0920.
413. **Vidal-Jordana, A.** New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis. // *Neurologic Clinics*, 36, 2018, № 1, p. 173-183. ISSN 0733-8619.
414. **Villarejo Galende, A., E. Gómez Ontañón.** Quo vadis, neuropharmacology? = ¿Quo vadis, neurofarmacología? // *Kranion*, 9, 2012, № 1, p. 26-30. ISSN 1577-8843.
415. **Visaria, J., N. Thomas, T. Gu et al.** Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice. // *Clinical Therapeutics*, 40, 2018, № 6, p. 926-939. ISSN 0149-2918.

416. **Vital, E.M., J. Kay, P. Emery.** Rituximab biosimilars. // *Expert Opinion on Biological Therapy*, 13, 2013, № 7, p. 1049-1062. ISSN 1471-2598.
417. **Vital, E.M., S. Dass, P. Emery.** B-cell depletion. – In: *Rheumatology: Sixth Edition*, 1-2, 2015, p. 472-478. ISBN 9780323325851; 9780323091381.
418. **Voge, N.V., E. Alvarez.** Monoclonal antibodies in multiple sclerosis: Present and future. // *Biomedicines*, 7, 2019, № 1, art. no. 20. ISSN 2227-9059.
419. **Von Büdingen, H.-C., A. Palanichamy, K. Lehmann-Horn.** et al. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. // *European Neurology*, 73, 2015, № 3/4, p. 238-246. ISSN 0014-3022.
420. **Von Essen, M.R., C. Ammitzbøll, R.H.** et al. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. // *Brain*, 142, 2019, № 1, p. 120-132. ISSN 0006-8950.
421. **von Kutzleben, S., G. Pryce, G. Giovannoni, D. Baker.** Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immunetolerance promoting CD8 t-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. // *Immunology*, 150, 2017, № 4, p. 444-455. ISSN 0019-2805.
422. **Voo, V.T.F., T. O'Brien, H. Butzkueven** et al. The role of vitamin D and P2X7R in multiple sclerosis. // *Journal of Neuroimmunology*, 330, 2019, p. 159-169. ISSN 0165-5728.
423. **Wang, A., O. Rojas, D. Lee** et al. Regulation of neuroinflammation by B cells and plasma cells. // *Immunological Reviews*, 299, 2021, № 1, p. 45-60. ISSN 0105-2896.
424. **Ward, P., M. Bodmer.** Antibodies in Phase III Studies for Immunological Disorders. – In: *Handbook of Therapeutic Antibodies: Second Edition*, 2-4, 2014, p. 851-926. ISBN 9783527682423; 9783527329373.
425. **Warnke, C., B.C. Kieseier, H.-P. Hartung.** Biotherapeutics for the treatment of multiple sclerosis: Hopes and hazards. // *Journal of Neural Transmission*, 120, 2013, Suppl. 1, p. S55-S60. ISSN 0300-9564.
426. **Weber, M.S.** Is intrathecal anti-CD20 an option to target compartmentalized CNS inflammation in progressive MS? // *Neurology: Neuroimmunology and NeuroInflammation*, 2, 2015, № 2, p. e84. ISSN 2332-7812.
427. **Weber, M.S., T. Menge, K. Lehmann-Horn** et al. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. // *Current Pharmaceutical Design*, 18, 2012, № 2, p. 209-219. ISSN 1381-6128.

428. **Weinstock-Guttman, B.** An update on new and emerging therapies for relapsing-remitting multiple sclerosis. // *American Journal of Managed Care*, 1, 2013, № 9, Suppl. 17, p. S343-S354. ISSN 1088-0224.
429. **Weinstock-Guttman, B., D. Horakova, R. Zivadinov et al.** Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. // *Journal of Neuroimmunology*, 263, 2013, № 1-2, p. 121-127. ISSN 0165-5728.
430. **Westerlind, H., L. Stawiarz, K. Fink et al.** A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. // *Multiple Sclerosis*, 22, 2016, № 8, p. 1071-1079. ISSN 1352-4585.
431. **Wiese, M.D., V. Suppiah, C. O'Doherty.** Metabolic and safety issues for multiple sclerosis pharmacotherapy- opportunities for personalised medicine. // *Expert Opinion on Drug Metabolism and Toxicology*, 10, 2014, № 8, p. 1145-1159. ISSN 1742-5255.
432. **Wilbanks, B., L.J. Maher III, M. Rodriguez.** Glial cells as therapeutic targets in progressive multiple sclerosis. // *Expert Review of Neurotherapeutics*, 19, 2019, № 6, p. 481-494. ISSN 1473-7175.
433. **Wilbanks, J.** Disease-modifying therapies for multiple sclerosis: Focus on future direction. // *Formulary*, 47, 2012, № 11, p. 392-393. ISSN 1082-801X.
434. **Wilson, H.L.** B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms. // *Biologics: Targets and Therapy*, 6, 2012, p. 117-123. ISSN 1177-5475.
435. **Winger, R.C., S.S. Zamvil.** Antibodies in multiple sclerosis oligoclonal bands target debris. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 113, 2016, № 28, p. 7696-7698. ISSN 0027-8424.
436. **Wingerchuk, D.M., J.L. Carter.** Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. // *Mayo Clinic Proceedings*, 89, 2014, № 2, p. 225-240. ISSN 0025-6196.
437. **Winkelmann, A., M. Löbermann, E.C., Reisinger et al.** Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs = Infektiologische Risiken in der Multiple-Sklerose-Therapie durch infundierbare Immuntherapeutika. // *Nervenarzt*, 86, 2015, № 8, p. 971-977. ISSN 0028-2804.
438. **Winkelmann, A., M. Loebermann, E.C. Reisinger et al.** Disease-modifying therapies and infectious risks in multiple sclerosis. // *Nature Reviews Neurology*, 12, 2016, № 4, p. 217-233. ISSN 1759-4758.



439. **Wootla, B., J.O. Watzlawik, N. Stavropoulos et al.** Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. // *Expert Opinion on Biological Therapy*, 16, 2016, № 6, p. 827-839. ISSN 1471-2598.
440. **Xie, Q., X. Li, J. Sun et al.** A meta-analysis to determine the efficacy and tolerability of anti-B-cell monoclonal antibodies in multiple sclerosis. // *Experimental and Therapeutic Medicine*, 13, 2017, № 6, p. 3061-3066. ISSN 1792-0981.
441. **Xu, X., S. Chi, Q. Wang et al.** Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis. // *Multiple Sclerosis and Related Disorders*, 25, 2018, p. 322-328. ISSN 2211-0348.
442. **Yong, H., G. Chartier, J. Quandt.** Modulating inflammation and neuroprotection in multiple sclerosis. // *Journal of Neuroscience Research*, 96, 2018, № 6, p. 927-950. ISSN 0360-4012.
443. **Zecca, C., F. Bovis, G. Novi et al.** Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience. // *Multiple Sclerosis Journal*, 26, 2020, № 12, p. 1519-1531. ISSN 1352-4585.
444. **Zhong, M., A. van der Walt, M.P. Campagna et al.** The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. // *Neurotherapeutics*, 17, 2020, № 4, p. 1768-1784. ISSN 1933-7213.
445. **Zouali, M.** DNA methylation signatures of autoimmune diseases in human B lymphocytes. // *Clinical Immunology*, 222, 2021, art. no. 108622. ISSN 1521-6616.

## **2012**

Petrova D., D. Maslarov, I. Angelov, D. Zekin. Analysis of therapeutic efficacy of Citicolone in patients with vertigo of central origin and vascular aetiology. // *American Journal of Neuroprotection and Neuroregeneration*, 1, 2012, № 4, p. 1-8. ISSN 1947-296X.

### **Cited by:**

446. **Martines, F., P. Salvago, F. Dispenza et al.** Treatment with a new nutraceutical compound on patients suffering from balance disorders: Dizziness handicap inventory scores. // *Acta Medica Mediterranea*, 35, 2019, p. 2029-2034. ISSN 0393-6384.  
Достъпно на: <https://iris.unipa.it/retrieve/handle/10447/367274.14/734774/pdf.pdf>
447. **Nemkova, S.A., D. Semenov, E. Petrova et al.** Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan

- (citicoline). // *Zhurnal nevrologii i psikiatrii imeni S.S. Korsakova*, 118, 2018, № 12, p. 11-18. ISSN 1997-7298. Доступно на: <https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikiatrii-im-s-s-korsakova/2018/12/downloads/ru/1199772982018121011>
448. **Nemkova, S.A., D. Semenov, E. Petrova** et al. Current treatment options for autonomic, cognitive and emotional disorders in patients with asthenic syndrome treated with recognan (citicoline). // *Zhurnal nevrologii i psikiatrii imeni S.S. Korsakova*, 119, 2019, № 7, p. 27-34. ISSN 1997-7298. Доступно на: <https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikiatrii-im-s-s-korsakova/2019/7/downloads/ru/1199772982019071027>
449. **Putilina, M.** A personalized selection of choline precursors in evidence - based medicine. // *Zhurnal nevrologii i psikiatrii imeni S.S. Korsakova*, 120, 2020, № 6, p. 144-151. ISSN 1997-7298.
450. **Secades, J.J.** Citicoline: pharmacological and clinical review, 2016 update. // *Revista de Neurologia*, 63, 2017, 73 p. ISSN 0210-0010. Доступно на: [https://www.researchgate.net/profile/Julio-Secades/publication/331117491\\_Citicolina\\_revision\\_farmacologica\\_y\\_clinica\\_actualizacion\\_2010/links/58fe02f2aca2728fa70fc7e4/Citicolina-revision-farmacologica-y-clinica-actualizacion-2010.pdf](https://www.researchgate.net/profile/Julio-Secades/publication/331117491_Citicolina_revision_farmacologica_y_clinica_actualizacion_2010/links/58fe02f2aca2728fa70fc7e4/Citicolina-revision-farmacologica-y-clinica-actualizacion-2010.pdf)
451. **Vakhnina, N.N., V. Zakharov.** Disturbances of gait and postural stability in chronic cerebral ischemia. // *Zhurnal nevrologii i psikiatrii imeni S.S. Korsakova*, 117, 2017, № 1, p. 78-84 . ISSN 1997-7298. Доступно на: <https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikiatrii-im-s-s-korsakova/2017/1/downloads/ru/1199772982016011078>
452. **Дубров, С.О., А.Ю. Лиманська, Ю.В. Давидова.** Головокружение и беременность: оптимизация лечения. // *Перинатология и педиатрия*, 72, 2017, № 4, с. 37-40. ISSN 2412-4613. Доступно на: <http://pip.med-expert.com.ua/article/view/PP.2017.72.37>
453. **Шавловская, О. А.** Цитиколин: новые терапевтические возможности. // *Лечащий врач*, 2014, № 10. ISSN 1560-5175. Доступно на: <https://www.lvrach.ru/2014/10/15436066>

## **2013**

Khan, O., P. Rieckmann, A. Boyko, K. Selmaj, R. Zivadinov, for the GALA Study Group. Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. **D. Maslarov.** // *Annals of Neurology*, 2013, 10.1002/ana.23938, p. 705-713.

**Cited by:**

454. **Abolfazli, R., S. Pournourmohammadi, A. Shamshiri** et al. Tolerability and Safety Profile of a New Brand-Generic Product of Glatiramer Acetate in Iranian Patients with Relapsing-Remitting Multiple Sclerosis: An Observational Cohort Study. // *Current Therapeutic Research - Clinical and Experimental*, 88, 2018, p. 47-51. ISSN 0011-393X.
455. **Alroughani, R., J. Inshasi, A. Al-Asmi** et al. Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. // *Postgraduate Medicine*, 132, 2020, № 4, p. 368-376. ISSN 0032-5481.
456. **Altmann, P., F. Leutmezer.** Therapy options of multiple sclerosis=Aktuelle Therapiemöglichkeiten der Multiplen Sklerose. // *Journal für Neurologie, Neurochirurgie und Psychiatrie*, 19, 2018, № 1, p. 3-13. ISSN 1608-1587.
457. **Arends, R.J., D. Wang, M. Buurman** et al. Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate. // *Pharmazie*, 74, 2019, № 8, p. 449-461. ISSN 0031-7144.
458. **Asendorf, T., R. Henderson, H. Schmidli** et al. Modelling and sample size reestimation for longitudinal count data with incomplete follow up. // *Statistical Methods in Medical Research*, 2019, 28 № 1, p. 117-133. ISSN 0962-2802.
459. **Auricchio, F., C. Scavone, D. Cimmaruta** et al. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. // *Expert Opinion on Drug Safety*, 16, 2017, № 12, p. 1359-1371. ISSN 1474-0338.
460. **Ayrignac, X., P.A. Bilodeau, A. Prat** et al. Assessing the risk of multiple sclerosis disease-modifying therapies. *Expert Review of Neurotherapeutics*, 19, 2019, № 7, p. 695-706. ISSN 1473-7175.
461. **Bašić Kes, V., M.J. Jurašić, I. Zavoreo** et al. Update on guidelines for pharmacological treatment of multiple sclerosis by the croatian society for neurovascular disorders of the Croatian medical association and Croatian society of neuroimmunology and neurogenetics [Osuvmernjene smjernice za farmakološko liječenje oboljelih od multiple skleroze hrvatskog društva za neurovaskularne poremećaje Hrvatskog liječničkog zbora I hrvatskog društva za neuroimunologiju i neurogenetiku]. // *Acta Medica Croatica*, 72, 2018, № 3, p. 431-445. ISSN 1330-0164.
462. **Bell, C., J. Anderson, T. Ganguly** et al. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis. // *Journal of Pharmacy Practice*, 31, 2018, № 5, p. 481-488. ISSN 0897-1900.

463. **Berger, T.** Early intervention in multiple sclerosis: how can we maximise patient prospects? // *Expert Review of Clinical Immunology*, 13, 2017, № 7, p. 649-651. ISSN 1744-666X.
464. **Biotti, D., J. Ciro.** First-line therapy in relapsing remitting multiple sclerosis. // *Revue Neurologique*, 174, 2018, № 6, p. 419-428. ISSN 0035-3787.
465. **Borchard, G., D.J.A.Crommelin.** Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes. // *Expert Opinion on Drug Delivery*, 15, 2018, № 3, p. 247-259. ISSN 17425247.
466. **Boster, A.L., C.C. Ford, O. Neudorfer et al.** Glatiramer acetate: Long-term safety and efficacy in relapsing-remitting multiple sclerosis. // *Expert Review of Neurotherapeutics*, 15, 2015, № 6, p. 575-586. ISSN 1473-7175.
467. **Bourdette, D., D. Hartung.** Equivalence of glatiramer acetate generics with branded glatiramer acetate in efficacy and cost for the treatment of multiple sclerosis. // *JAMA Neurology*, 72, 2015, № 12, p. 1411-1413. ISSN 2168-6149.
468. **Boyko, A.N.** An additional analysis of the efficacy and safety of therapy in the russian population of patients with multiple sclerosis participated in phase III international multicenter clinical trials: Results of alemtuzumab study. // *Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova*, 119, 2019, № 10, p. 147-152. ISSN 1997-7298.
469. **Boyko, A.N., N.N. Spirin, Ya.V. Vlasov et al.** Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis [Современные требования к исследованиям лекарственных средств для патогенетического лечения рассеянного склероза]. // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 11, 2019, № 4, p. 166-171. ISSN 2074-2711.
470. **Broadley, S.A., M.H. Barnett, M. Boggild et al.** A new era in the treatment of multiple sclerosis. // *Medical Journal of Australia*, 203, 2015, № 3, p. 139-141. ISSN 0025-729X.
471. **Broadley, S.A., M.H. Barnett, M. Boggild et al.** Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. // *Journal of Clinical Neuroscience*, 21, 2014, № 11, p. 1835-1846. ISSN 0967-5868.
472. **Caporro, M., G. Disanto, C. Gobbi et al.** Two decades of subcutaneous glatiramer acetate injection: Current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. // *Patient Preference and Adherence*, 8, 2014, p. 1123-1134. ISSN 1177-889X.

473. **Casadevall, N., O. Flossmann, D. Hunt.** Evolution of biological agents: How established drugs can become less safe. // *BMJ (Online)*, 357, 2017, art. no. j1707. ISSN 0959-8146.
474. **Casanova, B., L. Lacruz, M.L. Villar et al.** Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients. // *Neurological Sciences*, 39, 2018, № 8, p. 1423-1430. ISSN 1590-1874.
475. **Chisari, C.G., S. Toscano, E. D'Amico et al.** An update on the safety of treating relapsing-remitting multiple sclerosis. // *Expert Opinion on Drug Safety*, 18, 2019, № 10, p. 925-948. ISSN 1474-0338.
476. **Comi, G., F. Nicoletti, P.L. Canonico et al.** Letter to the Editor Regarding: A Comprehensive Review on Copemy. // *Neurology and Therapy*, 7, 2018, № 2, p. 385-390. ISSN 2193-8253.
477. **Corboy, J.R.** Changing Paradigms in MS therapies. // *Journal of Managed Care Medicine*, 17, 2014, № 1, p. 16-21. ISSN 1094-1525.
478. **Cortese, I., A. Nath.** Immunomodulatory therapy for multiple sclerosis. – In: *Neuroimmune Pharmacology*, 2016, p. 713-736. ISBN 9783319440224; 9783319440200.
479. **Cree, B.A.C.** Multiple Sclerosis Therapeutic Update. // *The Neurohospitalist*, 4, 2014, № 2, p. 63-65. ISSN 1941-8744.
480. **Cross, A.H., R.T. Naismith.** Established and novel disease-modifying treatments in multiple sclerosis. // *Journal of Internal Medicine*, 275, 2014, № 4, p. 350-363. ISSN 0954-6820.
481. **Cutter, G., A. Veneziano, A. Grinspan et al.** Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD. // *Multiple Sclerosis and Related Disorders*, 40, 2020, art. no. 101957. ISSN 2211-0348.
482. **D'Amico, E., A. Zanghi, F. Patti.** Personalized therapy in multiple sclerosis: state of art and future perspectives. // *Expert Review of Precision Medicine and Drug Development*, 1, 2016, № 4, p. 353-360. ISSN 2380-8993.
483. **Deleu, D., B. Canibano, B. Mesraoua et al.** Management of relapsing-remitting multiple sclerosis in Qatar: an expert consensus. // *Current Medical Research and Opinion*, 36, 2020, № 2, p. 251-260. ISSN 0300-7995.
484. **Deleu, D., B. Mesraoua, H. El Khider et al.** Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective

- from Qatar. // *Current Medical Research and Opinion*, 33, 2017, № 3, p. 439-458. ISSN 0300-7995.
485. **Demircan, C., N. Akdogan, L. Elmas.** Nicolau Syndrome Secondary to Subcutaneous Glatiramer Acetate Injection. // *International Journal of Lower Extremity Wounds*, 2020. ISSN 1534-7346.
  486. **Du, J., W. Lv, S. Yang** et al. Glatiramer acetate protects against oxygen-glucose deprivation/reperfusion-induced injury by inhibiting Egr-1 in H9c2 cells. // *Molecular Immunology*, 2020, № 120, p. 61-66. ISSN 0161-5890.
  487. **Eckstein, C., M.T.Bhatti.** Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. // *Survey of Ophthalmology*, 61, 2016, № 3, p. 318-332. ISSN 0039-6257.
  488. **English, C., J.J.Aloi.** New FDA-approved disease-modifying therapies for multiple sclerosis. // *Clinical Therapeutics*, 37, 2015, № 4, p. 691-715. ISSN 0149-2918.
  489. **Farber, R.S., I.K. Sand.** Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 8, 2015, № 5, p. 212-232. ISSN 1756-2856.
  490. **Fernández, Ó., A. Rodríguez-Antigüedad, J. Olascoaga** et al. Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting = Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS. // *Revista de Neurologia*, 62, 2016, № 12, p. 559-569. ISSN 0210-0010.
  491. **Findling, O., J. Sellner.** Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors? // *Drug Discovery Today*, 26, 2021, № 2, p. 416-428. ISSN 1359-6446.
  492. **Finkelsztejn, A., A. Finkelsztejn.** Multiple sclerosis: Overview of Disease-Modifying agents. // *Perspectives in Medicinal Chemistry*, 6, 2014, p. 65-72. ISSN 1177-391X.
  493. **Fogarty, E., S. Schmitz, N. Tubridy** et al. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. // *Multiple Sclerosis and Related Disorders*, 9, 2016, p. 23-30. ISSN 2211-0348.
  494. **Grossman, I., V. Knappertz, D. Laifenfeld** et al. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. // *Progress in Neurobiology*, 152, 2017, p. 114-130. ISSN 0301-0082.

495. **Habibi, M., H.M. Kuttab.** Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems. // *American Journal of Health-System Pharmacy*, 73, 2016, № 11, p. 811-819. ISSN 1079-2082.
496. **Harel, A., I. Katz-San.** Treatment strategies in multiple sclerosis. – In: *Handbook of Relapsing-Remitting Multiple Sclerosis*, 2017, p. 67-97. ISBN 9783319406282; 978331940626.
497. **Hegen, H., M. Auer, F. Deisenhammer.** Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients. // *Drugs*, 76, 2016, № 15, p. 1421-1445. ISSN 0012-6667.
498. **Hernandez, L., S. Guo, E. Kinter.** Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. // *Journal of Medical Economics*, 19, 2016, № 7, p. 684-695. ISSN 1369-6998.
499. **Hua, L.H., H. Harris, D. Conway et al.** Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy. // *Journal of Neurology*, 267, 2020, № 8, p. 2214-2220. ISSN 0340-5354.
500. **Hua, L.H., J.A.Cohen.** Considerations in the development of generic disease therapies for multiple sclerosis. // *Neurology: Clinical Practice*, 6, 2016, № 4, p. 369-376. ISSN 2163-0402.
501. **Ingwersen, J., O. Aktas, H.P. Hartung.** Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. // *Neurotherapeutics*, 13, 2016, № 1, p. 47-57. ISSN 1933-7213.
502. **Inshasi, J.S., A. Almadani, S. Al Fahad et al.** High-efficacy therapies for relapsing-remitting multiple sclerosis: Implications for adherence. An expert opinion from the United Arab Emirates. // *Neurodegenerative Disease Management*, 10, 2020, № 4, p. 257-266. ISSN 1758-2024.
503. **Izquierdo, A.Y., M.J.S. Palomo, I.S. Herán et al.** Treatment of multiple sclerosis = Tratamiento de la esclerosis múltiple. // *Medicine (Spain)*, 12, 2019, № 78, p. 4598-4605. ISSN 0304-5412.
504. **Jelinek, G.A., T.J. Weiland, E.J. Hadgkiss et al.** Medication use in a large international sample of people with multiple sclerosis: Associations with quality of life, relapse rate and disability. // *Neurological Research*, 37, 2015, № 8, p. 662-673. ISSN 0161-6412.
505. **Jha, L.K., S. Mukherjee.** Drugs that act on the immune system: Immunosuppressive and immunostimulatory drugs. // *Side Effects of Drugs Annual*, 36, 2014, p. 591-602. ISSN 0378-6080.

506. **Kalincik, T., V. Jokubaitis, G. Izquierdo** et al. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. // *Multiple Sclerosis*, 21, 2015, № 9, p. 1159-1171. ISSN 1352-4585.
507. **Karmon, Y., N. Gadoth.** Present drug therapy of demyelinating disorders. // *Current Drug Therapy*, 13, 2018, № 1, p. 25-42. ISSN 1574-8855.
508. **Kimbrough, D.J., S.D. Newsome.** Two cases of Nicolau syndrome associated with glatiramer acetate. // *International Journal of MS Care*, 19, 2017, № 3, p. 148-150. ISSN 1537-2073.
509. **Klineova, S., N. Mitiku, A.E. Miller.** Disease-modifying therapy for multiple sclerosis. // *Future Neurology*, 10, 2015, № 3, p. 253-279. ISSN 1479-6708.
510. **Kremer, I.E.H., M. Hiligsmann, J. Carlson** et al. Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. // *Medical Decision Making*, 40, 2020, № 8, p. 1003-1019. ISSN 0272-989X.
511. **La Mantia, L., C. Di Pietrantonj, M. Rovaris** et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. // *Cochrane Database of Systematic Reviews*, 2016, № 11, art. no. CD009333. ISSN 1469-493X.
512. **La Mantia, L., C. Di Pietrantonj, M. Rovaris** et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. // *Cochrane Database of Systematic Reviews*, 2014, № 7, art. no. CD009333. ISSN 1469-493X.
513. **Loleit, V., V. Biberacher, B. Hemmer.** Current and future therapies targeting the immune system in multiple sclerosis. // *Current Pharmaceutical Biotechnology*, 15, 2014, № 3, p. 276-296. ISSN 1389-2010.
514. **Mallucci, G., L. Peruzzotti-Jametti, J.D. Bernstock** et al. The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. // *Progress in Neurobiology*, 2015, 127/128, p. 1-22. ISSN 0301-0082.
515. **Marques, V.D., G.R. Dos Passos, M.F Mendes** et al. Brazilian consensus for the treatment of multiple sclerosis: Brazilian academy of neurology and brazilian committee on treatment and research in multiple sclerosis=Consenso Brasileiro para o tratamento da esclerose múltipla: Academia brasileira de neurologia e comitê brasileiro de tratamento e pesquisa em esclerose múltipla. // *Arquivos de Neuro-Psiquiatria*, 76, 2018, № 8, p. 539-554. ISSN 0004-282X.
516. **Márquez-Rebollo, C., L.Vergara-Carrasco, R. Díaz-Navarro** et al. Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing–



- Relapsing Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate. // *Advances in Therapy*, 31, 2014, № 8, p. 904-914. ISSN 0741-238X.
517. **Marziniak, M.** Multiple sclerosis - New therapeutic options and news about the long-standing drugs [Aktuelles zu Bewährtem und neue Optionen in der Therapie]. // *Nervenheilkunde*, 33, 2014, № 12, p. 905-910. ISSN 0722-1541.
  518. **Marziniak, M., S. Meuth.** Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis. // *Advances in Therapy*, 31, 2014, № 9, p. 915-931. ISSN 0741-238X.
  519. **Mäurer, M., K. Tiel-Wilck, E. Oehm et al.** Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 12, 2019. ISSN 1756-2856.
  520. **McKeage, K.** Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. // *CNS Drugs*, 29, 2015, № 5, p. 425-432. ISSN 1172-7047.
  521. **Melendez-Torres, G.J., P. Auguste, X. Armoiry et al.** Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: Systematic review and economic evaluation. // *Health Technology Assessment*, 21, 2017, № 52, 396 p. ISSN 1366-5278.
  522. **Messina, S., F. Patti.** The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. // *Expert Opinion on Drug Metabolism and Toxicology*, 9, 2013, № 10, p. 1349-1359. ISSN 1742-5255.
  523. **Michel, L., C. Larochelle, A. Prat.** Update on treatments in multiple sclerosis. // *Presse Medicale*, 44, 2015, № 4, p. e137-e151. ISSN 0755-4982.
  524. **Milo, R.** Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs. // *Expert Opinion on Pharmacotherapy*, 16, 2015, № 5, p. 659-673. ISSN 1465-6566.
  525. **Mindur, J.E., R.M. Valenzuela, S.K. Yadav et al.** IL-27: a potential biomarker for responders to glatiramer acetate therapy. // *Journal of Neuroimmunology*, 304, 2017, p. 21-28. ISSN 0165-5728.
  526. **Moss, B.P., J.A. Cohen.** The emergence of follow-on disease-modifying therapies for multiple sclerosis. // *Multiple Sclerosis Journal*, 25, 2019, № 12, p. 1560-1565. ISSN 1352-4585.
  527. **Mott, S.E., Z.G. Peña, R.I. Spain et al.** Nicolau syndrome and localized panniculitis: a report of dual diagnoses with an emphasis on morphea profunda-like changes following injection with glatiramer acetate. // *Journal of Cutaneous Pathology*, 43, 2016, № 11, p. 1056-1061. ISSN 0303-6987.

528. **Neuteboom, R., C. Wilbur, D. Van Pelt et al.** The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children. // *Seminars in Pediatric Neurology*, 24, 2017, № 3, p. 189-200. ISSN 10719-091.
529. **Nicholas, J.A., A.L. Boster, M.K.Racke.** Multiple sclerosis Five new things. // *Neurology: Clinical Practice*, 3, 2013, № 5, p. 404-412. ISSN 2163-0402.
530. **Oh, J., P.W. O'Connor.** Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis. // *Current Opinion in Neurology*, 28, 2015, № 3, p. 230-236. ISSN 1350-7540.
531. **Ontaneda, D., S. Cohn, R.J. Fox.** Risk stratification and mitigation in multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 3, 2014, № 5, p. 639-649. ISSN 2211-0348.
532. **Paul, F., K. Ruprecht.** Current immunotherapy of multiple sclerosis = Aktuelle Immuntherapie der Multiplen Sklerose. // *Nervenarzt*, 86, 2015, № 8, p. 1031-1044. ISSN 0028-2804.
533. **Piehl, F.** Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. // *Journal of Internal Medicine*, 2020. ISSN 0954-6820.
534. **Pitarokoili, K., R. Gold.** Review of current immunomodulatory treatment in multiple sclerosis. Summary and highlights of the new aspects in the treatment of multiple sclerosis after the approval of new oral and parenteral immunomodulators [Aktuelle übersicht zur immuntherapie der multiplen sklerose: Neue aspekte der therapie der multiplen sklerose nach der zulassung mehrerer oraler und parenteraler immuntherapien]. // *Psychopharmakotherapie*, 21, 2014, № 5, p. 181-190. ISSN 0944-6877.
535. **Prod'homme, T., S.S. Zamvil.** The evolving mechanisms of action of glatiramer acetate. // *Cold Spring Harbor Perspectives in Medicine*, 9, 2019, № 2, art. no. a029249, 16 p. ISSN 2157-1422.
536. **Puz, P., A. Lasek-Bal.** Safety and efficacy of fingolimod and natalizumab in multiple sclerosis after the failure of first-line therapy: Single center experience based on the treatment of forty-four patients. // *Medical Science Monitor*, 22, 2016, p. 277-4282. ISSN 1234-1010.
537. **Rocca, M.A., P. Preziosa, M. Filippi.** Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. // *Expert Review of Neurotherapeutics*, 19, 2019, № 9, p. 835-866. ISSN 1473-7175.
538. **Rocco, P., I. Eberini, U.M. Musazzi et al.** Glatiramer acetate: A complex drug beyond biologics. // *European Journal of Pharmaceutical Sciences*, 133, 2019, p. 8-14. ISSN 0928-0987.

539. **Rommer, P.S., R. Milo, M.H. Han** et al. Immunological aspects of approved MS therapeutics. // *Frontiers in Immunology*, 10, 2019, art. no. 1564. ISSN 1664-3224.
540. **Ross, C.J., F. Towfic, J. Shankar** et al. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. // *Genome Medicine*, 9, 2017, № 1, art. no. 50 . ISSN 1756-994X.
541. **Salhofer-Polanyi, S., F. Leutmezer**. Contemporary treatment options for relapsing-remitting multiple sclerosis. // *Drugs of Today*, 50, 2014, № 5, p. 365-383. ISSN 1699-3993.
542. **Salmen, A., A. Chan**. New therapeutic options in multiple sclerosis=Neue Therapieoptionen bei der Multiplen Sklerose. // *Fortschritte der Neurologie Psychiatrie*, 83, 2015, № 3, p. 174-186. ISSN 0720-4299.
543. **Samjoo, I.A., E. Worthington, C. Drudge** et al. Efficacy classification of modern therapies in multiple sclerosis. // *Journal of Comparative Effectiveness Research*, 10, 2021, № 6, p. 495-507. ISSN 2042-6305.
544. **Scott, L.J.** Glatiramer acetate: A review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. // *CNS Drugs*, 27, 2013, № 11, p. 971-988. ISSN 1172-7047.
545. **Scott, T.F., R. Su, K. Xiong** et al. Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate. // *Therapeutic Advances in Neurological Disorders*, 2021, № 14. ISSN 1756-2856.
546. **Sedal, L., I.B. Wilson, E.A.Mcdonald**. Current management of relapsing-remitting multiple sclerosis. // *Internal Medicine Journal*, 44 , 2014, № 10, p. 950-957. ISSN 1444-0903.
547. **Shmidt, T.E.** Glatiramer acetate is a first-line dual-Action drug for the treatment of relapsing-remitting multiple sclerosis. // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 8, 2016, № 4, p. 77-80. ISSN 2074-2711.
548. **Shvarts, G.Y., G.V. Ramenskaya** .Selected Issues on Regulation of the Circulation of Non-Biological Complex Drugs. // *Pharmaceutical Chemistry Journal*, 49, 2015, №4, p. 213-219. ISSN 0091-150X.
549. **Siddiqui, M.K., I.S. Khurana, S. Budhia** et al. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. // *Current Medical Research and Opinion*, 34, 2018 № 8, p. 1361-1371. ISSN 0300-7995.

550. **Singer, B.A.** Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies. // *Seminars in Neurology*, 36, 2016, № 2, p. 140-147. ISSN 0271-8235.
551. **Singh, S.K., H.C. Mahler, C. Hartman et al.** Are Injection Site Reactions in Monoclonal Antibody Therapies Caused by Polysorbate Excipient Degradants? // *Journal of Pharmaceutical Sciences*, 107, 2018, № 11, p. 2735-2741. ISSN 0022-3549.
552. **Song, Z., Y.M. Khaw, L.A Pacheco et al.** Induction of a higher-ordered architecture in glatiramer acetate improves its biological efficiency in an animal model of multiple sclerosis. // *Biomaterials Science*, 8, 2020, № 19, p. 5271-5281. ISSN 2047-4830.
553. **Stolyarov, I.D., A.M. Petrov, E.V.Ivashkova et al.** Drug trials in multiple sclerosis: Scientific, clinical and ethical aspects = [Исследования лекарственных средств при рассеянном склерозе: научные, клинические и этические аспекты. // *Nevrologicheskii Zhurnal*, 23, 2018, № 1, p. 16-21. ISSN 1560-9545.
554. **Tanasescu, R., C.S.Constantinescu.** Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. // *Expert Opinion on Drug Metabolism and Toxicology*, 10, 2014, № 4, p. 621-630. ISSN 1742-5255.
555. **The frequency of application can be reduced by high dose of glatiramer acetate in multiple sclerosis?** = Multipl sklerozda glatiramer asetatin yüksek dozu uygulama sıklığını azaltılabilir mi? // *Turk Noroloji Dergisi*, 19, 2013, № 3, p. 121. ISSN 1301-062X.
556. **Tintore, M., A. Vidal-Jordana, J. Sastre-Garriga.** Treatment of multiple sclerosis — success from bench to bedside. // *Nature Reviews Neurology*, 15, 2019, № 1, p. 53-58. ISSN 1759-4758.
557. **Tostanoski, L.H., H.B. Eppler, B. Xia et al.** Engineering release kinetics with polyelectrolyte multilayers to modulate TLR signaling and promote immune tolerance. // *Biomaterials Science*, 7, 2019, № 3, p. 798-808. ISSN 2047-4830.
558. **Tramacere, I., C. Del Giovane, G. Salanti.** Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis. // *Cochrane Database of Systematic Reviews*, 2015, № 9, art. no. CD011381. ISSN 14694-93X.
559. **Tsivgoulis, G., A.H. Katsanos, N. Grigoriadis et al.** The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. // *PLoS ONE*, 10, 2015, № 12, art. no. e0144538. ISSN 1932-6203.

560. **Tur, C., M. Moccia, F. Barkhof** et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. // *Nature Reviews Neurology*, 14, 2018, № 2, p. 75-93. ISSN 1759-4758.
561. **Uitdehaag, B.M.J.** Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis. // *CNS Drugs*, 32, 2018, № 6, p. 543-558. ISSN 1172-7047.
562. **Vågberg, M., M. Axelsson, R. Birgander** et al. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. // *Acta Neurologica Scandinavica*, 135, 2017, № 1, p. 17-24. ISSN 0001-6314.
563. **Vermersch, P., J. Oh, M. Cascione** et al. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. // *Multiple Sclerosis and Related Disorders*, 43, 2020, art. no. 102158. ISSN 2211-0348.
564. **Vialatte, A.L., Pr.T. Moreau.** Multiple sclerosis: Actuality and therapeutic prospects = Sclérose en plaques: Actualités et perspectives thérapeutiques. // *Revue de l'Infirmiere*, 211, 2015, p. 16-18. ISSN 1293-8505.
565. **Vidal-Jordana, A., X. Montalban.** Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects. // *Neuroimaging Clinics of North America*, 27, 2017, № 2, p. 195-204. ISSN 1052-5149.
566. **Vlahova, L., L. Kretschmer, M.P. Schön** et al. Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate. // *Case Reports in Dermatology*, 13, 2021 № 1, p. 114-120. ISSN 1662-6567.
567. **Weigel, M.R.** Adherence and compliance: Applying concepts to practice to improve outcomes. // *International Journal of MS Care*, 16, 2014, p. 17-23. ISSN 1537-2073.
568. **Weinstock-Guttman, B., K.V. Nair, J.L.** et al. Glajch et al. Two decades of glatiramer acetate: From initial discovery to the current development of generics. // *Journal of the Neurological Sciences*, 2017, 376, p. 255-259. ISSN 0022-510X.
569. **Wiendl, H., S.G. Meuth.** Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. // *Drugs*, 75, 2015, № 9, art. no. 411, p. 947-977. ISSN 0012-6667.
570. **Wiese, M.D., V. Suppiah, C.O'Doherty.** Metabolic and safety issues for multiple sclerosis pharmacotherapy- opportunities for personalised medicine. // *Expert Opinion on Drug Metabolism and Toxicology*, 10, 2014, № 8, p. 1145-1159. ISSN 1742-5255.

571. **Wilbur, C., E.A. Yeh.** Acute and Chronic Therapies in Pediatric Inflammatory Central Nervous System Diseases. // *Journal of Pediatric Neurology*, 16, 2018, № 3, p. 202-216. ISSN 1304-2580.
572. **Wilbur, C., E.A. Yeh.** Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments. // *Pediatric Drugs*, 21, 2019, № 3, p. 137-152. ISSN 1174-5878.
573. **Wingerchuk, D.M., B.G. Weinshenker.** Disease modifying therapies for relapsing multiple sclerosis. // *BMJ (Online)*, 354, 2016, art. no. i3518 . ISSN 0959-8146.
574. **Wingerchuk, D.M., J.L. Carter.** Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies. // *Mayo Clinic Proceedings*, 89, 2014, № 2, p. 225-240. ISSN 0025-6196
575. **Winkelmann, A., M. Löbermann, E.C. Reisinger et al.** Immunotherapy and infectious issues in multiple sclerosis: Self-injectable and oral drugs for immunotherapy=Immuntherapien und infektiologische Probleme bei Multipler Sklerose: Selbst injizierbare und orale Immuntherapeutika. // *Nervenarzt*, 86, 2015, № 8, p. 960-970. ISSN 0028-2804.
576. **Winkelmann, A., M. Loebermann, E.C. Reisinger et al.** Disease-modifying therapies and infectious risks in multiple sclerosis. // *Nature Reviews Neurology*, 12, 2016, № 4, p. 217-233. ISSN 1759-4758.
577. **Wolinsky, J.S., T.E. Borresen, D.W. Dietrich et al.** GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 4, 2015, № 4, p. 370-376. ISSN 2211-0348.
578. **Yamamura, T., N. Ashtamker, D. Ladkani et al.** Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis. // *Clinical and Experimental Neuroimmunology*, 8, 2017, № 2, p. 129-137. ISSN 1759-1961.
579. **Yamamura, T., T. Fukazawa, M. Tanaka et al.** Long-term, single-arm, open-label, multicenter phase 2/4 study of glatiramer acetate by subcutaneous injection in Japanese patients with relapsing–remitting multiple sclerosis. // *Clinical and Experimental Neuroimmunology*, 10, 2019, № 1, p. 49-56. ISSN 1759-1961.
580. **Zagmutt, F.J., C.A. Carroll.** Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. // *International Journal of Neuroscience*, 125, 2015, № 11, p. 798-807. ISSN 0020-7454.

581. **Zecca, C., G. Bellavia, L. Brambilla et al.** Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration? // *CNS Drugs*, 32, 2018, № 7, p. 653-660. ISSN 1172-7047.
582. **Ziemssen, T., N. Ashtamker, S. Rubinchick et al.** Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. // *Expert Opinion on Drug Safety*, 16, 2017, № 2, p. 247-255. ISSN 1474-0338.
583. **Zimmermann, M., E. Brouwer, J.A. Tice et al.** Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. // *CNS Drugs*, 32, 2018, № 12, p. 1145-1157. ISSN 1172-7047.

Kalliomäki J, Attal N, Jonzon B, Bach FW, Huizar K, Ratcliffe S, Eriksson B, Janecki M, Danilov A, Bouhassira D; AZD2423 PTN Study Group. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Collaborators: **Maslarov D**, Handberg G, Bach F, Sonne J, et al. // *Pain*, 154, 2013, № 5, p. 761-767. ISSN 0304-3959; E-ISSN 1872-6623.

#### Cited by:

584. **Alfonso Romero-Sandoval, E., S. Sweitzer.** Nonneuronal central mechanisms of pain: Glia and immune response. // *Progress in Molecular Biology and Translational Science*, 131, 2015, p. 325-358. ISSN 1877-1173.
585. **Arakawa, A., M. Kaneko, M. Narukawa.** An Investigation of Factors Contributing to Higher Levels of Placebo Response in Clinical Trials in Neuropathic Pain: A Systematic Review and Meta-Analysis. // *Clinical Drug Investigation*, 35, 2015, № 2, p. 67-81. ISSN 1173-2563.
586. **Biber, K., T. Möller, E. Boddeke et al.** Central nervous system myeloid cells as drug targets: Current status and translational challenges. // *Nature Reviews Drug Discovery*, 15, 2016, № 2, p. 110-124. ISSN 1474-1776.
587. **Bjurstrom, M.F., S.E. Giron, C.A. Griffis.** Cerebrospinal Fluid Cytokines and Neurotrophic Factors in Human Chronic Pain Populations: A Comprehensive Review. // *Pain Practice*, 16, 2016, № 2, p. 183-203. ISSN 1530-7085.
588. **Botz, B., K. Bölskei, Z. Helyes.** Challenges to develop novel anti-inflammatory and analgesic drugs. // *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 9, 2017, № 3, art. no. e1427. ISSN 1939-5116.
589. **Brody, S.L., S.P. Gunsten, H.P. Luehmann et al.** Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. // *American Journal of Respiratory and Critical Care Medicine*, 203, 2021, № 1, p. 78-89. ISSN 1073-449X.

590. **Buqué, A., N. Bloy, F. Aranda et al.** Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. // *OncoImmunology*, 5, 2016, № 6, art. no. e1149674. ISSN 2162-4011.
591. **Calcutt, N.A.** Diabetic neuropathy and neuropathic pain: A (CoN) fusion of pathogenic mechanisms? // *Pain*, 161, 2020, № 9, p. S65-S86. ISSN 0304-3959.
592. **Chen, G., C.K. Park, R.G. Xie et al.** Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice. // *Brain*, 137, 2014, № 8, p. 2193-2209. ISSN 0006-8950.
593. **Clark, A.K., E.A. Old, M. Malcangio.** Neuropathic pain and cytokines: Current perspectives. // *Journal of Pain Research*, 6, 2013, p. 803-814. ISSN 1178-7090.
594. **Covino, D.A., M. Sabbatucci, L. Fantuzzi.** The ccl2/ccr2 axis in the pathogenesis of hiv-1 infection: A new cellular target for therapy? // *Current Drug Targets*, 17, 2016, № 1, p. 76-110. ISSN 1389-4501.
595. **Davis, K.D., N. Aghaeepour, A.H. Ahn et al.** Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. // *Nature Reviews Neurology*, 16, 2020, № 7, p. 381-400. ISSN 1759-4758.
596. **Dawes, J.M., S.B. McMahon.** Chemokines as peripheral pain mediators. // *Neuroscience Letters*, 557, 2013, p. 1-8. ISSN 0304-3940.
597. **Finnerup, N.B., R. Kuner, T.S. Jensen.** Neuropathic pain: From mechanisms to treatment. // *Physiological Reviews*, 101, 2021, № 1, p. 259-301. ISSN 0031-9333.
598. **Fiore, N.T., P.J. Austin.** Are the emergence of affective disturbances in neuropathic pain states contingent on supraspinal neuroinflammation? // *Brain, Behavior, and Immunity*, 56, 2016, p. 397-411. ISSN 0889-1591.
599. **Freitag, C.M., R.J. Miller.** Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: A link to chemokines? // *Frontiers in Cellular Neuroscience*, 8, 2014, art. no. 238. ISSN 1662-5102.
600. **Gallagher, J.J., M. Tajerian, T. Guo et al.** Acute and chronic phases of complex regional pain syndrome in mice are accompanied by distinct transcriptional changes in the spinal cord. // *Molecular Pain*, 9, 2013, № 1, art. no. 40. ISSN 1744-8069.
601. **Grace, P.M., M.R. Hutchinson, S.F. Maier et al.** Pathological pain and the neuroimmune interface. // *Nature Reviews Immunology*, 14, 2014, № 4, p. 217-231. ISSN 14741733.



602. **Hanke, T., D. Merk, D. Steinhilber** et al. Small molecules with anti-inflammatory properties in clinical development. // *Pharmacology and Therapeutics*, 157, 2016, p. 163-187. ISSN 0163-7258.
603. **Hayes, A.G., L. Arendt-Nielsen, S. Tate.** Multiple mechanisms have been tested in pain - How can we improve the chances of success? // *Current Opinion in Pharmacology*, 14, 2014, № 1, p. 11-17. ISSN 1471-4892.
604. **Helfert, S.M., M. Reimer, J. Höper** et al. Individualized pharmacological treatment of neuropathic pain. // *Clinical Pharmacology and Therapeutics*, 97, 2015, № 2, p. 135-142. ISSN 0009-9236.
605. **Hurley, R.W., M.C.B. Adams, H.T. Benzon.** Neuropathic pain: Treatment guidelines and updates. // *Current Opinion in Anaesthesiology*, 26, 2013, № 5, p. 580-587. ISSN 0952-7907.
606. **Ji, R. R., Z. Z. Xu, Y. J Gao.** Emerging targets in neuroinflammation-driven chronic pain. // *Nature Reviews Drug Discovery*, 13, 2014, № 7, p. 533-548. ISSN 1474-1776.
607. **Ji, R.R., T. Berta, M. Nedergaard.** Glia and pain: Is chronic pain a gliopathy? // *Pain*, 154, 2013, suppl. 1, p. S10-S28. ISSN 0304-3959.
608. **Knezevic, N.N., N. Cicmil, I. Knezevic** et al. Discontinued neuropathic pain therapy between 2009-2015. // *Expert Opinion on Investigational Drugs*, 24, 2015, № 12, p. 1631-1646. ISSN 1354-3784.
609. **Kojima, H., J. Kim, L. Chan.** Emerging roles of hematopoietic cells in the pathobiology of diabetic complications. // *Trends in Endocrinology and Metabolism*, 25, 2014, № 4, p. 178-187. ISSN 1043-2760.
610. **Lacagnina, M.J., L.R Watkins, P.M. Grace.** Toll-like receptors and their role in persistent pain. // *Pharmacology and Therapeutics*, 184, 2018, p. 145-158. ISSN 0163-7258.
611. **Lan, L., L. Shen, Y.G. Huang.** Roles of inflammatory reaction and cytokines in chronic postsurgical pain. // *Acta Academiae Medicinae Sinicae*, 37, 2015, № 6, p. 741-745. ISSN 1000-503X.
612. **McKeown, A., J.S. Gewandter, M.P. McDermott** et al. Reporting of sample size calculations in analgesic clinical trials: ACTION systematic review. // *Journal of Pain*, 16, 2015, № 3, p. 199-206.e7. ISSN 1526-5900.
613. **Mcmahon, S.B., F. La Russa, D.L.H.Bennett.** Crosstalk between the nociceptive and immune systems in host defence and disease. // *Nature Reviews Neuroscience*, 16, 2015, № 7, p. 389-402. ISSN 1471-003X.

614. **Noda, M., D. Tomonaga, K. Kitazono et al.** Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. // *Neurochemistry International*, 119, 2018, p. 184-189. ISSN 01970186.
615. **Reimer, M., S.M. Helfert, R. Baron.** Phenotyping neuropathic pain patients: Implications for individual therapy and clinical trials. // *Current Opinion in Supportive and Palliative Care*, 8, 2014, № 2, p. 124-129. ISSN 1751-4258.
616. **Ren, K., R. Dubner.** Activity-triggered tetrapartite neuron-glia interactions following peripheral injury. // *Current Opinion in Pharmacology*, 26, 2016, p. 16-25. ISSN 1471-4892.
617. **Sawicki, C.M., M.L. Humeidan, J.F. Sheridan.** Neuroimmune Interactions in Pain and Stress: An Interdisciplinary Approach. // *Neuroscientist*, 27, 2021, № 2, p. 113-128. ISSN 1073-8584.
618. **Sisignano, M., R. Baron, K. Scholich et al.** Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. // *Nature Reviews Neurology*, 10, 2014, № 12, p. 694-707. ISSN 1759-4758.
619. **Smith, E.M.D., M.W. Beresford.** Urinary biomarkers in childhood lupus nephritis. // *Clinical Immunology*, 185, 2017, p. 21-31. ISSN 1521-6616.
620. **Tiwari, V., Y. Guan, S.N. Raja.** Modulating the delicate glial-neuronal interactions in neuropathic pain: Promises and potential caveats. // *Neuroscience and Biobehavioral Reviews*, 45, 2014, p. 19-27. ISSN 0149-7634.
621. **Van Steenwinckel, J., C. Auvynet, A. Sapienza et al.** Stromal cell-derived CCL2 drives neuropathic pain states through myeloid cell infiltration in injured nerve. // *Brain, Behavior, and Immunity*, 45, 2015, p. 198-210. ISSN 0889-1591.
622. **Vilums, M., A.J.M. Zweemer, F. Barmare et al.** When structure-affinity relationships meet structure-kinetics relationships: 3-((Inden-1-yl)amino)-1-isopropyl-cyclopentane-1-carboxamides as CCR2 antagonists. // *European Journal of Medicinal Chemistry*, 93, 2015, p. 121-134. ISSN 0223-5234.
623. **Walters, E.T.** Neuroinflammatory contributions to pain after SCI: Roles for central glial mechanisms and nociceptor-mediated host defense. // *Experimental Neurology*, 258, 2014, p. 48-61. ISSN 0014-4886.
624. **Yekkirala, A.S., D.P. Roberson, B.P. Bean et al.** Breaking barriers to novel analgesic drug development. // *Nature Reviews Drug Discovery*, 16, 2017, № 8, p. 545-564. ISSN 1474-1776.
625. **Yeziarski, R.P., P. Hansson.** Inflammatory and Neuropathic Pain From Bench to Bedside: What Went Wrong? // *Journal of Pain*, 19, 2018, № 6, p. 571-588. ISSN 1526-5900.

626. **Zhang, J.** Peripheral and Central Immune Mechanisms in Neuropathic Pain. – In: *Neuroinflammation: New Insights into Beneficial and Detrimental Functions*, 2015, p. 107-121. ISBN 9781118732748; 9781118732823.
627. **Zhang, Z.J., B.C. Jiang, Y.J. Gao.** Chemokines in neuron–glial cell interaction and pathogenesis of neuropathic pain. // *Cellular and Molecular Life Sciences*, 74, 2017, № 18, p. 3275-3291. ISSN 1420-682X.
628. **Zhou, Y.Q., Z. Liu, H.Q. Liu et al.** Targeting glia for bone cancer pain. // *Expert Opinion on Therapeutic Targets*, 20, 2016, № 11, p. 1365-1374. ISSN 1472-8222.

## **2014**

French, J. A., P. Bartoldi, S. T. Brittain, J. K. Johnson, on behalf of the PROSPER Investigators Study Group (**D. Maslarov**, Sofia). Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. // *Acta Neurol Scandinavica*, 2014, № 129, p. 143-153. ISSN 0364-5134.

## **Cited by:**

629. **Anderson, G.D., R.P. Saneto.** Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects. // *CNS Drugs*, 29, 2015, № 8, p. 669-681. ISSN 1172-7047.
630. **Banach, M., B. Miziak, K.K. Borowicz-Reutt et al.** Advances with extended and controlled release formulations of antiepileptics in the elderly. // *Expert Opinion on Pharmacotherapy*, 20, 2019, № 3, p. 333-341. ISSN 1465-6566.
631. **Bocato, M.Z., M.A. Bortoleto, M.T. Pupo et al.** A new enantioselective CE method for determination of oxcarbazepine and lincarbazepine after fungal biotransformation. // *Electrophoresis*, 35, 2014, № 19, p. 2877-2884. ISSN 0173-0835.
632. **Brandt, C., S. Borghs, S. Elmoufti et al.** Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis. // *Epilepsy and Behavior*, 69, 2017, p. 80-85. ISSN 1525-5050.
633. **Brandt, C., T.W. May.** Extended-release drug formulations for the treatment of epilepsy. // *Expert Opinion on Pharmacotherapy*, 19, 2018, № 8, p. 843-850. ISSN 1465-6566.
634. **Bresnahan, R., M. Atim-Oluk, A.G. Marson.** Oxcarbazepine add-on for drug-resistant focal epilepsy. // *Cochrane Database of Systematic Reviews*, 2020, 3, art. no. CD012433. ISSN 1469-493X.

635. **Chiossi, L., A. Negro, M. Capi** et al. Sodium channel antagonists for the treatment of migraine. // *Expert Opinion on Pharmacotherapy*, 15, 2014, № 12, p. 1697-1706. ISSN 1465-6566.
636. **Chong, D.J., A.M. Lerman.** Practice Update: Review of Anticonvulsant Therapy. // *Current Neurology and Neuroscience Reports*, 16, 2016, № 4, art. no. 39. ISSN 1528-4042.
637. **Faison, S., R. Gomeni, S. Mendes** et al. Predicted efficacy of once-daily extended-release oxcarbazepine (Oxtellar xr®) monotherapy in adults and children with partial-onset seizures: Exposure-response modeling and simulation. // *Clinical Pharmacology: Advances and Applications*, 12, 2020, p. 135-147. ISSN 1179-1438.
638. **Fong, J.K.Y., E.L.Y., Chan, H. Leung** et al. Subcommittee on the Consensus Statement of The Hong Kong Epilepsy Society. An update of the Hong Kong Epilepsy Guideline: Consensus statement on the use of antiepileptic drugs in Hong Kong. // *Hong Kong Medical Journal*, 23, 2017, № 1, p. 74-88. ISSN 1024-2708.
639. **Kaur, H., B. Kumar, B. Medhi.** Antiepileptic drugs in development pipeline: A recent update. // *eNeurologicalSci*, 4, 2016, p. 42-51. ISSN 24056502.
640. **Perucca, E.** From clinical trials of antiepileptic drugs to treatment. // *Epilepsia Open*, 3, 2018, S2, p. 220-230. ISSN 24709239.
641. **Perucca, E., S. Wiebe.** Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy. // *Epilepsia Open*, 1, 2016 0 1-2, p. 9-21. ISSN 2470-9239.
642. **Rocamora, R., J. Peltola, G. Assenza** et al. Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice. // *Seizure*, 75, 2020, p. 121-128. ISSN 1059-1311.
643. **Sattler, A., M. Schaefer, T.W. May.** Relationship between mono-hydroxycarbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy. // *Seizure*, 2015, 31, p. 149-154. ISSN 1059-1311.
644. **Schmid, E., G. Kuchukhidze, M. Kirschner** et al. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study. // *Acta Neurologica Scandinavica*, 135, 2017, № 4, p. 449-453. ISSN 0001-6314.
645. **Shih, J.J., J.B. Whitlock, N. Chimato** et al. Epilepsy treatment in adults and adolescents: Expert opinion, 2016. // *Epilepsy and Behavior*, 69, 2017, p. 186-222. ISSN 1525-5050.

646. **Vlasov, P.N.** Clinical results of and prospects for the use of controlled-release antiepileptic drugs: A new once-daily levetiracetam formulation. // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 9, 2017, № 3, p. 98-104. ISSN 2074-2711.
647. **Willems, L.M., J.P. Zöllner, E. Paule et al.** Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence. // *Expert Review of Clinical Pharmacology*, 11, 2018, № 3, p. 309-324. ISSN 1751-2433.
648. **Zhao, T., X. Feng, J. Liu, Gao, J. et al.** Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis. // *Journal of Cellular Biochemistry*, 118, 2017, № 9, p. 2850-2864. ISSN 0730-2312.
649. **Zhuo, C., R. Jiang, G. Li et al.** Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis. // *Scientific Reports*, 7, 2017, № 1, art. no. 2535. ISSN 2045-2322.

Vollmer, T.L., P.S. Sorensen, K. Selmaj, F. Zipp, E. Havrdova, J.A. Cohen, N. Sasson, Y. Gilgun-Sherki, D.L. Arnold, BRAVO Study Group. Maslarov D. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. // *Journal of neurology*, 261, 2014, № 4, p. 773-783. ISSN 0340-5354. doi: 10.1007/s00415-014-7264-4.

#### **Cited by:**

650. **Almaani, S., A. Meara, B.H. Rovin.** Update on lupus nephritis. // *Clinical Journal of the American Society of Nephrology*, 12, 2017, № 5, p. 825-835. ISSN 1555-9041.
651. **Alroughani, R., D. Deleu, K. El Salem et al.** A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. // *BMC Neurology*, 16, 2016, № 1, art. no. 240. ISSN 1471-2377.
652. **Baldassari, L.E., R.J. Fox.** Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. // *Drugs*, 78, 2018, № 15, p. 1549-1566. ISSN 0012-6667.
653. **Berg, J., Y. Mahmoudjanlou, A. Dusha et al.** The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor. // *Journal of Neuroimmunology*, 298, 2016, p. 9-15. ISSN 0165-5728.
654. **Bhise, V., S. Dhib-Jalbut.** Further understanding of the immunopathology of multiple sclerosis: impact on future treatments. // *Expert Review of Clinical Immunology*, 12, 2016, № 10, p. 1069-1089. ISSN 1744-666X.

655. **Binks, S., R. Dobson.** Established, new and future disease modifying therapies for MS. // *Progress in Neurology and Psychiatry*, 19, 2015, № 5, p. 27-35. ISSN 1367-7543.
656. **Boros, F., Vécsei, L.** Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs. // *Expert Opinion on Investigational Drugs*, 29, 2020, № 11, p. 1223-1247. ISSN 1354-3784.
657. **Bovis, F., A. Signori, L. Carmisciano** et al. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. // *Annals of Neurology*, 84, 2018, № 4, p. 621-625. ISSN 0364-5134.
658. **Bovis, F., L. Carmisciano, A. Signori** et al. Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data. // *BMC Medicine*, 17, 2019, № 1, art. no. 113. ISSN 1741-7015.
659. **Bovis, F., N. De Stefano, J.R. Steinerman** et al. Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS. // *Multiple Sclerosis Journal*, 25, 2019, № 2, p. 217-223. ISSN 1352-4585.
660. **Boyko, A.N., N.N Spirin, Ya.V. Vlasov** et al. Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis = Современные требования к исследованиям лекарственных средств для патогенетического лечения рассеянного склероза. // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 11, 2019, № 4, p. 166-171. ISSN 2074-2711.
661. **Bridel, C., P.H. Lalive.** Update on multiple sclerosis treatments. // *Swiss Medical Weekly*, 144, 2014, art. no. w14012. ISSN 1424-7860.
662. **Bross, M., M. Hackett, E. Bernitsas.** Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis. // *International Journal of Molecular Sciences*, 21, 2020, № 12, art. no. 4312, p. 1-15. ISSN 1661-6596.
663. **Catalan-Serra, I., Ø. Brenna.** Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. // *Human Vaccines and Immunotherapeutics*, 14, 2018, № 11, p. 2597-2611. ISSN 2164-5515.
664. **Chiurchiù, V.** Novel targets in multiple sclerosis: To oxidative stress and beyond. // *Current Topics in Medicinal Chemistry*, 14, 2014, № 22, p. 2590-2599. ISSN 1568-0266.
665. **Coclitu, C., C.S. Constantinescu, R. Tanasescu.** The future of multiple sclerosis treatments. // *Expert Review of Neurotherapeutics*, 16, 2016, № 12, p. 1341-1356. ISSN 1473-7175.

666. **Constantinescu, S.E., C.S. Constantinescu.** Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis. // *Expert Review of Clinical Pharmacology*, 9, 2016, № 1, p. 49-57. ISSN 1751-2433.
667. **Cortese, I., A. Nath.** Immunomodulatory therapy for multiple sclerosis. – In: *Neuroimmune Pharmacology*, 2016, p. 713-736. ISBN 9783319440224; 9783319440200.
668. **Cree, B.A.C., J. Mares, H.P. Hartung.** Current therapeutic landscape in multiple sclerosis: An evolving treatment paradigm. // *Current Opinion in Neurology*, 32, 2019, № 3, p. 365-377. ISSN 1350-7540.
669. **D'Amico, E., C. Leone, C. Caserta et al.** Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal. // *Expert Review of Neurotherapeutics*, 15, 2015, № 7, p. 803-824. ISSN 1473-7175.
670. **D'Amico, E., S. Messina, C. Caserta et al.** A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. // *Expert Opinion on Drug Safety*, 14, 2015, № 7, p. 1157-1168. ISSN 1474-0338.
671. **De Stefano, N., M.L. Stromillo, A. Giorgio et al.** Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. // *Journal of Neurology, Neurosurgery and Psychiatry*, 87, 2016, № 1, p. 93-99. ISSN 0022-3050.
672. **Décard, B.F., T. Derfuss.** Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future. // *Seminars in Neurology*, 36, 2016, № 2, p. 128-139. ISSN 0271-8235.
673. **Dobson, L., U. Träger, R. Farmer et al.** Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. // *Journal of Neurochemistry*, 137, 2016, № 5, p. 782-794. ISSN 0022-3042.
674. **Einarson, T.R., B.G. Berez, M. Machado.** Comparative effectiveness of interferons in relapsing–remitting multiple sclerosis: a meta-analysis of real-world studies. // *Current Medical Research and Opinion*, 33, 2017, № 3, p. 579-593. ISSN 0300-7995.
675. **Elgart, A., A.A. Zur, D. Mimrod.** The effect of laquinimod, a novel immunomodulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women. // *European Journal of Clinical Pharmacology*, 75, 2019, № 1, p. 41-49. ISSN 0031-6970.
676. **Elgart, A., D.J. Greenblatt, P.S. Loupe et al.** The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator. // *Clinical Pharmacology in Drug Development*, 9, 2020, № 8, p. 1015-1024. ISSN 2160-763X.

677. **Faissner, S., R. Gold.** Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. // *CNS Drugs*, 32, 2018, № 3, p. 269-287. ISSN 1172-7047.
678. **Faissner, S., R. Gold.** Oral therapies for multiple sclerosis. // *Cold Spring Harbor Perspectives in Medicine*, 9, 2019, № 1, art. no. a032011, 15 p. ISSN 2157-1422.
679. **Filippini, G., M. Clerico, O. Beiki et al.** Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. // *Cochrane Database of Systematic Reviews*, 2016, № 5, art. no. CD012200. ISSN 1469-493X.
680. **Finkelsztejn, A., A. Finkelsztejn.** Multiple sclerosis: Overview of Disease-Modifying agents. // *Perspectives in Medicinal Chemistry*, 2014, № 6, p. 65-72. ISSN 1177-391X.
681. **Fogarty, E., S. Schmitz, N. Tubridy et al.** Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. // *Multiple Sclerosis and Related Disorders*, 9, 2016, p. 23-30. ISSN 2211-0348.
682. **Forsthuber, T.G., O. Stuve.** Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium? // *Neurology: Neuroimmunology and NeuroInflammation*, 3, 2016, № 5, art. no. e283. ISSN 2332-7812.
683. **Freedman, M.S.** Emerging Therapies for Multiple Sclerosis. – In: *Translational Neuroimmunology in Multiple Sclerosis: From Disease Mechanisms to Clinical Applications*, 2016, p. 285-304. ISBN 9780128020074; 9780128019146.
684. **Gajofatto, A., M. Turatti, M.D. Benedetti.** Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. // *Expert Review of Neurotherapeutics*, 17, 2017, № 4, p. 393-406. ISSN 1473-7175.
685. **Gholamzad, M., M. Ebtekar, M.S. Ardestani et al.** A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. // *Inflammation Research*, 68, 2019, № 1, p. 25-38. ISSN 1023-3830.
686. **Grzegorski, T., J. Losy.** Multiple sclerosis-the remarkable story of a baffling disease. // *Reviews in the Neurosciences*, 30, 2019, № 5, p. 511-526. ISSN 0334-1763.
687. **Hainke, U., K. Thomas, T. Ziemssen.** Laquinimod in the treatment of relapsing remitting multiple sclerosis. // *Expert Opinion on Drug Metabolism and Toxicology*, 12, 2016, № 6, p. 701-709. ISSN 1742-5255.
688. **Harlow, D.E., J.M. Honce, A.A. Miravalle.** Remyelination therapy in multiple sclerosis. // *Frontiers in Neurology*, 6 Dec. 2015, art. no. 257. ISSN 1664-2295.



689. **Houtchens, M.K., R. Bove.** A case for gender-based approach to multiple sclerosis therapeutics. // *Frontiers in Neuroendocrinology*, 50, 2018, p. 123-134. ISSN 0091-3022.
690. **Hussain, R.Z., W.A. Miller-Little, D. Lambracht-Washington et al.** Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease. // *Journal of Neuroimmunology*, 309, 2017, p. 100-110. ISSN 0165-5728.
691. **Jones, D.E., M.D. Goldman.** Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: A review of its clinical pharmacology, efficacy and safety. // *Expert Review of Clinical Immunology*, 10, 2014, № 10, p. 1281-1291. ISSN 1744-666X.
692. **Karussis, D.** Multiple Sclerosis. – In: *International Encyclopedia of Public Health*, 2016, p. 145-179. ISBN 9780128037089; 9780128036785.
693. **Katsumoto, A., A.S. Miranda, O. Butovsky et al.** Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model. // *Journal of Neuroinflammation*, 15, 2018, № 1, art. no. 26. ISSN 1742-2094.
694. **Kaye, J., V. Piryatinsky, T. Birnberg et al.** Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. // *Proceedings of the National Academy of Sciences of the United States of America*, 113, 2016, № 4, p. E6145-E6152. ISSN 0027-8424.
695. **Kerschbaumer, A., J.S. Smolen, H. Herkner et al.** Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. // *Nature Medicine*, 26, 2020, № 6, p. 974-980. ISSN 10788-956.
696. **Kim, W., M.E. Zandoná, S.H. Kim et al.** Oral disease-modifying therapies for multiple sclerosis. // *Journal of Clinical Neurology (Korea)*, 11, 2015, № 1, p. 9-19. ISSN 1738-6586.
697. **Kotra, L.P., J. Park.** Therapeutic Approaches to MS and Other Neurodegenerative Diseases. - In: *Comprehensive Medicinal Chemistry III*, 2017, 5-8, p. 439-473. ISBN 9780128032008; 9780128032015.
698. **Kremer, I.E.H., M. Hiligsmann, J. Carlson et al.** Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. // *Medical Decision Making*, 40, 2020, № 8, p. 1003-1019. ISSN 0272-989X.

699. **Kretzschmar, B., H. Pellkofer, M.S. Weber.** The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis. // *Current Neurology and Neuroscience Reports*, 16, 2016, № 4, art. no. 38. ISSN 1528-4042.
700. **Leibowitz, S.M., J. Yan.** NF- $\kappa$ B pathways in the pathogenesis of multiple sclerosis and the therapeutic implications. // *Frontiers in Molecular Neuroscience*, 9 Sep. 2016, art. no. 84. ISSN 1662-5099.
701. **Li, Z., J. Chen, , L. LeiJiang** et al. Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea. // *Frontiers in Medicine*, 7, 2020, art. no. 598056. ISSN 2296-858X.
702. **Linnerbauer, M., Rothhammer, V.** Protective Functions of Reactive Astrocytes Following Central Nervous System Insult. // *Frontiers in Immunology*, 11, 2020, art. no. 573256. ISSN 1664-3224.
703. **Lorefice, L., G. Fenu, J. Frau** et al. Oral agents in multiple sclerosis. // *Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry*, 14, 2015, № 1, p. 15-25. ISSN 1871-5230.
704. **Lovelace, M.D., B. Varney, G. Sundaram** et al. Current evidence for a role of the kynurenine pathway of tryptophan metabolism in multiple sclerosis. // *Frontiers in Immunology*, 7 Aug. 2016, art. no. 246. ISSN 1664-3224.
705. **Lühder, F., H. Kebir, F. Odoardi** et al. Laquinimod enhances central nervous system barrier functions. // *Neurobiology of Disease*, 102, 2017, p. 60-69. ISSN 0969-9961.
706. **Machado, C.A., A.C.S.E. Silva, A.S. de Miranda** et al. Immune-based therapies for traumatic brain injury: Insights from pre-clinical studies. // *Current Medicinal Chemistry*, 27, 2020, № 32, p. 5374-5402. ISSN 0929-8673.
707. **Majláth, Z., Á. Annus, L. Vécsei.** Kynurenine system and multiple sclerosis, pathomechanism and drug targets with an emphasis on laquinimod. // *Current Drug Targets*, 19, 2018, № 7, p. 805-814. ISSN 1389-4501.
708. **Malek, G., Choudhary, M.** The aryl hydrocarbon receptor: A mediator and potential therapeutic target for ocular and non-ocular neurodegenerative diseases. // *International Journal of Molecular Sciences*, 21, 2020, № 18, art. no. 6777, p. 1-17. ISSN 1661-6596.
709. **Mark, V.W., T. Geng.** Multiple sclerosis. – In: *Neurorestoratology*: Vol. 2: Clinical Progress of Neurorestoratology, 2015, p. 137-163. ISBN 9781634636247; 9781634636001.

710. **Marziniak, M.** Multiple sclerosis: New treatment options = Multiple Sklerose: Neue therapieoptionen. // *MMW-Fortschritte der Medizin*, 156, 2014, № 23, p. 69-76. ISSN 1438-3276.
711. **Meca-Lallana, J.E., R. Hernández-Clares, E. Carreón-Guarnizo.** Oral treatments in multiple sclerosis [Tratamientos orales en esclerosis múltiple]. // *Medicina Clinica*, 143, 2014, S3, p. 23-29. ISSN 0025-7753.
712. **Melendez-Torres, G.J., P. Auguste, X. Armoiry et al.** Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: Systematic review and economic evaluation. // *Health Technology Assessment*, 21, 2017, № 52, 396 p. ISSN 1366-5278.
713. **Melendez-Torres, G.J., X. Armoiry, R. Court et al.** Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: Systematic review and network meta-analysis of trials including recommended dosages. // *BMC Neurology*, 18, 2018, № 1, art. no. 162. ISSN 1471-2377.
714. **Modoux, M., N. Rolhion, S. Mani et al.** Tryptophan Metabolism as a Pharmacological Target. // *Trends in Pharmacological Sciences*, 42, 2021, № 1, p. 60-73. ISSN 0165-6147.
715. **Nedelcu, J., C. Reinbach, M. Brendel et al.** Laquinimod ameliorates secondary brain inflammation. // *Neurobiology of Disease*, 134, 2020, art. no. 104675. ISSN 0969-9961.
716. **Oesterle, A., M.A. Hofmann Bowman.** S100A12 and the S100/Calgranulins: Emerging Biomarkers for Atherosclerosis and Possibly Therapeutic Targets. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 35, 2015, № 12, p. 2496-2507. ISSN 1079-5642.
717. **Ontaneda, D., E. Tallantyre, T. Kalincik et al.** Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. // *The Lancet Neurology*, 18, 2019, № 10, p. 973-980. ISSN 1474-4422.
718. **Pawate, S., F. Bagnato.** Newer agents in the treatment of multiple sclerosis. // *Neurologist*, 19, 2015, № 4, p. 104-117. ISSN 1074-7931.
719. **Pfeuffer, S., T. Ruck, C. Kleinschnitz et al.** Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010–2015. // *Expert Review of Neurotherapeutics*, 16, 2016, № 6, p. 689-700. ISSN 1473-7175.
720. **Pichler, A., M. Khalil, C. Langkammer et al.** Combined analysis of global and compartmental brain volume changes in early multiple sclerosis in clinical practice. // *Multiple Sclerosis*, 22, 2016, № 3, p. 340-346. ISSN 1352-4585.

721. **Piehl, F.** Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. // *Journal of Internal Medicine*, 289, 2021, № 6, p. 771-791. ISSN 0954-6820.
722. **Prokopec, S.D., R. Pohjanvirta, S. Mahiout et al.** Transcriptomic impact of IMA-08401, a novel AHR agonist resembling laquinimod, on rat liver. // *International Journal of Molecular Sciences*, 20, 2019, № 6, art. no. 1370. ISSN 1661-6596.
723. **Quintana, F.J., A. Yeste, I.D. Mascalfroni.** Role and therapeutic value of dendritic cells in central nervous system autoimmunity. // *Cell Death and Differentiation*, 22, 2015, № 2, p. 215-224. ISSN 1350-9047.
724. **Radick, L., S.R. Mehr.** The latest innovations in the drug pipeline for multiple sclerosis. // *American Health and Drug Benefits*, 8, 2015, № 8, p. 448-453. ISSN 1942-2962.
725. **Rae-Grant, A., G.S. Day, R.A. Marrie et al.** Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. // *Neurology*, 90, 2018, № 17, p. 789-800. ISSN 0028-3878.
726. **Rocca, M.A., P. Preziosa, M. Filippi.** Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. // *Expert Review of Neurotherapeutics*, 19, 2019, № 9, p. 835-866. ISSN 1473-7175.
727. **Ross, C.J., F. Towfic, J. Shankar et al.** A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. // *Genome Medicine*, 9, 2017, № 1, art. no. 50. ISSN 1756-994X.
728. **Rothhammer, V., D.M. Borucki, M.I.G. Sanchez et al.** Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS. // *Neurology: Neuroimmunology and NeuroInflammation*, 4, 2017, № 4. ISSN 2332-7812.
729. **Rothhammer, V., F.J. Quintana.** The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. // *Nature Reviews Immunology*, 19, 2019, № 3, p. 184-197. ISSN 1474-1733.
730. **Rouhi, F., Z. Mohammadpour, S.K. Nouredini et al.** The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials. // *European Journal of Clinical Pharmacology*, 76, 2020, № 5, p. 611-622. ISSN 0031-6970.
731. **Russi, A.E., M.A. Brown.** The meninges: New therapeutic targets for multiple sclerosis. // *Translational Research*, 165, 2015, № 2, p. 255-269. ISSN 1931-5244.
732. **Sabino, J., B. Verstockt, S. Vermeire et al.** New biologics and small molecules in inflammatory bowel disease: an update. // *Therapeutic Advances in Gastroenterology*, 12, 2019. ISSN 1756-283X.

733. **Safavi, M., S. Nikfar, M. Abdollahi.** A systematic review of drugs in late-stage development for the treatment of multiple sclerosis: A focus on oral synthetic drugs. // *Inflammation and Allergy - Drug Targets*, 13, 2015, № 6, p. 351-366. ISSN 1871-5281.
734. **Samjoo, I.A., E. Worthington, C. Drudge et al.** Efficacy classification of modern therapies in multiple sclerosis. // *Journal of Comparative Effectiveness Research*, 10, 2021, № 6, p. 495-507. ISSN 2042-6305.
735. **Siddiqui, M.K., I.S. Khurana, S. Budhia et al.** Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. // *Current Medical Research and Opinion*, 34, 2018, № 8, p. 1361-1371. ISSN 0300-7995.
736. **Sormani, M.P.** The most frequently asked question to a statistician: The sample size. // *Multiple Sclerosis*, 23, 2017, № 5, p. 644-646. ISSN: 1352-4585.
737. **Spiegelstein, O., D. Mimrod, L. Rabinovich et al.** A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease. // *Clinical Pharmacology in Drug Development*, 8, 2019, № 1, p. 49-59. ISSN 2160-763X.
738. **Stasiolek, M., R.A. Linker, L. Hayardeny et al.** Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: Results from a double-blind placebo-controlled study. // *Immunity, Inflammation and Disease*, 3, 2015, № 2, p. 45-55. ISSN 2050-4527.
739. **Staun-Ram, E., A. Miller.** Effector and regulatory B cells in Multiple Sclerosis. // *Clinical Immunology*, 184, 2017, p. 11-25. ISSN 1521-6616.
740. **Thöne, J., R.A. Linker.** Laquinimod in the treatment of multiple sclerosis: A review of the data so far. // *Drug Design, Development and Therapy*, 10, 2016, p. 1111-1118. ISSN 1177-8881.
741. **Tolley, K., M. Hutchinson, X. You et al.** A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. // *PLoS ONE*, 10, 2015, № 6, art. no. e0127960. ISSN 1932-6203.
742. **Tomassini, V., F. Fanelli, L. Prosperini et al.** Predicting the profile of increasing disability in multiple sclerosis. // *Multiple Sclerosis Journal*, 25, 2019, № 9, p. 1306-1315. ISSN 1352-4585.
743. **Tong, J., Q. Zou, Y. Chen et al.** Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. // *Neurological Sciences*, 42, 2021, № 5, p. 1687-1695. ISSN 1590-1874.

744. **Tramacere, I., C. Del Giovane, G. Salanti et al.** Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis. // *Cochrane Database of Systematic Reviews*, 2015, № 9, art. no. CD011381. ISSN 1469-493X.
745. **Tramacere, I., M.D. Benedetti, M. Capobussi et al.** Adverse effects of immunotherapies for multiple sclerosis: A network meta-analysis. // *Cochrane Database of Systematic Reviews*, 2016, № 5, art. no. CD012186. ISSN 1469-493X.
746. **Tur, C., M. Moccia, F. Barkhof et al.** Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. // *Nature Reviews Neurology*, 14, 2018, № 2, p. 75-93. ISSN 1759-4758.
747. **Uitdehaag, B.M.J.** Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis. // *CNS Drugs*, 32, 2018, № 6, p. 543-558. ISSN 1172-7047.
748. **Varrin-Doyer, M., K.L. Pekarek, C.M. Spencer et al.** Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. // *Neurology: Neuroimmunology and NeuroInflammation*, 3, 2016, № 5, art. no. e272. ISSN 2332-7812.
749. **Varrin-Doyer, M., S.S. Zamvil, U. Schulze-Topphoff.** Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. // *Experimental Neurology*, 262, 2014, Part A, p. 66-71. ISSN 0014-4886.
750. **Vidal-Jordana, A., J. Sastre-Garriga, A. Rovira et al.** Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. // *Journal of Neurology*, 262, 2016, № 12, p. 2617-2626. ISSN 03405354.
751. **Waddingham, E., Matthews, P.M., Ashby, D.** Exploiting relationships between outcomes in Bayesian multivariate network meta-analysis with an application to relapsing-remitting multiple sclerosis. // *Statistics in Medicine*, 39, 2020, № 24, p. 3329-3346. ISSN 0277-6715.
752. **Wheeler, M.A., F.J. Quintana.** Regulation of astrocyte functions in multiple sclerosis. // *Cold Spring Harbor Perspectives in Medicine*, 9, 2019, № 1, art. no. a029009, 12 p. ISSN 2157-1422.
753. **Wheeler, M.A., V. Rothhammer, F.J. Quintana.** Control of immune-mediated pathology via the aryl hydrocarbon receptor. // *Journal of Biological Chemistry*, 292, 2017, № 30, p. 12383-12389. ISSN 0021-9258.
754. **Wiendl, H., S.G. Meuth.** Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. // *Drugs*, 75, 2015, № 9, art. no. 411, p. 947-977. ISSN 0012-6667.

755. **Wilbanks, B., L.J. Maher, M. Rodriguez.** Glial cells as therapeutic targets in progressive multiple sclerosis. // *Expert Review of Neurotherapeutics*, 19, 2019, № 6, p. 481-494. ISSN 1473-7175.
756. **Wilmes, A.T., S. Reinehr, S. Kühn et al.** Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model. // *Journal of Neuroinflammation*, 15, 2018, № 1, art. no. 183. ISSN 1742-2094.
757. **Xie, Z.X., H.L. Zhang, X.J. Wu et al.** Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis. // *Mediators of Inflammation*, 2015, art. no. 513295. ISSN 0962-9351.
758. **Yong, H., G. Chartier, J. Quandt.** Modulating inflammation and neuroprotection in multiple sclerosis. // *Journal of Neuroscience Research*, 96, 2018, № 6, p. 927-950. ISSN 0360-4012.
759. **Ziemssen, T., H. Tumani, T. Sehr et al.** Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. // *Journal of Neuroinflammation*, 14, 2017, № 1, art. no. 172. ISSN 1742-2094.

Miller, A.E, Wolinsky J.S, Kappos L, Comi G, Freedman M.S, Olsson T.P, Bauer D, Benamor M, Truffinet P, O'Connor P.W; TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. // *The Lancet Neurology*, 13, 2014, № 10, p. 977-986. ISSN 1474-4422 doi: 10.1016/S1474-4422(14)70191-7.

#### **Cited by:**

760. **Aguilar-Juárez, P.A., R.A. Castillo-Lara, M. Ceballos-Godina et al.** Consensus for the diagnosis and treatment of multiple sclerosis in ISSSTE patients [Consenso para el diagnóstico y tratamiento de la esclerosis múltiple en pacientes del ISSSTE]. // *Medicina Interna de Mexico*, 35, 2019, № 5, p. 732-771. ISSN 0186-4866.
761. **Al-Namaeh, M.** Systematic review and meta-analysis of the development of multiple sclerosis in clinically isolated syndrome. // *European Journal of Ophthalmology*, 2020. ISSN 1120-6721.
762. **Alroughani, R., J. Inshasi, A. Al-Asmi et al.** Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. // *Postgraduate Medicine*, 132, 2020, № 4, p. 368-376. ISSN 0032-5481.
763. **Aly, L., B. Hemmer, T. Korn.** From leflunomide to teriflunomide: Drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis. // *Current Neuropharmacology*, 15, 2017, № 6, p. 874-891. ISSN 1570-159X.

764. **Anna, I., P. Zsuzsanna, S. Magdolna.** Oral disease-modifying agents in relapsing-remitting multiple sclerosis [Szájon át szedhető immunmoduláns kezelési lehetőségek szklerózis multiplexben]. // *Neuropsychopharmacologia Hungarica*, 17, 2015, № 4, p. 197-205. ISSN 1419-8711.
765. **Armoiry, X., A. Kan, G.J. Melendez-Torres.** Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis. // *Journal of Neurology*, 265, 2018, № 5, p. 999-1009. ISSN 0340-5354.
766. **Auricchio, F., C. Scavone, D. Cimmaruta et al.** Drugs approved for the treatment of multiple sclerosis: review of their safety profile. // *Expert Opinion on Drug Safety*, 16, 2017, № 12, p. 1359-1371. ISSN 1474-0338.
767. **Aw-Zoretic, J., A. Harrell, J.P. Rubin et al.** Pediatric demyelinating disease: Emerging patterns from multiple sclerosis to anti-myelin oligodendrocyte glycoprotein– associated encephalomyelitis. // *Neurographics*, 10, 2020, № 3, p. 139-151. ISSN 2637-8329.
768. **Ayrignac, X., P.A. Bilodeau, A. Prat et al.** Assessing the risk of multiple sclerosis disease-modifying therapies. // *Expert Review of Neurotherapeutics*, 19, 2019, № 7, p. 695-706. ISSN 1473-7175.
769. **Bahrani, E., C.E. Nunneley, S. Hsu et al.** Cutaneous Adverse Effects of Neurologic Medications. // *CNS Drugs*, 30, 2016, № 4, p. 245-267. ISSN 1172-7047.
770. **Baidya, F., M. Bohra, A. Datta et al.** Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases. // *Immunology*, 162, 2021, № 2, p. 160-178. ISSN 0019-2805.
771. **Bakaeva, T., S. Prasad.** For Massachusetts Eye and Ear Special Issue: Updates on Therapies for Multiple Sclerosis for the Ophthalmologist. // *Seminars in Ophthalmology*, 34, 2019, № 4, p. 270-278. ISSN 0882-0538.
772. **Barkat, M.A., A. El-Agawany, A.A. Khanfour et al.** The potential therapeutic effect of adipose tissue-derived mesenchymal stem cell transplantation on cuprizone model of multiple sclerosis in the mice. // *Egyptian Journal of Histology*, 43, 2020, № 1, p. 122-143. ISSN 1110-0559.
773. **Bašić Kes, V., M.J. Jurašić, I. Zavoreo et al.** Update on guidelines for pharmacological treatment of multiple sclerosis by the croatian society for neurovascular disorders of the Croatian medical association and Croatian society of neuroimmunology and neurogenetics [Osuvmernjene smjernice za farmakološko liječenje oboljelih od multiple skleroze hrvatskog društva za neurovaskularne



poremećaje Hrvatskog liječničkog zbora I hrvatskog društva za neuroimunologiju i neurogenetiku]. // *Acta Medica Croatica*, 72, 2018, № 3, p. 431-445. ISSN 1330-0164.

774. **Bastakis, G.G., N. Ktena, D. Karageos** et al. Models and treatments for traumatic optic neuropathy and demyelinating optic neuritis. // *Developmental Neurobiology*, 79, 2019, № 8, p. 819-836. ISSN 1932-8451.
775. **Bayas, A., M. Mäurer.** Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: Patient preference and adherence. // *Patient Preference and Adherence*, 9, 2015, p. 265-274. ISSN 1177-889X.
776. Beckmann, Y., S. Türe. Headache characteristics in multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 27, 2019, p. 112-116. ISSN 2211-0348.
777. **Bencsik, K., C. Rózsa, L. Vécsei.** Teriflunomide. New oral imaaunmodulant drug in therapy of multiple sclerosis [Teriflunomid: Új orális immun moduláló kezelés sclerosis multiplexben]. // *Ideggyógyászati Szemle*, 68, 2015, № 3/4, p. 79-87. ISSN 0019-1442.
778. **Binks, S., R. Dobson.** Established, new and future disease modifying therapies for MS. // *Progress in Neurology and Psychiatry*, 19, 2015, № 5, p. 27-35. ISSN 1367-7543.
779. **Biotti, D., J. Ciron.** First-line therapy in relapsing remitting multiple sclerosis. // *Revue Neurologique*, 174, 2018, № 6, p. 419-428. ISSN 0035-3787.
780. **Bsteh, G., E. Monz, L. Zamarian** et al. Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice – The PeRiCoMS-Study I. // *Journal of the Neurological Sciences*, 376, 2017, p. 71-75. ISSN 0022-510X.
781. **Bsteh, G., R. Ehling, L.M. Walchhofer** et al. Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis - The PaSiMS II study. // *PLoS ONE*, 12, 2017, № 7, art. no. e0181458. ISSN 1932-6203.
782. **Bucello, S., P. Annovazzi, P. Ragonese** et al. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. // *Journal of Neurology*, 2021. ISSN 0340-5354.
783. **Buron, M.D., T.A. Chalmer, F. Sellebjerg** et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study. // *Neurology*, 92, 2019, № 16, p. E1811-E1820. ISSN 0028-3878.

784. **Chan, A., J. De Seze, M. Comabella.** Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis. // *CNS Drugs*, 30, 2016, № 1, p. 41-51. ISSN 1172-7047.
785. **Chisari, C.G., S. Toscano, E. D'Amico et al.** An update on the safety of treating relapsing-remitting multiple sclerosis. // *Expert Opinion on Drug Safety*, 18, 2019, № 10, p. 925-948. ISSN 1474-0338.
786. **Coclitu, C., C.S. Constantinescu, R. Tanasescu.** The future of multiple sclerosis treatments. // *Expert Review of Neurotherapeutics*, 16, 2016, № 12, p. 1341-1356. ISSN 1473-7175.
787. **Cree, B.A.C.** Is TOPIC the last trial for clinically isolated syndrome? // *Nature Reviews Neurology*, 11, 2015, № 1, p. 6-7. ISSN 1759-4758.
788. **Cree, B.A.C., J.D. Bowen, H.P. Hartung et al.** Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. // *Multiple Sclerosis and Related Disorders*, 49, 2021, art. no. 102695. ISSN 2211-0348.
789. **Cristiano, E., J.I. Rojas, R. Alonso et al.** Consensus recommendations on the management of multiple sclerosis patients in Argentina. // *Journal of the Neurological Sciences*, 409, 2020, art. no. 116609. ISSN 0022-510X.
790. **Dahdaleh, M., R. Alroughani, M. Aljumah et al.** Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet? // *International Journal of Neuroscience*, 127, 2017, № 10, p. 944-951. ISSN: 0020-7454.
791. **D'Amico, E., C. Leone, C. Caserta et al.** Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal. // *Expert Review of Neurotherapeutics*, 15, 2015, № 7, p. 803-824. ISSN 1473-7175.
792. **Deleu, D., B. Mesraoua, B. Canibano et al.** Oral disease-modifying therapies for multiple sclerosis in the Middle Eastern and North African (MENA) region: an overview. // *Current Medical Research and Opinion*, 35, 2019, № 2, p. 249-260. ISSN 0300-7995.
793. **Deleu, D., B. Mesraoua, H. El Khider et al.** Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar. // *Current Medical Research and Opinion*, 33, 2017, № 3, p. 439-458. ISSN 0300-7995.
794. **Díaz Sánchez, M., M.D. Jiménez Hernández.** Treatment of demyelinating diseases. Multiple sclerosis [Tratamiento de las enfermedades desmielinizantes. Esclerosis múltiple]. // *Medicine (Spain)*, 12, 2016, № 23, p. 1337-1349. ISSN 0304-5412.

795. **Diebold, M., T. Derfuss.** Immunological treatment of multiple sclerosis. // *Seminars in Hematology*, WB Saunders, 53, 2016, art. no. 50869, p. S54-S57. ISSN 0037-1963.
796. **Donzé, C., C. Papeix, C. Lebrun-Frenay et al.** Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. // *Revue Neurologique*, 176, 2020, № 10, p. 804-822. ISSN 0035-3787.
797. **Duquette, P., P.S. Giacomini, V. Bhan et al.** Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis. // *Canadian Journal of Neurological Sciences*, 43, 2015, № 1, p. 33-43. ISSN 0317-1671.
798. **Eckstein, C., M.T. Bhatti.** Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. // *Survey of Ophthalmology*, 61, 2016, № 3, p. 318-332. ISSN 0039-6257.
799. **Ehling, R., G. Bsteh, F. Di Pauli et al.** Rethinking the importance of paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis: They do matter. // *Multiple Sclerosis and Related Disorders*, 9, 2016, p. 150-154. ISSN: 2211-0348.
800. **Elkjaer, M.L., T., Molnar, Z. Illes.** Teriflunomide for multiple sclerosis in real-world setting. // *Acta Neurologica Scandinavica*, 136, 2017, № 5, p. 447-453. ISSN 0001-6314
801. **English, C., J.J. Aloï.** New FDA-approved disease-modifying therapies for multiple sclerosis. // *Clinical Therapeutics*, 37, 2015, № 4, p. 691-715. ISSN 0149-2918.
802. **Epstein, D.J., J. Dunn, S. Deresinski et al.** Infectious complications of multiple sclerosis therapies: Implications for screening, prophylaxis, and management. // *Open Forum Infectious Diseases*, 5, 2018, № 8. ISSN 2328-8957.
803. **Faissner, S., R. Gold.** Oral therapies for multiple sclerosis. // *Cold Spring Harbor Perspectives in Medicine*, 9, 2019, № 1, art. no. a032011, 15 p. ISSN 2157-1422.
804. **Farber, R.S., A. Harel, F. Lublin.** Novel agents for relapsing forms of multiple sclerosis. // *Annual Review of Medicine*, 67, 2016, p. 309-321. ISSN 0066-4219.
805. **Farber, R.S., I.K. Sand.** Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 8, 2015, № 5, p. 212-232. ISSN 1756-2856.
806. **Fernández, Ó., J.C. Álvarez-Cermeño, R. Arroyo et al.** Review of the novelties from the 2014 ectrims-actrims joint congress, presented at the 7th post-ectrims meeting (i) [Revisión de las novedades del congreso conjunto ECTRIMS-ACTRIMS 2014, presentadas en la VII Reunión Post-ECTRIMS (I)]. // *Revista de Neurologia*, 61, 2015, № 5, p. 215-224. ISSN 0210-0010.

807. **Feucht, N., M. Maier, G. Lepenmetier** et al. Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis. // *Multiple Sclerosis Journal*, 25, 2019, № 2, p. 224-234. ISSN 1352-4585.
808. **Filippini, G., C. Del Giovane, M. Clerico** et al. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. // *Cochrane Database of Systematic Reviews*, 2017, № 4, art. no. CD012200. ISSN 1469-493X.
809. **Förster, M., J. Graf, J. Mares** et al. Drug Treatment of Clinically Isolated Syndrome. // *CNS Drugs*, 33, 2019, № 7, p. 659-676. ISSN 1172-7047.
810. **Fragoso, Y.D., J.B.B. Brooks**. Leflunomide and teriflunomide: Altering the metabolism of pyrimidines for the treatment of autoimmune diseases. // *Expert Review of Clinical Pharmacology*, 8, 2015, № 3, p. 315-320. ISSN 1751-2433.
811. **García Merino, A., J. Ramón Ara Callizo, O. Fernández Fernández** et al. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016 [Consenso para el tratamiento de la esclerosis múltiple 2016. Sociedad Española de Neurología]. // *Neurologia*, 32, 2017, № 2, p. 113-119. ISSN 0213-4853.
812. **Gasim, M., C.N. Bernstein, L.A. Graff** et al. Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. // *Multiple Sclerosis and Related Disorders*, 26, 2018, p. 124-156. ISSN 2211-0348.
813. **Gebhardt, M., P. Kropp, F. Hoffmann** et al. Headache in multiple sclerosis = Kopfschmerzen bei Multipler Sklerose. // *Nervenarzt*, 91, 2020, № 10, p. 926-935. ISSN 0028-2804.
814. **Gerardi, C., V. Bertele, S. Rossi** et al. Preapproval and postapproval evidence on drugs for multiple sclerosis. // *Neurology*, 90, 2018, № 21, p. 964-973. ISSN 0028-3878.
815. **Gerschenfeld, G., A. Servy, L. Valeyrie-Allanore** et al. Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis. // *Multiple Sclerosis*, 21, 2015, № 11, p. 1476-1477. ISSN 1352-4585.
816. **Ghezzi, A., M.P. Amato, N. Makhani**. Pediatric multiple sclerosis: Conventional first-line treatment and general management. // *Neurology*, 87, 2016, № 9, p. S97-S102. ISSN: 0028-3878.
817. **Ghezzi, A., T. Chitnis, A. K-Lafamme** et al. Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the

- FREEDOMS/FREEDOMS II Trials. // *Neurology and Therapy*, 8, 2019, № 2, p. 461-475. ISSN 2193-8253.
818. **Gholamzad, M., M. Ebtekar, M.S. Ardestani** et al. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. // *Inflammation Research*, 68, 2019, № 1, p. 25-38. ISSN 1023-3830.
  819. **Ginestal López, R.C.** Efficiency of the new therapeutic options for the treatment of multiple sclerosis; a pharmacoeconomic review [Eficiencia de las nuevas opciones terapéuticas para el tratamiento de la esclerosis múltiple; una revisión farmacoeconómica]. // *Pharmacoeconomics - Spanish Research Articles*, 15, 2018, № 1-4, p. 3-12. ISSN 1695-405X.
  820. **Giovannoni, G., H. Butzkueven, S. Dhib-Jalbut** et al. Brain health: time matters in multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 9, 2016, p. S5-S48. ISSN 2211-0348.
  821. **Grand'Maison, F., M. Yeung, S.A. Morrow** et al. Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment. // *Current Medical Research and Opinion*, 34, 2018, № 8, p. 1419-1430. ISSN 0300-7995.
  822. **Gregson, A., K. Thompson, S.E. Tsirka.** Emerging small-molecule treatments for multiple sclerosis: Focus on B cells [version 1; referees: 2 approved]. // *F1000Research*, 8, 2019, art. no. 245. ISSN 2046-1402.
  823. **Gross, R., F. Lublin.** Multiple sclerosis: An overview. – In: *Handbook of Relapsing-Remitting Multiple Sclerosis*, 2017, p. 1-16. ISBN 9783319406282; 9783319406268.
  824. **Grzegorski, T., J. Losy.** What do we currently know about the clinically isolated syndrome suggestive of multiple sclerosis? An update. // *Reviews in the Neurosciences*, 31, 2020, № 3, p. 335-349. ISSN 0334-1763.
  825. **Guarnera, C., P. Bramanti, E. Mazzon.** Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis. // *Drug Design, Development and Therapy*, 11, 2017, p. 2193-2207. ISSN 1177-8881.
  826. **Hainline, C., A. Lloyd-Smith, J.C. Rucker** et al. Acute Visual Deficits. – In: *Handbook of Neuroemergency Clinical Trials: Second Edition*, 2018, p. 281-302. ISBN 9780128041017; 9780128040645.
  827. **Harel, A., I. Katz-Sand.** Treatment strategies in multiple sclerosis. – In: *Handbook of Relapsing-Remitting Multiple Sclerosis*, 2017, p. 67-97. ISBN 9783319406282; 9783319406268.

828. **Hartung, H.P., J. Graf, D. Kremer.** Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. // *Journal of Neurology*, 267, 2020, № 2, p. 308-316. ISSN 0340-5354.
829. **He, D., C. Zhang, X. Zhao et al.** Teriflunomide for multiple sclerosis. // *Cochrane Database of Systematic Reviews*, 2016, № 3, art. no. CD009882. ISSN 1469-493X.
830. **Hosseini, Z., J. Matusinec, D.A. Rudko et al.** Morphology-specific discrimination between MS white matter lesions and benign white matter hyperintensities using ultra-high-field MRI. // *American Journal of Neuroradiology*, 39, 2018, № 8, p. 1473-1479. ISSN 0195-6108.
831. **Huang, D.R.** Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics. // *Neuroscience Bulletin*, 31, 2015, № 6, p. 745-754. ISSN 1673-7067.
832. **Iaffaldano, P., G. Lucisano, H. Butzkueven et al.** Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. // *Multiple Sclerosis Journal*, 2021. ISSN 1352-4585.
833. **Jakimovski, D., C.B. Vaughn, S. Eckert et al.** Long-term drug treatment in multiple sclerosis: safety success and concerns. // *Expert Opinion on Drug Safety*, 19, 2020, № 9, p. 1121-1142. ISSN 1474-0338.
834. **Jones, D.E.** Early Relapsing Multiple Sclerosis. // *CONTINUUM Lifelong Learning in Neurology*, 22, 2016, № 3, p. 744-760. ISSN 1080-2371.
835. **Kalincik, T.** Multiple sclerosis relapses: Epidemiology, outcomes and management. A systematic review. // *Neuroepidemiology*. 44, 2015, № 4, p. 199-214. ISSN: 0251-5350.
836. **Kallmann, B.A., K. Tiel-Wilck, J.S. Kullmann et al.** Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. // *Therapeutic Advances in Neurological Disorders*, 12, 2019. ISSN 1756-2856.
837. **Kretzschmar, B., H. Pellkofer, M.S. Weber.** The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis. // *Current Neurology and Neuroscience Reports*, 16, 2016, № 4, art. no. 38. ISSN 1528-4042.
838. **La Mantia, L., V. Prone.** Headache in multiple sclerosis and autoimmune disorders. // *Neurological Sciences*, 36, 2015, p. 75-78. ISSN 1590-1874.
839. **Landais, A., R. Alhendi, A. Gouverneur et al.** A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 17, 2017, p. 92-94. ISSN 2211-0348.

840. **Lander, B., M. Alvarado, I.C. Álvarez et al.** Venezuelan consensus guidelines on the use of magnetic resonance in diagnosis and follow up of patients with multiple sclerosis [Consenso venezolano para el uso de la resonancia magnética en el diagnóstico y seguimiento de pacientes con esclerosis múltiple]. // *Revista de Neurologia*, 65, 2017, № 3, p. 117-126. ISSN 0210-0010.
841. **Lebrun, C., J. De Seze.** Two new oral disease modifying therapies in relapsing remitting multiple sclerosis [Deux nouveaux traitements par voie orale dans la sclérose en plaques rémittente]. // *Revue Neurologique*, 170, 2014, № 12, p. 721-722. ISSN 0035-3787.
842. **Li, Z., X. Chen, Y. Chen et al.** Teriflunomide suppresses T helper cells and dendritic cells to alleviate experimental autoimmune uveitis. // *Biochemical Pharmacology*, 170, 2019, art. no. 113645. ISSN 0006-2952.
843. **Lineberry, N., J.A. Berlin, B. Mansi et al.** Recommendations to improve adverse event reporting in clinical trial publications: A joint pharmaceutical industry/journal editor perspective. // *BMJ (Online)*, 355, 2016, art. no. linn033422. ISSN 0959-8146.
844. **Linker, R., B.A. Kallmann, C. Kleinschnitz et al.** “Time is brain” in relapsing remitting multiple sclerosis: Current treatment concepts in immunotherapy [„Time is brain“ bei der schubförmigen Multiplen Sklerose: Aktuelle Behandlungskonzepte in der Immuntherapie]. // *Nervenarzt*, 86, 2015, № 12, p. 1528-1537. ISSN 0028-2804.
845. **Ma, L.L., Z.T. Wu, L. Wang et al.** Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity. // *Acta Pharmacologica Sinica*, 37, 2016, № 3, p. 415-424. ISSN 1671-4083.
846. **Malla, B., S. Cotten, R. Ulshoefer et al.** Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations. // *Therapeutic Advances in Chronic Disease*, 11, 2020. ISSN 2040-6223.
847. **Marques, V.D., G.R. Dos Passos, M.F. Mendes et al.** Brazilian consensus for the treatment of multiple sclerosis: Brazilian academy of neurology and brazilian committee on treatment and research in multiple sclerosis [Consenso Brasileiro para o tratamento da esclerose múltipla: Academia brasileira de neurologia e comitê brasileiro de tratamento e pesquisa em esclerose múltipla]. // *Arquivos de Neuro-Psiquiatria*, 76, 2018, № 8, p. 539-554. ISSN 0004-282X.
848. **Marziniak, M., K. Ghorab, W. Kozubski.** Variations in multiple sclerosis practice within Europe - Is it time for a new treatment guideline? // *Multiple Sclerosis and Related Disorders*, 8, 2016, p. 35-44. ISSN 2211-0348.

849. **Meltzer, E., E.M. Frohman, F.E. Costello** et al. Should Spinal MRI Be Routinely Performed in Patients with Clinically Isolated Optic Neuritis? // *Journal of Neuro-Ophthalmology*, 38, 2018, № 4, p. 502-510. ISSN 1070-8022.
850. **Meltzer, E., S. Prasad.** Updates and controversies in the management of acute optic neuritis. // *Asia-Pacific Journal of Ophthalmology*, 7, 2018, № 4, p. 251-256. ISSN 2162-0989.
851. **Merkel, B., H. Butzkueven, A.L. Traboulsee** et al. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. // *Autoimmunity Reviews*, 16, 2017, № 6, p. 658-665. ISSN 1568-9972.
852. **Metz, L.M.** Clinically isolated syndrome and early relapsing multiple sclerosis. // *CONTINUUM Lifelong Learning in Neurology*, 25, 2019, № 3, p. 670-688. ISSN 1080-2371.
853. **Michel, L., C. Laroche, A. Prat.** Update on treatments in multiple sclerosis. // *Presse Medicale*, 44, 2015, № 4, p. e137-e151. ISSN 0755-4982.
854. **Mike, A., Z.T. Kincses, L. Vécsei.** Magnetic resonance imaging in the course of alemtuzumab and teriflunomide therapy [Mágnese-szerezonancia-képalkotas alemtuzumab- és teriflunomidkezelés során]. // *Ideggyógyászati Szemle*, 70, 2017, № 1-2, p. 15-24. ISSN 0019-1442.
855. **Milo, R.** Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs. // *Expert Opinion on Pharmacotherapy*, 16, 2015, № 5, p. 659-673. ISSN 1465-6566.
856. **Modica, C.M., F. Schweser, M.L., Sudyn** et al. Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis. // *PLoS ONE*, 12, 2017, № 8, art. no. e0182729. ISSN 1932-6203.
857. **Montalban, X., J. Sastre-Garriga.** Diagnosis and trials of clinically isolated syndrome. // *The Lancet Neurology*, 13, 2014, № 10, p. 962-963. ISSN 1474-4422.
858. **Moss, H.E.** Visual consequences of medications for multiple sclerosis: The good, the bad, the ugly, and the unknown. // *Eye and Brain*, 9, 2017, p. 13-21. ISSN 1179-2744.
859. **Nandoskar, A., J. Raffel, A.S. Scalfari** et al. Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. // *Drugs*, 77, 2017, № 8, p. 885-910. ISSN 0012-6667.



860. **Niino, M., Y. Miyazaki.** Radiologically isolated syndrome and clinically isolated syndrome. // *Clinical and Experimental Neuroimmunology*, 8, 2017, p. 24-32. ISSN 1759-1961.
861. **Pagani Cassará, F., M.C. Curbelo, G. Vazquez et al.** Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina. // *Multiple Sclerosis and Related Disorders*, 41, 2020, art. no. 102043. ISSN 2211-0348.
862. **Pavelek, Z., L. Sobišek, J. Šarláková et al.** Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS. // *Frontiers in Neurology*, 11, 2021, art. no. 593527. ISSN 1664-2295.
863. **Pol, S., M. Sveinsson, M. Sudyn et al.** Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study. // *Journal of Neuroimaging*, 29, 2019, № 1, p. 52-61.
864. **Rae-Grant, A., G.S. Day, R.A. Marrie et al.** Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. // *Neurology*, 90, 2018, № 17, p. 777-788. ISSN 0028-3878.
865. **Reen, G.K., E. Silber, D.W. Langdon.** Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review. // *Journal of the Neurological Sciences*, 375, 2017, p. 107-122. ISSN 0022-510X.
866. **Rizvi, S.A.** Disease-Modifying Agents. // *Current Clinical Neurology*, 2020, p. 137-157. ISSN 1559-0585.
867. **Rizvi, S.A., J.A. Stone, S.T. Chaudhry et al.** Clinical Decision-Making in the Management of Multiple Sclerosis. // *Current Clinical Neurology*, 2020, p. 159-177. ISSN 1559-0585.
868. **Rocca, M.A., P. Preziosa, M. Filippi.** Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. // *Expert Review of Neurotherapeutics*, 19, 2019, № 9, p. 835-866. ISSN 1473-7175.
869. **Rojas, J.I., A. Pappolla, L. Patrucco et al.** Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis? // *Multiple Sclerosis and Related Disorders*, 39, 2020, art. no. 101931. ISSN 2211-0348.
870. **Rommer, P.S., R. Milo, M.H. Han et al.** Immunological aspects of approved MS therapeutics. // *Frontiers in Immunology*, 2019, art. no. 1564. ISSN 1664-3224.

871. **Salmen, A., A. Chan.** New therapeutic options in multiple sclerosis [Neue Therapieoptionen bei der Multiplen Sklerose]. // *Fortschritte der Neurologie Psychiatrie*, 83, 2015, № 3, p. 174-186. ISSN 0720-4299.
872. **Sand, I.K.** Classification, diagnosis, and differential diagnosis of multiple sclerosis. // *Current Opinion in Neurology*, 28, 2015. № 3, p. 193-205. ISSN 1350-7540.
873. **Sastre-Garriga, J., D. Pareto, M. Battaglini** et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. // *Nature Reviews Neurology*, 16, 2020, № 3, p. 171-182. ISSN 1759-4758.
874. **Scolding, N., D. Barnes, S. Cader.** Association of British Neurologists: Revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. // *Practical Neurology*, 15, 2015, № 4, p. 273-279. ISSN 1474-7758.
875. **Scott, L.J.** Teriflunomide: A Review in Relapsing–Remitting Multiple Sclerosis. // *Drugs*, 2019. ISSN 0012-6667.
876. **Scotto, R., A. Reia, A.R. Buonomo** et al. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. // *Expert Opinion on Drug Safety*, 2021. ISSN 1474-0338.
877. **Skundric, D.S.** Basic approaches in therapy of multiple sclerosis (MS) and related diseases: Current achievement and prospective. // *Central Nervous System Agents in Medicinal Chemistry*, 18, 2018, № 1, p. 21-31. ISSN: 1871-5249.
878. **Soini, E., J. Joutseno, M.L. Sumelahti.** Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis. // *Clinical Therapeutics*, 39, 2017, № 3, p. 537-557.e10. ISSN 0149-2918.
879. **Sorensen, P.S., F. Sellebjerg, H.P. Hartung** et al. The apparently milder course of multiple sclerosis: Changes in the diagnostic criteria, therapy and natural history. // *Brain*, 143, 2020, № 9, p. 2637-2652. ISSN 0006-8950.
880. **Subei, A.M., D. Ontaneda.** Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. // *CNS Drugs*, 29, 2015, № 9, p. 759-771. ISSN 1172-7047. CODEN: CNDRE
881. **Thouvenot, E.** Should we treat patients with radiologically isolated syndrome (RIS)? Yes. // *Revue Neurologique*, 174, 2018, № 10, p. 689-692. ISSN 0035-3787.
882. **Thouvenot, É.** Update on clinically isolated syndrome. // *Presse Medicale*, 44, 2015, № 4, p. e121-e136. ISSN 0755-4982.
883. **Tintore, M., A. Vidal-Jordana, J. Sastre-Garriga.** Treatment of multiple sclerosis — success from bench to bedside. // *Nature Reviews Neurology*, 15, 2019, № 1, p. 53-58. ISSN 1759-4758.

884. **Torkildsen, O., K.M. Myhr, L. Bø.** Disease-modifying treatments for multiple sclerosis - a review of approved medications. // *European Journal of Neurology*, 23, 2016, p. 18-27. ISSN 1351-5101.
885. **Totaro, R., C. Di Carmine, C. Marini et al.** Multiple sclerosis - New treatment modalities. // *Indian Journal of Medical Research*, 142, 2015, № 6, p. 647-654. ISSN 0971-5916.
886. **Trojano, M., M. Tintore, X. Montalban et al.** Treatment decisions in multiple sclerosis-insights from real-world observational studies. // *Nature Reviews Neurology*, 13, 2017, № 2, p. 105-118. ISSN 1759-4758.
887. **Tsetso, S., A.O. Rossetti, P. Michel et al.** News in neurology 2014 [Neurologie]. // *Revue Medicale Suisse*, 11, 2015, № 456/457, p. 91-96. ISSN 1660-9379.
888. **Tsivgoulis, G., A.H. Katsanos, N. Grigoriadis et al.** The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: A systematic review and meta-analysis. // *Therapeutic Advances in Neurological Disorders*, 8, 2015, № 5, p. 193-202. ISSN 1756-2856.
889. **Tur, C., A.J. Thompson.** Early accurate diagnosis crucial in multiple sclerosis. // *Practitioner*, 259, 2015, № 1785, p. 21-28. ISSN 0032-6518.
890. **Tur, C., M. Moccia, F. Barkhof et al.** Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. // *Nature Reviews Neurology*, 14, 2018, № 2, p. 75-93. ISSN 1759-4758.
891. **Van Wijmeersch, B., C. Oreja-Guevara, R. Milo.** Can we offer more to patients with multiple sclerosis? // *European Neurological Review*, 10, 2015, № 2, p. 139-147. ISSN 1758-3837.
892. **Vaughn, C.B., D. Jakimovski, K.S. Kavak et al.** Epidemiology and treatment of multiple sclerosis in elderly populations. // *Nature Reviews Neurology*, 15, 2019, № 6, p. 329-342. ISSN 1759-4758.
893. **Vermersch, P.** New and evolving treatment goals in multiple sclerosis – The role of teriflunomide. // *European Neurological Review*, 12, 2017, № 1, p. 37-41. ISSN 1758-3837.
894. **Vermersch, P., J. Hobart, C. Dive-Pouletty et al.** Measuring treatment satisfaction in MS: Is the treatment satisfaction questionnaire for medication fit for purpose? // *Multiple Sclerosis*, 23, 2017, № 4, p. 604-613. ISSN 1352-4585.
895. **Vermersch, P., J. Hobart, C. Dive-Pouletty et al.** Measuring treatment satisfaction in MS: Is the treatment satisfaction questionnaire for medication fit for purpose? // *Multiple Sclerosis*, 23, 2017, № 4, p. 604-613. ISSN 1352-4585.

896. **Vermersch, P., J. Oh, M. Cascione et al.** Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. // *Multiple Sclerosis and Related Disorders*, 43, 2020, art. no. 102158. ISSN 2211-0348.
897. **Vieira, M.C., D. Conway, G.M. Cox et al.** Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study. // *Current Medical Research and Opinion*, 36, 2020, № 2, p. 261-270. ISSN 0300-7995.
898. **Voelter, H.U., H. Hildebrandt, A. Kastrup.** Impact of disease-modifying therapies on fatigue in multiple sclerosis [MS-assozierte Fatigue - Welche Immuntherapie hilft?]. // *Aktuelle Neurologie*, 43, 2016, № 8, p. 511-518. ISSN 0302-4350.
899. **Weinstock-Guttman, B., E. Grazioli, C. Kolb.** Multiple Sclerosis Subtypes: How the Natural History of Multiple Sclerosis Was Challenged due to Treatment. In: *Translational Neuroimmunology in Multiple Sclerosis: From Disease Mechanisms to Clinical Applications*, 2016, p. 55-65. ISBN 9780128020074; 9780128019146.
900. **Wiendl, H., S.G. Meuth.** Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. // *Drugs*, 75, 2015, № 9, art. no. 411, p. 947-977. ISSN 0012-6667.
901. **Wilbur, C., E.A. Yeh.** Acute and Chronic Therapies in Pediatric Inflammatory Central Nervous System Diseases. // *Journal of Pediatric Neurology*, 16, 2018, № 3, p. 202-216. ISSN 1304-2580.
902. **Wilbur, C., E.A. Yeh.** Radiologically isolated syndrome in children: Current knowledge and future directions. // *Multiple sclerosis and related disorders* 24, 2018, p. 79-84. ISSN 2211-0348.
903. **Wilbur, C., E.A. Yeh.** Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments. // *Pediatric Drugs*, 21, 2019, № 3, p. 137-152. ISSN 1174-5878.
904. **Wingerchuk, D.M., B.G. Weinshenker.** Disease modifying therapies for relapsing multiple sclerosis. // *BMJ (Online)*, 354, 2016, art. no. i3518. ISSN 0959-8146.
905. **Winkelmann, A., M. Loebermann, E.C. Reisinger.** Disease-modifying therapies and infectious risks in multiple sclerosis. // *Nature Reviews Neurology*, 12, 2016, № 4, p. 217-233. ISSN 1759-4758.
906. **Xie, Z.X., H.L. Zhang, X.J. Wu et al.** Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis. // *Mediators of Inflammation*, 2015, art. no. 513295. ISSN 0962-9351.

907. **Xu, M., X. Lu, J. Fang** et al. The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials. // *Journal of Clinical Neuroscience*, 2016, 33, p. 28-31. ISSN 0967-5868.
908. **Yong, H., G. Chartier, J. Quandt**. Modulating inflammation and neuroprotection in multiple sclerosis. // *Journal of Neuroscience Research*, 96, 2018, № 6, p. 927-950. ISSN 0360-4012.
909. **Zhou, R., Q. Zeng, H. Yang** et al. Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018. // *Frontiers in Neurology*, 12, 2021, art. no. 651511. ISSN 1664-2295.
910. **Ziemssen, T., T. Derfuss, N. de Stefano** et al. Optimizing treatment success in multiple sclerosis. // *Journal of Neurology*, 263, 2016, № 6, p. 1053-1065. ISSN 0340-5354.
911. **Zivadinov, R., K. Kresa-Reahl, B. Weinstock-Guttman** et al. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. // *Journal of Comparative Effectiveness Research*, 8, 2019, № 5, p. 305-316. ISSN 2042-6305.
912. **Zivadinov, R., M. Ramanathan, J. Hagemer** et al. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 36, 2020, art. no. 101388. ISSN 2211-0348.
913. **Zivadinov, R., M.G. Dwyer, D.P. Ramasamy** et al. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. // *Journal of Neuroimaging*, 25, 2015, № 6, p. 989-995. ISSN 1051-2284.
914. **Zivadinov, R., M.G. Dwyer, E. Carl**. Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. // *Therapeutic Advances in Neurological Disorders*, 13, 2020. ISSN 1756-2856.
915. **Zivadinov, R., N. Bergsland, J. Hagemer**. Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. // *Journal of the Neurological Sciences*, 388, 2018, p. 175-181. ISSN 0022-510X.

Ferreira, J.J, Lees A, Rocha J-F, Poewe W, Rakol O, Soares-da-Silva P. for the Bi-Park 1 investigators (... **Dimitar Maslarov**, Bulgaria, First MHAT-Sofia, Clinic of nerve diseases, 8 patients enrolled). Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomized, double-blind, controlled trial. // *The Lancet Neurology*, 15, 2016, № 2, p. 154-165. ISSN 1474-4422 published online Dec, 22 2015, [http://dx.doi.org/10.1016/S1474-4422\(15\)00336-1](http://dx.doi.org/10.1016/S1474-4422(15)00336-1)

#### Cited by:

916. **Annus, Á., L. Vécsei.** Spotlight on opicapone as an adjunct to levodopa in parkinson's disease: Design, development and potential place in therapy. // *Drug Design, Development and Therapy*, 11, 2017, p. 143-151. ISSN 1177-8881.
917. **Antonini, A., E. Moro, C. Godeiro** et al. Medical and surgical management of advanced Parkinson's disease. // *Movement Disorders*, 33, 2018, № 6, p. 900-908. ISSN 0885-3185.
918. **Anwar, F., S. Naqvi, F.A. Al-Abbasi** et al. Targeting COVID-19 in Parkinson's patients: Drugs repurposed. // *Current Medicinal Chemistry*, 28, 2021, № 12, p. 2392-2408. ISSN 0929-8673.
919. **Aradi, S.D., R.A. Hauser.** Medical Management and Prevention of Motor Complications in Parkinson's Disease. // *Neurotherapeutics*, 17, 2020, № 4, p. 1339-1365. ISSN 1933-7213.
920. **Bogetofte, H., A. Alamyar, M. Blaabjerg** et al. Levodopa therapy for parkinson's disease: History, current status and perspectives. // *CNS and Neurological Disorders - Drug Targets*, 19, 2020, № 8, p. 572-583. ISSN 1871-5273.
921. **Bonifácio, M.J., F. Sousa, P. Soares-da-Silva.** Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. // *European Journal of Pharmacology*, 892, 2021, art. no. 173742. ISSN 0014-2999.
922. **Borzi, L., M. Varrecchia, G. Olmo** et al. Home monitoring of motor fluctuations in Parkinson's disease patients. // *Journal of Reliable Intelligent Environments*, 5, 2019, № 3, p. 145-162. ISSN 2199-4668.
923. **Bougea, A., N. Spantideas, A. Katoulis** et al. Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach. // *Acta Neurologica Belgica*, 119, 2019, № 3, p. 325-336. ISSN 0300-9009.
924. **Boyle, A., J. Suescun, M.C. Schiess.** Opicapone a novel adjunct for an old standard. // *JAMA Neurology*, 74, 2017, № 2, p. 153-154. ISSN 2168-6149.
925. **Buhmann, C., R. Hilker, P. Lingor** et al. Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. // *Journal of Neural Transmission*, 124, 2017, № 8, p. 1005-1013. ISSN 0300-9564.

926. **Cabreira, V., P. Soares-da-Silva, J. Massano.** Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. // *Drugs*, 79, 2019, № 6, p. 593-608. ISSN 0012-6667.
927. **Cacciatore, I., M. Ciulla, L. Marinelli et al.** Advances in prodrug design for Parkinson's disease. // *Expert Opinion on Drug Discovery*, 13, 2018, № 4, p. 295-305. ISSN 1746-0441.
928. **Castro Caldas, A., T. Teodoro, J.J. Ferreira.** The launch of opicapone for Parkinson's disease: negatives versus positives. // *Expert Opinion on Drug Safety*, 17, 2018, № 3, p. 331-337. ISSN 1474-0338.
929. **Cellai, L., K. Carvalho, E. Faivre et al.** The adenosinergic signaling: A complex but promising therapeutic target for Alzheimer's disease. // *Frontiers in Neuroscience*, 12, 2018, art. no. 520. ISSN 1662-4548.
930. **Corvol, J.-C.** Optimisation of classic treatments and new therapeutic perspectives in Parkinson's disease = Optimisation des traitements classiques et nouvelles perspectives thérapeutiques dans la maladie de Parkinson. // *Bulletin de l'Academie Nationale de Medecine*, 204, 2020, № 1, p. 60-65. ISSN 0001-4079.
931. **Devos, D., C. Moreau.** Opicapone for motor fluctuations in Parkinson's disease. // *The Lancet Neurology*, 15, 2016, № 2, p. 127-128. ISSN 1474-4422.
932. **Ettcheto, M., O. Busquets, E. Sánchez-Lopez et al.** The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. // *Expert Opinion on Drug Discovery*, 15, 2020, № 9, p. 993-1004. ISSN 1746-0441.
933. **Fabbri, M., M.M. Rosa, J.J. Ferreira.** Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach. // *Drugs and Aging*, 35, 2018, № 12, p. 1041-1054. ISSN 1170-229X.
934. **Fernandes, B.J.D., A.D.S.A. Filho.** Pharmacological profile of opicapone in patients with Parkinson's disease under treatment with levodopa = Perfil farmacológico da opicapona em pacientes com doença de Parkinson sob tratamento com levodopa. // *Revista Brasileira de Neurologia e Psiquiatria*, 22, 2018, № 1, p. 60-72. ISSN 1414-0365.
935. **Fernández-Espejo, E., F. Rodriguez de Fonseca, J. Suárez et al.** Cerebrospinal fluid lactoperoxidase level is enhanced in idiopathic Parkinson's disease, and correlates with levodopa equivalent daily dose. // *Brain Research*, 1761, 2021, art. no. 147411. ISSN 0006-8993.
936. **Fernández-espejo, E., F.R. de Fonseca, J. Suárez et al.** Native  $\alpha$ -synuclein, 3-nitrotyrosine proteins, and patterns of nitro- $\alpha$ -synuclein-immunoreactive inclusions

- in saliva and submandibular gland in parkinson's disease. // *Antioxidants*, 10, 2021, № 5, art. no. 715. ISSN 2076-3921.
937. **Fietzek, U.M., A.O. Ceballos-Baumann.** Pharmacotherapy in Parkinson's disease = Update Pharmakotherapie bei Parkinson. // *Nervenheilkunde*, 37, 2018, № 4, p. 233-242. ISSN 0722-1541.
  938. **Finberg, J.P.M.** Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease. // *Journal of Neural Transmission*, 126, 2019, № 4, p. 433-448. ISSN 0300-9564.
  939. **Fox, S.H., R. Katzenschlager, S.-Y. Lim** et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. // *Movement Disorders*, 33, 2018, № 8, p. 1248-1266. ISSN 0885-3185.
  940. **Frouni, I., C. Kwan, S.G. Nuara** et al. Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. // *Journal of Neural Transmission*, 128, 2021, № 1, p. 73-81. ISSN 0300-9564.
  941. **Greten, S., J.I. Müller-Funogea, F. Wegner** et al. Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. // *Journal of Neural Transmission*, 128, 2021, № 1, p. 49-60. ISSN 0300-9564.
  942. **Hansen, R.N., K. Suh, M. Serbin** et al. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. // *Journal of Medical Economics*, 24, 2021, № 1, p. 563-569. ISSN 1369-6998.
  943. **Hauser, R.A., R.R. Walsh, R. Pahwa** et al. Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. // *Frontiers in Neurology*, 12, 2021, art. no. 645706. ISSN 1664-2295.
  944. **Hayes, M.W., V.S.C. Fung, T.E. Kimber** et al. Updates and advances in the treatment of Parkinson disease. // *Medical Journal of Australia*, 211, 2019, № 6, p. 277-283. ISSN 0025-729X.
  945. **Hengartner, D., H.H. Fernandez.** The next chapter in symptomatic Parkinson disease treatments. // *Parkinsonism and Related Disorders*, 59, 2019, p. 39-48. ISSN 1353-8020.
  946. **Jost, W.H.** Pharmacological treatment of motor symptoms in Parkinson's diseases = Medikamentöse Therapie der motorischen Symptome beim Morbus Parkinson. // *Nervenarzt*, 88, 2017, № 4, p. 373-382. ISSN 0028-2804.



947. **Katsaiti, I., J. Nixon.** Are there benefits in adding catechol-O methyltransferase inhibitors in the pharmacotherapy of Parkinson's disease patients? A systematic review. // *Journal of Parkinson's Disease*, 8, 2018, № 2, p. 217-231. ISSN 1877-7171.
948. **Kayki-Mutlu, G., M.C. Michel.** A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. // *Naunyn-Schmiedeberg's Archives of Pharmacology*, 394, 2021, № 5, p. 839-852. ISSN 0028-1298.
949. **Klietz, M., S. Greten, F. Wegner et al.** Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients. // *Drugs and Aging*, 2019. ISSN 1170-229X.
950. **Kobylecki, C.** Update on the diagnosis and management of Parkinson's disease. // *Clinical Medicine, Journal of the Royal College of Physicians of London*, 20, 2020, № 4, p. 393-398. ISSN 1470-2118.
951. **Kropf, W. M.** Parkinson – A challenge in individual and multimodal treatment = Morbus Parkinson - individuelle Therapie mit multimodaler Herausforderung. // *Krankenhauspharmazie*, 40, 2019, № 5, p. 227-239. ISSN 0173-7597.
952. **Kulisevsky, J., L. Oliveira, S.H. Fox.** Update in therapeutic strategies for Parkinson's disease. // *Current Opinion in Neurology*, 31, 2018, № 4, p. 439-447. ISSN 1350-7540.
953. **Kurtis, M.M., C. Rodriguez-Blazquez, I. Pareés.** A Review of Randomized Phase III Pharmacological Clinical Trials for Motor Symptoms in Parkinson's Disease Patients and Quality of Evidence Recommendations. // *Neuromethods*, 160, 2021, p. 87-108. ISSN 0893-2336.
954. **Laurencin, C., T. Danaila, E. Broussolle et al.** Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited. // *Revue Neurologique*, 172, 2016, № 8/9, p. 512-523. ISSN 0035-3787.
955. **Leta, V., D.J. Van Wamelen, A. Sauerbier et al.** Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward towards Cost Savings for Healthcare Systems? // *Journal of Parkinson's Disease*, 10, 2020, № 4, p. 1535-1539. ISSN 1877-7171.
956. **Linazasoro-Cristóbal, G., L.J. López del Val, P.G. Ruiz-Espiga et al.** Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts = Optimización del manejo clínico de opicapona en la enfermedad de Parkinson. Recomendaciones de expertos españoles. // *Revista de Neurologia*, 70, 2020, № 1, p. S1-S11. ISSN 0210-0010.

957. **Marsili, L., R. Marconi, C. Colosimo.** Treatment Strategies in Early Parkinson's Disease. // *International Review of Neurobiology*, 132, 2017, p. 345-360. ISSN 0074-7742.
958. **Meira-Carvalho, F., J.D. Da Silva, M. Rodrigues.** Opicapone in Parkinson's Disease: Real-World Data from a Portuguese Center. // *European Neurology*, 2021. ISSN 0014-3022.
959. **Müller, T.** Opicapone. // *Psychopharmakotherapie*, 23, 2016, № 5, p. 189-196. ISSN 0944-6877.
960. **Nagao, K.J., N.J. Patel.** From medications to surgery: Advances in the treatment of motor complications in Parkinson's disease. // *Drugs in Context*, 8, 2019, art. no. 212592. ISSN 1745-1981.
961. **Nomoto, M., A. Takeda, K. Iwai et al.** Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study. // *Clinical Pharmacology in Drug Development*, 10, 2021, № 2, p. 173-179. ISSN 2160-763X.
962. **Oertel, W.H.** Recent advances in treating Parkinson's disease. // *F1000Research*, 6, 2017, art. no. 260. ISSN 2046-1402.
963. **Olanow, C.W., F. Stocchi.** Levodopa: A new look at an old friend. // *Movement Disorders*, 33, 2018, № 6, p. 859-866. ISSN 0885-3185.
964. **Opicapone (Ongentys) — A comt inhibitor for Parkinson's disease.** // *Medical Letter on Drugs and Therapeutics*, 63, 2021, № 1615, p. 3-5. ISSN 0025-732X.
965. **Opicapone (ongentys<sup>o</sup>) and Parkinson's disease with motor fluctuations A single daily dose, but more dyskinesia.** // *Prescrire International*, 29, 2020, № 211, p. 5-6. ISSN 1167-7422.
966. **Paul, A., K.S. Yadav.** Parkinson's disease: Current drug therapy and unraveling the prospects of nanoparticles. // *Journal of Drug Delivery Science and Technology*, 58, 2020, art. no. 101790. ISSN 1773-2247.
967. **Pfister, F.M.J., T.T. Um, D.C. Pichler et al.** High-Resolution Motor State Detection in Parkinson's Disease Using Convolutional Neural Networks. // *Scientific Reports*, 10, 2020, № 1, art. no. 5860. ISSN 2045-2322.
968. **Pinheiro, S.D., M.P. Serrão, T. Silva et al.** Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors. // *European Journal of Pharmacology*, 847, 2019, p. 53-60. ISSN 0014-2999.
969. **Rath, S.N., L. Jena, R. Bhuyan et al.** In silico discovery and evaluation of phytochemicals binding mechanism against human Catechol-O-methyltransferase

as a putative bioenhancer of L-DOPA therapy in parkinson disease. // *Genomics and Informatics*, 19, 2021, № 1, art. no. e7. ISSN 2234-0742.

970. **Rodríguez-Sanz, A., E. Peña-Llamas, A. Alonso-Cánovas** et al. Clinical experience in the treatment of motor fluctuations in Parkinson's disease. Delphi consensus of a group of experts in movement disorders = Experiencia clínica en el tratamiento de las fluctuaciones motoras en la enfermedad de Parkinson. Consenso Delphi de un grupo de expertos en trastornos del movimiento. // *Revista de Neurologia*, 71, 2020, № 11, p. 407-420. ISSN 0210-0010.
971. **Salamon, A., D. Zádori, L. Szpisjak** et al. Opicapone for the treatment of Parkinson's disease: an update. // *Expert Opinion on Pharmacotherapy*, 20, 2019, № 18, p. 2201-2207. ISSN 1465-6566.
972. **Scott, L.J.** Opicapone in Parkinson's disease: a profile of its use. // *Drugs and Therapy Perspectives*, 33, 2017, № 7, p. 303-310. ISSN 1172-0360.
973. **Scott, L.J.** Opicapone: A Review in Parkinson's Disease. // *CNS Drugs*, 35, 2021, № 1, p. 121-131. ISSN 1172-7047.
974. **Scott, L.J.** Opicapone: A Review in Parkinson's Disease. // *Drugs*, 76, 2016, № 13, p. 1293-1300. ISSN 0012-6667.
975. **Silva, M., V. Caro, C. Guzmán** et al.  $\alpha$ -Synuclein and tau, two targets for dementia. // *Studies in Natural Products Chemistry*, 67, 2021, p. 1-25. ISSN 1572-5995.
976. **Silva, S., A.J. Almeida, N. Vale.** Importance of nanoparticles for the delivery of antiparkinsonian drugs. // *Pharmaceutics*, 13, 2021, № 4, art. no. 508. ISSN 1999-4923.
977. **St. Onge, E., M. Vanderhoof, S. Miller.** Ongentys (Opicapone): A New COMT Inhibitor for the Treatment of Parkinson's Disease. // *Annals of Pharmacotherapy*, 2020. ISSN 1060-0280.
978. **Straka, Skorvánek, M., K. Danterova, M. Grofik** et al. Meeting reporter. // *Current Opinion in Neurology*, 31, 2018, p. 1-24. ISSN 1350-7540.
979. **Svetel, M., A. Tomić, N. Kresojević** et al. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease. // *Expert Opinion on Drug Metabolism and Toxicology*, 14, 2018, № 3, p. 353-360. ISSN 1742-5255.
980. **Takeda, A., R. Takahashi, Y. Tsuboi** et al. Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations. // *Journal of Neural Transmission*, 128, 2021, № 3, p. 337-344. ISSN 0300-9564.

981. **Takeda, A., R. Takahashi, Y. Tsuboi** et al. Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations. // *Movement Disorders*, 36, 2021, № 2, p. 415-423. ISSN 0885-3185.
982. **Trenkwalder, C., M. Kuoppamäki, M. Vahteristo** et al. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial. // *Neurology*, 92, 2019, № 13, p. E1487-E1496. ISSN 0028-3878.
983. **Vaz, R.L., D. Chapela, J.E. Coelho** et al. Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia. // *Neuroscience*, 424, 2020, p. 58-71. ISSN 0306-4522.
984. **Verber, D., D. Novak, M. Borovič** et al. EQUIDopa: A responsive web application for the levodopa equivalent dose calculator. // *Computer Methods and Programs in Biomedicine*, 196, 2020, art. no. 105633. ISSN 0169-2607.
985. **Vijiaratnam, N., T. Foltynie**. Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease. // *Drugs*, 80, 2020, № 8, p. 775-796. ISSN 0012-6667.
986. **Vokurka, P., A. Barron, S. Sumaria** et al. Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone. // *Movement Disorders Clinical Practice*, 7, 2020, № 8, p. 955-960. ISSN 2330-1619.
987. **Waldthaler, J., L. Timmermann**. Update on diagnostics and therapy of idiopathic Parkinson's disease = Neues zu Diagnostik und Therapie des idiopathischen Parkinson-Syndroms. // *Fortschritte der Neurologie Psychiatrie*, 87, 2019, № 8, p. 445-461. ISSN 0720-4299.
988. **Woitalla, D., R. Krüger, S. Lorenzl** et al. The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease = Grundlagen und Stellenwert der COMT- und MAO-B-Inhibitoren in der Therapie des idiopathischen Parkinson-Syndroms. // *Fortschritte der Neurologie Psychiatrie*, 88, 2020, № 9, p. 620-633. ISSN 0720-4299.
989. **You, H., L.-L. Mariani, G. Mangone** et al. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. // *Cell and Tissue Research*, 373, 2018, № 1, p. 111-135. ISSN 0302-766X.
990. **Yuan, S., Y.-Q. Luo, J.-H. Zuo** et al. New drug approvals for 2020: Synthesis and clinical applications. // *European Journal of Medicinal Chemistry*, 215, 2021, art. no. 113284. ISSN 0223-5234.

991. **Zeuner, K.E., E. Schäffer, F. Hopfner et al.** Progress of Pharmacological Approaches in Parkinson's Disease. // *Clinical Pharmacology and Therapeutics*, 105, 2019, № 5, p. 1106-1120. ISSN 0009-9236.

Kolyovska, V., V. Pavlova, I. Iliev, S. Todorov, **D. Maslarov**. Low salt diet is associated with the prevention of exacerbation in patients with relapsing remitting MS. // *Journal of Pharmacy and Pharmacology*, 2015, № 3, p. 170-172. ISSN 2328-2150.

**Cited by:**

992. **Abdoli, A.** Salt and miscarriage: Is there a link?. // *Medical hypotheses*, 89, 2016, p. 58-62. ISSN 0306-9877.

Petrova, J., V. Manolov, B. Milev, D. Vasilev, V. Velchev, V. Vasilev and **D. Maslarov**. Assessment of biomarkers in patients with carotid atherosclerosis. // *American journal of neuroprotection and neuroregeneration*, 7, 2015, № 1, p. 69-71. ISSN 1947-2951; ISSN 1947-296X.

**Cited by:**

993. **Psycheva, M., Z. Zahariev T. Deneva**. Biomarkers for unstable atherosclerotic plaques in carotid arteries. // *Trakia journal of sciences*, 17, 2019, № 3, p. 290-294. ISSN 1313-7050. Достъпно на: [https://pdfs.semanticscholar.org/4196/1defcd745f512d5a561d66db0b66e9f056b4.pdf?\\_ga=2.213857236.1554188850.1621924828-1554326389.1617187129](https://pdfs.semanticscholar.org/4196/1defcd745f512d5a561d66db0b66e9f056b4.pdf?_ga=2.213857236.1554188850.1621924828-1554326389.1617187129)

Zadeh, W., A. Escartin, W. Byrnes, F. Tennigkeit, S. Borghs, T. Li, P. Dedeken, Marc De Backer on behalf of the SP0954 Study Group: ... **Maslarov D.** Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial W. *Seizure*, Elsevier 31, 2015, 72-79.

**Cited by:**

994. **Adigun, M., J. McLemore, K. Williamson**. Antiepileptic drugs for epilepsy. // *U.S. Pharmacist*, 42, 2017, № 1. ISSN 0148-4818.
995. **Arabi, M., T. Alsaadi, W. Nasreddine et al.** Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region. // *Epilepsy and Behavior*, 84, 2018, p. 118-121. ISSN 1525-5050.
996. **Borzi, G., G. Di Gennaro, F.C. Schmitt et al.** Lacosamide in patients with temporal lobe epilepsy: An observational multicentric open-label study. // *Epilepsy and Behavior*, 58, 2016, p. 111-114. ISSN 1525-5050.

997. **Coppola, G., G. Iapadre, F.F. Operto et al.** New developments in the management of partial-onset epilepsy: Role of brivaracetam. // *Drug Design, Development and Therapy*, 11, 2017, p. 643-657. ISSN 1177-8881.
998. **De Greef, B.T.A., J.G.J. Hoeijmakers, M. Geerts et al.** Lacosamide in patients with Na v 1.7 mutations-related small fibre neuropathy: A randomized controlled trial. // *Brain*, 142, 2019, № 2, p. 263-275. ISSN 0006-8950.
999. **Devinsky, O., J.H. Cross, L. Laux et al.** Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. // *New England Journal of Medicine*, 376, 2017, № 21, p. 2011-2020. ISSN 0028-4793.
1000. **Fishman, J., M. Martin, D.M. Labiner et al.** Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States. // *Epilepsy and Behavior*, 99, 2019, art. no. 106331. ISSN 1525-5050.
1001. **Fong, J.K.Y., E.L.Y. Chan, H. Leung et al.** An update of the Hong Kong Epilepsy Guideline: Consensus statement on the use of antiepileptic drugs in Hong Kong. // *Hong Kong Medical Journal*, 23, 2017, № 1, p. 74-88. ISSN 1024-2708.
1002. **Hoy, S.M.** Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy. // *CNS Drugs*, 32, 2018, № 5, p. 473-484. ISSN 1172-7047.
1003. **Karlov, V.A., A.B. Guekht, V.I. Guzeva et al.** Algorithms of mono- and polytherapy in clinical epileptology. // *Zhurnal Nevrologii i Psichiatrii imeni S.S. Korsakova*, 116, 2016, № 7, p. 120-129. ISSN 1997-7298.
1004. **Kay, L., S. Bauer, F. Rosenow et al.** Medical treatment of acute seizures and epilepsy = Medikamentöse Therapie von epileptischen Anfällen und Epilepsien. // *Nervenheilkunde*, 38, 2019, № 12, p. 887-899. ISSN 0722-1541.
1005. **Kondrat-Wróbel, M.W., J.J. Łuszczki.** Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in a mouse tonic-clonic seizure model. // *Advances in Clinical and Experimental Medicine*, 27, 2018, № 7, p. 881-886. ISSN 1899-5276.
1006. **Kurada, A.V., T. Srinivasan, S. Hammond et al.** Seizure detection devices for use in antiseizure medication clinical trials: A systematic review. // *Seizure*, 66, 2019, p. 61-69. ISSN 1059-1311.
1007. **Kuramochi, I., M. Watanabe, T. Hiwatashi et al.** Effect of lacosamide on patients with drug-resistant epilepsy. // *Journal of the Japan Epilepsy Society*, 36, 2019, № 3, p. 621-629. ISSN 0912-0890.

1008. **Li, J., M. Sun, X Wang.** The adverse-effect profile of lacosamide. // *Expert Opinion on Drug Safety*, 19, 2020, № 2, p. 131-138. ISSN 1474-0338.
1009. **Maschio, M., A. Zarabla, A. Maialetti et al.** Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. // *Epilepsy and Behavior*, 73, 2017, p. 83-89. ISSN 1525-5050.
1010. **McGinty, R.N., D.J. Costello.** Long-term lacosamide retention—Real-world experience at a tertiary epilepsy center in Ireland. // *Epilepsy and Behavior*, 68, 2017, p. 141-145. ISSN 1525-5050.
1011. **Nakhutina, L., S.D. Kunnakkat, M. Coleman et al.** Effects of adjunctive lacosamide on mood and quality of life in patients with epilepsy. // *Epilepsy and Behavior*, 73, 2017, p. 90-94. ISSN 1525-5050.
1012. **Rapacz, A.** Advances and limitations in pharmacotherapy of epilepsy. // *Acta Poloniae Pharmaceutica - Drug Research*, 75, 2018, № 5, p. 1069-1082. ISSN 0001-6837.
1013. **Rudà, R., A. Pellerino, F. Franchino et al.** Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. // *Journal of Neuro-Oncology*, 136, 2018, № 1, p. 105-114. ISSN 0167-594X.
1014. **Sarkis, R.A., J. Nicolas, J.W. Lee.** Tolerability of lacosamide or zonisamide in elderly patients with seizures. // *Seizure*, 49, 2017, p. 1-4. ISSN 1059-1311.
1015. **Scott, L.J.** Lacosamide: A Review in Focal Seizures in Patients with Epilepsy. // *Drugs*, 75, 2015, № 18, p. 2143-2154. ISSN 0012-6667.
1016. **Svendsen, T., E. Brodtkorb, A. Baftiu et al.** Clinical experience combined with therapeutic drug monitoring of lacosamide. // *Acta Neurologica Scandinavica*, 141, 2020, № 4, p. 279-286. ISSN 0001-6314.
1017. **Thiele, E., E. Marsh, M. Mazurkiewicz-Beldzinska et al.** Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. // *Epilepsia*, 60, 2019, № 3, p. 419-428. ISSN 0013-9580.
1018. **Zhao, T., H.-J. Li, L. Ma et al.** Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China. // *Epilepsy and Behavior*, 117, 2021, art. no. 107814. ISSN 1525-5050.

## **2016**

**Maslarov D.** Effects of Citicoline on Neuropsychological Status after Stroke. 18<sup>th</sup> World Congress of Psychophysiology (IOP2016) of the International Organization of

Psychophysiology (IOP), Havana, Cuba, August 31<sup>st</sup> to September 4<sup>th</sup>, 2016. Proceedings in International Journal of Psychophysiology, vol. 108, October 2016, ISSN 0167-8760-108-1-174, p. 94, doi:10.2016/j/ijpsycho.2016.07.290.

#### Cited by:

1019. **Secades, J. J.** Citicoline: pharmacological and clinical review, 2016 update. // *Revista de neurologia*, 63, 2016, № S03, p. S1-S73. ISSN 0210-0010. Доступно на: [https://www.researchgate.net/profile/Julio-Secades/publication/331117491\\_Citicolina\\_revision\\_farmacologica\\_y\\_clinica\\_actualizacion\\_2010/links/58fe02f2aca2728fa70fc7e4/Citicolina-revision-farmacologica-y-clinica-actualizacion-2010.pdf](https://www.researchgate.net/profile/Julio-Secades/publication/331117491_Citicolina_revision_farmacologica_y_clinica_actualizacion_2010/links/58fe02f2aca2728fa70fc7e4/Citicolina-revision-farmacologica-y-clinica-actualizacion-2010.pdf)

[Kappos L.](#), [D. L Arnold](#), [A. Bar-Or](#), [J. Camm](#), [T. Derfuss](#), [B. C Kieseier](#), [T. Sprenger](#), [K. Greenough](#), [P. Ni](#), [T. Harada](#) (Trial Principal Investigators ... **Dimitar Maslarov**, Bulgaria). Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol*, 2016 Oct; 15 (11):1148-59, doi: 10.1016/S1474-4422(16)30192-2.

#### Cited by:

1020. **Al-Bawardy, B., R. Shivashankar, D.D. Proctor.** Novel and Emerging Therapies for Inflammatory Bowel Disease. // *Frontiers in Pharmacology*, 12, 2021, art. no. 651415. ISSN 1663-9812.
1021. **Bordet, R., W. Camu, J. De Seze et al.** Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement. // *Revue Neurologique*, 176, 2020, № 1/2, p. 100-112. ISSN 0035-3787.
1022. **Chun, J., G. Giovannoni, S.F. Hunter.** Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. // *Drugs*, 81, 2021, № 2, p. 207-231. ISSN 0012-6667.
1023. **Comi, G., H.-P. Hartung, R. Bakshi et al.** Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. // *Drugs*, 77, 2017, № 16, p. 1755-1768. ISSN 0012-6667.
1024. **Dyckman, A.J.** Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives. // *Journal of Medicinal Chemistry*, 60, 2017, № 13, p. 5267-5289. ISSN 0022-2623.
1025. **Elnour, A.A., A. Sadeq, F.H. Farah et al.** Protocol for a systematic review and meta-analysis on randomized clinical trials on the efficacy and safety of



- sphingosine-1-phosphatase receptor modulators. // *Systematic Reviews in Pharmacy*, 11, 2020, № 11, p. 1252-1262. ISSN 0975-8453.
1026. **Emekli, A.S.** Amiselimod: A new oral agent in the treatment of multiple sclerosis = Multipl skleroz tedavisinde yeni oral ajan amiselimod. // *Turk Noroloji Dergisi*, 23, 2017, № 3, p. 148-149. ISSN 1301-062X.
  1027. **Florian, P., K.R. Flechsenhar, E. Bartnik** et al. Translational drug discovery and development with the use of tissue-relevant biomarkers: Towards more physiological relevance and better prediction of clinical efficacy. // *Experimental Dermatology*, 29, 2020, № 1, p. 4-14. ISSN 0906-6705.
  1028. **Gajofatto, A.** Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: The evidence to date. // *Drug Design, Development and Therapy*, 11, 2017, p. 3153-3157. ISSN 1177-8881.
  1029. **Gajofatto, A., M. Turatti.** Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. // *Expert Opinion on Investigational Drugs*, 27, 2018, № 3, p. 273-286. ISSN 1354-3784.
  1030. **Gregson, A., K. Thompson, S.E. Tsirka** et al. Emerging small-molecule treatments for multiple sclerosis: Focus on B cells [version 1; referees: 2 approved]. // *F1000Research*, 8, 2019, art. no. 245. ISSN 2046-1402.
  1031. **Ikeda, T., T. Kakuma, M. Watari** et al. Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of lymphocytes. // *Scientific Reports*, 8, 2018, № 1, art. no. 16430. ISSN 2045-2322.
  1032. **Kifuji, T., S. Inoue, M. Furukawa** et al. Absorption, disposition and metabolic pathway of amiselimod (MT-1303) in healthy volunteers in a mass balance study. // *Xenobiotica*, 49, 2019, № 9, p. 1033-1043. ISSN 0049-8254.
  1033. **Lasa, J.S., P.A. Olivera, S. Bonovas** et al. Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. // *Drug Safety*, 2021. ISSN 0114-5916.
  1034. **Li, M., J.-Z. Miao, S. Xu.** Recent advances in research and development of new small molecule immunosuppressants for inflammatory bowel disease. // *Yaoxue Xuebao*, 53, 2018, № 8, p. 1289-1301. ISSN 0513-4870.
  1035. **Mao-Draayer, Y., J. Sarazin, D. Fox** et al. The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. // *Clinical Immunology*, 175, 2017, p. 10-15. ISSN 1521-6616.

1036. **Paul, F.** What is the future of proof of concept studies in multiple sclerosis? // *The Lancet Neurology*, 15, 2016, № 11, p. 1107-1109. ISSN 1474-4422.
1037. **Peyrin-Biroulet, L., R. Christopher, D. Behan** et al. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. // *Autoimmunity Reviews*, 16, 2017, № 5, p. 495-503. ISSN 1568-9972.
1038. **Piehl, F.** Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. // *Journal of Internal Medicine*, 289, 2020, № 6, p. 771-791. ISSN 0954-6820.
1039. **Pyne, N.J., S. Pyne.** Sphingosine 1-phosphate receptor 1 signaling in mammalian cells. // *Molecules*, 22, 2017, № 3, art. no. 344. ISSN 1420-3049.
1040. **Roy, R., A.A. Alotaibi, M.S. Freedman.** Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. // *CNS Drugs*, 35, 2021, № 4, p. 385-402. ISSN 1172-7047.
1041. **Sandborn, W.J., L. Peyrin-Biroulet, J. Zhang** et al. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. // *Gastroenterology*, 158, 2020, № 3, p. 550-561. ISSN 0016-5085.
1042. **Shimano, K., Y. Maeda, H. Kataoka** et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells. // *PLoS ONE*, 14, 2019, № 12, art. no. e0226154. ISSN 1932-6203.
1043. **Sugahara, K., Y. Maeda, K. Shimano** et al. Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 modulator, potentially inhibits the progression of lupus nephritis in two murine sle models. // *Journal of Immunology Research*, 2019, art. no. 5821589. ISSN 2314-8861.
1044. **Tanaka, Y., K. Kondo, A. Ichibori** et al. Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study. // *Lupus*, 29, 2020, № 14, p. 1902-1913. ISSN 0961-2033.
1045. **Thomas, K., U. Proschmann, T. Ziemssen.** Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. // *Expert Opinion on Pharmacotherapy*, 18, 2017, № 15, p. 1649-1660. ISSN 1465-6566.
1046. **Tong, J., Q. Zou, Y. Chen** et al. Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. // *Neurological Sciences*, 42, 2021, № 5, p. 1687-1695. ISSN 1590-1874.
1047. **Vermersch, P.** Sphingosine-1-phosphate receptor modulators in multiple sclerosis. // *European Neurological Review*, 13, 2017, № 1, p. 25-30. ISSN 1758-3837.

1048. **Vidal-Jordana, A.** New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis. // *Neurologic Clinics*, 36, 2018, № 1, p. 173-183. ISSN 0733-8619.

Chung, S.S, Johnson J.K, Brittain S.T, Baroldi P. Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR®) in adults with partial-onset seizures. // *Acta Neurologica Scandinavica*, 133, 2016, № 2, p. 124-130. ISSN 1600-0404. doi: 10.1111/ane.12467. Epub 2015 Aug 6. PMID: 26248506; PMCID: PMC5042072.

#### Cited by: (4)

1049. **Banach, M., B. Miziak, K.K. Borowicz-Reutt** et al. Advances with extended and controlled release formulations of antiepileptics in the elderly. // *Expert Opinion on Pharmacotherapy*, 20, 2019, № 3, p. 333-341. ISSN 1465-6566.
1050. **Brandt, C., T.W. May.** Extended-release drug formulations for the treatment of epilepsy. // *Expert Opinion on Pharmacotherapy*, 19, 2018, № 8, p. 843-850. ISSN 1465-6566.
1051. **Devinsky, O.** Everolimus for epilepsy in paediatric tuberous sclerosis complex. // *The Lancet Child and Adolescent Health*, 2, 2018, № 7, p. 467-469. ISSN 2352-4642.
1052. **Toledo, M., R. Beale, J.S. Evans** et al. Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam. // *Epilepsy Research*, 138, 2017, p. 53-61. ISSN 0920-1211.

Johnston, S.C., P. Amarenco, G.W. Albers, H. Denison, J.D. Easton, S.R. Evans, P. Held, J. Jonasson, K. Minematsu, C.A. Molina, Y. Wang, and K.S. L. Wong, for the SOCRATES Steering Committee and Investigators\*. (Prof. **Dimitar Maslarov**, First MHAT AD, Neurology department). Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. // *New England Journal of Medicine*, 375, 2016, 1, p. 35-43. ISSN 0028-4793; E-ISSN 1533-4406.

#### Cited by:

1053. **Albay, C.E.Q., F.G.D. Leyson, F.C. Cheng.** Dual versus mono antiplatelet therapy for acute non-cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis-updated meta-analysis. // *BMC Neurology*, 20, 2020, № 1, art. no. 224. ISSN 1471-2377.
1054. **Appleton, J.P., R. Mullhi, N. Singh.** Initial management of acute ischaemic stroke. // *British Journal of Hospital Medicine*, 82, 2021, № 1. ISSN 1750-8460.

1055. **Armahizer, M., A. Blackman, M. Plazak** et al. Early Acute Ischemic Stroke Management for Pharmacists. // *Hospital Pharmacy*, 55, 2020, № 1, p. 12-25. ISSN 0018-5787.
1056. **Bates, E.R.** Antiplatelet therapy in patients with coronary disease and type 2 diabetes. // *New England Journal of Medicine*, 381, 2019, № 14, p. 1373-1375. ISSN 0028-4793.
1057. **Bates, E.R.** Net Adverse Clinical Events with Antiplatelet Therapy in Acute Coronary Syndromes. // *JAMA - Journal of the American Medical Association*, 324, 2020, № 16, p. 1613-1615. ISSN 0098-7484.
1058. **Borchert, R.J., D. Simonato, C. R Hickman** et al. P2Y12 inhibitors for the neurointerventionalist. // *Interventional Neuroradiology*, 2021. ISSN 1591-0199.
1059. **Bulwa, Z., F.G. Saleh Velez, J.R. Brorson** et al. Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial. // *Journal of Stroke and Cerebrovascular Diseases*, 29, 2020, № 11, art. no. 105115. ISSN 1052-3057.
1060. **Calderone, D., D. Capodanno, D.J. Angiolillo.** An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. // *Expert Review of Cardiovascular Therapy*, 2020. ISSN 1477-9072.
1061. **Cassese, S., G. Ndrepepa, R.A. Byrne** et al. Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease—A meta-analysis of randomized clinical trials. // *American Heart Journal*, 219, 2020, p. 109-116. ISSN 0002-8703.
1062. **Chien, L.-N., H.-Y. Liu, H.-Y. Chiou** et al. Efficacy and safety of clopidogrel and aspirin do not differ in patients with stable ischemic stroke. // *Journal of the Chinese Medical Association*, 83, 2020, № 7, p. 651-656. ISSN 1726-4901.
1063. **Clissold, B., T.G. Phan, J. Ly** et al. Current aspects of TIA management. // *Journal of Clinical Neuroscience*, 72, 2020, p. 20-25. ISSN 0967-5868.
1064. **Collet, J.-P., G. Montalescot, M. Zeitouni.** Aspirin-Free Strategies After PCI: Still Not Out of the Twilight. // *Journal of the American College of Cardiology*, 74, 2019, № 16, p. 2028-2031. ISSN 0735-1097.
1065. **Coveney, S., J.J. McCabe, S. Murphy** et al. Anti-inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack. // *Cochrane Database of Systematic Reviews*, 2020, № 5, art. no. CD012825. ISSN 1469-493X.
1066. **D'Alessandro, E., C. Becker, W. Bergmeier** et al. Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht

- Consensus Conference on Thrombosis. // *Thrombosis and Haemostasis*, 120, 2020, № 4, p. 538-564. ISSN 0340-6245.
1067. **Diener, H.-C.** Klinische Wirkungen des Komplementinhibitors Zilucoplan. // *Arzneimitteltherapie*, 38, 2020, № 9, p. 377-389. ISSN 0723-6913.
1068. **Diener, H.C., G. Nickenig.** Secondary stroke prevention after TIA or ischemic stroke = Sekundärprävention nach TIA oder ischämischem Schlaganfall. // *Herz*, 2021. ISSN 0340-9937.
1069. **Diener, H.-C., G.J. Hankey.** Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. // *Journal of the American College of Cardiology*, 75, 2020, № 15, p. 1804-1818. ISSN 0735-1097.
1070. **Egidi, G.** Platelet aggregation inhibitors what should i prescribe when? And what about a simultaneous anticoagulation? = Thrombozytenaggregationshemmer welche soll ich wann verordnen? Und wie sieht es mit einer gleichzeitigen antikoagulation aus? // *Zeitschrift für Allgemeinmedizin*, 96, 2020, № 4, p. 170-175. ISSN 1433-6251.
1071. **English, S.W., D.R. Landzberg, N.R. Bhatt** et al. Safety of Ticagrelor in Moderate and Severe Acute Ischemic Stroke: A Single-Center Retrospective Review. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 6, art. no. 105767. ISSN 1052-3057.
1072. **Fasth, O., E. Lesén, P. Appelros** et al. Age in relation to comorbidity and outcome in patients with high-risk TIA or minor ischemic stroke: A Swedish national observational study. // *European Stroke Journal*, 6, 2021, № 1, p. 53-61. ISSN 2396-9873.
1073. **Franzone, A., E. McFadden, S. Leonardi** et al. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. // *Journal of the American College of Cardiology*, 74, 2019, № 18, p. 2223-2234. ISSN 0735-1097.
1074. **Garg, S., P. Chichareon, N. Kogame** et al. Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. // *Catheterization and Cardiovascular Interventions*, 96, 2020, № 7, p. 1369-1378. ISSN 1522-1946.
1075. **Gates, S., E. Ealing.** Reporting and interpretation of results from clinical trials that did not claim a treatment difference: Survey of four general medical journals. // *BMJ Open*, 9, 2019, № 9, art. no. e024785. ISSN 2044-6055.
1076. **Giacoppo, D., Y. Matsuda, L.N. Fovino** et al. Short dual antiplatelet therapy followed by P2Y<sub>12</sub>inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting

- stents: A systematic review and meta-analysis of randomized clinical trials. // *European Heart Journal*, 42, 2021, № 4, p. 308-319. ISSN 0195-668X.
1077. **Gower, M.N., L.R. Ratner, A.K. Williams** et al. Clinical utility of cyp2c19 genotype-guided antiplatelet therapy in patients at risk of adverse cardiovascular and cerebrovascular events: A review of emerging evidence. // *Pharmacogenomics and Personalized Medicine*, 13, 2020, p. 239-252. ISSN 1178-7066.
  1078. **Javalkar, V., O. Kuybu, A. Amireh** et al. Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment. // *Southern Medical Journal*, 113, 2020, № 11, p. 585-592. ISSN 0038-4348.
  1079. **Jensen, M., G. Thomalla**. Causes and secondary prevention of acute ischemic stroke in adults. // *Hamostaseologie*, 40, 2020, № 1, p. 22-30. ISSN 0720-9355.
  1080. **Kalladka, D., E. Rounis**. Antiplatelet therapy for transient ischaemic attack and minor ischaemic stroke. // *British Journal of Hospital Medicine*, 81, 2020, № 6. ISSN 1750-8460.
  1081. **Kamada, A., M. Shimizu, K. Oura** et al. Inhibitory Effects of P2Y<sub>12</sub> Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 3, art. no. 105547. ISSN 1052-3057.
  1082. **Kanorskii, S.G.** Combined Antithrombotic Therapy in Patients with a Stable Atherosclerotic Cardiovascular Diseases: What Direction did COMPASS Show? // *Kardiologiya*, 60, 2020, № 2, p. 131-141. ISSN 0022-9040.
  1083. **Kariasa, I.M., E. Nurachmah, R.A. Setyowati, Koestoer**. Analysis of participants' characteristics and risk factors for stroke recurrence. // *Enfermeria Clinica*, 29, 2019, p. 286-290. ISSN 1130-8621.
  1084. **Katsanos, A.H., R.G. Hart**. New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. // *JAMA Neurology*, 77, 2020, № 10, p. 1308-1317. ISSN 2168-6149.
  1085. **Kercher, M.J., D. Ramanathan, B.C. Dahlin** et al. Mechanical Thrombectomy for Sequential Bilateral Middle Cerebral Artery Occlusions in a Patient With Recurrent Cryptogenic Strokes: A Case Report. // *Neurohospitalist*, 11, 2021, № 1, p. 54-58. ISSN 1941-8744.
  1086. **Kim, A.S.** Medical Management for Secondary Stroke Prevention. // *CONTINUUM Lifelong Learning in Neurology*, 26, 2020, № 2, p. 435-456. ISSN 1080-2371.
  1087. **Kim, J.-T., B.J. Kim, J.-M. Park** et al. Risk of recurrent stroke and antiplatelet choice in breakthrough stroke while on aspirin. // *Scientific Reports*, 10, 2020, № 1, art. no. 16723. ISSN 2045-2322.

1088. **Köhrmann, M., C. Kleinschnitz.** Update on antithrombotic secondary prevention of ischemic stroke = Update antithrombotische Sekundärprophylaxe des ischämischen Schlaganfalls. // *Nervenarzt*, 90, 2019, № 10, p. 995-1004. ISSN 0028-2804.
1089. **Krasteva, M.P., K.K. Lau, P. Mordasini et al.** Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options. // *Advances in Therapy*, 37, 2020, № 5, p. 1829-1865. ISSN 0741-238X.
1090. **Lebas, H., K. Yahiaoui, R. Martos et al.** Platelets Are at the Nexus of Vascular Diseases. // *Frontiers in Cardiovascular Medicine*, 6, 2019, art. no. 132. ISSN 2297-055X.
1091. **Li, K.H.C., A. Jesuthasan, C. Kui et al.** Acute ischemic stroke management: concepts and controversies. A narrative review. // *Expert Review of Neurotherapeutics*, 21, 2021, № 1, p. 65-79. ISSN 1473-7175.
1092. **Meah, M.N., M.A. Denvir, N.L. Mills et al.** Clinical endpoint adjudication. // *The Lancet*, 395, 2020, № 10240, p. 1878-1882. ISSN 0140-6736.
1093. **Mendelson, S.J., S. Prabhakaran.** Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review. // *JAMA - Journal of the American Medical Association*, 325, 2021, № 11, p. 1088-1098. ISSN 0098-7484.
1094. **Moss, A.J., M.R. Dweck, M.K. Doris et al.** Ticagrelor to Reduce Myocardial Injury in Patients With High-Risk Coronary Artery Plaque. // *JACC: Cardiovascular Imaging*, 13, 2020, № 7, p. 1549-1560. ISSN 1936-878X.
1095. **Mullen, L., M.N. Meah, A. Elamin et al.** Risk of major bleeding with potent antiplatelet agents after an acute coronary event: A comparison of ticagrelor and clopidogrel in 5116 consecutive patients in clinical practice. // *Journal of the American Heart Association*, 10, 2021, № 8, art. no. e019467. ISSN 2047-9980.
1096. **Muller, C., M. Roizman, A. Wong.** Secondary prevention of ischaemic stroke. // *Internal Medicine Journal*, 49, 2019, № 10, p. 1221-1228. ISSN 1444-0903.
1097. **Naqvi, I.A., A.K. Kamal, H. Rehman.** Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. // *Cochrane Database of Systematic Reviews*, 2020, № 8, art. no. CD009716. ISSN 1469-493X.
1098. **Narasimhalu, K., Y.K. Ang, D.S.Y. Tan et al.** Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations. // *Clinical Drug Investigation*, 40, 2020, № 11, p. 1063-1070. ISSN 1173-2563.

1099. **Natsuaki, M., T. Morimoto, H. Watanabe** et al. Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke. // *Journal of the American Heart Association*, 8, 2019, № 22, art. no. e013356. ISSN 2047-9980.
1100. **Pace, W.D., A. Earl, C. Bryant** et al. Antiplatelet therapy for secondary prevention of ischemic stroke. // *U.S. Pharmacist*, 45, 2020, № 1, p. HS-8-HS-12. ISSN 0148-4818.
1101. **Parker, W.A.E., D.A. Gorog, T. Geisler** et al. Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. // *European Heart Journal, Supplement*, 22, 2021, p. M26-M34. ISSN 1520-765X.
1102. **Parker, W.A.E., R.F. Storey**. Novel approaches to P2Y12 inhibition and aspirin dosing. // *Platelets*, 32, 2021, № 1, p. 7-14. ISSN 0953-7104.
1103. **Patti, G., G. Micieli, C. Cimminiello** et al. The Role of Clopidogrel in 2020: A Reappraisal. // *Cardiovascular Therapeutics*, 2020, art. no. 8703627. ISSN 1755-5914.
1104. **Pollack, C.V., Jr., T.Y. Wang**. Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why? // *American Journal of Cardiology*, 144, 2021, p. S10-S14. ISSN 0002-9149.
1105. **Qureshi, A.I., M.U. Jahngir, K. Qualls** et al. The Effect of Ticagrelor on Platelet Reactivity in Patients with Clopidogrel Resistance Undergoing Neuroendovascular Procedures. // *Journal of Neuroimaging*, 30, 2020, № 3, p. 327-334. ISSN 1051-2284.
1106. **Rawish, E., H. Nording, T. Münte** et al. Platelets as Mediators of Neuroinflammation and Thrombosis. // *Frontiers in Immunology*, 11, 2020, art. no. 548631. ISSN 1664-3224.
1107. **Reiff, T., P.A. Ringleb**. Secondary prevention of cerebral infarction = Sekundärprophylaxe der zerebralen Ischämie. // *Nervenheilkunde*, 39, 2020, № 10, p. 644-650. ISSN 0722-1541.
1108. **Ringler, J., M. Steck, S.P. Shah** et al. Indications and Evidence for Dual Antiplatelet Therapy after Acute Ischemic Stroke. // *Critical Care Nursing Quarterly*, 43, 2020, № 2, p. 122-137. ISSN 0887-9303.
1109. **Röther, J.** Stroke and intracerebral hemorrhage under anticoagulation or platelet inhibition—when should treatment be restarted and how? = Schlaganfall und Hirnblutung unter Antikoagulation oder Thrombozytenfunktionshemmung – wann und wie erneut starten? // *Internist*, 61, 2020, № 4, p. 424-430. ISSN 0020-9554.



1110. **Rothwell, P.M.** Antiplatelet treatment to prevent early recurrent stroke. // *New England Journal of Medicine*, 383, 2020, № 3, p. 276-278. ISSN 0028-4793.
1111. **Saba, L., A.R. Moody, T. Saam et al.** Vessel Wall–Imaging Biomarkers of Carotid Plaque Vulnerability in Stroke Prevention Trials. // *JACC: Cardiovascular Imaging*, 13, 2020, № 11, p. 2445-2456. ISSN 1936-878X.
1112. **Šaňák, D., P. Divišová, M. Hutýra et al.** Risk of recurrent ischemic stroke in young cryptogenic patients with embolic stroke of undetermined source. // *Journal of the Neurological Sciences*, 416, 2020, art. no. 116985. ISSN 0022-510X.
1113. **Sarmiento, R.J.C., J.D.B. Diestro, A.I. Espiritu et al.** Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review. // *Journal of Stroke and Cerebrovascular Diseases*, 28, 2019, № 10, art. no. 104290. ISSN 1052-3057.
1114. **Sibbing, D., S. Cassese.** Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass. // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 457-460. ISSN 1936-8798.
1115. **Sloane, K.L., E.C. Camargo.** Antithrombotic Management of Ischemic Stroke. // *Current Treatment Options in Cardiovascular Medicine*, 21, 2019, № 11, art. no. 78. ISSN 1092-8464.
1116. **Storey, R.F.** The long journey of individualizing antiplatelet therapy after acute coronary syndromes. // *European Heart Journal*, 41, 2020, № 37, p. 3546-3548. ISSN 0195-668X.
1117. **Strambo, D., A. Zachariadis, D. Lambrou et al.** A score to predict one-year risk of recurrence after acute ischemic stroke. // *International Journal of Stroke*, 2020. ISSN 1747-4930.
1118. **Strong, B., J. Pudar, A.G. Thrift et al.** Sex Disparities in Enrollment in Recent Randomized Clinical Trials of Acute Stroke: A Meta-analysis. // *JAMA Neurology*, 2021. ISSN 2168-6149.
1119. **Tan, L., B. Lü, Q. Li.** Pharmaceutical care for one patients with thrombosis after intravascular interventional treatment of intracranial aneurysms. // *Pharmaceutical Care and Research*, 19, 2019, № 5, p. 377-380. ISSN 1671-2838.
1120. **Tanashyan, M.M., A.A. Raskurazhev, A.A. Kornilova.** Cerebrovascular diseases and personalized prevention. // *Profilakticheskaya Meditsina*, 24, 2021, № 2, p. 76-81. ISSN 2305-4948.
1121. **Tantry, U.S., P.A. Gurbel.** Secondary prevention of ischaemic stroke: More evidence to block two pathways affecting platelet activation. // *European Heart*

*Journal - Quality of Care and Clinical Outcomes*, 5, 2019, № 4, p. 275-278. ISSN 2058-5225.

1122. **Toyoda, K., S. Uchiyama, Y. Hagihara** et al. Dabigatran vs. aspirin for secondary prevention after embolic stroke of undetermined source - Japanese subanalysis of the RE-SPECT ESUS randomized controlled trial. // *Circulation Journal*, 84, 2020, № 12, p. 2286-2295. ISSN 1346-9843.
1123. **Tuo, Q.-Z., S.-T. Zhang, P. Lei.** Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications. // *Medicinal Research Reviews*, 2021. ISSN 0198-6325.
1124. **Verdoia, M., S. Savonitto, D. Dudek** et al. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials. // *Vascular Pharmacology*, 137, 2021, art. no. 106828. ISSN 1537-1891.
1125. **Vizcaíno, G., J.P.M. Herdoiza, A. Siteneski** et al. Secondary prevention in minor ischemic stroke with antiplatelet treatment. Systematic review and meta-analysis of comparative studies with aspirin under non-inferiority criteria = Prevención secundaria en el ictus isquémico menor con el tratamiento antiplaquetario. Revisión sistemática y metanálisis de estudios comparativos con aspirina bajo criterios de no inferioridad. // *Investigacion Clinica (Venezuela)*, 61, 2020, № 3, p. 265-282. ISSN 0535-5133.
1126. **Von Scheidt, M., D. Bongiovanni, U. Tebbe** et al. Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: A meta-analysis of randomized controlled trials. // *European Journal of Cardio-thoracic Surgery*, 57, 2020, № 3, p. 520-528. ISSN 1010-7940.
1127. **Wiśniewski, A.** Multifactorial background for a low biological response to antiplatelet agents used in stroke prevention. // *Medicina (Lithuania)*, 57, 2021, № 1, art. no. 59, p. 1-10. ISSN 1010-660X.
1128. **Xiong, Y., P.M. Bath.** Antiplatelet therapy for transient ischemic attack and minor stroke. // *Stroke*, 2020, p. 3472-3474. ISSN 0039-2499.
1129. **Zhao, G., F. Lin, Z. Wang** et al. Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke. // *European Neurology*, 82, 2020, № 4/6, p. 93-98. ISSN 0014-3022.
1130. **Zhao, L.-H., D.-D. Tang, W.-L. Lu** et al. Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. // *European Review for Medical and Pharmacological Sciences*, 24, 2020, № 10, p. 5750-5757. ISSN 1128-3602.

1131. **Zhou, J., T. Limsakun, O. Yin** et al. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects. // *Journal of Clinical Pharmacology*, 59, 2019, № 12, p. 1669-1677. ISSN 0091-2700.
1132. **Zhu, S., J.C. Gilbert, Z. Liang** et al. Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200. // *Journal of Thrombosis and Haemostasis*, 18, 2020, № 7, p. 1695-1704. ISSN 1538-7933.

## **2017**

Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. // *The Lancet Neurology*, 16, 2017, № 4, p. 301-310. ISSN 1474-4422 doi: 10.1016/S1474-4422(17)30038-8. Epub 2017 Feb 23. PMID: 28238711.

## **Cited by:**

1133. **Alkhalifah, M.M., P.M. Gadiant, S. Chaturvedi**. Medical therapy for carotid and vertebral artery stenosis. – In: *Extracranial Carotid and Vertebral Artery Disease: Contemporary Management*, 2018, p. 127-134. ISBN 9783319915333; 9783319915326.
1134. **Bath, P.M., L.J. Woodhouse, J.P. Appleton** et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. // *The Lancet*, 391, 2018, № 10123, p. 850-859. ISSN 0140-6736.
1135. **Bath, P.M., L.J. Woodhouse, J.P. Appleton** et al. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: The TARDIS RCT. // *Health Technology Assessment*, 22, 2018, № 48, p. 1-75. ISSN 1366-5278.
1136. **Buchtele, N., M. Schwameis, J.C. Gilbert** et al. Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence. // *Thrombosis and Haemostasis*, 118, 2018, № 6, p. 959-978. ISSN 0340-6245.
1137. **Bulwa, Z., F.G. Saleh Velez, J.R. Brorson** et al. Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT

- Randomized Clinical Trial. // *Journal of Stroke and Cerebrovascular Diseases*, 29, 2020, № 11, art. no. 105115. ISSN 1052-3057.
1138. **Carnes-Vendrell, A., J. Deus, J. Molina-Seguin** et al. Depression and Apathy After Transient Ischemic Attack or Minor Stroke: Prevalence, Evolution and Predictors. // *Scientific Reports*, 9, 2019, № 1, art. no. 16248. ISSN 2045-2322.
  1139. **Cattaneo, M.** P2Y12 antagonists. – In: *Platelets*, 2019, p. 937-956. ISBN 9780128134566.
  1140. **Cereda, C.W., J.-M. Olivot.** Emergency Department (ED) Triage for Transient Ischemic Attack (TIA). // *Current Atherosclerosis Reports*, 20, 2018, № 11, art. no. 56. ISSN 1523-3804.
  1141. **Chen, J., S. Pi, C. Yu** et al. SLRP1 (Soluble Low-Density Lipoprotein Receptor-Related Protein 1): A Novel Biomarker for P2Y12 (P2Y Purinoceptor 12) Receptor Expression in Atherosclerotic Plaques. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2020, p. E166-E179. ISSN 1079-5642.
  1142. **Chung, J.-W., S.J. Kim, J. Hwang** et al. Comparison of clopidogrel and ticlopidine/Ginkgo biloba in patients with clopidogrel resistance and carotid stenting. // *Frontiers in Neurology*, 10, 2019, art. no. 44. ISSN 1664-2295.
  1143. **Das, A.S., R.W. Regenhardt, S.K. Feske** et al. Treatment Approaches to Lacunar Stroke. // *Journal of Stroke and Cerebrovascular Diseases*, 28, 2019, № 8, p. 2055-2078. ISSN 1052-3057.
  1144. **Del Brutto, V.J., S. Chaturvedi, H.-C. Diener** et al. Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel. // *Journal of the American College of Cardiology*, 74, 2019, № 6, p. 786-803. ISSN 0735-1097.
  1145. **Deng, W., T. Tang, Y. Hou** et al. Extracellular vesicles in atherosclerosis. // *Clinica Chimica Acta*, 495, 2019, p. 109-117. ISSN 0009-8981.
  1146. **Diener, H.-C.** The cause of stroke matters for secondary prevention. // *The Lancet Neurology*, 16, 2017, № 4, p. 256-257. ISSN 1474-4422.
  1147. **Diener, H.C., G. Nickenig.** Secondary stroke prevention after TIA or ischemic stroke = Sekundärprävention nach TIA oder ischämischem Schlaganfall. // *Herz*, 2021. ISSN 0340-9937.
  1148. **Doehner, W., M. Mazighi, B.M. Hofmann** et al. Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. // *European Journal of Preventive Cardiology*, 27, 2020, № 7, p. 682-692. ISSN 2047-4873.

1149. **English, S.W., D.R. Landzberg, N.R. Bhatt** et al. Safety of Ticagrelor in Moderate and Severe Acute Ischemic Stroke: A Single-Center Retrospective Review. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 6, art. no. 105767. ISSN 1052-3057.
1150. **Ganesh, A., J.H. Wong, B.K. Menon.** Practice current: How do you manage patients with a "hot carotid"? // *Neurology: Clinical Practice*, 8, 2018, № 6, p. 527-536. ISSN 2163-0402.
1151. **Gao, Y., C. Yu, S. Pi** et al. The role of P2Y<sub>12</sub> receptor in ischemic stroke of atherosclerotic origin. // *Cellular and Molecular Life Sciences*, 76, 2019, № 2, p. 341-354. ISSN 1420-682X.
1152. **Girotra, T., F. Lowe, W. Feng** et al. Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose. // *Current Treatment Options in Neurology*, 20, 2018, № 8, art. no. 32. ISSN 1092-8480.
1153. **Giustino, G., B. Redfors, A.J. Kirtane** et al. Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. // *JACC: Cardiovascular Interventions*, 11, 2018, № 13, p. 1277-1286. ISSN 1936-8798.
1154. **Gomez, C.R., M.J. Schneck, J. Biller.** Recent advances in the management of transient ischemic attacks. // *F1000Research*, 6, 2017, art. no. 1893. ISSN 2046-1402.
1155. **Gutierrez, J.** Letter by Gutierrez Regarding Article, "dual Antiplatelet Therapy Improves Functional Outcome in Patients with Progressive Lacunar Strokes". // *Stroke*, 50, 2019, № 7, p. e215. ISSN 0039-2499.
1156. **Hackam, D.G., J.D. Spence.** Antiplatelet therapy in ischemic stroke and transient ischemic attack: An overview of major trials and meta-analyses. // *Stroke*, 50, 2019, № 3, p. 773-778. ISSN 0039-2499.
1157. **Hankey, G.J.** Pooled RCTs: In symptomatic carotid stenosis, endarterectomy had lower periprocedural risk than stenting. // *Annals of Internal Medicine*, 167, 2017, № 8, p. JC45. ISSN 0003-4819.
1158. **Harima, K., S. Honda, K. Mikami** et al. Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. // *Journal of Stroke and Cerebrovascular Diseases*, 28, 2019, № 8, p. 2302-2310. ISSN 1052-3057.
1159. **Haybar, H., Z.D. Zayeri.** The value of using polymorphisms in anti-platelet therapy. // *Frontiers in Biology*, 12, 2017, № 5, p. 349-356. ISSN 1674-7984.

1160. **Henriksson, R., F. Björklund, T. Moos.** The introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after myocardial infarction. // *PLoS ONE*, 14, 2019, № 5, art. no. e0216404. ISSN 1932-6203.
1161. **Hirt, L., E. Carrera.** Antiplatelet therapy in secondary stroke prevention = Antiagrégation plaquettaire en prévention secondaire de l'AVC ischémique. // *Revue Medicale Suisse*, 13, 2017, № 560, p. 907-910. ISSN 1660-9379.
1162. **Hurford, R., P.M. Rothwell.** Prevalence, prognosis, and treatment of atherosclerotic intracranial stenosis in Caucasians. // *International Journal of Stroke*, 16, 2021, № 3, p. 248-264. ISSN 1747-4930.
1163. **Jafari, M., T.N. Nguyen, S. Ortega-Gutierrez et al.** Current Advances in Endovascular Treatment of Intracranial Atherosclerotic Disease and Future Prospective. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 3, art. no. 105556. ISSN 1052-3057.
1164. **Javalkar, V., O. Kuybu, A. Amireh et al.** Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment. // *Southern Medical Journal*, 113, 2020, № 11, p. 585-592. ISSN 0038-4348.
1165. **Jones, D.W., T.G. Brott, M.L. Schermerhorn.** Trials and Frontiers in Carotid Endarterectomy and Stenting. // *Stroke*, 49, 2018, № 7, p. 1776-1783. ISSN 0039-2499.
1166. **Kamel, H., P.M. Okin, A.E. Merkler et al.** Relationship between left atrial volume and ischemic stroke subtype. // *Annals of Clinical and Translational Neurology*, 6, 2019, № 8, p. 1480-1486. ISSN 2328-9503.
1167. **Keller, M., A. Grau.** Recent developments in secondary stroke prevention and aftercare = Neue Entwicklungen in der Sekundärprophylaxe und Nachsorge des Schlaganfalls. // *Tagliche Praxis*, 60, 2018, № 3, p. 386-395. ISSN 0494-464X.
1168. **Keller, M., A. Grau.** Recent developments in secondary stroke prevention and aftercare = Neue Entwicklungen in der Sekundärprophylaxe und Nachsorge des Schlaganfalls. // *Internistische Praxis*, 59, 2018, № 3, p. 386-395. ISSN 0020-9570.
1169. **Kim, D., J.-M. Park, K. Kang et al.** Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke: A Retrospective Analysis of the Nationwide Multicenter Stroke Registry. // *Stroke*, 50, 2019, № 5, p. 1184-1192. ISSN 0039-2499.
1170. **Kim, J.S., O.Y. Bang.** Medical treatment of intracranial atherosclerosis: An update. // *Journal of Stroke*, 19, 2017, № 3, p. 261-270. ISSN 2287-6391.

1171. **Kleiman, N.S.** Never So Simple: Bedside Measurement of Platelet Reactivity and the Risk of Stroke After Coronary Stenting. // *JACC: Cardiovascular Interventions*, 11, 2018, № 13, p. 1287-1289. ISSN 1936-8798.
1172. **Köhrmann, M., C. Kleinschnitz.** Update on antithrombotic secondary prevention of ischemic stroke = Update antithrombotische Sekundärprophylaxe des ischämischen Schlaganfalls. // *Nervenarzt*, 90, 2019, № 10, p. 995-1004. ISSN 0028-2804.
1173. **Krasteva, M.P., K.K. Lau, P. Mordasini et al.** Intracranial Atherosclerotic Stenoses: Pathophysiology, Epidemiology, Risk Factors and Current Therapy Options. // *Advances in Therapy*, 37, 2020, № 5, p. 1829-1865. ISSN 0741-238X.
1174. **Kubisa, M.J., M.P. Jezewski, A. Gasecka et al.** Ticagrelor – toward more efficient platelet inhibition and beyond. // *Therapeutics and Clinical Risk Management*, 14, 2018, p. 129-140. ISSN 1176-6336.
1175. **Landzberg, D.R., S. English, M. Frankel et al.** Stroke Thrombolysis in Patients Taking Ticagrelor –Two Successful Cases and a Review of the Literature. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 2, art. no. 105520. ISSN 1052-3057.
1176. **Lebas, H., K. Yahiaoui, R. Martos et al.** Platelets Are at the Nexus of Vascular Diseases. // *Frontiers in Cardiovascular Medicine*, 6, 2019, art. no. 132. ISSN 2297-055X.
1177. **Leng, X., T.W. Leung, K.S. Lawrence Wong.** Antiplatelet therapy after stroke: Should it differ in the acute and chronic phase after stroke. // *Current Opinion in Neurology*, 31, 2018, № 1, p. 14-22. ISSN 1350-7540.
1178. **Liu, D., J. Liu, Y. Cai et al.** Is the future of symptomatic intracranial atherosclerotic stenosis management promising? // *Journal of Neurology, Neurosurgery and Psychiatry*, 91, 2020, № 2, p. 122-124. ISSN 0022-3050.
1179. **Malhotra, K., N. Goyal, A.S. Kasunich et al.** Ticagrelor for stroke prevention in patients with vascular risk factors: A systematic review and meta-analysis. // *Journal of the Neurological Sciences*, 390, 2018, p. 212-218. ISSN 0022-510X.
1180. **Markus, H.** Personalising secondary prevention: Different treatments for different strokes. // *Practical Neurology*, 20, 2020, № 1, p. 34-38. ISSN 1474-7758.
1181. **Meschia, J.F., T. Brott.** Ischaemic stroke. // *European Journal of Neurology*, 25, 2018, № 1, p. 35-40. ISSN 1351-5101.
1182. **Messas, E., G. Goudot, A. Halliday et al.** Management of carotid stenosis for primary and secondary prevention of stroke: State-of-the-art 2020: A critical

- review. // *European Heart Journal*, Supplement, 22, 2020, p. M35-M42B. ISSN 1520-765X.
1183. **Narasimhalu, K., Y.K. Ang, D.S.Y. Tan** et al. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations. // *Clinical Drug Investigation*, 40, 2020, № 11, p. 1063-1070. ISSN 1173-2563.
  1184. **Oana Darabont, R., C. Stoicescu, C. Tiu.** Therapeutic challenges in patients with noncardioembolic acute ischemic stroke in need of double antiplatelet therapy for coronary artery disease. // *American Journal of Therapeutics*, 26, 2019, № 2, p. E213-E221. ISSN 1075-2765.
  1185. **Osanai, T., K. Mikami, M. Kitajima** et al. Incidence and characteristics of spontaneous platelet macro-aggregation in acute ischemic stroke. // *Journal of Thrombosis and Thrombolysis*, 51, 2021, № 1, p. 96-101. ISSN 0929-5305.
  1186. **Paciaroni, M., H. Kamel.** Do the Results of RE-SPECT ESUS Call for a Revision of the Embolic Stroke of Undetermined Source Definition? // *Stroke*, 50, 2019, № 4, p. 1032-1033. ISSN 0039-2499.
  1187. **Papanikolaou, P., A.S. Antonopoulos, I. Mastorakou** et al. Antithrombotic therapy in carotid artery disease. // *Current Pharmaceutical Design*, 26, 2020, № 23, p. 2725-2734. ISSN 1381-6128.
  1188. **Park, J.-H., J.-H. Lee.** Carotid artery stenting. // *Korean Circulation Journal*, 48, 2018, № 2, p. 97-113. ISSN 1738-5520.
  1189. **Pi, S., L. Mao, J. Chen** et al. The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis. // *Autophagy*, 17, 2021, № 4, p. 980-1000. ISSN 1554-8627.
  1190. **Raper, D.M.S., A.A. Abba.** Commentary: Encephaloduroarteriosynangiosis Averts Stroke in Atherosclerotic Patients with Border-Zone Infarct: Post Hoc Analysis from a Performance Criterion Phase II Trial. // *Neurosurgery*, 88, 2021, № 4, p. E319-E320. ISSN 0148-396X.
  1191. **Reiff, T., P.A. Ringleb.** Secondary prevention of cerebral infarction = Sekundärprophylaxe der zerebralen Ischämie. // *Nervenheilkunde*, 39, 2020, № 10, p. 644-650. ISSN 0722-1541.
  1192. **Rothwell, P.M.** Antiplatelet treatment to prevent early recurrent stroke. // *New England Journal of Medicine*, 383, 2020, № 3, p. 276-278. ISSN 0028-4793.
  1193. **Sharrief, A., J.C. Grotta.** Stroke in the elderly. // *Handbook of Clinical Neurology*, 167, 2019, p. 393-418. ISSN 0072-9752.



1194. **Song, J., Z. Piao, L. Wang.** Application progress of antiplatelet aggregation drugs in prevention and treatment of stroke. // *Chinese Journal of Cerebrovascular Diseases*, 15, 2018, № 12, p. 666-672. ISSN 1672-5921.
1195. **Spanos, K., G. Kouvelos, M. Matsagkas et al.** Antiplatelet Resistance in Ischaemic Stroke Patients. // *European Journal of Vascular and Endovascular Surgery*, 54, 2017, № 1, p. 3-4. ISSN 1078-5884.
1196. **Spence, J.D.** Recent advances in preventing stroke recurrence. // *F1000Research*, 6, 2017, art. no. 1017. ISSN 2046-1402.
1197. **Tantry, U.S., P.A. Gurbel.** Secondary prevention of ischaemic stroke: More evidence to block two pathways affecting platelet activation. // *European Heart Journal - Quality of Care and Clinical Outcomes*, 5, 2019, № 4, p. 275-278. ISSN 2058-5225.
1198. **Tirschwell, D.L., B.L. Taylor.** Is Embolic Stroke of Undetermined Source Shrinking? // *Stroke*, 50, 2019, № 9, p. 2290-2291. ISSN 0039-2499.
1199. **Tsivgoulis, G., A. Safouris, D.-E. Kim et al.** Recent advances in primary and secondary prevention of atherosclerotic stroke. // *Journal of Stroke*, 20, 2018, № 2, p. 145-166. ISSN 2287-6391.
1200. **Vališ, M., B. Klímová, M. Novotný et al.** Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review. // *Frontiers in Neurology*, 12, 2021, art. no. 626106. ISSN 1664-2295.
1201. **Venturelli, P.M., J.P. Appleton, C.S. Anderson et al.** Acute Treatment of Stroke (Except Thrombectomy). // *Current Neurology and Neuroscience Reports*, 18, 2018, № 11, art. no. 77. ISSN 1528-4042.
1202. **Vinogradov, O.I., M.A. Jablonskij, A.N. Kuznecov.** Embolic stroke of undetermined source. // *Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova*, 120, 2020, № 12, p. 42-48. ISSN 1997-7298.
1203. **Wabnitz, A.M., T.N. Turan.** Symptomatic Carotid Artery Stenosis: Surgery, Stenting, or Medical Therapy? // *Current Treatment Options in Cardiovascular Medicine*, 19, 2017, № 8, art. no. 62. ISSN 1092-8464.
1204. **Wang, Z., P. Korantzopoulos, T. Liu.** Carotid Atherosclerosis in Patients with Atrial Fibrillation. // *Current Atherosclerosis Reports*, 21, 2019, № 12, art. no. 55. ISSN 1523-3804.
1205. **Wiśniewski, A., K. Filipka.** The role of resistance to acetylsalicylic acid in patients with ischemic stroke = Rola oporności na kwas acetylosalicylowy u

chorych z udarem niedokrwiennym MÓZGU. // *Postepy Psychiatrii i Neurologii*, 28, 2019, № 4, p. 257-266. ISSN 1230-2813.

1206. **Xiong, Y., P.M. Bath.** Antiplatelet therapy for transient ischemic attack and minor stroke. // *Stroke*, 2020, p. 3472-3474. ISSN 0039-2499.
1207. **Yaghi, S., S. Prabhakaran, P. Khatri** et al. Intracranial Atherosclerotic Disease: Mechanisms and Therapeutic Implications. // *Stroke*, 50, 2019, № 5, p. 1286-1293. ISSN 0039-2499.
1208. **Zhang, Z., L. Zhou, N. Xie** et al. Overcoming cancer therapeutic bottleneck by drug repurposing. // *Signal Transduction and Targeted Therapy*, 5, 2020, № 1, art. no. 113. ISSN 2095-9907.
1209. **Zhao, L.-H., D.-D. Tang, W.-L. Lu** et al. Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. // *European Review for Medical and Pharmacological Sciences*, 24, 2020, № 10, p. 5750-5757. ISSN 1128-3602.

Amarenco, P., Albers, G.W., Denison, H., Easton, J.D., Evans, S.R., Held, P., Hill, M.D., Jonasson, J., Kasner, S.E., Ladvall, P., Minematsu, K., Molina, C.A., Wang, Y., Wong, K.S.L., Johnston, S.C. SOCRATES Steering Committee and Investigators. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. // *Stroke*, 48, 2017, № 9, p. 2480-2487. ISSN 0039-2499; E-ISSN 1524-4628 doi: 10.1161/STROKEAHA.117.017217. Epub 2017 Jul 18. PMID: 28720658.

#### Cited by:

1210. **Del Brutto, V.J., S. Chaturvedi, H.-C. Diener** et al. Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel. // *Journal of the American College of Cardiology*, 74, 2019, № 6, p. 786-803. ISSN 0735-1097.
1211. **Fu, J., K. Fang, X. Cheng.** Diagnosis, management and research prospect of embolic strokes of undetermined source = 不明原因栓塞性卒中的诊治及研究展望. // *Chinese Journal of Neurology*, 53, 2020, № 9, p. 721-727. ISSN 1006-7876.
1212. **Geisler, T., A. Mengel, U. Ziemann** et al. Management of Embolic Stroke of Undetermined Source (ESUS). // *Drugs*, 78, 2018, № 8, p. 823-831. ISSN 0012-6667.
1213. **Khan, R.** Examining the evidence for PFO closure and novel oral anticoagulants for treatment of cryptogenic stroke. // *Expert Review of Cardiovascular Therapy*, 18, 2020, № 3, p. 139-148. ISSN 1477-9072.

1214. **Kleiman, N.S.** Never So Simple: Bedside Measurement of Platelet Reactivity and the Risk of Stroke After Coronary Stenting. // *JACC: Cardiovascular Interventions*, 11, 2018, № 13, p. 1287-1289. ISSN 1936-8798.
1215. **Komatsu, T., Y. Iguchi, A. Arai et al.** Large but nonstenotic carotid artery plaque in patients with a history of embolic stroke of undetermined source. // *Stroke*, 49, 2018, № 12, p. 3054-3056. ISSN 0039-2499.
1216. **Papanikolaou, P., A.S. Antonopoulos, I. Mastorakou et al.** Antithrombotic therapy in carotid artery disease. // *Current Pharmaceutical Design*, 26, 2020, № 23, p. 2725-2734. ISSN 1381-6128.
1217. **Varma, P.K., H. Ahmed, N. Krishna et al.** Bleeding complications after dual antiplatelet therapy with ticagrelor versus dual antiplatelet therapy with clopidogrel—a propensity-matched comparative study of two antiplatelet regimes in off-pump coronary artery bypass grafting. // *Indian Journal of Thoracic and Cardiovascular Surgery*, 37, 2021, № 1, p. 27-37. ISSN 0970-9134.
1218. **Yaghi, S., S. Prabhakaran, P. Khatri et al.** Intracranial Atherosclerotic Disease: Mechanisms and Therapeutic Implications. // *Stroke*, 50, 2019, № 5, p. 1286-1293. ISSN 0039-2499.
1219. **Ziemann, U.** Embolic stroke of undetermined source (ESUS): Has the concept proven its worth? = Embolischer Schlaganfall unbekannter Quelle (ESUS). // *Klinikerarzt*, 48, 2019, № 3, p. 78-81. ISSN 0341-2350.
1220. **Zlotnik, D., B. Cholley, A. Godier.** Ticagrelor and aspirin increased vein graft patency after coronary artery bypass grafting but does it matter? // *Journal of Thoracic Disease*, 10, 2018, p. S3263-S3265. ISSN 2072-1439.

Hauser, S.L., Bar-Or A., G. Comi, G. Giovannoni, H.-P. Hartung, B. Hemmer, F. Lublin, X. Montalban ... for the OPERA I and OPERA II Clinical Investigators (OPERA I Principal Investigators ... **Dimitar Maslarov**, Bulgaria). Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. // *The Lancet Neurology*, 376, 2017, № 3, p. 221-234. ISSN 1474-4422.

#### **Cited by: (518)**

1221. **Afrasiabi, A., G.P. Parnell, S. Swaminathan et al.** The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis. // *Scientific Reports*, 10, 2020, № 1, art. no. 193. ISSN 2045-2322.
1222. **Aguilar-Juárez, P.A., R.A. Castillo-Lara, M. Ceballos-Godina et al.** Consensus for the diagnosis and treatment of multiple sclerosis in ISSSTE patients = Consenso para el diagnóstico y tratamiento de la esclerosis múltiple en pacientes del ISSSTE. // *Medicina Interna de Mexico*, 35, 2019, № 5, p. 732-771. ISSN 0186-4866.

1223. **Airas, L., M. Nylund, I. Mannonen** et al. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. // *Multiple Sclerosis and Related Disorders*, 40, 2020, art. no. 101980. ISSN 2211-0348.
1224. **Akaishi, T., I. Nakashima**. Efficiency of antibody therapy in demyelinating diseases. // *International Immunology*, 29, 2017, № 7, p. 327-335. ISSN 0953-8178.
1225. **Alenazy, M.F., F. Saheb Sharif-Askari, M.A. Omair** et al. Abatacept enhances blood regulatory B cells of rheumatoid arthritis patients to a level that associates with disease remittance. // *Scientific Reports*, 11, 2021, № 1, art. no. 5629. ISSN 2045-2322.
1226. **Ali, Z.K., D.E. Baker**. Formulary drug review: Ocrelizumab. // *Hospital Pharmacy*, 52, 2017, № 9, p. 599-606. ISSN 0018-5787.
1227. **Allen-Philbey, K., R. Middleton, K. Tuite-Dalton** et al. Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement? // *Frontiers in Neurology*, 11, 2020, art. no. 464. ISSN 1664-2295.
1228. **Alonso-Moreno, M., M. Ladrón-Guevara, P. Ciudad-Gutiérrez**. Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis = Revisión sistemática sobre el sesgo de género en los ensayos clínicos de anticuerpos monoclonales para el tratamiento de la esclerosis múltiple. // *Neurologia*, 2021. ISSN 0213-4853.
1229. **Alroughani, R., J. Inshasi, A. Al-Asmi** et al. Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. // *Postgraduate Medicine*, 132, 2020, № 4, p. 368-376. ISSN 0032-5481.
1230. **Alroughani, R., J.S. Inshasi, D. Deleu** et al. An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion. // *Neurology and Therapy*, 8, 2019, № 1, p. 13-23. ISSN 2193-8253.
1231. **AlSharqi, I.A., M. Aljumah, S. Bohlega** et al. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review. // *Neurology and Therapy*, 9, 2020, № 1, p. 55-66. ISSN 2193-8253.
1232. **Alstadhaug, K.B., K.-M. Myhr, C.H. Rinaldo**. Progredierende multifokal leukoencefalopati. // *Tidsskrift for den Norske Laegeforening*, 137, 2017, № 23-24, 25 p. ISSN 0029-2001.

1233. **Altmann, P., F. Leutmezer.** Therapy options of multiple sclerosis = Aktuelle Therapiemöglichkeiten der Multiplen Sklerose. // *Journal für Neurologie, Neurochirurgie und Psychiatrie*, 19, 2018, № 1, p. 3-13. ISSN 1608-1587.
1234. **Amato, M.P., M. Fonderico, E. Portaccio et al.** Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. // *Brain*, 143, 2020, № 10, p. 3013-3024. ISSN 0006-8950.
1235. **Amor, S., D. Baker, S.J. Khoury et al.** SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad. // *Annals of Neurology*, 87, 2020, № 6, p. 794-797. ISSN 0364-5134.
1236. **Annibaldi, V., R. Umeton, A. Palermo et al.** Analysis of coding and non-coding transcriptome of peripheral B cells reveals an altered interferon response factor (IRF)-1 pathway in multiple sclerosis patients. // *Journal of Neuroimmunology*, 324, 2018, p. 165-171. ISSN 0165-5728.
1237. **Araki, M., T. Yamamura.** Neuromyelitis optica spectrum disorders: Emerging therapies. // *Clinical and Experimental Neuroimmunology*, 8, 2017, № 2, p. 107-116. ISSN 1759-1961.
1238. **Aringer, M., N. Leuchten, T. Dörner.** Biologicals and small molecules for systemic lupus erythematosus = Biologika und „small molecules“ beim systemischen Lupus erythematosus. // *Zeitschrift für Rheumatologie*, 79, 2020, № 3, p. 232-240. ISSN 0340-1855.
1239. **Armoiry, X., H.-M. Späth, A.-M. Henaine et al.** Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE. // *Expert Opinion on Biological Therapy*, 2020. ISSN 1471-2598.
1240. **Atkins, H.L., M.S. Freedman.** Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis. // *Neurotherapeutics*, 14, 2017, № 4, p. 888-893. ISSN 1933-7213.
1241. **Avasarala, J.** FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patients. // *CNS Spectrums*, 24, 2019, № 3, p. 279-280. ISSN 1092-8529.
1242. **Avasarala, J.** It's time for combination therapies in multiple sclerosis. // *Innovations in Clinical Neuroscience*, 14, 2017, № 5-6, p. 28-30. ISSN 2158-8333.
1243. **Avasarala, J., P. Zachariah, B. Turner.** Pivotal clinical trial enrollment of blacks in MS or NMOSD: When will we achieve parity? // *CNS Spectrums*, 2021. ISSN 1092-8529.

1244. **Aygnac, X., P.-A. Bilodeau, A. Prat** et al. Assessing the risk of multiple sclerosis disease-modifying therapies. // *Expert Review of Neurotherapeutics*, 19, 2019, № 7, p. 695-706. ISSN 1473-7175.
1245. **Baber, U., A. Bouley, E. Egnor** et al. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients. // *Journal of Neurology*, 265, 2018, № 10, p. 2342-2345. ISSN 0340-5354.
1246. **Baecher-Allan, C., B.J. Kaskow, H.L. Weiner.** Multiple Sclerosis: Mechanisms and Immunotherapy. // *Neuron*, 97, 2018, № 4, p. 742-768. ISSN 0896-6273.
1247. **Bail, K., Q. Notz, D.M. Rovituso** et al. Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis. // *Journal of Neuroinflammation*, 14, 2017, № 1, art. no. 148. ISSN 1742-2094.
1248. **Bakaeva, T., S. Prasad.** For Massachusetts Eye and Ear Special Issue: Updates on Therapies for Multiple Sclerosis for the Ophthalmologist. // *Seminars in Ophthalmology*, 34, 2019, № 4, p. 270-278. ISSN 0882-0538.
1249. **Baker, D., E. Nutma, H. O'Shea** et al. Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model. // *Annals of Clinical and Translational Neurology*, 6, 2019, № 8, p. 1362-1372. ISSN 2328-9503.
1250. **Baker, D., G. Pryce, L.K. James** et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 44, 2020, art. no. 102279. ISSN 2211-0348.
1251. **Baker, D., G. Pryce, S.S. Herrod** et al. Potential mechanisms of action related to the efficacy and safety of cladribine. // *Multiple Sclerosis and Related Disorders*, 30, 2019, p. 176-186. ISSN 2211-0348.
1252. **Baker, K.F., J.D. Isaacs.** Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? // *Annals of the Rheumatic Diseases*, 77, 2018, № 2, p. 175-187. ISSN 0003-4967.
1253. **Baldassari, L.E., J.W. Rose.** Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis. // *Neurotherapeutics*, 14, 2017, № 4, p. 842-858. ISSN 1933-7213.
1254. **Baldassari, L.E., R.J. Fox.** Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. // *Drugs*, 78, 2018, № 15, p. 1549-1566. ISSN 0012-6667.
1255. **Baranzini, S.E., J.R. Oksenberg.** The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. // *Trends in Genetics*, 33, 2017, № 12, p. 960-970. ISSN 0168-9525.

1256. **Bartels, F., K. Nobis, G. Cooper** et al. Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure. // *Multiple Sclerosis Journal*, 25, 2019, № 7, p. 927-936. ISSN 1352-4585.
1257. **Barun, B., T. Gabelić, I. Adamec** et al. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. // *Multiple Sclerosis and Related Disorders*, 48, 2021, art. no. 102704. ISSN 2211-0348.
1258. **Bašić Kes, V., M.J. Jurašić, I. Zavoreo** et al. Update on guidelines for pharmacological treatment of multiple sclerosis by the croatian society for neurovascular disorders of the Croatian medical association and Croatian society of neuroimmunology and neurogenetics = Osvremenjene smjernice za farmakološko liječenje oboljelih od multiple skleroze hrvatskog društva za neurovaskularne poremećaje Hrvatskog liječničkog zbora I hrvatskog društva za neuroimunologiju i neurogenetiku. // *Acta Medica Croatica*, 72, 2018, № 3, p. 431-445. ISSN 1330-0164.
1259. **Batcheller, L., D. Baker**. Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer? // *Journal of the Neurological Sciences*, 404, 2019, p. 19-28. ISSN 0022-510X.
1260. **Bauer, B., B. Brockmeier, V. Devonshire** et al. An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis. // *Neurodegenerative Disease Management*, 10, 2020, № 6, p. 369-382. ISSN 1758-2024.
1261. **Bayas, A., M. Christ**. Immunotherapy for the treatment of multiple sclerosis = Immuntherapie der Multiplen Sklerose. // *Internistische Praxis*, 63, 2020, № 3, p. 457-471. ISSN 0020-9570.
1262. **Bell, L., T. Koeniger, S. Tacke** et al. Characterization of blood–brain barrier integrity in a B-cell-dependent mouse model of multiple sclerosis. // *Histochemistry and Cell Biology*, 151, 2019, № 6, p. 489-499. ISSN 0948-6143.
1263. **Bellinvia, A., E. Prestipino, E. Portaccio** et al. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. // *Neurological Sciences*, 41, 2020, № 10, p. 2939-2945. ISSN 1590-1874.
1264. **Bellizzi, M.J., J.W. Hammond, H. Li** et al. The mixed-lineage kinase inhibitor URM-099 protects hippocampal synapses in experimental autoimmune encephalomyelitis. // *eNeuro*, 5, 2018, № 6, art. no. e0245-18.2018. ISSN 2373-2822.
1265. **Bergman, J., J. Burman, T. Bergenheim** et al. Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension. // *Journal of Neurology*, 268, 2021, № 2, p. 651-657. ISSN 0340-5354.

1266. **Bermel, R.A., E. Waubant, G. Pardo** et al. Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial. // *Annals of Clinical and Translational Neurology*, 8, 2021, № 3, p. 711-715. ISSN 2328-9503.
1267. **Beyzaee, A.M., G. Rahmatpour Rokni, A. Patil** et al. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review. // *Dermatologic Therapy*, 34, 2021, № 1, art. no. e14405. ISSN 1396-0296.
1268. **Bhargava, P., C. Wicken, M.D. Smith** et al. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. // *Multiple Sclerosis and Related Disorders*, 30, 2019, p. 136-140. ISSN 2211-0348.
1269. **Bhise, V., S. Dhib-Jalbut**. Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives. // *Neurotherapeutics*, 18, 2021, № 1, p. 244-251. ISSN 1933-7213.
1270. **Bigaut, K., J. De Seze, N. Collongues**. Ocrelizumab for the treatment of multiple sclerosis. // *Expert Review of Neurotherapeutics*, 19, 2019, № 2, p. 97-108. ISSN 1473-7175.
1271. **Bigaut, K., N. Collongues**. Interest of rituximab in progressive MS = Intérêt du rituximab dans les SEP progressives. // *Pratique Neurologique - FMC*, 11, 2020, № 1, p. 1-9. ISSN 1878-7762.
1272. **Bigaut, K., T. Fabacher, L. Kremer** et al. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. // *Multiple Sclerosis Journal*, 27, 2021, № 5, p. 729-741. ISSN 1352-4585.
1273. **Blumenfeld-Kan, S., E. Staun-Ram, A. Miller**. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire. // *Multiple Sclerosis and Related Disorders*, 34, 2019, p. 29-37. ISSN 2211-0348.
1274. **Boremalm, M., A. Juto, M. Axelsson** et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. // *European Journal of Neurology*, 26, 2019, № 8, p. 1060-1067. ISSN 1351-5101.
1275. **Bose, G., M.S. Freedman**. Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment. // *Multiple Sclerosis Journal*, 26, 2020, № 5, p. 540-547. ISSN 1352-4585.
1276. **Bose, G., M.S. Freedman**. Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis. // *Journal of the Neurological Sciences*, 421, 2021, art. no. 117324. ISSN 0022-510X.



1277. **Bose, G., S. Thebault, C.A. Rush** et al. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. // *Multiple Sclerosis Journal*, 27, 2021, № 2, p. 167-173. ISSN 1352-4585.
1278. **Bove, R.M., A.J. Green.** Remyelinating Pharmacotherapies in Multiple Sclerosis. // *Neurotherapeutics*, 14, 2017, № 4, p. 894-904. ISSN 1933-7213.
1279. **Bovis, F., A. Signori, L. Carmisciano** et al. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. // *Annals of Neurology*, 84, 2018, № 4, p. 621-625. ISSN 0364-5134.
1280. **Bowen, J.D.** Highly aggressive multiple sclerosis. // *CONTINUUM Lifelong Learning in Neurology*, 25, 2019, № 3, p. 689-714. ISSN 1080-2371.
1281. **Boyden, A.W., A.A. Brate, N.J. Karandikar.** Early IFN $\gamma$ -mediated and late perforin-mediated suppression of pathogenic CD4 T cell responses are both required for inhibition of demyelinating disease by CNS-specific autoregulatory CD8 T cells. // *Frontiers in Immunology*, 9, 2018, art. no. 2336. ISSN 1664-3224.
1282. **Boyden, A.W., A.A. Brate, N.J. Karandikar.** Novel B cell-dependent multiple sclerosis model using extracellular domains of myelin proteolipid protein. // *Scientific Reports*, 10, 2020, № 1, art. no. 5011. ISSN 2045-232.
1283. **Boyko, A.N.** Cancers and multiple sclerosis: Risk of comorbidity and influence of disease modifying therapy. // *Zhurnal Nevrologii i Psichiatrii imeni S.S. Korsakova*, 119, 2019, № 2, p. 86-93. ISSN 1997-7298.
1284. **Boyko, A.N., M.R. Guseva, N.V. Khachanova** et al. Issues of the current terminology in multiple sclerosis. // *Zhurnal Nevrologii i Psichiatrii imeni S.S. Korsakova*, 118, 2018, № 8, p. 121-127. ISSN 1997-7298.
1285. **Boyko, A.N., M.V. Davydovskaya, N.V. Khachanova** et al. Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis = Клинические рекомендации по применению препарата окрелизумаб у пациентов с рассеянным склерозом. // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 11, 2019, № 3, p. 16-25. ISSN 2074-2711.
1286. **Boyko, A.N., N.V. Khachanova, M.V. Melnikov** et al. New directions of immunocorrection in multiple sclerosis. // *Zhurnal Nevrologii i Psichiatrii imeni S.S. Korsakova*, 120, 2020, № 2, p. 103-109. ISSN 1997-7298.
1287. **Boyko, A.N., N.Yu. Lashch, M.E. Guseva.** New drugs for anti-B-cell therapy of multiple sclerosis. // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 10, 2018, № 1, p. 70-73. ISSN 2074-2711.

1288. **Boyko, O.V., A.N. Boyko, P.A. Yakovlev** et al. Results of a phase i clinical study of anti-CD20 monoclonal antibody (BCD-132): Pharmacokinetics, pharmacodynamics and safety. // *Zhurnal Nevrologii i Psikiatrii imeni S.S. Korsakova*, 119, 2019, № 10, p. 87-95. ISSN 1997-7298.
1289. **Boyko, O.V., I.I. Choroshilova, S.V. Petrov** et al. Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab. // *Zhurnal Nevrologii i Psikiatrii imeni S.S. Korsakova*, 119, 2019, № 10, p. 120-127. ISSN 1997-7298.
1290. **Boyko, O.V., I.I. Khoroshylova, S.V. Petrov** et al. Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report. // *Zhurnal Nevrologii i Psikiatrii imeni S.S. Korsakova*, 118, 2018, № 8, p. 116-120. ISSN 1997-7298.
1291. **Boyko, O.V., S.V. Petrov, N.Yu. Lashch** et al. Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis. // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 11, 2019, № 1, p. 59-65. ISSN 2074-2711.
1292. **Brate, A.A., A.W. Boyden, F.R. Itani** et al. Therapeutic intervention in relapsing autoimmune demyelinating disease through induction of myelin-specific regulatory CD8 T cell responses. // *Journal of Translational Autoimmunity*, 2, 2019, art. no. 100010. ISSN 2589-9090.
1293. **Brod, S.A.** In MS: Immunosuppression is passé. // *Multiple Sclerosis and Related Disorders*, 40, 2020, art. no. 101967. ISSN 2211-0348.
1294. **Bross, M., M. Hackett, E. Bernitsas.** Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis. // *International Journal of Molecular Sciences*, 21, 2020, № 12, art. no. 4312, p. 1-15. ISSN 1661-6596.
1295. **Bsteh, G., H. Hegen, P. Altmann** et al. Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis. // *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, 6, 2020, № 4. ISSN 2055-2173.
1296. **Bsteh, G., R. Ehling, L.-M. Walchhofer** et al. Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis - The PaSiMS II study. // *PLoS ONE*, 12, 2017, № 7, art. no. e0181458. ISSN 1932-6203.
1297. **Bülau, B.** First treatment option for early primary progressive multiple sclerosis is approved = Erste Behandlungsoption bei früher primär progredienter multipler sklerose zugelassen. // *Neurologie und Rehabilitation*, 24, 2018, № 1, p. 91-92. ISSN 0947-2177.
1298. **Burt, R.K., P. Tappenden, X. Han** et al. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for

- relapsing remitting multiple sclerosis in the United States of America. // *Multiple Sclerosis and Related Disorders*, 45, 2020, art. no. 102404. ISSN 2211-0348.
1299. **Burton, J.M., M.S. Freedman.** The shifting landscape of disease-modifying therapies for relapsing multiple sclerosis. // *Journal of Neuro-Ophthalmology*, 38, 2018, № 2, p. 210-216. ISSN 1070-8022.
  1300. **Butzkueven, H., M. Trojano, L. Kappos et al.** Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP). // *Multiple Sclerosis Journal*, 27, 2021, № 3, p. 410-419. ISSN 1352-4585.
  1301. **Bykova, O.V., Y.A. Klimov, S.V. Tikhonov et al.** Clinical observation experience of a pediatric patient with primary progressive multiple sclerosis in the moscow office for the treatment of children and adolescents with multiple sclerosis. // *Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova*, 120, 2020, № 10, p. 45-50. ISSN 1997-7298.
  1302. **Cai, X.-J., Z.-W. Li, J.-Y. Xi et al.** Myasthenia gravis and specific immunotherapy: monoclonal antibodies. // *Annals of the New York Academy of Sciences*, 1452, 2019, № 1, p. 18-33. ISSN 0077-8923.
  1303. **Calabresi, P.A.** Advances in multiple sclerosis: from reduced relapses to remedies. // *The Lancet Neurology*, 17, 2018, № 1, p. 10-12. ISSN 1474-4422.
  1304. **Calabresi, P.A.** B-cell depletion - A frontier in monoclonal antibodies for multiple sclerosis. // *New England Journal of Medicine*, 376, 2017, № 3, p. 280-282. ISSN 0028-4793.
  1305. **Caldito, N.G., A. Shirani, A. Salter et al.** Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. // *Multiple Sclerosis Journal*, 2020. ISSN 1352-4585.
  1306. **Capasso, N., A. Nozzolillo, G. Scalia et al.** Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 49, 2021, art. no. 102802. ISSN 2211-0348.
  1307. **Castro-Sanchez, P., A.R. Teagle, S. Prade et al.** Modulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy. // *Frontiers in Cell and Developmental Biology*, 8, 2020, art. no. 608747. ISSN 2296-634X.
  1308. **Çelik, Ş.Y.** The effect of ocrelizumab in the treatment of multiple sclerosis = Multiple skleroz tedavisinde okrelizumabın etkinliği. // *Türk Noroloji Dergisi*, 23, 2017, № 3, p. 146-147. ISSN 1301-062X.
  1309. **Cerqueira, J.J., D.A.S. Compston, R. Geraldes et al.** Time matters in multiple sclerosis: Can early treatment and long-term follow-up ensure everyone benefits

- from the latest advances in multiple sclerosis? // *Journal of Neurology, Neurosurgery and Psychiatry*, 89, 2018, № 8, p. 844-850. ISSN 0022-3050.
1310. **Chalkley, J.** Treatment of pediatric multiple sclerosis. – In: *Multiple Sclerosis in Children and Adolescents*, 2018, p. 47-72. ISBN 9781536129809; 9781536129793.
  1311. **Chamberlin, K.W., A. Gentry.** Ocrelizumab for multiple sclerosis. // *Drug Topics*, 161, 2017, № 8. ISSN 0012-6616.
  1312. **Chilimuri, S., N. Mantri, S. Gongati** et al. Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab. // *Vaccines*, 9, 2021, № 3, art. no. 219, p. 1-3. ISSN 2076-393X.
  1313. **Chirikov, V., I. Ma, N. Joshi** et al. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. // *Value in Health*, 22, 2019, № 2, p. 168-176. ISSN 1098-3015.
  1314. **Chisari, C.G., S. Toscano, E. D'Amico** et al. An update on the safety of treating relapsing-remitting multiple sclerosis. // *Expert Opinion on Drug Safety*, 18, 2019, № 10, p. 925-948. ISSN 1474-0338.
  1315. **Ciardi, M.R., M. Iannetta, M.A. Zingaropoli** et al. Reactivation of Hepatitis B Virus with Immune-Escape Mutations after Ocrelizumab Treatment for Multiple Sclerosis. // *Open Forum Infectious Diseases*, 6, 2019, № 1. ISSN 2328-8957.
  1316. **Collongues, N., L. Michel, J. de Seze.** Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications. // *Current Treatment Options in Neurology*, 19, 2017, № 5, art. no. 19. ISSN 1092-8480.
  1317. **Comi, G., G. Dalla Costa, L. Moiola.** Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials? // *Expert Review of Neurotherapeutics*, 21, 2021, № 1, p. 21-34. ISSN 1473-7175.
  1318. **Conte, W.L.** Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia. // *Multiple Sclerosis and Related Disorders*, 44, 2020, art. no. 102315. ISSN 2211-0348.
  1319. **Conte, W.L.** Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study. // *Multiple Sclerosis and Related Disorders*, 52, 2021, art. no. 103014. ISSN 2211-0348.
  1320. **Conte, W.L., N. Arndt, V.P. Cipriani** et al. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. // *Multiple Sclerosis and Related Disorders*, 27, 2019, p. 397-399. ISSN 2211-0348.

1321. **Conway, D.S., C.M. Hersh, H.C. Harris** et al. Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. // *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, 6, 2020, № 1. ISSN 2055-2173.
1322. **Costa-Frossard, L., I. Moreno-Torres, V. Meca-Lallana** et al. EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic = Documento EMCAM (Esclerosis Múltiple Comunidad Autónoma de Madrid) para el manejo de pacientes con esclerosis múltiple durante la pandemia de SARS-CoV-2. // *Revista de Neurologia*, 70, 2020, № 9, p. 329-340. ISSN 0210-0010.
1323. **Cotchett, K.R., B.N. Dittel, A.Z. Obeidat**. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis. // *Multiple Sclerosis and Related Disorders*, 49, 2021, art. no. 102787. ISSN 2211-0348.
1324. **Cotsapas, C., M. Mitrovic, D. Hafler**. Multiple sclerosis. – In: *Handbook of Clinical Neurology*, 148, 2018, p. 723-730. ISSN 0072-9752. ISBN 9780444640765.
1325. **Cotzomi, E., P. Stathopoulos, C.S. Lee** et al. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. // *Brain*, 14, 2019, № 2, № 6, p. 1598-1615. ISSN 0006-8950.
1326. **Coyle, P.K.** Immunopathogenesis. // *Current Clinical Neurology*, 2020, p. 45-69. ISSN 1559-0585.
1327. **Coyle, P.K., S. Shang, Z. Xiao** et al. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week. // *Multiple Sclerosis and Related Disorders*, 22, 2018, p. 134-138. ISSN 2211-0348.
1328. **Cree, B.A.C.** Multiple sclerosis therapy: Are we ready for a one-size-fits-all approach? // *Journal of Neuro-Ophthalmology*, 38, 2018, № 2, p. 258-262. ISSN 1070-8022.
1329. **Cunniffe, N., A. Coles**. Promoting remyelination in multiple sclerosis. // *Journal of Neurology*, 268, 2021, № 1, p. 30-44. ISSN 0340-5354.
1330. **Current strategies in the treatment of multiple sclerosis**. // *American Journal of Managed Care*, 2018, 2018, p. 3-12. ISSN 1088-0224.
1331. **D'Souza, M., A. Heikkilä, J. Lorscheider** et al. Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials. // *Multiple Sclerosis Journal*, 26, 2020, № 8, p. 993-996. ISSN 1352-4585.

1332. **da Silva, J.G., M.F. Pezzini, J. Poeta.** Advances in the treatment of multiple sclerosis through monoclonal antibody Ocrelizumab = Avanços no tratamento da esclerose múltipla através do anticorpo monoclonal Ocrelizumabe. // *Medicina (Brazil)*, 53, 2020, № 1, p. 35-41. ISSN 0076-6046.
1333. **D'Amico, E., A. Zanghi, M. Gastaldi et al.** Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. // *Autoimmunity Reviews*, 18, 2019, № 7, p. 665-672. ISSN 1568-9972.
1334. **Das, J., B. Sharrack, J.A. Snowden.** Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists. // *Current Hematologic Malignancy Reports*, 14, 2019, № 2, p. 127-135. ISSN 1558-8211.
1335. **Das, J., B. Sharrack, J.A. Snowden.** Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions. // *Expert Review of Neurotherapeutics*, 20, 2020, № 12, p. 1299-1313. ISSN 1473-7175.
1336. **Davis, J.S., D. Ferreira, E. Paige et al.** Infectious complications of biological and small molecule targeted immunomodulatory therapies. // *Clinical Microbiology Reviews*, 33, 2020, № 3, art. no. e00035-19, p. 1-117. ISSN 0893-8512.
1337. **De Angelis, F., D. Plantone, J. Chataway.** Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. // *CNS Drugs*, 32, 2018, № 6, p. 499-526. ISSN 1172-7047.
1338. **De Angelis, F., N.A., W.J. Brownlee.** Disease-modifying therapies John, for multiple sclerosis. // *BMJ (Online)*, 363, 2018, art. no. k4674. ISSN 0959-8146.
1339. **De Flon, P., L. Söderström, K. Laurell et al.** Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls. // *PLoS ONE*, 13, 2018, № 2, art. no. e0192516. ISSN 1932-6203.
1340. **De Giglio, L., A.E. Grimaldi, F. Fubelli et al.** Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis. // *Expert Review of Neurotherapeutics*, 19, 2019, № 5, p. 417-429. ISSN 1473-7175.
1341. **de Sitter, A., T. Verhoeven, J. Burggraaff et al.** Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. // *Journal of Neurology*, 267, 2020, № 12, p. 3541-3554. ISSN 0340-5354.
1342. **De Stefano, N., A. Giorgio.** Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al. // *Multiple Sclerosis Journal*, 24, 2018, № 10, p. 1388-1389. ISSN 1352-4585.

1343. **De Stefano, N., D.G. Silva, M.H. Barnett.** Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis. // *CNS Drugs*, 31, 2017, № 4, p. 289-305. ISSN 1172-7047.
1344. **Deeb, O., M. Nabulsi.** Exploring multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) as neurodegenerative diseases and their treatments: A review study. // *Current Topics in Medicinal Chemistry*, 20, 2020, № 26, p. 2391-2403. ISSN 1568-0266.
1345. **Deftereos, S.N., E. Koutlas, E. Koutsouraki et al.** Seasonal adherence to, and effectiveness of, subcutaneous interferon  $\beta$ -1a administered by RebiSmart® in patients with relapsing multiple sclerosis: Results of the 1-year, observational GEPAT-SMART study. // *BMC Neurology*, 18, 2018, № 1, art. no. 186. ISSN 1471-2377.
1346. **Deleu, D., B. Canibano, B. Mesraoua et al.** Management of relapsing–remitting multiple sclerosis in Qatar: an expert consensus. // *Current Medical Research and Opinion*, 36, 2020, № 2, p. 251-260. ISSN 0300-7995.
1347. **Demir, S., M.M. Atmaca, R.E. Togrol.** The first cure experience of a clinic: Approach to the patient to start ocrelizumab = Bir Kliniğin İlk Kür Tecrübesi: Okrelizumab Başlanacak Hastaya Yaklaşım. // *Noropsikiyatri Arsivi*, 58, 2021, № 1, p. 52-56. ISSN 1300-0667.
1348. **Dendrou, C.A., L. Fugger.** Immunomodulation in multiple sclerosis: promises and pitfalls. // *Current Opinion in Immunology*, 49, 2017, p. 37-43. ISSN 0952-7915.
1349. **Dirks, P., V. Zingler, J. Leemhuis et al.** Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - The CONFIDENCE study protocol. // *BMC Neurology*, 20, 2020, № 1, art. no. 95. ISSN 1471-2377.
1350. **Dive, D., S. Dauby, E. Lommers et al.** Multiple sclerosis : Therapy update = Actualités thérapeutiques dans la sclérose en plaques. // *Revue Medicale de Liege*, 75, 2020, № 5/6, p. 382-385. ISSN 0370-629X.
1351. **Donzé, C., C. Papeix, C. Lebrun-Frenay et al.** Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. // *Revue Neurologique*, 176, 2020, № 10, p. 804-822. ISSN 0035-3787.
1352. **Dorst, J., T. Fangerau, D. Taranu et al.** Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial. // *EClinicalMedicine*, 16, 2019, p. 98-106. ISSN 2589-5370.

1353. **Drori, T., J. Chapman.** Neurological Disorders. – In: *Mosaic of Autoimmunity: The Novel Factors of Autoimmune Diseases*, 2019, p. 541-548. ISBN 9780128143087; 9780128143070.
1354. **Drugs for multiple sclerosis.** // *Medical Letter on Drugs and Therapeutics*, 63, 2021, № 1620, p. 42-48. ISSN 0025-732X.
1355. **Drulovic, J., J. Ivanovic, S. Mesaros et al.** Long-term disability outcomes in relapsing-remitting multiple sclerosis: a 10-year follow-up study. // *Neurological Sciences*, 40, 2019, № 8, p. 1627-1636. ISSN 1590-1874.
1356. **Du, F.H., E.A. Mills, Y. Mao-Draayer.** Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. // *Autoimmunity Highlights*, 8, 2017, № 1, art. no. 12. ISSN 2038-0305.
1357. **Dubey, D., T. Forsthuber, E.P. Flanagan et al.** B-cell-Targeted therapies in relapsing forms of MS. // *Neurology: Neuroimmunology and NeuroInflammation*, 4, 2017, № 6, art. no. e405. ISSN 2332-7812.
1358. **Dumitrescu, L., C.S. Constantinescu, R. Tanasescu.** Recent developments in interferon-based therapies for multiple sclerosis. // *Expert Opinion on Biological Therapy*, 18, 2018, № 6, p. 665-680. ISSN 1471-2598.
1359. **Dungan, M., M.D. Carrithers.** Regulation of expansion of CD11c+ B cells and anti-viral immunity by epithelial V-like antigen. // *Immunobiology*, 225, 2020, № 2, art. no. 151883. ISSN 0171-2985.
1360. **Durozard, P., A. Maarouf, C. Boutiere et al.** Efficacy of rituximab in refractory RRMS. // *Multiple Sclerosis Journal*, 25, 2019, № 6, p. 828-836. ISSN 1352-4585.
1361. **Eckert, N.** Multiple sclerosis: Previous endpoints are not sufficient = Multiple sklerose: Bisherige Endpunkte reichen nicht. // *Deutsches Arzteblatt International*, 114, 2017, № 35-36, p. A1600 and A2. ISSN 1866-0452.
1362. **Ellrichmann, G., J. Bolz, M. Peschke et al.** Peripheral CD19 + B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. // *Journal of Neurology*, 266, 2019, № 1, p. 57-67. ISSN 0340-5354.
1363. **Ellwardt, E., L. Ellwardt, S. Bittner et al.** Monitoring B-cell repopulation after depletion therapy in neurologic patients. // *Neurology: Neuroimmunology and NeuroInflammation*, 5, 2018, № 4, art. no. e463. ISSN 2332-7812.
1364. **Epstein, D.J., J. Dunn, S. Deresinski.** Infectious complications of multiple sclerosis therapies: Implications for screening, prophylaxis, and management. // *Open Forum Infectious Diseases*, 5, 2018, № 8. ISSN 2328-8957.



1365. **Etemadifar, M., S. Ghourchian, N. Mahinparvar** et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. // *Acta Medica Iranica*, 57, 2019, № 8, p. 484-491. ISSN 0044-6025.
1366. **Ewing, E., L. Kular, S.J. Fernandes** et al. Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression. // *EBioMedicine*, 43, 2019, p. 411-423. ISSN 2352-3964.
1367. **Faissner, S., R. Gold.** Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. // *CNS Drugs*, 32, 2018, № 3, p. 269-287. ISSN 1172-7047.
1368. **Fakih, R., M. Matiello, T. Chitnis** et al. Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients. // *Journal of Neurology*, 265, 2018, № 11, p. 2688-2694. ISSN 0340-5354.
1369. **Fernandez-Diaz, E., J.A. Perez-Vicente, R. Villaverde-Gonzalez** et al. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. // *Annals of Clinical and Translational Neurology*, 8, 2021, № 2, p. 385-394. ISSN 2328-9503.
1370. **Ferreira, V.F.M., D. Meredith, J.M. Stankiewicz.** Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab. // *Neurology: Neuroimmunology and NeuroInflammation*, 6, 2019, № 5. ISSN 2332-7812.
1371. **Fiander, M.D.J., V. Bhan, S.A. Stewart** et al. Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab. // *Canadian Journal of Neurological Sciences*, 46, 2019, № 4, p. 455-458. ISSN 0317-1671.
1372. **Filipi, M., S. Jack.** Interferons in the treatment of multiple sclerosis: A clinical efficacy, safety, and tolerability update. // *International Journal of MS Care*, 22, 2020, № 4, p. 165-172. ISSN 1537-2073.
1373. **Findling, O., J. Sellner.** Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors? // *Drug Discovery Today*, 26, 2021, № 2, p. 416-428. ISSN 1359-6446.
1374. **Fischer, S.** Ocrelizumab: Treatment of relapsing-remitting and primary progressive multiple sclerosis = Ocrelizumab: Behandlung der schubförmigen und der primär progredienten multiplen Sklerose. // *Arzneimitteltherapie*, 36, 2018, № 6, p. 207-210. ISSN 0723-6913.
1375. **Florou, D., M. Katsara, J. Feehan** et al. Anti-cd20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab. // *Brain Sciences*, 10, 2020, № 10, art. no. 758, p. 1-13. ISSN 2076-3425.

1376. **Forsthuber, T.G., D.M. Cimbora, J.N. Ratchford** et al. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. // *Therapeutic Advances in Neurological Disorders*, 11, 2018. ISSN 1756-2856.
1377. **Fox, E., A.E. Lovett-Racke, M. Gormley** et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. // *Multiple Sclerosis Journal*, 27, 2021, № 3, p. 420-429. ISSN 1352-4585.
1378. **Fox, E.J., G.J. Buckle, B. Singer** et al. Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist. // *Neurology: Clinical Practice*, 9, 2019, № 1, p. 53-63. ISSN 2163-0402.
1379. **Fragoso, Y.D.** Adverse events and monitoring requirements associated with monoclonal antibody therapy in patients with multiple sclerosis. // *Drugs and Therapy Perspectives*, 35, 2019, № 12, p. 627-634. ISSN 1172-0360.
1380. **Frampton, J.E.** Ocrelizumab: First Global Approval. // *Drugs*, 77, 2017, № 9, p. 1035-1041. ISSN 00126667.
1381. **Frasco, M.A., T. Shih, D. Incerti** et al. Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon  $\beta$ -1a. // *Journal of Medical Economics*, 20, 2017, № 10, p. 1074-1082. ISSN 1369-6998.
1382. **Frau, J., G. Coghe, L. Lorefice** et al. New horizons for multiple sclerosis therapeutics: Milestones in the development of ocrelizumab. // *Neuropsychiatric Disease and Treatment*, 14, 2018, p. 1093-1099. ISSN 1176-6328.
1383. **Fraussen, J., S. Marquez, K. Takata** et al. Phenotypic and Ig repertoire analyses indicate a common origin of IgD-CD27- double negative B cells in healthy individuals and multiple sclerosis patients. // *Journal of Immunology*, 203, 2019, № 6, p. 1650-1664. ISSN 0022-1767.
1384. **Freedman, M.S., D. Selchen, A. Prat** et al. Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. // *Canadian Journal of Neurological Sciences*, 45, 2018, № 5, p. 489-503. ISSN 0317-1671.
1385. **Frisch, E.S., R. Pretzsch, M.S. Weber.** A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues. // *Neurotherapeutics*, 2021. ISSN 1933-7213.
1386. **Fugger, L., L.T. Jensen, J. Rossjohn.** Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. // *Cell*, 181, 2020, № 1, p. 63-80. ISSN 0092-8674.

1387. **Galli, E., F.J. Hartmann, B. Schreiner** et al. GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. // *Nature Medicine*, 25, 2019, № 8, p. 1290-1300. ISSN 1078-8956.
1388. **Gandoglia, I., F. Ivaldi, A. Laroni** et al. Teriflunomide treatment reduces B cells in patients with MS. // *Neurology: Neuroimmunology and NeuroInflammation*, 4, 2017, № 6, art. no. e403. ISSN 2332-7812.
1389. **Gaudet, A.D., L.K. Fonken, L.R. Watkins** et al. MicroRNAs: Roles in Regulating Neuroinflammation. // *Neuroscientist*, 24, 2018, № 3, p. 221-245. ISSN 1073-8584.
1390. **Gehr, S., T. Kaiser, R. Kreutz** et al. Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials. // *EPMA Journal*, 10, 2019, № 4, p. 425-436. ISSN 1878-5077.
1391. **Gerdes, L.A., C. Janoschka, M. Eveslage** et al. Immune signatures of prodromal multiple sclerosis in monozygotic twins. - In: *Proceedings of the National Academy of Sciences of the United States of America*, 117, 2020, № 35, p. 21546-21556. ISSN 0027-8424.
1392. **Ghione, E., N. Bergsland, M.G. Dwyer** et al. Disability improvement is associated with less brain atrophy development in multiple sclerosis. // *American Journal of Neuroradiology*, 41, 2020, № 9, p. 1577-1583. ISSN 0195-6108.
1393. **Gingele, S., T. Skripuletz, R. Jacobs**. Role of CD20+ T cells in multiple sclerosis: Implications for treatment with ocrelizumab. // *Neural Regeneration Research*, 15, 2020, № 4, p. 663-664. ISSN 1673-5374.
1394. **Gklinos, P., M. Papadopoulou, V. Stanulovic** et al. Monoclonal antibodies as neurological therapeutics. // *Pharmaceuticals*, 14, 2021, № 2, art. no. 92, pp. 1-31. ISSN 1424-8247.
1395. **Glanz, B.I., J. Zurawski, C.T. Gonzalez** et al. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 40, 2020, art. no. 101944. ISSN 2211-0348.
1396. **Godeau, B.** Monoclonal Anti-CD20 (B-Cell) antibody and autoimmune diseases. – In: *Antibody Therapy: Substitution - Immunomodulation - Monoclonal Immunotherapy*, 2018, p. 343-363. ISBN 9783319680385; 9783319680378.
1397. **Golay, J.** Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias? // *Journal of Autoimmunity*, 85, 2017, p. 6-19. ISSN 0896-8411.
1398. **Goldschmidt, C., M.P. McGinley**. Advances in the Treatment of Multiple Sclerosis. // *Neurologic Clinics*, 39, 2021, № 1, p. 21-33. ISSN 0733-8619.

1399. **Goodman, A.D., N. Anadani, L. Gerwitz.** Siponimod in the treatment of multiple sclerosis. // *Expert Opinion on Investigational Drugs*, 28, 2019, № 12, p. 1051-1057. ISSN 1354-3784.
1400. **Gordon-Lipkin, E., B. Banwell.** An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future. // *Expert Review of Clinical Immunology*, 13, 2017, № 10, p. 975-989. ISSN 1744-666X.
1401. **Graetz, C., S. Groppa, F. Zipp et al.** Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?. // *Expert Review of Neurotherapeutics*, 18, 2018, № 3, p. 203-219. ISSN 1473-7175.
1402. **Grand'Maison, F., M. Yeung, S.A. Morrow et al.** Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment. // *Current Medical Research and Opinion*, 34, 2018, № 8, p. 1419-1430. ISSN 0300-7995.
1403. **Granqvist, M., M. Boremalm, A. Poorghobad et al.** Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. // *JAMA Neurology*, 75, 2018, № 3, p. 320-327. ISSN 2168-6149.
1404. **Grebenciucova, E., A. Pruitt.** Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies. // *Current Neurology and Neuroscience Reports*, 17, 2017, № 11, art. no. 88. ISSN 1528-4042.
1405. **Gregson, A., K. Thompson, S.E. Tsirka et al.** Emerging small-molecule treatments for multiple sclerosis: Focus on B cells [version 1; referees: 2 approved]. // *F1000Research*, 8, 2019, art. no. 245. ISSN 2046-1402.
1406. **Gross, R.H., J.R. Corboy.** Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies. // *CONTINUUM Lifelong Learning in Neurology*, 25, 2019, № 3, p. 715-735. ISSN 1080-2371.
1407. **Gysling, E.** Ocrelizumab = Ocrelizumab. // *Pharma-Kritik*, 40, 2018, № 3, p. 9-11. ISSN 1010-5409.
1408. **Haas, J., H. Rudolph, L. Costa et al.** The Choroid Plexus Is Permissive for a Preactivated Antigen-Experienced Memory B-Cell Subset in Multiple Sclerosis. // *Frontiers in Immunology*, 11, 2021, art. no. 618544. ISSN 1664-3224.
1409. **Haase, S., R.A. Linker.** Inflammation in multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 14, 2021. ISSN 1756-2856.

1410. **Habek, M.** Treatment of multiple sclerosis during the covid-19 pandemic = Liječenje multiple skleroze za vrijeme covid-19 pandemije. // *Medicus*, 29, 2020, № 2, p. 225-232. ISSN 1330-013X.
1411. **Haberli, N., H. Coban, C. Padam** et al. Babesia microti infection in a patient with Multiple Sclerosis treated with Ocrelizumab. // *Multiple Sclerosis and Related Disorders*, 48, 2021, art. no. 102731. ISSN 2211-0348.
1412. **Hacohen, Y., B. Banwell, O. Ciccarelli.** What does first-line therapy mean for paediatric multiple sclerosis in the current era? // *Multiple Sclerosis Journal*, 2020. ISSN 1352-4585.
1413. **Hagens, M.H.J., J. Killestein, M.M. Yaqub** et al. Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study. // *Multiple Sclerosis Journal*, 24, 2018, № 4, p. 543-545. ISSN 1352-4585.
1414. **Han, J., K. Zhu, X.-M. Zhang** et al. Enforced microglial depletion and repopulation as a promising strategy for the treatment of neurological disorders. // *GLIA*, 67, 2019, № 2, p. 217-231. ISSN 0894-1491.
1415. **Haselkorn, J.K., L. Hillman, K. Tortorice** et al. Multiple sclerosis. – In: *Spinal Cord Medicine: Third Edition*, 2018, p. 645-666. ISBN 9780826137753; 9780826137746.
1416. **Häusler, D., S. Häusser-Kinzel, L. Feldmann** et al. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 115, 2018, № 39, p. 9773-9778. ISSN 0027-8424.
1417. **Havrdova, E., J.A. Cohen, D. Horakova** et al. Understanding the positive benefit:Risk profile of alemtuzumab in relapsing multiple sclerosis: Perspectives from the alemtuzumab clinical development program. // *Therapeutics and Clinical Risk Management*, 13, 2017, p. 1423-1437. ISSN 1176-6336.
1418. **He, A., B. Merkel, J.W.L. Brown** et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. // *The Lancet Neurology*, 19, 2020, № 4, p. 307-316. ISSN 1474-4422.
1419. **Healy, B.C., B.I. Glanz, J.D. Zurawski** et al. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. // *Journal of the Neurological Sciences*, 394, 2018, p. 127-131. ISSN 0022-510X.
1420. **Hegen, H., G. Bsteh, T. Berger.** ‘No evidence of disease activity’ – is it an appropriate surrogate in multiple sclerosis? // *European Journal of Neurology*, 25, 2018, № 9, p. 1107-e101. ISSN 1351-5101.

1421. **Hemond, C.C., R. Chu, S. Tummala et al.** Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis. // *Brain and Behavior*, 8, 2018, № 8, art. no. e01068. ISSN 2162-3279.
1422. **Hernandez, J., L. Tornes, J.Y. Maldonado.** Demyelinating syndrome: Multiple sclerosis. – In: *Handbook of Neurosurgery, Neurology, and Spinal Medicine for Nurses and Advanced Practice Health Professionals*, 2017, p. 511-519. ISBN 9781315382760; 9781138556959.
1423. **Hernandez, L., M. O'Donnell, M. Postma.** Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies. // *PharmacoEconomics*, 39, 2021, № 2, p. 243-256. ISSN 1170-7690.
1424. **Hiltensperger, M., T. Korn.** The interleukin (IL)-23/T helper (Th)17 axis in experimental autoimmune encephalomyelitis and multiple sclerosis. // *Cold Spring Harbor Perspectives in Medicine*, 8, 2018, № 1, art. no. a029637, 16 p. ISSN 2157-1422.
1425. **Hjaltason, H., Ó. Sveinsson.** MS update: Risk factors, diagnosis and treatment = Nýjungar í MS: Áhættupættir, greining og meðferð. // *Laeknabladid*, 2020, № 5, p. 241-246. ISSN 0023-7213.
1426. **Hoffmann, O., R. Gold.** Disease-modifying treatment of secondary progressive multiple sclerosis = Krankheitsmodifizierende Therapie der sekundär progredienten Multiplen Sklerose. // *Nervenarzt*, 2021. ISSN 0028-2804.
1427. **Höftberger, R., H. Lassmann.** Inflammatory demyelinating diseases of the central nervous system. – In: *Handbook of Clinical Neurology*, 145, 2018, p. 263-283. ISSN 0072-9752.
1428. **Höglund, R.A., A. Lossius, J.N. Johansen et al.** In silico prediction analysis of idiotope-driven T-B cell collaboration in multiple sclerosis. // *Frontiers in Immunology*, 8, 2017, art. no. 1255. ISSN 1664-3224.
1429. **Höglund, R.A., J. Polak, F. Vartdal et al.** B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate. // *Multiple Sclerosis and Related Disorders*, 26, 2018, p. 90-95. ISSN 2211-0348.
1430. **Höglund, R.A., R.D. Bremel, E.J. Homan et al.** CD4+ T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal Fluid. // *Frontiers in Immunology*, 11, 2020, art. no. 598. ISSN 1664-3224.
1431. **Hohlfeld, R.** B-cells as therapeutic targets in neuro-inflammatory diseases. // *Clinical Immunology*, 186, 2018, p. 51-53. ISSN 1521-6616.

1432. **Hohlfeld, R., E. Meinl.** Ocrelizumab in multiple sclerosis: markers and mechanisms. // *The Lancet Neurology*, 16, 2017, № 4, p. 259-261. ISSN 1474-4422.
1433. **Hohlfeld, R., L. Steinman.** T cell-transfer experimental autoimmune encephalomyelitis: Pillar of multiple sclerosis and autoimmunity. // *Journal of Immunology*, 198, 2017, № 9, p. 3381-3383. ISSN 0022-1767.
1434. **Holmøy, T., Ø. Torkildsen, K.-M. Myhr.** An update on cladribine for relapsing-remitting multiple sclerosis. // *Expert Opinion on Pharmacotherapy*, 18, 2017, № 15, p. 1627-1635. ISSN 1465-6566.
1435. **Homma, G., T. Daimon.** A simple test for the treatment effect in clinical trials with a sequential parallel comparison design and negative binomial outcomes. // *Pharmaceutical Statistics*, 18, 2019, № 2, p. 184-197. ISSN 1539-1604.
1436. **Homma, G., T. Daimon.** Sample Size Calculation for “Gold-Standard” Noninferiority Trials With Fixed Margins and Negative Binomial Endpoints. // *Statistics in Biopharmaceutical Research*, 2020. ISSN 1946-6315.
1437. **Hongell, K., S. Kurki, M.-L. Sumelahti et al.** Risk of cancer among Finnish multiple sclerosis patients. // *Multiple Sclerosis and Related Disorders*, 35, 2019, p. 221-227. ISSN 2211-0348.
1438. **Houtchens, M.K., R. Bove.** A case for gender-based approach to multiple sclerosis therapeutics. // *Frontiers in Neuroendocrinology*, 50, 2018, p. 123-134. ISSN 0091-3022.
1439. **Howlett-Prieto, Q., X. Feng, J.F. Kramer et al.** Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis. // *Multiple Sclerosis Journal*, 2021. ISSN 1352-4585.
1440. **Hua, L.H., H. Harris, D. Conway et al.** Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy. // *Journal of Neurology*, 267, 2020, № 8, p. 2214-2220. ISSN 0340-5354.
1441. **Huber, J.E., Y. Chang, I. Meinl et al.** Fingolimod profoundly reduces frequencies and alters subset composition of circulating t follicular helper cells in multiple sclerosis patients. // *Journal of Immunology*, 204, 2020, № 5, p. 1101-1110. ISSN 0022-1767.
1442. **Hughes, R., L. Whitley, K. Fitovski et al.** COVID-19 in ocrelizumab-treated people with multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 49, 2021, art. no. 102725. ISSN 2211-0348.

1443. **Husain, F., G. Pardo, M. Rabadi.** Headache and Its Management in Patients With Multiple Sclerosis. // *Current Treatment Options in Neurology*, 20, 2018, № 4, art. no. 10. ISSN 1092-8480.
1444. **Hussain, R.Z., P.D. Cravens, W.A. Miller-Little et al.**  $\alpha$ 4-integrin deficiency in B cells does not affect disease in a T-cell-mediated EAE disease model. // *Neurology: Neuroimmunology and NeuroInflammation*, 6, 2019, № 4, art. no. e563. ISSN 2332-7812.
1445. **Iannetta, M., N. Cesta, C. Stingone et al.** Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. // *Multiple Sclerosis and Related Disorders*, 45, 2020, art. no. 102442. ISSN 2211-0348.
1446. **Inshasi, J.S., A. Almadani, S. Al Fahad et al.** High-efficacy therapies for relapsing-remitting multiple sclerosis: Implications for adherence. An expert opinion from the United Arab Emirates. // *Neurodegenerative Disease Management*, 10, 2020, № 4, p. 257-266. ISSN 1758-2024.
1447. **Islas, M.Á.M., E. Ciampi.** Assessment and impact of cognitive impairment in multiple sclerosis: An overview. // *Biomedicines*, 7, 2019, № 1, art. no. 22. ISSN 2227-9059.
1448. **Izquierdo, A.Y., M.J.S. Palomo, I.S. Herán et al.** Treatment of multiple sclerosis = Tratamiento de la esclerosis múltiple. // *Medicine (Spain)*, 12, 2019, № 78, p. 4598-4605. ISSN 0304-5412.
1449. **Jakimovski, D., B. Weinstock-Guttman, M. Ramanathan et al.** Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. // *Expert Opinion on Biological Therapy*, 17, 2017, № 9, p. 1163-1172. ISSN 1471-2598.
1450. **Jakimovski, D., C.B. Vaughn, S. Eckert et al.** Long-term drug treatment in multiple sclerosis: safety success and concerns. // *Expert Opinion on Drug Safety*, 19, 2020, № 9, p. 1121-1142. ISSN 1474-0338.
1451. **Jalkh, G., R. Abi Nahed, G. Macaron et al.** Safety of newer disease modifying therapies in multiple sclerosis. // *Vaccines*, 9, 2021, № 1, art. no. 12, p. 1-30. ISSN 2076-393X.
1452. **Jalusic, K.O., D. Ellenberger, P. Rommer et al.** Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care. // *Multiple Sclerosis Journal*, 2021. ISSN 1352-4585.
1453. **James, T., M. Lindén, H. Morikawa et al.** Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients. // *Human Molecular Genetics*, 27, 2018, № 5, p. 912-928. ISSN 0964-6906.



1454. **Jog, N.R., M.T. McClain, L.D. Heinlen** et al. // Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. // *Journal of Autoimmunity*, 106, 2020, art. no. 102332. ISSN 0896-8411.
1455. **Jonasson, E., T. Sejbaek.** Diroximel fumarate in the treatment of multiple sclerosis. // *Neurodegenerative Disease Management*, 10, 2020, № 5, p. 267-276. ISSN 1758-2024.
1456. **Jongen, P.J.** Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs. // *CNS Drugs*, 31, 2017, № 7, p. 585-602. ISSN 1172-7047.
1457. **Juanatey, A., L. Blanco-García, N. Téllez.** Ocrelizumab: Its efficacy and safety in multiple sclerosis = Ocrelizumab: Eficacia y seguridad en la esclerosis múltiple. // *Revista de Neurologia*, 66, 2018, № 12, p. 423-433. ISSN 0210-0010.
1458. **Juto, A., K. Fink, F. Al Nimer** et al. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. // *Multiple Sclerosis and Related Disorders*, 37, 2020, art. no. 101468. ISSN 2211-0348.
1459. **Kamm, C.P., L. Barin, C. Gobbi** et al. Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study. // *Journal of Neurology*, 267, 2020, № 1, p. 153-161. ISSN 0340-5354.
1460. **Kaplon, H., J.M. Reichert.** Antibodies to watch in 2018. // *mAbs*, 10, 2018, № 2, p. 183-203. ISSN 1942-0862.
1461. **Karim, M.R., Y.-F. Wang.** Phenotypic identification of CD19+CD5+CD1d+ regulatory B cells that produce interleukin 10 and transforming growth factor  $\beta$ 1 in human peripheral blood. // *Archives of Medical Science*, 15, 2019, № 5, p. 1176-1183. ISSN 1734-1922.
1462. **Karimian-Jazi, K., B. Wildemann, R. Diem** et al. Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. // *Neurology: Neuroimmunology and NeuroInflammation*, 5, 2018, № 5. ISSN 2332-7812.
1463. **Karmon, Y., N. Gadoth.** Present drug therapy of demyelinating disorders. // *Current Drug Therapy*, 13, 2018, № 1, p. 25-42. ISSN 1574-8855.
1464. **Khachanova, N.V.** Highly active multiple sclerosis: Options for monoclonal antibody therapy. // *Zhurnal Nevrologii i Psikiatrii imeni S.S. Korsakova*, 11, 2019, № 10, p. 49-57. ISSN 1997-7298.

1465. **Kim, W., H.J. Kim.** Monoclonal antibody therapies for multiple sclerosis and neuromyelitis optica spectrum disorder. // *Journal of Clinical Neurology (Korea)*, 16, 2020, № 3, p. 355-368. ISSN 1738-6586.
1466. **Kinzel, S., M.S. Weber.** The role of peripheral CNS-directed antibodies in promoting inflammatory CNS demyelination. // *Brain Sciences*, 7, 2017, № 7, art. no. 70. ISSN 2076-3425.
1467. **Klöß, S., S. Dehmel, A. Braun et al.** From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. // *Frontiers in Immunology*, 11, 2020, art. no. 1423. ISSN 1664-3224.
1468. **Klotz, L., J. Havla, N. Schwab et al.** Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. // *Therapeutic Advances in Neurological Disorders*, 12, 2019. ISSN 1756-2856.
1469. **Korn, T., M. Oukka.** A BAFFling association between malaria resistance and the risk of multiple sclerosis. // *New England Journal of Medicine*, 376, 2017, № 17, p. 1680-1681. ISSN 0028-4793.
1470. **Kosa, P., C. Barbour, A. Wichman et al.** NeurEx: digitalized neurological examination offers a novel high-resolution disability scale. // *Annals of Clinical and Translational Neurology*, 5, 2018, № 10, p. 1241-1249. ISSN 2328-9503.
1471. **Kotelnikova, E., N.A. Kiani, D. Messinis et al.** MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 116, 2019, № 19, p. 9671-9676. ISSN 0027-8424.
1472. **Kratz, A.L., K.N. Alschuler, D.M. Ehde et al.** A randomized pragmatic trial of telephone-delivered cognitive behavioral-therapy, modafinil, and combination therapy of both for fatigue in multiple sclerosis: The design of the “COMBO-MS” trial. // *Contemporary Clinical Trials*, 84, 2019, art. no. 105821. ISSN 1551-7144.
1473. **Kremer, I.E.H., M. Hilgsmann, J. Carlson et al.** Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. // *Medical Decision Making*, 40, 2020, № 8, p. 1003-1019. ISSN 0272-989X.
1474. **Kretzschmar, A.** Multiple sclerosis (MS). Ocrelizumab: New option in the treatment of relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis [Multiple Sklerose (MS): Ocrelizumab: Neue Option bei der RRMS und PPMS]. // *Psychopharmakotherapie*, 24, 2017, № 5, p. 237-238. ISSN 0944-6877.

1475. **Krysko, K.M., J.S. Graves, M. Rensel et al.** Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. // *Annals of Neurology*, 88, 2020, № 1, p. 42-55. ISSN 0364-5134.
1476. **Kuerten, S., L.J. Jackson, J. Kaye et al.** Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis. // *CNS Drugs*, 32, 2018, № 11, p. 1039-1051. ISSN 1172-7047.
1477. **Kuerten, S., T.V. Lanz, N. Lingampalli et al.** Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 117, 2020, № 35, p. 21512-21518. ISSN 0027-8424.
1478. **Kumar, N.N., M.E. Pizzo, G. Nehra et al.** Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. // *Bioconjugate Chemistry*, 29, 2018, № 12, p. 3937-3966. ISSN 1043-1802.
1479. **Kwiatkowski, A.J., J.M. Stewart, J.J. Cho et al.** Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes. // *Advanced Healthcare Materials*, 9, 2020, № 11, art. no. 2000164. ISSN 2192-2640.
1480. **La Starza, S., M. Ferraldeschi, M.C. Buscarinu et al.** Genome-wide multiple sclerosis association data and coagulation. // *Frontiers in Neurology*, 10, 2019, art. no. 95. ISSN 1664-2295.
1481. **Lanz, T.V., A.-K. Pröbstel, I. Mildenerger et al.** Single-cell high-throughput technologies in cerebrospinal fluid research and diagnostics. // *Frontiers in Immunology*, 10, 2019, art. no. 1302. ISSN 1664-3224.
1482. **Lashch, N.Yu.** Monoclonal antibodies in the treatment of multiple sclerosis: From clinical research to practical application. // *Meditinskiy Sovet*, 2020, 2020, № 8, p. 88-94. ISSN 2079-701X.
1483. **Lazear, H.M., J.W. Schoggins, M.S. Diamond.** Shared and Distinct Functions of Type I and Type III Interferons. // *Immunity*, 50, 2019, № 4, p. 907-923. ISSN 1074-7613.
1484. **Le Page, E., G. Edan.** Induction or escalation therapy for patients with multiple sclerosis? // *Revue Neurologique*, 174, 2018, № 6, p. 449-457. ISSN 0035-3787.
1485. **Lebrun, C., F. Rocher.** Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs. // *CNS Drugs*, 32, 2018, № 10, p. 939-949. ISSN 1172-7047.

1486. **Lee, D.S.W., O.L. Rojas, J.L. Gommerman.** B cell depletion therapies in autoimmune disease: advances and mechanistic insights. // *Nature Reviews Drug Discovery*, 20, 2021, № 3, p. 179-199. ISSN 1474-1776.
1487. **Lees, J.R.** Targeting antigen presentation in autoimmunity. // *Cellular Immunology*, 339, 2019, p. 4-9. ISSN 0008-8749.
1488. **Lehmann-Horn, K., S. Kinzel, M.S. Weber.** Deciphering the role of B cells in multiple sclerosis—towards specific targeting of pathogenic function. // *International Journal of Molecular Sciences*, 18, 2017, № 10, art. no. 2048. ISSN 1661-6596.
1489. **Levin, S.N., C. Ezuma, L. Levine et al.** Switching from natalizumab to ocrelizumab in patients with multiple sclerosis. // *Multiple Sclerosis Journal*, 26, 2020, № 14, p. 1964-1965. ISSN 1352-4585.
1490. **Li, Q.-W., W. Lei, C. Chen et al.** Recent advances of long noncoding RNAs involved in the development of multiple sclerosis. // *Chinese Journal of Natural Medicines*, 18, 2020, № 1, p. 36-46. ISSN 1875-5364.
1491. **Linker, R.** Ocrelizumab for the treatment of multiple sclerosis = Ocrelizumab in der Therapie der multiplen Sklerose. // *Psychopharmakotherapie*, 25, 2018, № 5, p. 234-239. ISSN 0944-6877.
1492. **Lisak, M., V. Bašić Kes.** Monoclonal antibodies in the treatment of multiple sclerosis = Monoklonska antitijela u liječenju multiple skleroze. // *Acta Medica Croatica*, 72, 2018, № 3, p. 399-408. ISSN 1330-0164.
1493. **LoPresti, P.** Silent free fall at disease onset: A perspective on therapeutics for progressive multiple sclerosis. // *Frontiers in Neurology*, 9, 2018, art. no. 973. ISSN 1664-2295.
1494. **Lovett-Racke, A.E., M. Gormley, Y. Liu et al.** B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. // *Journal of Neuroimmunology*, 332, 2019, p. 187-197. ISSN 0165-5728.
1495. **Lu, T., Y. Shu, Y. Dai et al.** B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder. // *Multiple Sclerosis and Related Disorders*, 22, 2018, p. 83-85. ISSN 2211-0348.
1496. **Lucca, L.E., M. Dominguez-Villar.** Modulation of regulatory T cell function and stability by co-inhibitory receptors. // *Nature Reviews Immunology*, 20, 2020, № 11, p. 680-693. ISSN 1474-1733.
1497. **Luna, G., P. Alping, J. Burman et al.** Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and

- Injectable Therapies. // *JAMA Neurology*, 77, 2020, № 2, p. 184-191. ISSN 2168-6149.
1498. **Lundqvist, S., S. Modvig, E.A. Fischer** et al. Frequency and immunophenotype of IL10-producing regulatory B cells in optic neuritis. // *Immunology*, 156, 2019, № 3, p. 259-269. ISSN 0019-2805.
1499. **Lundtoft, C., P. Pucholt, J. Imgenberg-Kreuz** et al. Function of multiple sclerosis-protective HLA class I alleles revealed by genome-wide protein-quantitative trait loci mapping of interferon signalling. // *PLoS Genetics*, 16, 2020, № 10, art. no. e1009199. ISSN 1553-7390.
1500. **Lycke, J.** Trials of antivirals in the treatment of multiple sclerosis. // *Acta Neurologica Scandinavica*, 136, 2017, p. 45-48. ISSN 0001-6314.
1501. **Ma, L.-H., M.-J. Sun, B.-Y. Yuan** et al. Ocrelizumab in the treatment of relapsing multiple sclerosis: a Meta-analysis = [奥克雷珠单抗治疗复发型多发性硬化的Meta分析]. // *Chinese Journal of New Drugs*, 28, 2019, № 11, p. 1397-1403. ISSN 1003-3734.
1502. **Maarouf, A., C. Boutière, A. Rico** et al. How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update. // *Revue Neurologique*, 174, 2018, № 6, p. 429-440. ISSN 0035-3787.
1503. **Macaron, G., J. Feng, M. Moodley** et al. Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis. // *Current Treatment Options in Neurology*, 21, 2019, № 10, art. no. 50. ISSN 1092-8480.
1504. **Madsen, C.** The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis. // *Brain and Behavior*, 7, 2017, № 6, art. no. e00696. ISSN 2162-3279.
1505. **Magliozzi, R., D. Marastoni, M. Calabrese.** The BAFF / APRIL system as therapeutic target in multiple sclerosis. // *Expert Opinion on Therapeutic Targets*, 2020. ISSN 1472-8222.
1506. **Makshakov, G.S., V.D. Nazarov, N.A. Totolyan** et al. The association of intrathecal production of immunoglobulin free light chains and progression of multiple sclerosis. // *Zhurnal Nevrologii i Psikiatrii imeni S.S. Korsakova*, 117, 2017, № 10, p. 4-10. ISSN 1997-7298.
1507. **Mariottini, A., E. De Matteis, P.A. Muraro.** Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status. // *BioDrugs*, 34, 2020, № 3, p. 307-325. ISSN 1173-8804.

1508. **Marques, V.D., G.R. Dos Passos, M.F. Mendes** et al. Brazilian consensus for the treatment of multiple sclerosis: Brazilian academy of neurology and brazilian committee on treatment and research in multiple sclerosis = Consenso Brasileiro para o tratamento da esclerose múltipla: Academia brasileira de neurologia e comitê brasileiro de tratamento e pesquisa em esclerose múltipla. // *Arquivos de Neuro-Psiquiatria*, 76, 2018, № 8, p. 539-554. ISSN 0004-282X.
1509. **Mathew, T., S.K. John, V. Kamath** et al. Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country. // *Multiple Sclerosis and Related Disorders*, 43, 2020, art. no. 102210. ISSN 2211-0348.
1510. **Mayberry, C.L., C.D.S. Nelson, M.S. Maginnis**. JC Polyomavirus Attachment and Entry: Potential Sites for PML Therapeutics. // *Current Clinical Microbiology Reports*, 4, 2017, № 3, p. 132-141. ISSN 2196-5471.
1511. **Mayne, K., J.A. White, C.E. McMurran** et al. Aging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe? // *Frontiers in Aging Neuroscience*, 12, 2020, art. no. 572090. ISSN 1663-4365.
1512. **McCool, R., K. Wilson, M. Arber** et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 29, 2019, p. 55-61. ISSN 2211-0348.
1513. **McGinley, M., I.T. Rossman**. Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis. // *Neurotherapeutics*, 14, 2017, № 4, p. 985-998. ISSN 1933-7213.
1514. **McGinley, M.P., C.H. Goldschmidt, A.D. Rae-Grant**. Diagnosis and Treatment of Multiple Sclerosis: A Review. // *JAMA - Journal of the American Medical Association*, 325, 2021, № 8, p. 765-779. ISSN 0098-7484.
1515. **McWilliam, O., F. Sellebjerg, H.V. Marquart** et al. B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LT $\alpha$  and TGF $\beta$ 1 response. // *Journal of Neuroimmunology*, 324, 2018, p. 157-164. ISSN 0165-5728.
1516. **Melamed, E., M.W. Lee**. Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies. // *Frontiers in Immunology*, 10, 2020, art. no. 2954. ISSN 1664-3224.
1517. **Memon, A.B., A. Javed, C. Caon** et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. // *PLoS ONE*, 13, 2018, № 1, art. no. e0190425. ISSN 1932-6203.
1518. **Metaxakis, A., D. Petratos, N. Tavernarakis**. Molecular interventions towards multiple sclerosis treatment. // *Brain Sciences*, 10, 2020, № 5, art. no. 299. ISSN 2076-3425.

1519. **Meyer zu Hörste, G., C.C. Gross, L. Klotz** et al. Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity. // *Trends in Immunology*, 41, 2020, № 4, p. 341-354. ISSN 1471-4906.
1520. **Michel, L.** Therapeutic news in multiple sclerosis = Actualités thérapeutiques dans la sclérose en plaques. // *Pratique Neurologique - FMC*, 10, 2019, № 3, p. 183-186. ISSN 1878-7762.
1521. **Migotto, M.-A., K. Mardon, J. Orian** et al. Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice. // *Frontiers in Immunology*, 10, 2019, art. no. 2437. ISSN 1664-3224.
1522. **Mikulska, M., S. Lanini, C. Gudiol** et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). // *Clinical Microbiology and Infection*, 24, 2018, p. S71-S82. ISSN 1198-743X.
1523. **Mildiner, S., S. Malnick.** Ocrelizumab in primary progressive and relapsing multiple sclerosis. // *New England Journal of Medicine*, 376, 2017, № 17, p. 1692-1693. ISSN 0028-4793.
1524. **Milo, R.** Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis. // *European Neurological Review*, 15, 2020, № 1, p. 27-35. ISSN 1758-3837.
1525. **Milo, R.** Therapies for multiple sclerosis targeting B cells. // *Croatian Medical Journal*, 60, 2019, 2, p. 87-98. ISSN 0353-9504.
1526. **Milstein, J.L., C.R. Barbour, K. Jackson** et al. Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis. // *Frontiers in Neurology*, 10, 2019, art. no. 1232. ISSN 1664-2295.
1527. **Mimpen, M., J. Smolders, R. Hupperts** et al. Natural killer cells in multiple sclerosis: A review. // *Immunology Letters*, 222, 2020, p. 1-11. ISSN 0165-2478.
1528. **Miyazaki, Y., M. Niino.** Regulatory B cells in neuroimmunological diseases. // *Clinical and Experimental Neuroimmunology*, 11, 2020, № 3, p. 156-162. ISSN 1759-1961.

1529. **Moccia, M., N. de Stefano, F. Barkhof.** Imaging outcome measures for progressive multiple sclerosis trials. // *Multiple Sclerosis*, 23, 2017, № 12, p. 1614-1626. ISSN 1352-4585.
1530. **Mohammadi, R., A. Aryan, M.D. Omrani** et al. Autologous hematopoietic stem cell transplantation (Ahsct): An evolving treatment avenue in multiple sclerosis. // *Biologics: Targets and Therapy*, 15, 2021, p. 53-59. ISSN 1177-5475.
1531. **Moiola, L., V. Barcella, S. Benatti** et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. // *Multiple Sclerosis Journal*, 27, 2021, № 3, p. 331-346. ISSN 1352-4585.
1532. **Moore, J.J., J.C. Massey, C.D. Ford** et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. // *Journal of Neurology, Neurosurgery and Psychiatry*, 90, 2019, № 5, p. 514-521. ISSN 0022-3050.
1533. **Moreira Ferreira, V.F., D.J. Kimbrough, J.M. Stankiewicz.** A possible case of serum sickness after ocrelizumab infusion. // *Multiple Sclerosis Journal*, 27, 2021, № 1, p. 155-158. ISSN 1352-4585.
1534. **Mørkholt, A.S., K. Kastaniegaard, M.S. Trabjerg** et al. Identification of brain antigens recognized by autoantibodies in experimental autoimmune encephalomyelitis-induced animals treated with etomoxir or interferon- $\beta$ . // *Scientific Reports*, 8, 2018, № 1, art. no. 7092. ISSN 2045-2322.
1535. **Mortales, C.-L., S.-U. Lee, A. Manousadjian** et al. N-Glycan Branching Decouples B Cell Innate and Adaptive Immunity to Control Inflammatory Demyelination. // *iScience*, 23, 2020, № 8, art. no. 101380. ISSN 2589-0042.
1536. **Moss, B.P., J.A. Cohen.** The emergence of follow-on disease-modifying therapies for multiple sclerosis. // *Multiple Sclerosis Journal*, 25, 2019, № 12, p. 1560-1565. ISSN 1352-4585.
1537. **Murphy, K.A., K. Bhamidipati, S.J.S. Rubin** et al. Immunomodulatory receptors are differentially expressed in B and T cell subsets relevant to autoimmune disease. // *Clinical Immunology*, 209, 2019, art. no. 108276. ISSN 1521-6616.
1538. **Musette, P., J.D. Bouaziz.** B cell modulation strategies in autoimmune diseases: New concepts. // *Frontiers in Immunology*, 9, 2018, art. no. 622. ISSN 1664-3224.
1539. **Mycko, M.P.** B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection?. // *Neurologia i Neurochirurgia Polska*, 54, 2021, № 6, p. 490-501. ISSN 0028-3843.



1540. **Myhr, K.-M., Ø. Torkildsen, A. Lossius** et al. B cell depletion in the treatment of multiple sclerosis. // *Expert Opinion on Biological Therapy*, 19, 2019, № 3, p. 261-271. ISSN 1471-2598.
1541. **Naegelin, Y., P. Naegelin, S. Von Felten** et al. Association of Rituximab Treatment with Disability Progression among Patients with Secondary Progressive Multiple Sclerosis. // *JAMA Neurology*, 76, 2019, № 3, p. 274-281. ISSN 2168-6149.
1542. **Najafi, S., E. Rajaei, R. Moallemian** et al. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. // *Clinical Rheumatology*, 39, 2020, № 11, p. 3223-3235. ISSN 0770-3198.
1543. **Nakamura, Y., K. Igaki, K. Uga** et al. Pharmacological evaluation of TAK-828F, a novel orally available ROR $\gamma$ t inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model. // *Journal of Neuroimmunology*, 335, 2019, art. no. 577016. ISSN 0165-5728.
1544. **Naser Moghadasi, A., A. Darki, P. Masoumi** et al. Evaluating the efficacy and safety of Zytux<sup>TM</sup> (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. // *Multiple Sclerosis and Related Disorders*, 36, 2019, art. no. 101419. ISSN 2211-0348.
1545. **Nasralla, S., H. Abboud**. Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events. // *Multiple Sclerosis and Related Disorders*, 46, 2020, art. no. 102451. ISSN 2211-0348.
1546. **Neuberger, E.E., I.M. Abbass, E. Jones** et al. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis. // *Neurology and Therapy*, 2020. ISSN 2193-8253.
1547. **Neuteboom, R., C. Wilbur, D. Van Pelt** et al. The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children. // *Seminars in Pediatric Neurology*, 24, 2017, № 3, p. 189-200. ISSN 1071-9091.
1548. **Ng, H.S., C.L. Rosenbult, H. Tremlett**. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. // *Expert Opinion on Drug Safety*, 19, 2020, № 9, p. 1069-1094. ISSN 1474-0338.
1549. **Nguyen, A.-L., M. Gresle, T. Marshall** et al. Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. // *British Journal of Pharmacology*, 174, 2017, № 13, p. 1895-1907. ISSN 0007-1188.
1550. **Nicolini, L.A., P. Canepa, P. Caligiuri** et al. Fulminant Hepatitis Associated with Echovirus 25 during Treatment with Ocrelizumab for Multiple Sclerosis. // *JAMA Neurology*, 76, 2019, № 7, p. 866-867. ISSN 2168-6149.

1551. **Nissimov, N., Z. Hajiyeve, S. Torke** et al. B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 117, 2020, № 41, p. 25690-25699. ISSN 0027-8424.
1552. **Nitsch, L., J. Zimmermann, M. Krauthausen** et al. CNS-Specific Synthesis of Interleukin 23 Induces a Progressive Cerebellar Ataxia and the Accumulation of Both T and B Cells in the Brain: Characterization of a Novel Transgenic Mouse Model. // *Molecular Neurobiology*, 56, 2019, № 12, p. 7977-7993. ISSN 0893-7648.
1553. **Noto, D., S. Miyake**. B cells in autoimmune diseases of the central nervous system. // *Clinical and Experimental Neuroimmunology*, 11, 2020, № 3, p. 163-170. ISSN 1759-1961.
1554. **Nourbakhsh, B., E.M. Mowry**. Multiple sclerosis risk factors and pathogenesis. // *CONTINUUM Lifelong Learning in Neurology*, 25, 2019, № 3, p. 596-610. ISSN 1080-2371.
1555. **Novotna, M., A. Tvaroh, J. Mares**. Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis. // *Frontiers in Neurology*, 11, 2020, art. no. 944. ISSN 1664-2295.
1556. **Ochi, H.** Clinical trials for multiple sclerosis: Outcome measures and impact on cognitive function. // *Clinical and Experimental Neuroimmunology*, 10, 2019, № 3, p. 169-179. ISSN 1759-1961.
1557. **Ocrelizumab (Ocrevus) for MS**. // *Medical Letter on Drugs and Therapeutics*, 59, 2017, № 1523, p. 98-101. ISSN 0025-732X.
1558. **Oftedal, B.E., A.S.B. Wolff**. New era of therapy for endocrine autoimmune disorders. // *Scandinavian Journal of Immunology*, 92, 2020, № 5, art. no. e12961. ISSN 0300-9475.
1559. **Oh, J., K. Alikhani, T. Bruno** et al. Diagnosis and management of secondary-progressive multiple sclerosis: Time for change. // *Neurodegenerative Disease Management*, 9, 2019, № 6, p. 301-317. ISSN 1758-2024.
1560. **Oksbjerg, N.R., S.D. Nielsen, M. Blinkenberg** et al. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. // *Multiple Sclerosis and Related Disorders*, 52, 2021, art. no. 102988. ISSN 2211-0348.
1561. **O'Neill-Meyer, H., O.E. Wei, J.A. Ruiz** et al. Risk factors for infusion-related reactions following Ocrelizumab infusion in a community setting: Development of

- an electronic medical record-based explanatory model. // *Multiple Sclerosis and Related Disorders*, 48, 2021, art. no. 102700. ISSN 2211-0348.
1562. **Ontaneda, D., E. Tallantyre, T. Kalincik** et al. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. // *The Lancet Neurology*, 18, 2019, № 10, p. 973-980. ISSN 1474-4422.
1563. **Ontaneda, D., E.C. Tallantyre, P.C. Raza** et al. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. // *Contemporary Clinical Trials*, 95, 2020, art. no. 106009. ISSN 1551-7144.
1564. **Ortiz, M.Á., L. Espino-Paisán, C. Nuñez** et al. New life to an old treatment: Pegylated interferon beta 1a in the management of multiple sclerosis. // *Current Medicinal Chemistry*, 25, 2018, № 27, p. 3272-3283. ISSN 0929-8673.
1565. **Osharov, M., R. Milo.** CHAPTER 7: B Cell-based Therapies for Multiple Sclerosis. – In: *RSC Drug Discovery Series*, 2019, № 70, p. 134-169. ISSN 2041-3203. ISBN 9781782621454; 9781782629498; 9781788010832; 9781788012096; 9781788013949; 9781788014502.
1566. **Otallah, S., B. Banwell.** Pediatric Multiple Sclerosis: an Update. // *Current Neurology and Neuroscience Reports*, 18, 2018, № 11, art. no. 76. ISSN 1528-4042.
1567. **Otero-Romero, S., A. Sánchez-Montalvá, A. Vidal-Jordana.** Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. // *Expert Review of Clinical Immunology*, 17, 2021, № 3, p. 285-300. ISSN 1744-666X.
1568. **Otero-Romero, S., J. Rodríguez-García, A. Vilella** et al. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement = Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español. // *Neurologia*, 36, 2021, № 1, p. 50-60. ISSN 0213-4853.
1569. **Oveland, E., I. Ahmad, R.R. Lereim** et al. Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. // *Scientific Reports*, 11, 2021, № 1, art. no. 7174. ISSN 2045-2322.
1570. **Ozakbas, S., B.P. Cinar, T. Kahraman** et al. The 20-year history: Change of multiple sclerosis patient profile over 20 years. // *Multiple Sclerosis and Related Disorders*, 33, 2019, p. 1-4. ISSN 2211-0348.
1571. **Pan, S., J.R. Chan.** Regulation and dysregulation of axon infrastructure by myelinating glia. // *Journal of Cell Biology*, 216, 2017, № 12, p. 3903-3916. ISSN 0021-9525.

1572. **Pantazou, V., C. Pot, R. Du Pasquier** et al. Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. // *Multiple Sclerosis and Related Disorders*, 51, 2021, art. no. 102918. ISSN 2211-0348.
1573. **Pape, K., F. Zipp, S. Bittner**. New aspects of immunotherapy in multiple sclerosis = Neues aus der Immuntherapie bei Multipler Sklerose. // *Nervenarzt*, 89, 2018, № 12, p. 1365-1370. ISSN 0028-2804.
1574. **Pape, K., R. Tamouza, M. Leboyer** et al. Immunoneuropsychiatry — novel perspectives on brain disorders. // *Nature Reviews Neurology*, 15, 2019, № 6, p. 317-328. ISSN 1759-4758.
1575. **Pardo, G., D.E. Jones**. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. // *Journal of Neurology*, 264, 2017, № 12, p. 2351-2374. ISSN 0340-5354.
1576. **Parker Harp, C.R., A.S. Archambault, J. Sim** et al. B cells are capable of independently eliciting rapid reactivation of encephalitogenic CD4 T cells in a murine model of multiple sclerosis. // *PLoS ONE*, 13, 2018, № 6, art. no. e0199694. ISSN 1932-6203.
1577. **Parker Harp, C.R., A.S. Archambault, M. Cheung** et al. Neutrophils promote VLA-4-dependent B cell antigen presentation and accumulation within the meninges during neuroinflammation. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 116, 2019, № 48, p. 24221-24230. ISSN 0027-8424.
1578. **Parks, N.E., C.S. Jackson-Tarlton, L. Vacchi** et al. Dietary interventions for multiple sclerosis-related outcomes. // *Cochrane Database of Systematic Reviews*, 2020, 2020, № 5, art. no. CD004192. ISSN 1469-493X.
1579. **Parks, N.E., E.P. Flanagan, C.F. Lucchinetti** et al. NEDA treatment target? No evident disease activity as an actionable outcome in practice. // *Journal of the Neurological Sciences*, 383, 2017, p. 31-34. ISSN 0022-510X.
1580. **Parnell, G.P., D.R. Booth**. The Multiple Sclerosis (MS) genetic risk factors indicate both acquired and innate immune cell subsets contribute to MS pathogenesis and identify novel therapeutic opportunities. // *Frontiers in Immunology*, 8, 2017, art. no. 425. ISSN 1664-3224.
1581. **Patel, A., J. Sul, M.L. Gordon** et al. Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated with Ocrelizumab Monotherapy. // *JAMA Neurology*, 2021. ISSN 2168-6149.
1582. **Patel, S.Y., J. Carbone, S. Jolles**. The expanding field of secondary antibody deficiency: Causes, diagnosis, and management. // *Frontiers in Immunology*, 10, 2019, art. no. 33. ISSN 1664-3224.

1583. **Paul, F., O. Murphy, S. Pardo** et al. Investigational drugs in development to prevent neuromyelitis optica relapses. // *Expert Opinion on Investigational Drugs*, 27, 2018, № 3, p. 265-271. ISSN 1354-3784.
1584. **Pavelek, Z., M. Novotný, B. Klímová** et al. ORADA adherence study: full view into RebiSmart subdomains parameters in multiple sclerosis treatment. // *Current Medical Research and Opinion*, 37, 2021, № 4, p. 589-596. ISSN 0300-7995.
1585. **Pentón-Rol, G., J. Marín-Prida, V. Falcón-Cama.** C-phycocyanin and phycocyanobilin as remyelination therapies for enhancing recovery in multiple sclerosis and ischemic stroke: A preclinical perspective. // *Behavioral Sciences*, 8, 2018, № 1, art. no. 0015. ISSN 2076-328X.
1586. **Perez, J., F. Reymond, É. Brudieu** et al. Role of ocrelizumab in the treatment of multiple sclerosis: Challenges for the hospital pharmacist = [Place de l'ocrelizumab dans la prise en charge de la sclérose en plaque: enjeux pour le pharmacien hospitalier. // *Pharmacien Hospitalier et Clinicien*, 2021. ISSN 2211-1042.
1587. **Piehl, F.** Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. // *Journal of Internal Medicine*, 2020. ISSN 0954-6820.
1588. **Piehl, F., J. Hillert.** Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes. // *Multiple Sclerosis Journal*, 24, 2018, № 9, p. 1157-1159. ISSN 1352-4585.
1589. **Pirttisalo, A.-L., J.O.T. Sipilä, M. Soilu-Hänninen** et al. Adult hospital admissions associated with multiple sclerosis in Finland in 2004–2014. // *Annals of Medicine*, 50, 2018, № 4, p. 354-360. ISSN 0785-3890.
1590. **Pit'ha, J.** Treatment targeted for B lymphocytes – significant progress in the treatment of multiple sclerosis = Léčba cílená na B lymfocyty – významný pokrok v léčbě roztroušené sklerózy. // *Ceska a Slovenska Neurologie a Neurochirurgie*, 81, 2018, № 4, p. 395-402. ISSN: 1210-7859.
1591. **Pomeroy, I.M., A. Tennant, R.J. Mills** et al. The WHOQOL-BREF: a modern psychometric evaluation of its internal construct validity in people with multiple sclerosis. // *Quality of Life Research*, 29, 2020, № 7, p. 1961-1972. ISSN 0962-9343.
1592. **Popova, E.V., S.A. Ryabov.** The experience of using ocrelizumab in routine practice. // *Meditsinskiy Sovet*, 2020, 2020, № 2, p. 76-80. ISSN 2079-701X.
1593. **Pourcher, V.** What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature. // *Revue Neurologique*, 176, 2020, № 4, p. 235-243. ISSN 0035-3787.

1594. **Pröbstel, A.-K., S.E. Baranzini.** The Role of the Gut Microbiome in Multiple Sclerosis Risk and Progression: Towards Characterization of the “MS Microbiome”. // *Neurotherapeutics*, 15, 2018, № 1, p. 126-134. ISSN 1933-7213.
1595. **Prockl, V., F.T. Nickel, K.S. Utz et al.** Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients. // *Journal of the Neurological Sciences*, 415, 2020, art. no. 116973. ISSN 0022-510X.
1596. **Pryce, G., D. Baker.** Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter? // *Multiple Sclerosis and Related Disorders*, 25, 2018, p. 131-137. ISSN 2211-0348.
1597. **Puthenparampil, M., A. Zito, G. Pantano et al.** Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset. // *Multiple Sclerosis Journal*, 25, 2019, № 7, p. 918-926. ISSN 1352-4585.
1598. **Rae-Grant, A., G.S. Day, R.A. Marrie et al.** Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis. // *Neurology*, 90, 2018, № 17, p. 789-800. ISSN 0028-3878.
1599. **Rahmanzadeh, R., M.S. Weber, W. Brück et al.** B cells in multiple sclerosis therapy—A comprehensive review. // *Acta Neurologica Scandinavica*, 137, 2018, № 6, p. 544-556. ISSN 0001-6314.
1600. **Ramaglia, V., S. Sheikh-Mohamed, K. Legg et al.** Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry. // *eLife*, 8, 2019, art. no. e48051. ISSN 2050-084X.
1601. **Rapisarda, L., P. Valentino, S. Barone et al.** Varicella zoster immunity loss in multiple sclerosis patient treated with ocrelizumab. // *Clinical Immunology*, 223, 2021, art. no. 108554. ISSN 1521-6616.
1602. **Rasche, L., F. Paul.** Ozanimod for the treatment of relapsing remitting multiple sclerosis. // *Expert Opinion on Pharmacotherapy*, 19, 2018, № 18, p. 2073-2086. ISSN 1465-6566.
1603. **Rathbone, E., L. Durant, J. Kinsella et al.** Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis. // *Journal of Neurology, Neurosurgery and Psychiatry*, 89, 2018, № 10, p. 1044-1049. ISSN 0022-3050.
1604. **Rauer, S., M.-M. Hoshi, R. Pul et al.** Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany. // *Clinical Neurology and Neurosurgery*, 197, 2020, art. no. 106142. ISSN 0303-8467.
1605. **Ravindra, N., A. Sehanobish, J.L. Pappalardo et al.** Disease state prediction from single-cell data using graph attention networks. - In: *ACM CHIL 2020* -

Proceedings of the 2020 ACM Conference on Health, Inference, and Learning, 2020, p. 121-130. ISBN 9781450370462.

1606. **Raynowska, J., J.S. Graves.** Dermatographism associated with ocrelizumab. // *Multiple Sclerosis and Related Disorders*, 46, 2020, art. no. 102505. ISSN 2211-0348.
1607. **Realì, C., R. Magliozzi, F. Roncaroli et al.** B cell rich meningeal inflammation associates with increased spinal cord pathology in multiple sclerosis. // *Brain Pathology*, 30, 2020, № 4, p. 779-793. ISSN 1015-6305.
1608. **Rijvers, L., M.-J. Melief, J. Van Langelaar et al.** The role of autoimmunity-related gene CLEC16A in the B cell receptor-mediated HLA class II pathway. // *Journal of Immunology*, 205, 2020, № 4, p. 945-956. ISSN 0022-1767.
1609. **Risk-benefit analysis and personalized treatment in multiple sclerosis:** Basing treatment goals on the latest evidence. // *International Journal of MS Care*, 20, 2018, p. 1-20. ISSN 1537-2073.
1610. **Rivera-Izquierdo, M., M.D.C. Valero-Ubierna, P. Nieto-Gómez et al.** Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. // *Expert Review of Vaccines*, 19, 2020, № 8, p. 727-744. ISSN 1476-0584.
1611. **Roach, C.A., A.H. Cross.** Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis. // *Frontiers in Neurology*, 11, 2021, art. no. 595547. ISSN 1664-2295.
1612. **Rocca, M.A., P. Preziosa, M. Filippi.** Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives. // *Expert Review of Neurotherapeutics*, 19, 2019, № 9, p. 835-866. ISSN 1473-7175.
1613. **Rojas, J.I., A. Pappolla, L. Patrucco et al.** Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis? // *Multiple Sclerosis and Related Disorders*, 39, 2020, art. no. 101931. ISSN 2211-0348.
1614. **Rolfes, L., M. Pawlitzki, S. Pfeuffer et al.** Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020. // *BioDrugs*, 34, 2020, № 5, p. 587-610. ISSN 1173-8804.
1615. **Rommer, P.S., R. Milo, M.H. Han et al.** Immunological aspects of approved MS therapeutics. // *Frontiers in Immunology*, 10, 2019, art. no. 1564. ISSN 1664-3224.
1616. **Rommer, P.S., U.K. Zettl.** Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. // *Expert Opinion on Pharmacotherapy*, 19, 2018, № 5, p. 483-498. ISSN 1465-6566.

1617. **Rose, D.R., J.A. Cohen.** Long-term ocrelizumab in progressive multiple sclerosis. // *The Lancet Neurology*, 19, 2020, № 12, p. 966-968. ISSN 1474-4422.
1618. **Rothman, A., O.C. Murphy, K.C. Fitzgerald et al.** Retinal measurements predict 10-year disability in multiple sclerosis. // *Annals of Clinical and Translational Neurology*, 6, 2019, № 2, p. 222-232. ISSN 2328-9503.
1619. **Rubin, S.J.S., M.S. Bloom, W.H. Robinson.** B cell checkpoints in autoimmune rheumatic diseases. // *Nature Reviews Rheumatology*, 15, 2019, № 5, p. 303-315. ISSN 1759-4790.
1620. **Ruiz-Argüelles, G.J., J.C. Olivares-Gazca, M. Olivares-Gazca et al.** Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center. // *Clinical and Experimental Immunology*, 198, 2019, № 3, p. 351-358. ISSN 0009-9104.
1621. **S.A. Rizvi.** Disease-Modifying Agents. // *Current Clinical Neurology*, 2020, p. 137-157. ISSN 1559-0585.
1622. **Sabatino, J.J., Jr., A.-K. Pröbstel, S.S. Zamvil.** B cells in autoimmune and neurodegenerative central nervous system diseases. // *Nature Reviews Neuroscience*, 20, 2019, № 12, p. 728-745. ISSN 1471-003X.
1623. **Sabol, R.A., V. Noxon, O. Sartor et al.** Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). // *Cancer Medicine*, 6, 2017, № 7, p. 1541-1551. ISSN 2045-7634.
1624. **Sakoda, A., T. Matsushita, Y. Nakamura et al.** Environmental risk factors for multiple sclerosis in Japanese people. // *Multiple Sclerosis and Related Disorders*, 38, 2020, № art. no. 101872. ISSN 2211-0348.
1625. **Salapa, H.E., C.D. Libner, M.C. Levin.** Dysfunctional RNA-binding protein biology and neurodegeneration in experimental autoimmune encephalomyelitis in female mice. // *Journal of Neuroscience Research*, 98, 2020, № 4, p. 704-717. ISSN 0360-4012.
1626. **Samjoo, I.A., E. Worthington, A. Haltner et al.** The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. // *Current Medical Research and Opinion*, 36, 2020, № 7, p. 1145-1156. ISSN 0300-7995.
1627. **Samjoo, I.A., E. Worthington, C. Drudge et al.** Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: A network meta-



- analysis. // *Journal of Comparative Effectiveness Research*, 9, 2020, № 18, p. 1255-1274. ISSN 2042-6305.
1628. **Samjoo, I.A., E. Worthington, C. Drudge** et al. Efficacy classification of modern therapies in multiple sclerosis. // *Journal of Comparative Effectiveness Research*, 10, 2021, № 6, p. 495-507. ISSN 2042-6305.
1629. **Sartori, A., J. Fantini, P. Manganotti**. How far away from having an effective treatment option for progressive multiple sclerosis are we? // *Expert Opinion on Pharmacotherapy*, 18, 2017, № 10, p. 953-955. ISSN 1465-6566.
1630. **Scalfari, A., P.A. Muraro**. Monoclonal antibody therapy and long-term outcomes in multiple sclerosis - The challenge of treatment optimisation. // *European Neurological Review*, 13, 2018, № 2, p. 78-85. ISSN 1758-3837.
1631. **Schäfer, A.** Ocrelizumab in relapsing and primary progressive multiple sclerosis = Ocrelizumab bei schubförmiger und primär progredienter MS. // *Psychopharmakotherapie*, 26, 2019, № 2, p. 106. ISSN 0944-6877.
1632. **Schafflick, D., B.C. Kieseier, H. Wiendl** et al. Novel pathomechanisms in inflammatory neuropathies. // *Journal of Neuroinflammation*, 14, 2017, № 1, art. no. 232. ISSN 1742-2094.
1633. **Schafflick, D., C.A. Xu, M. Hartlehnert** et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. // *Nature Communications*, 11, 2020, № 1, art. no. 247. ISSN 2041-1723.
1634. **Schmidt, T., M. Schulze, S. Harendza** et al. Successful treatment of PLA2R1-antibody positive membranous nephropathy with ocrelizumab. // *Journal of Nephrology*, 34, 2021, 2, p. 603-606. ISSN 1121-8428.
1635. **Schmierer, K., A. McDowell, N. Petrova** et al. Quantifying multiple sclerosis pathology in post mortem spinal cord using MRI. // *NeuroImage*, 182, 2018, p. 251-258. ISSN 1053-8119.
1636. **Schmitz, K., G. Geisslinger, I. Tegeder**. Monoclonal antibodies in preclinical EAE models of multiple sclerosis: A systematic review. // *International Journal of Molecular Sciences*, 18, 2017, № 9, art. no. 1992. ISSN 1661-6596.
1637. **Scotti, B., G. Disanto, R. Sacco** et al. Effectiveness and safety of rituximab in multiple sclerosis: An observational study from southern Switzerland. // *PLoS ONE*, 13, 2018, № 5, art. no. e0197415. ISSN 1932-6203.
1638. **Scotto, R., A. Reia, A.R. Buonomo** et al. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. // *Expert Opinion on Drug Safety*, 2021. ISSN 1474-0338.

1639. **Seery, N., S. Sharmin, V. Li et al.** Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study. // *CNS Drugs*, 2021. ISSN 1172-7047.
1640. **Sellebjerg, F., M. Blinkenberg, P.S. Sorensen.** Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. // *CNS Drugs*, 34, 2020, № 3, p. 269-280. ISSN 1172-7047.
1641. **Sellner, J., P.S. Rommer.** Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: A systematic review. // *Autoimmunity Reviews*, 19, 2020, № 4, art. no. 102492. ISSN 1568-9972.
1642. **Sellner, J., P.S. Rommer.** Multiple sclerosis and SARS-CoV-2 vaccination: Considerations for immune-depleting therapies. // *Vaccines*, 9, 2021, № 2, art. no. 99, p. 1-12. ISSN 2076-393X.
1643. **Sempere, A.P., L. Berenguer-Ruiz, I. Borrego-Soriano et al.** Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain. // *Frontiers in Neurology*, 11, 2021, art. no. 592304. ISSN 1664-2295.
1644. **Senel, M., F. Mojib-Yezdani, U. Braisch et al.** CSF free light chains as a marker of intrathecal immunoglobulin synthesis in multiple sclerosis: A blood-CSF barrier related evaluation in a large cohort. // *Frontiers in Immunology*, 10, 2019, art. no. 641. ISSN 1664-3224.
1645. **Serafini, B., B. Rosicarelli, C. Veroni et al.** Epstein-Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: Clue for a virus-driven immunopathological mechanism. // *Journal of Virology*, 93, 2019, № 24, art. no. e00980-19. ISSN 0022538X.
1646. **Sharrack, B., R. Saccardi, T. Alexander et al.** Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). // *Bone Marrow Transplantation*, 55, 2020, № 2, p. 283-306. ISSN 02683369.
1647. **Shaygannejad, V., E. Fayyazi, S. Badihian et al.** Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. // *Journal of Neurology*, 266, 2019, № 3, p. 642-650. ISSN 0340-5354.
1648. **Siddiqui, M.K., I.S. Khurana, S. Budhia et al.** Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. // *Current Medical Research and Opinion*, 34, 2018, № 8, p. 1361-1371. ISSN 0300-7995.
1649. **Signoriello, E., G. Lus, S. Bonavita et al.** Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6

- months of ocrelizumab therapy. // *Multiple Sclerosis Journal*, 2021. ISSN 1352-4585.
1650. **Signoriello, E., S. Bonavita, A. Di Pietro** et al. BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab. // *Multiple Sclerosis and Related Disorders*, 43, 2020, art. no. 102186. ISSN 2211-0348.
1651. **Silva, B.A., E. Miglietta, C.C. Ferrari.** Insights into the role of B cells in the cortical pathology of Multiple sclerosis: evidence from animal models and patients. // *Multiple Sclerosis and Related Disorders*, 50, 2021, art. no. 102845. ISSN 2211-0348.
1652. **Simon, M., R. Ipek, G.A. Homola** et al. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis. // *Journal of Neuroinflammation*, 15, 2018, № 1, art. no. 225. ISSN 1742-2094.
1653. **Simpson, A., E.M. Mowry, S.D. Newsome.** Early Aggressive Treatment Approaches for Multiple Sclerosis. // *Current Treatment Options in Neurology*, 23, 2021, № 7, art. no. 19. ISSN 1092-8480.
1654. **Sinnecker, T., E. Ruberte, S. Schädelin** et al. New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis. // *Journal of Neurology*, 267, 2020, № 1, p. 192-202. ISSN 0340-5354.
1655. **Sipilä, J.O.T., M. Soilu-Hänninen, P. Rautava** et al. Hospital admission and prevalence trends of adult myasthenia gravis in Finland in 2004–2014: A retrospective national registry study. // *Journal of the Neurological Sciences*, 407, 2019, art. no. 116520. ISSN 0022-510X.
1656. **Sirbu, C.A., E. Dantes, C.F. Plesa** et al. Active pulmonary tuberculosis triggered by interferon beta-1b therapy of multiple sclerosis: Four case reports and a literature review. // *Medicina (Lithuania)*, 56, 2020, № 4, art. no. 202. ISSN 1010-660X.
1657. **Smets, I., B. Fiddes, J.E. Garcia-Perez** et al. Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. // *Brain*, 141, 2018, № 3, p. 786-796. ISSN 0006-8950.
1658. **Smith, A.L., J.A. Cohen, L.H. Hua.** Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions. // *Neurotherapeutics*, 14, 2017, № 4, p. 952-960. ISSN 1933-7213.
1659. **Soleimani, B., K. Murray, D. Hunt.** Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. // *Drug Safety*, 42, 2019, № 8, p. 941-956. ISSN 0114-5916.

1660. **Sorensen, P.S., F. Sellebjerg.** Pulsed immune reconstitution therapy in multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 12, 2019. ISSN 1756-2856.
1661. **Spelman, T., T. Frisell, F. Piehl et al.** Comparative effectiveness of rituximab relative to IFN- $\beta$  or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. // *Multiple Sclerosis Journal*, 24, 2018, № 8, p. 1087-1095. ISSN 1352-4585.
1662. **Stahnke, A.M., K.M. Holt.** Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis. // *Annals of Pharmacotherapy*, 52, 2018, № 5, p. 473-483. ISSN 1060-0280.
1663. **Stein, J., Q. Xu, K.C. Jackson et al.** Intrathecal B cells in MS have significantly greater lymphangiogenic potential compared to B cells derived from non-MS subjects. // *Frontiers in Neurology*, 9, 2018, art. no. 554. ISSN 1664-2295.
1664. **Steininger, P.A., T. Bobinger, W. Dietrich et al.** Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention. // *Open Forum Infectious Diseases*, 4, 2017, № 4, art. no. ofx204. ISSN 2328-8957.
1665. **Syed, Y.Y.** Ocrelizumab: A Review in Multiple Sclerosis. // *CNS Drugs*, 32, 2018, № 9, p. 883-890. ISSN 1172-7047.
1666. **Tallantyre, E.C., D.H. Whittam, S. Jolles et al.** Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. // *Journal of Neurology*, 265, 2018, № 5, p. 1115-1122. ISSN 0340-5354.
1667. **Tallantyre, E.C., N.P. Robertson, S. Jolles.** Secondary antibody deficiency in neurology. // *Current Opinion in Allergy and Clinical Immunology*, 18, 2018, № 6, p. 481-488. ISSN 1528-4050.
1668. **Theil, D., P. Smith, C. Huck.** Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys. // *Frontiers in Immunology*, 10, 2019, art. no. 1340. ISSN 1664-3224.
1669. **Thi Cuc, B., J. Pohar, S. Fillatreau.** Understanding regulatory B cells in autoimmune diseases: the case of multiple sclerosis. // *Current Opinion in Immunology*, 61, 2019, p. 26-32. ISSN 0952-7915.
1670. **Tintore, M., A. Vidal-Jordana, J. Sastre-Garriga.** Treatment of multiple sclerosis — success from bench to bedside. // *Nature Reviews Neurology*, 15, 2019, № 1, p. 53-58. ISSN 1759-4758.

1671. **Torgauten, H.M., K.-M. Myhr, S. Wergeland** et al. Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. // *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, 7, 2021, № 1. ISSN 2055-2173.
1672. **Torke, S., M.S. Weber.** Inhibition of Bruton's tyrosine kinase as a novel therapeutic approach in multiple sclerosis. // *Expert Opinion on Investigational Drugs*, 29, 2020, № 10, p. 1143-1150. ISSN 1354-3784.
1673. **Torke, S., R. Pretzsch, D. Häusler** et al. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. // *Acta Neuropathologica*, 140, 2020, № 4, p. 535-548. ISSN 0001-6322.
1674. **Torkildsen, Ø., K.-M. Myhr, V. Skogen** et al. Tenofovir as a treatment option for multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 46, 2020, art. no. 102569. ISSN 2211-0348.
1675. **Tran, K.R.** Reader response: Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. // *Neurology*, 93, 2019, № 17, p. 764-765. ISSN 0028-3878.
1676. **Traub, J., S. Häusser-Kinzel, M.S. Weber.** Differential effects of MS therapeutics on b cells—implications for their use and failure in AQP4-positive NMOSD patients. // *International Journal of Molecular Sciences*, 21, 2020, № 14, art. no. 5021, p. 1-30. ISSN 1661-6596.
1677. **Traub, J., S. Traffehn, J. Ochs** et al. Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis. // *Brain Pathology*, 29, 2019, № 5, p. 640-657. ISSN 1015-6305.
1678. **Traub, J.W., H.L. Pellkofer, K. Grondey** et al. Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients. // *Journal of Neuroinflammation*, 16, 2019, № 1, art. no. 228. ISSN 1742-2094.
1679. **Trend, S., J. Leffler, M.N. Cooper** et al. Narrowband UVB phototherapy reduces TNF production by B-cell subsets stimulated via TLR7 from individuals with early multiple sclerosis. // *Clinical and Translational Immunology*, 9, 2020, № 10, art. no. e1197. ISSN 2050-0068.
1680. **Tsantes, E., E. Curti, F. Collura** et al. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis. // *Journal of the Neurological Sciences*, 414, 2020, art. no. 116827. ISSN 0022-510X.

1681. **Turalde, C.W.R., A.I. Espiritu, V.M.M. Anlacan.** Memantine for Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Trials. // *Frontiers in Neurology*, 11, 2021, art. no. 574748. ISSN 1664-2295.
1682. **Tveito, K.** Lovende effekt av ocrelizumab ved multippel sklerose. // *Tidsskrift for den Norske Laegeforening*, 137, 2017, № 5, p. 351. ISSN 0029-2001.
1683. **Uncertain long-term harm-benefit balance.** // *Prescrire International*, 28, 2019, № 203, p. 92-94. ISSN 1167-7422.
1684. **van Langelaar, J., L. Rijvers, J. Smolders et al.** B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers. // *Frontiers in Immunology*, 11, 2020, art. no. 760. ISSN 1664-3224.
1685. **Vaughn, C.B., D. Jakimovski, K.S. Kavak et al.** Epidemiology and treatment of multiple sclerosis in elderly populations. // *Nature Reviews Neurology*, 15, 2019, № 6, p. 329-342. ISSN 1759-4758.
1686. **Vermersch, P.** New therapeutic strategies of inflammation and progression in multiple sclerosis (Clinical and imaging evaluation) = Nouvelles approches thérapeutiques de l'inflammation et de la progression dans la sclérose en plaques (évaluations cliniques et IRM). // *Pratique Neurologique - FMC*, 10, 2019, № 2, p. 126-130. ISSN 1878-7762.
1687. **Vidal-Jordana, A.** New Advances in Disease-Modifying Therapies for Relapsing and Progressive Forms of Multiple Sclerosis. // *Neurologic Clinics*, 36, 2018, № 1, p. 173-183. ISSN 0733-8619.
1688. **Visaria, J., N. Thomas, T. Gu et al.** Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice. // *Clinical Therapeutics*, 40, 2018, № 6, p. 926-939. ISSN 0149-2918.
1689. **Voge, N.V., E. Alvarez.** Monoclonal antibodies in multiple sclerosis: Present and future. // *Biomedicines*, 7, 2019, № 1, art. no. 20. ISSN 2227-9059.
1690. **Vollmer, B.L., K. Nair, S. Sillau et al.** Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. // *Annals of Clinical and Translational Neurology*, 7 2020, № 9, p. 1466-1476. ISSN 2328-9503.
1691. **Vollmer, B.L., K.V. Nair, S Sillau et al.** Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. // *Annals of Clinical and Translational Neurology*, 6, 2019, № 2, p. 252-262. ISSN 2328-9503.
1692. **Vollmer, T.L., J.A. Cohen, E. Alvarez et al.** Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 46, 2020, art. no. 102454. ISSN 2211-0348.

1693. **von Wyl, V., P. Benkert, A. Moser et al.** Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. // *Multiple Sclerosis Journal*, 27, 2021, № 3, p. 439-448. ISSN 1352-4585.
1694. **Waisman, A., A. Ebering.** Unraveling the T–B tangle in anti-CD20 multiple sclerosis therapy. – In: *Proceedings of the National Academy of Sciences of the United States of America*, 116, 2019, № 51, p. 25376-25377. ISSN 0027-8424.
1695. **Wallin, M.T.** Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – No. // *Multiple Sclerosis Journal*, 24, 2018, № 9, p. 1159-1161. ISSN 1352-4585.
1696. **Wang, A., O. Rojas, D. Lee et al.** Regulation of neuroinflammation by B cells and plasma cells. // *Immunological Reviews*, 299, 2021, № 1, p. 45-60. ISSN 0105-2896.
1697. **Warpakowski, A.** Primary progressive multiple sclerosis: Extensive therapeutic effects [Weitreichende Therapieeffekte]. // *Deutsches Arzteblatt International*, 115, 2018, № 47, p. A2187. ISSN 1866-0452.
1698. **Watkins, C., I. Bennett.** A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data. // *Research Synthesis Methods*, 9, 2018, № 3, p. 352-360. ISSN 1759-2887.
1699. **Webb, E.J.D., D., Meads, I. Eskyte et al.** A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. // *Patient*, 11, 2018, № 4, p. 391-402. ISSN 1178-1653.
1700. **Weber, M.S., T. Derfuss, I. Metz et al.** Defining distinct features of anti-MOG antibody associated central nervous system demyelination. // *Therapeutic Advances in Neurological Disorders*, 11, 2018. ISSN 1756-2856.
1701. **Weissert, R.** Adaptive immunity is the key to the understanding of autoimmune and paraneoplastic inflammatory central nervous system disorders. // *Frontiers in Immunology*, 8, 2017, art. no. 336. ISSN 1664-3224.
1702. **Wekerle, H.** Nature, nurture, and microbes: The development of multiple sclerosis. // *Acta Neurologica Scandinavica*, 136, 2017, p. 22-25. ISSN 0001-6314.
1703. **Wesley, S., D.A. Hafler.** Multiple sclerosis. – In: *The Autoimmune Diseases*, 2019, p. 961-986. ISBN 9780128121023; 9780128122426.
1704. **Wesselingh, R., H. Butzkueven, K. Buzzard et al.** Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle? // *Frontiers in Immunology*, 10, 2019, art. no. 2066. ISSN 1664-3224.
1705. **Whittam, D.H., A. Cobo-Calvo, A.S. Lopez-Chiriboga et al.** Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. //

- Multiple Sclerosis and Related Disorders*, 44, 2020, art. no. 102251. ISSN 2211-0348.
1706. **Whittam, D.H., E.C. Tallantyre, S. Jolles** et al. Rituximab in neurological disease: Principles, evidence and practice. // *Practical Neurology*, 19, 2019, № 1, p. 5-20. ISSN 1474-7758.
  1707. **Wicken, C., J. Nguyen, R. Karna** et al. Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies. // *Multiple Sclerosis and Related Disorders*, 26, 2018, p. 173-182. ISSN 2211-0348.
  1708. **Wiendl, H., T. Spelman, H. Butzkueven** et al. Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. // *Multiple Sclerosis Journal*, 27, 2021, № 5, p. 719-728. ISSN 1352-4585.
  1709. **Wijburg, M.T., C. Warnke, C. McGuigan** et al. Pharmacovigilance during treatment of multiple sclerosis: Early recognition of CNS complications. // *Journal of Neurology, Neurosurgery and Psychiatry*, 92, 2021, № 2, p. 177-188. ISSN 0022-3050.
  1710. **Wilbur, C., E.A. Yeh**. Acute and Chronic Therapies in Pediatric Inflammatory Central Nervous System Diseases. // *Journal of Pediatric Neurology*, 16, 2018, № 3, p. 202-216. ISSN 1304-2580.
  1711. **Wilbur, C., E.A. Yeh**. Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments. // *Pediatric Drugs*, 21, 2019, № 3, p. 137-152. ISSN 1174-5878.
  1712. **Wilkins, A.** Mechanisms of disease progression. – In: *Progressive Multiple Sclerosis: Second Edition*, 2017, p. 71-92. ISBN 9783319659213; 9783319659206.
  1713. **Wilkins, A., S. Hawkins**. General introduction: What is progressive multiple sclerosis? – In: *Progressive Multiple Sclerosis: Second Edition*, 2017, p. 1-29. ISBN 9783319659213; 9783319659206.
  1714. **Wrobel, J., M.L. Martin, R. Bakshi** et al. Intensity warping for multisite MRI harmonization. // *NeuroImage*, 223, 2020, art. no. 117242. ISSN 1053-8119.
  1715. **Wurth, S., B. Kuenz, G. Bsteh** et al. Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study. // *PLoS ONE*, 12, 2017, № 8, art. no. e0182462. ISSN 1932-6203.
  1716. **Xu, X., S. Chi, Q. Wang** et al. Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis. // *Multiple Sclerosis and Related Disorders*, 25, 2018, p. 322-328. ISSN 2211-0348.



1717. **Xue, T., J. Yu, S. Chen** et al. Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials. // *Frontiers in Neurology*, 11, 2020, art. no. 604445. ISSN 1664-2295.
1718. **Xue, T., Y. Yang, Q. Lu** et al. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials. // *Multiple Sclerosis and Related Disorders*, 43, 2020, art. no. 102166. ISSN 2211-0348.
1719. **Yamout, B., M. Sahraian, S. Bohlega** et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. // *Multiple Sclerosis and Related Disorders*, 37, 2020, art. no. 101459. ISSN 2211-0348.
1720. **Yamout, B.I., N.K. El-Ayoubi, J. Nicolas** et al. Safety and efficacy of rituximab in multiple sclerosis: A retrospective observational study. // *Journal of Immunology Research*, 2018, 2018, art. no. 9084759. ISSN 2314-8861.
1721. **Yamout, B.I., R. Alroughani**. Multiple Sclerosis. // *Seminars in Neurology*, 38, 2018, № 2, p. 212-225. ISSN 0271-8235.
1722. **Yang, H., E. Duchesneau, R. Foster** et al. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. // *Journal of Medical Economics*, 20, 2017, № 10, p. 1056-1065. ISSN 1369-6998.
1723. **Yarchoan, M., W.J. Ho, A. Mohan** et al. Effects of B cell-activating factor on tumor immunity. // *JCI Insight*, 5, 2020, № 10, art. no. e136417. ISSN 2379-3708.
1724. **Yi, J.S., J.T. Guptill, P. Stathopoulos** et al. B cells in the pathophysiology of myasthenia gravis. // *Muscle and Nerve*, 57, 2018, № 2, p. 172-184. ISSN 0148-639X.
1725. **Yong, H., G. Chartier, J. Quandt**. Modulating inflammation and neuroprotection in multiple sclerosis. // *Journal of Neuroscience Research*, 96, 2018, № 6, p. 927-950. ISSN 0360-4012.
1726. **Yoo, S.M., S.H. Chung**. Targets of monoclonal antibodies for immunological diseases. // *Archives of Pharmacal Research*, 42, 2019, № 4, p. 293-304. ISSN 0253-6269.
1727. **Zabalza, A., A. Vera, E. Alari-Pahissa** et al. Impact of cytomegalovirus infection on B cell differentiation and cytokine production in multiple sclerosis. // *Journal of Neuroinflammation*, 17, 2020, № 1, art. no. 161. ISSN 1742-2094.

1728. **Zanghi, A., E. D'Amico, F. Patti.** Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. // *Expert Review of Neurotherapeutics*, 20, 2020, № 8, p. 771-782. ISSN 1473-7175.
1729. **Zarzuelo Romero, M.J., C. Pérez Ramírez, M.I. Carrasco Campos et al.** Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis. // *Journal of Personalized Medicine*, 11, 2021, № 5, art. no. 335. ISSN 2075-4426.
1730. **Zdimerova, H., A. Murer, C. Engelmann et al.** Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15. // *European Journal of Immunology*, 51, 2021, № 1, p. 64-75. ISSN 0014-2980.
1731. **Zecca, C., F. Bovis, G. Novi et al.** Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience. // *Multiple Sclerosis Journal*, 26, 2020, № 12, p. 1519-1531. ISSN 1352-4585.
1732. **Zhang, Y., A. Salter, E. Wallström et al.** Evolution of clinical trials in multiple sclerosis. // *Therapeutic Advances in Neurological Disorders*, 12, 2019. ISSN 1756-2856.
1733. **Zheng, C., I. Kar, C.K. Chen et al.** Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. // *CNS Drugs*, 34, 2020, № 9, p. 879-896. ISSN 1172-7047.
1734. **Zhong, M., A. van der Walt, M.P. Campagna et al.** The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. // *Neurotherapeutics*, 17, 2020, № 4, p. 1768-1784. ISSN 1933-7213.
1735. **Zhuravleva, M.V., M.V. Davydovskaya, E.V. Luchinina et al.** Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis. // *Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova*, 120, 2020, № 8, p. 148-153. ISSN 1997-7298.
1736. **Zrzavy, T., H. Kollaritsch, P.S. Rommer et al.** Vaccination in multiple sclerosis: Friend or foe? // *Frontiers in Immunology*, 10, 2019, art. no. 1883. ISSN 1664-3224.
1737. **Zrzavy, T., I. Wimmer, P.S. Rommer et al.** Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. // *European Journal of Neurology*, 2020. ISSN 1351-5101.
1738. **Zurawski, J., J. Stankiewicz.** Multiple Sclerosis Re-Examined: Essential and Emerging Clinical Concepts. // *American Journal of Medicine*, 131, 2018, № 5, p. 464-472. ISSN 0002-9343.

Donald, J., Easton, M. Aunes, G. W. Albers, P. Amarenco, S. Bokelund-Singh, H. Denison, Scott R. Evans, P. Held, M. Jahreskog, J. Jonasson, K. Minematsu, Carlos A. Molina, Y.

Wang, K.S. Lawrence Wong, S. Claiborne Johnston, and For the SOCRATES Steering Committee and Investigators ...**Dimitar Maslarov**... Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). // *Circulation*, 136, 2017, № 10, p. 907–916. ISSN 0009-7322; E-ISSN 1524-4539 DOI: 10.1161/CIRCULATIONAHA.117.028566.

#### Cited by:

1739. **Caroff, J., R.M. King, G.J. Ughi** et al. Longitudinal monitoring of flow-diverting stent tissue coverage after implant in a bifurcation model using neurovascular high-frequency optical coherence tomography. // *Neurosurgery*, 87, 2020, № 6, p. 1311-1319. ISSN 0148-396X.
1740. **Claerhout, B., D. Kalra, C. Mueller** et al. Federated electronic health records research technology to support clinical trial protocol optimization: Evidence from EHR4CR and the InSite platform. // *Journal of Biomedical Informatics*, 90, 2019, art. no. 103090. ISSN 1532-0464.
1741. **Evoy, K.E., J. Isch, H. Raber**. Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. – In: *Side Effects of Drugs Annual*, 2018, p. 447-461. ISSN 0378-6080. ISBN 9780444641199.
1742. **Gomez, C.R., M.J. Schneck, J. Biller**. Recent advances in the management of transient ischemic attacks. // *F1000Research*, 6, 2017, art. no. 1893. ISSN 2046-1402.
1743. **Hara, H., K. Takahashi, N. Kogame** et al. Impact of bleeding and myocardial infarction on mortality in all-comer patients undergoing percutaneous coronary intervention. // *Circulation: Cardiovascular Interventions*, art. no. e009177, 2020. ISSN 1941-7640.
1744. **Honig, A., T. Sacagiu, A. Filioglo** et al. Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis. // *Journal of the Neurological Sciences*, 425, 2021, art. no. 117450. ISSN 0022-510X.
1745. **Kolandaivelu, K., D.L. Bhatt**. Novel antiplatelet therapies. – In: *Platelets*, 2019, p. 991-1015. ISBN 9780128134566.
1746. **Narata, A.P., A. Amelot, R. Bibi** et al. Dual antiplatelet therapy combining aspirin and ticagrelor for intracranial stenting procedures: A retrospective single center study of 154 consecutive patients with unruptured aneurysms. // *Clinical Neurosurgery*, 84, 2019, № 1, p. 77-82. ISSN 0148-396X.

Surcheva, S., L. Todorova, **D. Maslarov**, M. Vlaskovska. Preclinic and clinic effectiveness of gabapentin and pregabalin for treatment of neuropathic pain in rats and diabetic patients. // *Biotechnology & Biotechnological Equipment*, 31, 2017, 3, p. 568-573. ISSN 1310-2818 (print) DOI: 10.1080/13102818.2017.1290550.

**Cited by:**

1747. **Bhuanaputra, Mochamad Firdaus, Alya Tursina, Y. Kharisma.** Combination of Gabapentin and Vitamin B12 Compared with Gabapentin Monotherapy on Pain Improvement of Diabetic Neuropathy Patients. // *Global Medical & Health Communication*, 8, 2020, № 1, p. 1-6. ISSN 2301-9123. Достъпно на: [https://pdfs.semanticscholar.org/5c87/db19461a3f98b69ecbf753b77a499949d812.pdf?\\_ga=2.255628872.1554188850.1621924828-1554326389.1617187129](https://pdfs.semanticscholar.org/5c87/db19461a3f98b69ecbf753b77a499949d812.pdf?_ga=2.255628872.1554188850.1621924828-1554326389.1617187129)

Stocchi, F., O. Rascol, R. A. Hauser, S. Huyck, A. Tzontcheva, R. Capece, T.W. Ho, P. Sklar, C. Lines, D. Michelson, D.J. Hewitt, **D. Maslarov** et al. Randomized trial of pramipexole, given as monotherapy, in patients with early Parkinson disease. On behalf of the Pramipexole Early Parkinson Disease Study Group Published online before print May 10, 2017, doi: 10.1212/WNL.0000000000004003. // *Neurology*, 88, 2017, № 23, p. 2198-2206. ISSN 0028-3878; E-ISSN 1526-632X 10.1212/WNL.0000000000004003.

**Cited by:**

1748. **Andrejew, R., T. Glaser, Á. Oliveira-Giacomelli** et al. Targeting purinergic signaling and cell therapy in cardiovascular and neurodegenerative diseases. // *Advances in Experimental Medicine and Biology*, 1201, 2019, p. 275-353. ISSN 0065-2598.
1749. **Antonoli, L., M. Fornai, C. Blandizzi** et al. Adenosine regulation of the immune system. // *Receptors*, 34, 2018, p. 499-514. ISSN 1048-6909.
1750. **Atif, M., A. Alsrhani, F. Naz** et al. Targeting Adenosine Receptors in Neurological Diseases. // *Cellular Reprogramming*, 23, 2021, № 2, p. 57-72. ISSN 2152-4971.
1751. **Balestrino, R., A.H.V. Schapira.** Parkinson disease. // *European Journal of Neurology*, 27, 2020, № 1, p. 27-42. ISSN 1351-5101.
1752. **Binde, C.D., I.F. Tveté, J. Gåsemýr** et al. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. // *British Journal of Clinical Pharmacology*, 84, 2018, № 9, p. 1917-1927. ISSN 0306-5251.
1753. **Binde, C.D., I.F. Tveté, J.I. Gåsemýr** et al. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's

- disease: a multiple treatment comparison meta-analysis. // *European Journal of Clinical Pharmacology*, 76, 2020, № 12, p. 1731-1743. ISSN 0031-6970.
1754. **Borah, P., S. Deka, R.P. Mailavaram** et al. P1 receptor agonists/antagonists in clinical trials - Potential drug candidates of the future. // *Current Pharmaceutical Design*, 25, 2019, № 26, p. 2792-2807. ISSN 1381-6128.
1755. **Chen, J.-F., M.A. Schwarzschild**. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? // *Parkinsonism and Related Disorders*, 80, 2020, p. S45-S53. ISSN 1353-8020.
1756. **Chen, J.-F., R.A. Cunha**. The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease. // *Purinergic Signalling*, 16, 2020, № 2, p. 167-174. ISSN 1573-9538.
1757. **Duroux, R., L. Agouridas, N. Renault** et al. Antagonists of the adenosine A2A receptor based on a 2-arylbenzoxazole scaffold: Investigation of the C5- and C7-positions to enhance affinity. // *European Journal of Medicinal Chemistry*, 144, 2018, p. 151-163. ISSN 0223-5234.
1758. **Elkouzi, A., V. Vedam-Mai, R.S. Eisinger** et al. Emerging therapies in Parkinson disease - repurposed drugs and new approaches. // *Nature Reviews Neurology*, 15, 2019, № 4, p. 204-223. ISSN 1759-4758.
1759. **Ellis, J.M., M.J. Fell**. Current approaches to the treatment of Parkinson's Disease. // *Bioorganic and Medicinal Chemistry Letters*, 27, 2017, № 18, p. 4247-4255. ISSN 0960-894X.
1760. **Gonzalez-Latapi, P., S.S. Bhowmick, G. Saranza** et al. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update. // *CNS Drugs*, 34, 2020, № 10, p. 1025-1044. ISSN 1172-7047.
1761. **Kulisevsky, J., L. Oliveira, S.H. Fox**. Update in therapeutic strategies for Parkinson's disease. // *Current Opinion in Neurology*, 31, 2018, № 4, p. 439-447. ISSN 1350-7540.
1762. **Kumari, S., A.V. Carmona, A.K. Tiwari** et al. Amide Bond Bioisosteres: Strategies, Synthesis, and Successes. // *Journal of Medicinal Chemistry*, 63, 2020, № 21, p. 12290-12358. ISSN 0022-2623.
1763. **Kurtis, M.M., C. Rodriguez-Blazquez, I. Pareés**. A Review of Randomized Phase III Pharmacological Clinical Trials for Motor Symptoms in Parkinson's Disease Patients and Quality of Evidence Recommendations. // *Neuromethods*, 160, 2021, p. 87-108. ISSN 0893-2336.

1764. **Leonard, H., C. Blauwendraat, L. Krohn** et al. Genetic variability and potential effects on clinical trial outcomes: Perspectives in Parkinson's disease. // *Journal of Medical Genetics*, 57, 2020, № 5, p. 331-338. ISSN 0022-2593.
1765. **Leone, R.D., L.A. Emens.** Targeting adenosine for cancer immunotherapy. // *Journal for ImmunoTherapy of Cancer*, 6, 2018, № 1, art. no. 57. ISSN 2051-1426.
1766. **LeWitt, P.A., S.D. Aradi, R.A. Hauser** et al. The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. // *Parkinsonism and Related Disorders*, 80, 2020, p. S54-S63. ISSN 1353-8020.
1767. **Müller, C.E., Y. Baqi, V. Namasivayam.** Agonists and antagonists for purinergic receptors. // *Methods in Molecular Biology*, 2041, 2020, p. 45-64. ISSN 1064-3745.
1768. **Nazario, L.R., R.S. da Silva, C.D. Bonan.** Targeting adenosine signaling in Parkinson's disease: From pharmacological to non-pharmacological approaches. // *Frontiers in Neuroscience*, 11, 2017, art. no. 658. ISSN 1662-4548.
1769. **Ntetsika, T., P.-E. Papathoma, I. Markaki.** Novel targeted therapies for Parkinson's disease. // *Molecular Medicine*, 27, 2021, № 1, art. no. 17. ISSN 1076-1551.
1770. **Seamon, M., S. Purohit, B. Giri** et al. Niacin for Parkinson's disease. // *Clinical and Experimental Neuroimmunology*, 11, 2020, № 1, p. 47-56. ISSN 1759-1961.
1771. **Segura-Aguilar, J.** Neurotoxins as Preclinical Models for Parkinson's Disease. // *Neurotoxicity Research*, 34, 2018, № 4, p. 870-877. ISSN 1029-8428.
1772. **Taura, J., E.G. Nolen, G. Cabré** et al. Remote control of movement disorders using a photoactive adenosine A 2A receptor antagonist. // *Journal of Controlled Release*, 283, 2018, p. 135-142. ISSN 0168-3659.
1773. **Veyres, N., A. Hamadjida, P. Huot.** Predictive value of parkinsonian primates in pharmacologic studies: A comparison between the macaque, marmoset, and squirrel monkey. // *Journal of Pharmacology and Experimental Therapeutics*, 365, 2018, № 2, p. 379-397. ISSN 0022-3565.
1774. **Zeng, Z., A.-A. Roussakis, N.P. Lao-Kaim** et al. Astrocytes in Parkinson's disease: from preclinical assays to in vivo imaging and therapeutic probes. // *Neurobiology of Aging*, 95, 2020, p. 264-270. ISSN 0197-4580.
1775. **Zhang, C.-L., Q.-W. Han, N.-H. Chen** et al. Research on developing drugs for Parkinson's disease. // *Brain Research Bulletin*, 168, 2021, p. 100-109. ISSN 0361-9230.

1776. **Zyma, M., R. Pawliczak.** Characteristics and the role of purinergic receptors in pathophysiology with focus on immune response: Purinergic receptors are widely expressed in immune cells and regulate high variety of their functions, taking part in pathogenesis of many diseases. // *International Reviews of Immunology*, 39, 2020, № 3, p. 97-117. ISSN 0883-0185.

Wang, Y, Minematsu, K, Wong, K.S, Amarenco, P., Albers, G.W, Denison, H., Easton, J.D., Evans, S.R., Held, P., Jonasson, J., Molina, C.A., Johnston, S.C. SOCRATES Steering Committee and Investigators. Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). // *Stroke*, 48, 2017, № 1, p. 167-173. ISSN 0039-2499; E-ISSN 1524-4628 doi: 10.1161/STROKEAHA.116.014891. Epub 2016 Nov 29. PMID: 27899747.

#### Cited by:

1777. **Ahn, J.-H., P.A. Gurbel, Y.-H. Jeong.** Ticagrelor versus clopidogrel in peripheral artery disease. // *New England Journal of Medicine*, 376, 2017, № 15, p. 1487-1488. ISSN 0028-4793.
1778. **Del Brutto, V.J., S. Chaturvedi, H.-C. Diener** et al. Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel. // *Journal of the American College of Cardiology*, 74, 2019, № 6, p. 786-803. ISSN 0735-1097.
1779. **Evoy, K.E., J. Isch, H. Raber.** Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. – In: *Side Effects of Drugs Annual*, 2018, p. 447-461. ISSN 0378-6080. ISBN 9780444641199.
1780. **Gomez, C.R., M.J. Schneck, J. Biller.** Recent advances in the management of transient ischemic attacks. // *F1000Research*, 6, 2017, art. no. 1893. ISSN 2046-1402.
1781. **Kim, J.S., O.Y. Bang.** Medical treatment of intracranial atherosclerosis: An update. // *Journal of Stroke*, 19, 2017, № 3, p. 261-270. ISSN 2287-6391.
1782. **Kubisa, M.J., M.P. Jezewski, A. Gasecka** et al. Ticagrelor – toward more efficient platelet inhibition and beyond. // *Therapeutics and Clinical Risk Management*, 14, 2018, p. 129-140. ISSN 1176-6336.
1783. **Leng, X., T.W. Leung, K.S. Lawrence Wong.** Antiplatelet therapy after stroke: Should it differ in the acute and chronic phase after stroke. // *Current Opinion in Neurology*, 31, 2018, № 1, p. 14-22. ISSN 1350-7540.

1784. **Moris, D., C. Bakoyiannis, E. Avgerinos.** Letter by Moris et al Regarding Article, "ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes). // *Stroke*, 48, 2017, № 4, p. e110. ISSN 0039-2499.
1785. **Spence, J.D.** Recent advances in preventing stroke recurrence. // *F1000Research*, 6, 2017, art. no. 1017. ISSN 2046-1402.
1786. **Tripathy, S., S.R. Ahmad.** Neuropharmacology. – In: *Acute Neuro Care: Focused Approach to Neuroemergencies*, 2020, p. 57-78. ISBN 9789811540714; 9789811540707.

## **2018**

Kappos, L., D.L. Arnold, A. Bar-Or, T. Derfuss, T. Sprenger, M. Davies, A. Piotrowska, P.N, T. Harada. MOMENTUM study Group: (Bulgaria ... **D. Maslarov**...). Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. // *Multiple Sclerosis Journal*, 24, 2018, № 12, p. 1605-1616. ISSN 1352-4585; E-ISSN 1477-0970.

## **Cited by:**

1787. **Chun, J., G. Giovannoni, S.F. Hunter.** Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. // *Drugs*, 81, 2021, № 2, p. 207-231. ISSN 0012-6667.
1788. **Gajofatto, A., M. Turatti.** Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. // *Expert Opinion on Investigational Drugs*, 27, 2018, № 3, p. 273-286. ISSN 1354-3784.
1789. **Jozefczuk, E., T.J. Guzik, M. Siedlinski.** Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. // *Pharmacological Research*, 156, 2020, art. no. 104793. ISSN 1043-6618.
1790. **Lucchetta, R.C., L.P. Leonart, M.V.M. Gonçalves et al.** Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review. // *PLoS ONE*, 15, 2020, art. no. e0231722. ISSN 1932-6203.
1791. **Pérez-Jeldres, T., M. Alvarez-Lobos, J. Rivera-Nieves.** Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis. // *Drugs*, 2021. ISSN 0012-6667.
1792. **Roy, R., A.A. Alotaibi, M.S. Freedman.** Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. // *CNS Drugs*, 35, 2021, № 4, p. 385-402. ISSN 1172-7047.



1793. **Sandborn, W.J., L. Peyrin-Biroulet, J. Zhang et al.** Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. // *Gastroenterology*, 158, 2020, № 3, p. 550-561. ISSN 0016-5085.
1794. **Stepanovska, B., A. Huwiler.** Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. // *Pharmacological Research*, 154, 2020, art. no. 104170. ISSN 1043-6618.
1795. **Triantis, C., K. Chatzimichail, P. Theodosis-Nobelos et al.** New pharmaceutical approaches to the treatment of multiple sclerosis. // *Archives of Hellenic Medicine*, 37, 2020, № 5, p. 602-611. ISSN 1105-3992.

Wong, K.S.L, Amarenco, P., Albers, G.W., Denison, H., Easton, J.D., Evans, S.R., Held, P., Himmelmann, A., Kasner, S.E., Knutsson, M., Ladenvall, P., Minematsu, K., Molina, C.A., Wang, Y., Johnston, S.C. SOCRATES Steering Committee and Investigators. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. // *Stroke*, 49, 2018, № 7, p. 1678-1685. ISSN 0039-2499; E-ISSN 1524-4628. doi: 10.1161/STROKEAHA.118.020553. Epub 2018 Jun 18. PMID: 29915123; PMCID: PMC6019568.

#### Cited by:

1796. **Chou, P.-S., P.-S. Sung, C.-H. Liu et al.** Prevalence and Effect of Cerebral Small Vessel Disease in Stroke Patients With Aspirin Treatment Failure—A Hospital-Based Stroke Secondary Prevention Registry. // *Frontiers in Neurology*, 12, 2021, art. no. 645444. ISSN 1664-2295.
1797. **Fonseca, A.C., Á. Merwick, M. Dennis et al.** European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack. // *European Stroke Journal*, 2021. ISSN 2396-9873.
1798. **Hackam, D.G., J.D. Spence.** Antiplatelet therapy in ischemic stroke and transient ischemic attack: An overview of major trials and meta-analyses. // *Stroke*, 50, 2019, № 3, p. 773-778. ISSN 0039-2499.
1799. **Khan, H., R. Gallant, S. Jain et al.** Ticagrelor as an alternative antiplatelet therapy in cardiac patients non-sensitive to aspirin. // *Medicina (Lithuania)*, 56, 2020, № 10, art. no. 519, p. 1-11. ISSN 1010-660X.
1800. **Schmilovitz-Weiss, H., R. Gingold-Belfer, N. Peleg et al.** Use of proton pump inhibitors is associated with lower rates of first-time ischemic stroke in community-dwelling elderly. // *British Journal of Clinical Pharmacology*, 87, 2021, № 3, p. 1187-1193. ISSN 0306-5251.

1801. **Signorelli, S.S., I. Platania, S.D. Tomasello** et al. Insights from experiences on antiplatelet drugs in stroke prevention: A review. // *International Journal of Environmental Research and Public Health*, 17, 2020, № 16, art. no. 5840, p. 1-15. ISSN 1661-7827.

Trinka, E., E. Ben-Menachem, P. Kowach, C. Elger, B. Keller, K. Löffler, J. Rocha, P. Soares-da-Silva. (BIA-2093-311-PI List ... Assoc. Prof. Dr. **D. Maslarov**). Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, parallel-group, multicenter study. // *Epilepsia*, 59, 2018, № 2, p. 479-491. ISSN 0013-9580; E-ISSN 1528-1167.

#### Cited by:

1802. **Beydoun, A., S. DuPont, D. Zhou** et al. Current role of carbamazepine and oxcarbazepine in the management of epilepsy. // *Seizure*, 83, 2020, p. 251-263. ISSN 1059-1311.
1803. **Brandt, C., M. Holtkamp, T.W. May** et al. Effectiveness of eslicarbazepine acetate in 2 different cohorts of patients with epilepsy in clinical practice—Results from a retrospective data collection from 2 epilepsy centers in Germany = Effektivität von Eslicarbazepinacetat in 2 unterschiedlichen Kohorten von Patienten mit Epilepsie in der klinischen Praxis – Ergebnisse einer retrospektiven Datensammlung aus 2 Epilepsiezentren in Deutschland. // *Zeitschrift für Epileptologie*, 2019. ISSN 1617-6782.
1804. **Brigo, F., S. Lattanzi**. Comparing the dosages of lacosamide, eslicarbazepine acetate, and controlled-release carbamazepine in noninferiority epilepsy monotherapy trials: How much “fair” is “fair”? // *Epilepsia*, 59, 2018, № 4, p. 899-900. ISSN 0013-9580.
1805. **Chung, S., S.R. Sinha, A. Shah** et al. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures. // *Epilepsy Research*, 153, 2019, p. 59-65. ISSN 0920-1211.
1806. **Compagno Strandberg, M., K. Söderberg-Löfdal, E. Kimland** et al. Evidence-based anti-seizure monotherapy in newly diagnosed epilepsy: A new approach. // *Acta Neurologica Scandinavica*, 142, 2020, № 4, p. 323-332. ISSN 0001-6314.
1807. **de Biase, S., A. Nilo, A. Bernardini** et al. Timing use of novel anti-epileptic drugs: is earlier better? // *Expert Review of Neurotherapeutics*, 19, 2019, № 10, p. 945-954. ISSN 1473-7175.
1808. **Doherty, C.P., S. Rheims, G. Assenza** et al. Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: Clinical practice findings from the Euro-Esli study. // *Journal of the Neurological Sciences*, 402, 2019, p. 88-99. ISSN 0022-510X.

1809. **García-Peñas, J.J., P. Smeyers-Durá, S. Roldán-Aparicio** et al. The role of eslicarbazepine acetate in the treatment of focal-onset epilepsy in pediatric age: Practical issues = Papel del acetato de eslicarbazepina en el tratamiento de la epilepsia de origen focal en la edad pediátrica: Consideraciones prácticas. // *Revista de Neurologia*, 71, 2020, № 9, p. S1-S17. ISSN 0210-0010.
1810. **Giráldez, B.G., I. Garamendi-Ruiz, J. Zurita** et al. Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: A multicenter audit. // *Acta Neurologica Scandinavica*, 140, 2019, № 6, p. 422-428. ISSN 0001-6314.
1811. **Heo, Y.-A.** Eslicarbazepine Acetate: A Review in Focal-Onset Seizures. // *CNS Drugs*, 34, 2020, № 9, p. 989-1000. ISSN 1172-7047.
1812. **Hernández-Rubio, L., M. Asensio-Asensio, D. Tortosa-Conesa** et al. Alzemon: A prospective follow-up study of eslicarbazepine acetate monotherapy in patients with newly diagnosed epilepsy = Alzemon: Estudio de seguimiento prospectivo del acetato de eslicarbazepina en monoterapia en pacientes con epilepsia de diagnóstico reciente. // *Revista de Neurologia*, 72, 2021, № 8, p. 263-268. ISSN 0210-0010.
1813. **Herranz, J.L.** Antiepileptic drugs = Fármacos antiepilépticos. // *Revista de Neurologia*, 66, 2018, p. S21-S25. ISSN 0210-0010.
1814. **Hersi, H., J.T. Saarinen, J. Raitanen** et al. Response to first antiseizure medication in patients diagnosed with epilepsy. // *Acta Neurologica Scandinavica*, 2021. ISSN 0001-6314.
1815. **Hixson, J., B. Gidal, A. Pikalov** et al. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures. // *Epilepsy Research*, 171, 2021, art. no. 106561. ISSN 0920-1211.
1816. **Holtkamp, M., N. Delanty, F. Sales** et al. Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli. // *Acta Neurologica Scandinavica*, 139, 2019, № 1, p. 49-63. ISSN 0001-6314.
1817. **Janković, S.M.** Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects. // *Expert Opinion on Drug Metabolism and Toxicology*, 16, 2020, № 3, p. 169-177. ISSN 1742-5255.
1818. **Lawthom, C., J. Peltola, R. McMurray** et al. Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ? // *Neurology and Therapy*, 7, 2018, № 2, p. 195-206. ISSN 2193-8253.
1819. **León Ruiz, M., M.L. Rodríguez Sarasa, L. Sanjuán Rodríguez** et al. Levetiracetam-induced de novo psychosis: Is there a type of patient with epilepsy who is neurostructural and/or biologically more vulnerable to developing it? = Trastorno psicótico de novo inducido por levetiracetam: ¿existe un perfil de

paciente epiléptico neuroestructural y/o biológicamente más vulnerable a desarrollarlo? // *Neurologia*, 35, 2020, № 9, p. 684-687. ISSN 0213-4853.

1820. **Mehta, D., D. Shah, V. Desai** et al. Healthcare Resource Utilization Among Patients with Focal Seizure Treated with Eslicarbazepine Acetate in the US Long-Term Care Setting: A Retrospective Claims Database Analysis. // *Neurology and Therapy*, 2021. ISSN 2193-8253.
1821. **Mehta, D., M. Davis, A.J. Epstein** et al. Comparative economic outcomes in patients with focal seizure initiating first-line eslicarbazepine acetate monotherapy versus generic antiseizure drugs. // *ClinicoEconomics and Outcomes Research*, 13, 2021, p. 251-261. ISSN 1178-6981.
1822. **Mehta, D., M. Davis, A.J. Epstein** et al. Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses. // *Neurology and Therapy*, 9, 2020, № 2, p. 585-598. ISSN 2193-8253.
1823. **Mintzer, S., S. Dimova, Y. Zhang** et al. Effects of lacosamide and carbamazepine on lipids in a randomized trial. // *Epilepsia*, 61, 2020, № 12, p. 2696-2704. ISSN 0013-9580.
1824. **Mula, M.** Pharmacological treatment of focal epilepsy in adults: an evidence based approach. // *Expert Opinion on Pharmacotherapy*, 22, 2021, № 3, p. 317-323. ISSN 1465-6566.
1825. **Nakken, K.O., E. Brodtkorb.** Er nye legemidler mot epilepsi bedre enn gamle? // *Tidsskrift for den Norske Laegeforening*, 140, 2020, № 17, p. 1-5. ISSN 0029-2001.
1826. **Perucca, E.** From clinical trials of antiepileptic drugs to treatment. // *Epilepsia Open*, 3, 2018, № S2, p. 220-230. ISSN 2470-9239.
1827. **Perucca, E., M.J. Brodie, P. Kwan** et al. 30 years of second-generation antiseizure medications: impact and future perspectives. // *The Lancet Neurology*, 19, 2020, № 6, p. 544-556. ISSN 1474-4422.
1828. **Rocamora, R., J. Peltola, G. Assenza** et al. Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice. // *Seizure*, 75, 2020, p. 121-128. ISSN 1059-1311.
1829. **Söllner, B.** Eslicarbazepine acetate: Proven add-on approved also for the monotherapy of focal seizures in adults = Eslicarbazepinacetat: Bewährtes add-on auch für die monotherapie fokaler anfälle bei erwachsenen zugelassen. // *Journal für Pharmakologie und Therapie*, 27, 2018, № 4, p. 122-124. ISSN 1432-4334.
1830. **Villanueva, V., P. Bermejo, J. Montoya** et al. MONOZEB: Long-term observational study of eslicarbazepine acetate monotherapy. // *Epilepsy and Behavior*, 97, 2019, p. 51-59. ISSN 1525-5050.

1831. **Vlasov, P.N.** Use of valproate and carbamazepine in the therapy of epilepsy (guidelines for the practitioner). // *Nevrologiya, Neiropsikhiatriya, Psikhosomatika*, 10, 2018, № 4, p. 129-138. ISSN 2074-2711.
1832. **Weissinger, F., F. Losch, Y. Winter** et al. Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: Results from a German prospective multicenter clinical practice study. // *Epilepsy and Behavior*, 101, 2019, art. no. 106574. ISSN 1525-5050.
1833. **Zhydkova, I.A., V.A. Karlov, P.N. Vlasov.** New possibilities of pharmacotherapy of epilepsy: Eslicarbazepine acetate in treatment of focal epilepsy. // *Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova*, 118, 2018, № 4, p. 140-145. ISSN 1997-7298.

## **2019**

Hobart, J., Ziemssen, T., Feys, P., Linnebank, M., Goodman, A.D., Farrell, R., Hupperts, R., Blight, A.R., Englishby, V., McNeill, M., Chang, I., Lima, G., Elkins, J. ENHANCE study investigators. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. // *CNS Drugs*, 33, 2019, № 1, p. 61-79. ISSN 1172-7047; E-ISSN 1179-1934 doi: 10.1007/s40263-018-0586-5. PMID: 30535670; PMCID: PMC6328522.

## **Cited by:**

1834. **Arpín, E.C.** Efficacy and safety of fampridine for walking disability in multiple sclerosis. // *Neurodegenerative Disease Management*, 10, 2020, № 5, p. 277-287. ISSN 1758-2024.
1835. **Etemadifar, M., M. Saboori, A. Chitsaz** et al. The effect of fampridine on the risk of seizure in patients with multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 43, 2020, art. no. 102188. ISSN 2211-0348.
1836. **Foschi, M., A. Lugaresi.** Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium? // *Expert Opinion on Pharmacotherapy*, 20, 2019, № 11, p. 1309-1320. ISSN 1465-6566.
1837. **Giarraputo, J., S. Giamberardino, S. Arvai** et al. Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis. // *Journal of Neuroimmunology*, 354, 2021, art. no. 577541. ISSN 0165-5728.

1838. **Giglio, L.D., F. Cortese, E.M. Pennisi.** Aminopiridines in the treatment of multiple sclerosis and other neurological disorders. // *Neurodegenerative Disease Management*, 10, 2020, № 6, p. 409-423. ISSN 1758-2024.
1839. **González del Rio, M., M. Merchan Ruiz.** Twelve item multiple sclerosis walking scale: Analysis through nursing diagnoses = Escala de movilidad de 12 ítems para esclerosis múltiple: análisis mediante diagnósticos de enfermería. // *Revista Científica de la Sociedad Espanola de Enfermeria Neurologica*, 51, 2020, p. 23-26. ISSN 2013-5246.
1840. **Hofstoetter, U.S., B. Freundl, P. Lackner** et al. Transcutaneous spinal cord stimulation enhances walking performance and reduces spasticity in individuals with multiple sclerosis. // *Brain Sciences*, 11, 2021, № 4, art. no. 472. ISSN 2076-3425.
1841. **Li, X., D.-C. Tian, M. Fan** et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). // *Multiple Sclerosis and Related Disorders*, 44, 2020, art. no. 102325. ISSN 2211-0348.
1842. **Mitsikostas, D.D., T. Doskas, S. Gkatzonis** et al. A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study. // *Advances in Therapy*, 38, 2021, № 3, p. 1536-1551. ISSN 0741-238X.
1843. **Shi, J., X. Wu, Y. Chen.** Study on dalfampridine in the treatment of multiple sclerosis mobility disability: A metaanalysis. // *PLoS ONE*, 14, 2019, № 9, art. no. e0222288. ISSN 1932-6203.
1844. **Strijbis, E.M.M., J.A. Nij Bijvank, J. Killestein.** 4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes. // *Multiple Sclerosis Journal*, 26, 2020, № 11, p. 1309-1310. ISSN 1352-4585.
1845. **Zhang, E., X. Tian, R. Li** et al. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials. // *Orphanet Journal of Rare Diseases*, 16, 2021, № 1, art. no. 87. ISSN 1750-1172.

Montalban, X., Arnold, D.L., Weber, M.S., Staikov, I., Piasecka-Stryczynska, K., Willmer, J., Martin, E.C., Dangond, F., Syed, S., Wolinsky, J.S. Evobrutinib Phase 2 Study Group. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. // *New England Journal of Medicine*, 380, 2019, № 25, p. 2406-2417. ISSN 0028-4793; E-ISSN 1533-4406. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. PMID: 31075187.

**Cited by:**

1846. **Abboud, H.** Iatrogenic demyelinating disorders: New insights, new culprits. // *Multiple Sclerosis Journal*, 26, 2020, № 9, p. 1129-1130. ISSN 1352-4585.
1847. **Aslan, J.E.** Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease. // *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2021, p. 999-1011. ISSN 1079-5642.
1848. **Baker, D., B.M. Jacobs, S. Gnanapavan et al.** Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 35, 2019, p. 19-25. ISSN 2211-0348.
1849. **Bross, M., M. Hackett, E. Bernitsas.** Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis. // *International Journal of Molecular Sciences*, 21, 2020, № 12, art. no. 4312, p. 1-15. ISSN 1661-6596.
1850. **Burger, J.A.** Bruton Tyrosine Kinase Inhibitors: Present and Future. // *Cancer Journal (United States)*, 25, 2019, № 6, p. 386-393. ISSN 1528-9117.
1851. **Caldwell, R.D., H. Qiu, B.C. Askew et al.** Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. // *Journal of Medicinal Chemistry*, 62, 2019, № 17, p. 7643-7655. ISSN 0022-2623.
1852. **Carnero Contentti, E., J. Correale.** Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. // *Expert Opinion on Emerging Drugs*, 25, 2020, № 4, p. 377-381. ISSN 1472-8214.
1853. **Catlett, I.M., M. Nowak, S. Kundu et al.** Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants. // *British Journal of Clinical Pharmacology*, 86, 2020, № 9, p. 1849-1859. ISSN 0306-5251.
1854. **Cohen, S., K. Tuckwell, T.R. Katsumoto et al.** Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial. // *Arthritis and Rheumatology*, 72, 2020, № 9, p. 1435-1446. ISSN 2326-5191.
1855. **Das, D., J. Hong.** Irreversible kinase inhibitors targeting cysteine residues and their applications in cancer therapy. // *Mini-Reviews in Medicinal Chemistry*, 20, 2020, № 17, p. 1732-1753. ISSN 1389-5575.
1856. **Derfuss, T., M. Mehling, A. Papadopoulou et al.** Advances in oral immunomodulating therapies in relapsing multiple sclerosis. // *The Lancet Neurology*, 19, 2020, № 4, p. 336-347. ISSN 1474-4422.

1857. **Dörner, T., F. Szelinski, A.C. Lino** et al. Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus. // *RMD Open*, 6, 2020, № 2, art. no. e001258. ISSN 2056-5933.
1858. **Esfandiari, E., M. Chen, G. Smithson** et al. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects. // *Clinical and Translational Science*, 2021. ISSN 1752-8054.
1859. **Findling, O., J. Sellner**. Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors? // *Drug Discovery Today*, 26, 2021, № 2, p. 416-428. ISSN 1359-6446.
1860. **Goldmann, L., R. Duan, T. Kragh** et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): A new option in HIT? // *Blood Advances*, 3, 2019, № 23, p. 4021-4033. ISSN 2473-9529.
1861. **Graf, J., P. Albrecht, N. Goebels** et al. Ocrelizumab for treatment of multiple sclerosis = Ocrelizumab zur Behandlung der Multiplen Sklerose. // *Nervenarzt*, 91, 2020, № 8, p. 722-734. ISSN 0028-2804.
1862. **Harbi, M.H., C.W. Smith, P.L.R. Nicolson** et al. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. // *Platelets*, 32, 2021, № 1, p. 29-41. ISSN 0953-7104.
1863. **Homma, G., T. Daimon**. Sample Size Calculation for “Gold-Standard” Noninferiority Trials With Fixed Margins and Negative Binomial Endpoints. // *Statistics in Biopharmaceutical Research*, 2020. ISSN 1946-6315.
1864. **Kaul, M., P. End, M. Cabanski** et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. // *Clinical and Translational Science*, 2021. ISSN 1752-8054.
1865. **Kelsey, R.** Phase II trial of evobrutinib in multiple sclerosis. // *Nature Reviews Neurology*, 15, 2019, № 8, p. 434. ISSN 1759-4758.
1866. **Kwon, Y.N., B. Kim, S. Ahn** et al. Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). // *Journal of Neuroimmunology*, 348, 2020, art. no. 577361. ISSN 0165-5728.
1867. **Lee, D.S.W., O.L. Rojas, J.L. Gommerman**. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. // *Nature Reviews Drug Discovery*, 20, 2021, № 3, p. 179-199. ISSN 1474-1776.



1868. **Litzenburger, T., J. Steffgen, E. Benediktus** et al. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. // *British Journal of Clinical Pharmacology*, 87, 2021, № 4, p. 1824-1838. ISSN 0306-5251.
1869. **Liu, J., C. Chen, D. Wang** et al. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development. // *European Journal of Medicinal Chemistry*, 217, 2021, art. no. 113329. ISSN 0223-5234.
1870. **Ma, B., T. Bohnert, K.L. Otipoby** et al. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. // *Journal of Medicinal Chemistry*, 63, 2020, № 21, p. 12526-12541. ISSN 0022-2623.
1871. **Mycko, M.P.** B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection? // *Neurologia i Neurochirurgia Polska*, 54, 2021, № 6, p. 490-501. ISSN 0028-3843.
1872. **Negron, A., O. Stüve, T.G. Forsthuber.** Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control? // *Frontiers in Neurology*, 11, 2020, art. no. 607766. ISSN 1664-2295.
1873. **Nikolopoulos, D., A. Fanouriakis, D.T. Boumpas.** Update on the pathogenesis of central nervous system lupus. // *Current Opinion in Rheumatology*, 31, 2019, № 6, p. 669-677. ISSN 1040-8711.
1874. **Oliveira, M.L., R.C. Lucchetta, A.D.F. Bonetti** et al. Efficacy outcomes reported in trials of multiple sclerosis: A systematic scoping review. // *Multiple Sclerosis and Related Disorders*, 45, 2020, art. no. 102435. ISSN 2211-0348.
1875. **Pantazou, V., T. Roux, V.O. Moreira** et al. Interaction between neurons and the oligodendroglial lineage in multiple sclerosis and its preclinical models. // *Life*, 11, 2021, № 3, art. no. 231, p. 1-20. ISSN 2075-1729.
1876. **Piehl, F.** Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. // *Journal of Internal Medicine*, 289, 2021, № 6, p. 771-791. ISSN 0954-6820.
1877. **Piesche, M., J. Roos, B. Kühn** et al. The Emerging Therapeutic Potential of Nitro Fatty Acids and Other Michael Acceptor-Containing Drugs for the Treatment of Inflammation and Cancer. // *Frontiers in Pharmacology*, 11, 2020, art. no. 1297. ISSN 1663-9812.
1878. **Pinke, K., S. Zorzella-Pezavento, V. Lara** et al. Should mast cells be considered therapeutic targets in multiple sclerosis? // *Neural Regeneration Research*, 15, 2020, № 11, p. 1995-2007. ISSN 1673-5374.

1879. **Roach, C.A., A.H. Cross.** Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis. // *Frontiers in Neurology*, 11, 2021, art. no. 595547. ISSN 1664-2295.
1880. **Schwaid, A.G., K.B. Spencer.** Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space. // *Journal of Medicinal Chemistry*, 64, 2021, № 1, p. 101-122. ISSN 0022-2623.
1881. **Simpson, A., E.M. Mowry, S.D. Newsome.** Early Aggressive Treatment Approaches for Multiple Sclerosis. // *Current Treatment Options in Neurology*, 23, 2021, № 7, art. no. 19. ISSN 1092-8480.
1882. **Tichenor, M.S., J.J.M. Wiener, N.L. Rao et al.** Discovery of a Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase with Oral Anti-Inflammatory Activity. // *ACS Medicinal Chemistry Letters*, 2021. ISSN 1948-5875.
1883. **von Hundelshausen, P., W. Siess.** Bleeding by bruton tyrosine kinase-inhibitors: Dependency on drug type and disease. // *Cancers*, 13, 2021, № 5, art. no. 1103, p. 1-33. ISSN 2072-6694.
1884. **Wanleenuwat, P., P. Iwanowski.** Role of B cells and antibodies in multiple sclerosis. // *Multiple Sclerosis and Related Disorders*, 36, 2019, art. no. 101416. ISSN 2211-0348.
1885. **Yagishita, Y., T.N. Gatbonton-schwager, M.L. McCallum et al.** Current landscape of NRF2 biomarkers in clinical trials. // *Antioxidants*, 9, 2020, № 8, art. no. 716, p. 1-36. ISSN 2076-3921.
1886. **Zarrin, A.A., K. Bao, P. Lupardus et al.** Kinase inhibition in autoimmunity and inflammation. // *Nature Reviews Drug Discovery*, 20, 2021, № 1, p. 39-63. ISSN 1474-1776.

Johnson, S.C., P. Amarenco, H. Denison, S. Evans, A. Himmelmann, A. James, M. Knutsson, P. Ladenvall, C. Molina Y. Wang for the THALES Investigators ... **Dimitar Maslarov**...The Acute stroke or transient Ischemic attack treated with Ticagrelor and Aspirin for prevention of stroke and death (THALES) trial: Rationale and design. // *International Journal of Stroke*, 2019, p. 1-7. ISSN 1447-4930; 1747-4949. DOI: 10.1177/1747493019830307.

#### **Cited by:**

1887. **Borchert, R.J., D. Simonato, C.R. Hickman et al.** P2Y12 inhibitors for the neurointerventionalist. // *Interventional Neuroradiology*, 2021. ISSN 1591-0199.

1888. **Calderone, D., D. Capodanno, D.J. Angiolillo.** An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. // *Expert Review of Cardiovascular Therapy*, 2020. ISSN 1477-9072.
1889. **Del Brutto, V.J., S. Chaturvedi, H.-C. Diener** et al. Antithrombotic Therapy to Prevent Recurrent Strokes in Ischemic Cerebrovascular Disease: JACC Scientific Expert Panel. // *Journal of the American College of Cardiology*, 74, 2019, № 6, p. 786-803. ISSN 0735-1097.
1890. **Katsanos, A.H., R.G. Hart.** New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. // *JAMA Neurology*, 77, 2020, № 10, p. 1308-1317. ISSN 2168-6149.
1891. **Kaufman, B.G., S. Shah, A.S. Hellkamp** et al. Disease Burden Following Non-Cardioembolic Minor Ischemic Stroke or High-Risk TIA: A GWTG-Stroke Study. // *Journal of Stroke and Cerebrovascular Diseases*, 29, 2020, № 12, art. no. 105399. ISSN 1052-3057.
1892. **Kim, A.S.** Medical Management for Secondary Stroke Prevention. // *CONTINUUM Lifelong Learning in Neurology*, 26, 2020, № 2, p. 435-456. ISSN 1080-2371.
1893. **Köhrmann, M., C. Kleinschnitz.** Update on antithrombotic secondary prevention of ischemic stroke = Update antithrombotische Sekundärprophylaxe des ischämischen Schlaganfalls. // *Nervenarzt*, 90, 2019, № 10, p. 995-1004. ISSN 0028-2804.
1894. **Muller, C., M. Roizman, A. Wong.** Secondary prevention of ischaemic stroke. // *Internal Medicine Journal*, 49, 2019, № 10, p. 1221-1228. ISSN 1444-0903.
1895. **Parker, W.A.E., R.F. Storey.** Novel approaches to P2Y12 inhibition and aspirin dosing. // *Platelets*, 32, 2021, № 1, p. 7-14. ISSN 0953-7104.
1896. **Ringler, J., M. Steck, S.P. Shah** et al. Indications and Evidence for Dual Antiplatelet Therapy after Acute Ischemic Stroke. // *Critical Care Nursing Quarterly*, 43, 2020, № 2, p. 122-137. ISSN 0887-9303.
1897. **Röther, J.** Stroke and intracerebral hemorrhage under anticoagulation or platelet inhibition—when should treatment be restarted and how? = Schlaganfall und Hirnblutung unter Antikoagulation oder Thrombozytenfunktionshemmung – wann und wie erneut starten? // *Internist*, 61, 2020, № 4, p. 424-430. ISSN 0020-9554.
1898. **Xiong, Y., P.M. Bath.** Antiplatelet therapy for transient ischemic attack and minor stroke. // *Stroke*, 2020, p. 3472-3474. ISSN 0039-2499.

Easton, J.D., Denison, H., Evans, S.R., Knutsson, M., Amarenco, P., Albers, G.W., Ladvall, P., Minematsu, K., Molina, C.A., Wang, Y., Wong, K.L., Johnston, S.C. SOCRATES Steering Committee and Investigators. Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. // *International Journal of Stroke*, 14, 2019, № 9, p. 908-914. ISSN 1747-4930; E-ISSN 1747-4949; ISSN 1747-4930 doi: 10.1177/1747493019851282. Epub 2019 May 15. PMID: 31092152.

#### **Cited by:**

1899. **Godolphin, P.J., P.M. Bath, C. Partlett** et al. Outcome assessment by central adjudicators in randomised stroke trials: Simulation of differential and non-differential misclassification. // *European Stroke Journal*, 5, 2020, № 2, p. 174-183. ISSN 2396-9873.

Molina, C.A., Johnston, S.C., Ladvall, P., Amarenco, P., Albers, G.W., Denison, H., Easton, J.D., Evans, S.R., Held, P., Knutsson, M., Minematsu, K., Röther, J., Wang, Y., Wong, K.S.L. SOCRATES Steering Committee and Investigators. Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. // *Stroke*, 50, 2019, № 3, p. 675-682. ISSN 0039-2499; E-ISSN 1524-4628. doi: 10.1161/STROKEAHA.118.022675. Erratum in: *Stroke*. 2019 Apr;50(4):e118. PMID: 30776996.

#### **Cited by:**

1900. **Ikenberg, B., J. Rösler, C.L. Seifert** et al. Etiology of recurrent large vessel occlusions treated with repeated thrombectomy. // *Interventional Neuroradiology*, 26, 2020, № 2, p. 195-204. ISSN 1591-0199.

#### **2020**

Amarenco, P., H. Denison, S.R Evans, A. Himmelmann, S. James, M. Knutsson, Per Ladvall, C. A Molina, Y. Wang , S Claiborne Johnston , THALES Steering Committee and Investigators Collaborators, Affiliations expand D. Maslarov...Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke: A Randomized Clinical Trial. // *JAMA Neurol*, 78, 2020, № 2, p. 1-9. ISSN 2168-6149; E-ISSN 2168-6157 doi: 10.1001/jamaneurol.2020.4396. DOI: 10.1001/jamaneurol.2020.4396.

#### **Cited by: (2)**

1901. **Chou, P.-S., P.-S. Sung, C.-H. Liu** et al. Prevalence and Effect of Cerebral Small Vessel Disease in Stroke Patients With Aspirin Treatment Failure—A Hospital-Based Stroke Secondary Prevention Registry. // *Frontiers in Neurology*, 12, 2021, art. no. 645444. ISSN 1664-2295.

1902. **Vališ, M., B. Klímová, M. Novotný et al.** Antiplatelet Therapy in the Secondary Prevention of Non-cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review. // *Frontiers in Neurology*, 12, 2021, art. no. 626106. ISSN 1664-2295.

Amarenco, P., Denison, H., Evans, S.R., Himmelmann, A., James, S., Knutsson, M., Ladenvall, P., Molina, C.A., Wang, Y. Johnston SC; THALES Steering Committee and Investigators\*. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. // *Stroke*, 51, 2020, № 12, p. 3504-3513. ISSN 0039-2499; E-ISSN 1524-4628. doi: 10.1161/STROKEAHA.120.032239. Epub 2020 Nov 16. PMID: 33198608; PMCID: PMC7678660.

#### Cited by:

1903. **De Luca, L., E. Bellettini, D. Di Maio et al.** Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events. // *Journal of Clinical Medicine*, 10, 2021, № 8, art. no. 1721. ISSN 2077-0383.

Johnson, S.C., P. Amarenco, H. Denison, S. Evans, A. Himmelmann, A. James, M. Knutsson, P. Ladenvall, C. Molina Y. Wang for the THALES Investigators ... **Dimitar Maslarov**... Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. // *The New England Journal of Medicine*, 383, 2020, № 3, p. 207-217. ISSN 0028-4793; E-ISSN 1533-4406. DOI: 10.1056/NEJMoa1916870.

#### Cited by:

1904. **Anderson, S.L., M. Bassetti, A.A. Mangoni.** Drugs in context editorial: Review of 2020 and what lies ahead in therapeutic interventions. // *Drugs in Context*, 10, 2021, art. no. 10. ISSN 1745-1981.
1905. **Anichini, A., P.S. Chiabotti, J. Bally et al.** Recent advances in neurology = Neurologie. // *Revue Medicale Suisse*, 17, 2021, № 723, p. 196-200. ISSN 1660-9379.
1906. **Appleton, J.P., R. Mullhi, N. Singh.** Initial management of acute ischaemic stroke. // *British Journal of Hospital Medicine*, 82, 2021, № 1. ISSN 1750-8460.
1907. **Borchert, R.J., D. Simonato, C.R. Hickman et al.** P2Y12 inhibitors for the neurointerventionalist. // *Interventional Neuroradiology*, 2021. ISSN 1591-0199.
1908. **Cao, D., G. Dangas, R. Mehran.** Long-term ticagrelor in stable patients with prior myocardial infarction: Bleeding avoidance first and foremost. // *Journal of the*

- American Heart Association*, 10, 2021, № 4, art. no. e019889, p. 1-3. ISSN 2047-9980.
1909. **Chou, P.-S., P.-S. Sung, C.-H. Liu** et al. Prevalence and Effect of Cerebral Small Vessel Disease in Stroke Patients With Aspirin Treatment Failure—A Hospital-Based Stroke Secondary Prevention Registry. // *Frontiers in Neurology*, 12, 2021, art. no. 645444. ISSN 1664-2295.
  1910. **Dawson, J., Á. Merwick, A. Webb** et al. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. // *European Stroke Journal*, 2021. ISSN 2396-9873.
  1911. **Diener, H.C., G. Nickenig**. Secondary stroke prevention after TIA or ischemic stroke = Sekundärprävention nach TIA oder ischämischem Schlaganfall. // *Herz*, 2021. ISSN 0340-9937.
  1912. **Diener, H.C., R. Wachter**. Diagnosis and treatment of acute ischemic insults = Diagnose und Therapie des akuten ischämischen Insults. // *Herz*, 46, 2021, № 2, p. 195-204. ISSN 0340-9937.
  1913. **English, S.W., D.R. Landzberg, N.R. Bhatt** et al. Safety of Ticagrelor in Moderate and Severe Acute Ischemic Stroke: A Single-Center Retrospective Review. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 6, art. no. 105767. ISSN 1052-3057.
  1914. **Fonseca, A.C., Á. Merwick, M. Dennis** et al. European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack. // *European Stroke Journal*, 2021. ISSN 2396-9873.
  1915. **Hohlfeld, T., S. Twarock**. Platelet aggregation inhibitors in emergencies: Treatment options with antiplatelet drugs during EMS interventions and in the emergency room = Thrombozytenfunktionshemmer im Notfall: Einsatz von Medikamenten mit plättchenhemmender Wirkung im Rettungsdienst und in der Notaufnahme. // *Notfall und Rettungsmedizin*, 2021. ISSN 1434-6222.
  1916. **Honig, A., T. Sacagiu, A. Filioglo** et al. Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis. // *Journal of the Neurological Sciences*, 425, 2021, art. no. 117450. ISSN 0022-510X.
  1917. **Kamada, A., M. Shimizu, K. Oura** et al. Inhibitory Effects of P2Y<sub>12</sub> Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 3, art. no. 105547. ISSN: 1052-3057.
  1918. **Kasner, S.E.** Antithrombotic therapy for cervical arterial dissection. // *The Lancet Neurology*, 20, 2021, № 5, p. 328-329. ISSN 1474-4422.

1919. **Kovacevic, K.D., S. Greisenegger, A. Langer** et al. The aptamer BT200 blocks von Willebrand factor and platelet function in blood of stroke patients. // *Scientific Reports*, 11, 2021, № 1, art. no. 3092. ISSN 2045-2322.
1920. **Kow, C.S., A.F. Zaihan, S.S. Hasan.** CYP2C19 Genotype-Guided Antiplatelet Therapy Among Asian Patients with Ischaemic Stroke. // *Clinical Drug Investigation*, 41, 2021, № 1, p. 115-116. ISSN 1173-2563.
1921. **Kulesh, A.A., D.A. Demin, O.I. Vinogradov.** Cryptogenic stroke. Part 1: Aorto-arterial embolism. // *Meditinskiy Sovet*, 2021, № 4, p. 78-87. ISSN 2079-701X.
1922. **Landzberg, D.R., S. English, M. Frankel** et al. Stroke Thrombolysis in Patients Taking Ticagrelor –Two Successful Cases and a Review of the Literature. // *Journal of Stroke and Cerebrovascular Diseases*, 30, 2021, № 2, art. no. 105520. ISSN 1052-3057.
1923. **Li, F., D. Xu, K. Hou** et al. Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF- $\kappa$ B/NLRP3 Pathway in Ischemic Stroke. // *Journal of Neuroimmune Pharmacology*, 2021. ISSN 1557-1890.
1924. **Li, Z.-X., X.-W. Xie, Y. Xian.** In the THALES Trial, Past, Present, and Future Meet. // *Neuroscience Bulletin*, 37, 2021, № 4, p. 588-591. ISSN 1673-7067.
1925. **Mendelson, S.J., S. Prabhakaran.** Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review. // *JAMA - Journal of the American Medical Association*, 325, 2021, № 11, p. 1088-1098. ISSN 0098-7484.
1926. **Parker, W.A.E., D.A. Gorog, T. Geisler** et al. Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. // *European Heart Journal*, 2021, Suppl. № 22, p. M26-M34. ISSN 1520-765X.
1927. **Patel, P.A., R.A. Henderson, Jr, D. Bolliger** et al. The Year in Coagulation: Selected Highlights from 2020. // *Journal of Cardiothoracic and Vascular Anesthesia*, 2021. ISSN 1053-0770.
1928. **Pollack, C.V., Jr., T.Y. Wang.** Evolution of Clinical Thinking and Practice Regarding Aspirin: What Has Changed and Why? // *American Journal of Cardiology*, 144, 2021, p. S10-S14. ISSN 0002-9149.
1929. **Poredos, P., A. Blinc, S. Novo** et al. How to manage patients with polyvascular atherosclerotic disease position paper of the international union of angiology. // *International Angiology*, 40, 2021, № 1, p. 29-41. ISSN 0392-9590.
1930. **Rawish, E., H. Nording, T. Münte** et al. Platelets as Mediators of Neuroinflammation and Thrombosis. // *Frontiers in Immunology*, 11, 2020, art. no. 548631. ISSN 1664-3224.

1931. **Reiff, T., P.A. Ringleb.** Secondary prevention of cerebral infarction = Sekundärprophylaxe der zerebralen Ischämie. // *Nervenheilkunde*, 39, 2020, № 10, p. 644-650. ISSN 0722-1541.
1932. **Rothwell, P.M.** Antiplatelet treatment to prevent early recurrent stroke. // *New England Journal of Medicine*, 383, 2020, № 3, p. 276-278. ISSN 0028-4793.
1933. **Sandset, E.C., L.B. Goldstein.** Treatments-Preventive. // *Stroke*, 2021, p. 1118-1120. ISSN 0039-2499.
1934. **Škorňa, M.** What internist can do for the patient after the ischemic stroke = Co může internista udělat pro svého pacienta po ischemické cévní mozkové příhodě. // *Vnitřní Lekarství*, 67, 2021, № 1, p. 7-14. ISSN 0042-773X.
1935. **Tsivgoulis, G., A.H. Katsanos.** Important advances in stroke research in 2020. // *The Lancet Neurology*, 20, 2021, № 1, p. 2-3. ISSN 1474-4422.
1936. **Wegener, M.** Dual platelet inhibition is more effective: ASA plus ticagrelor is superior to the standard prophylaxis after stroke and transient ischemic attack = Duale Plättchenhemmung ist effektiver: ASS plus Ticagrelor ist der Standardprophylaxe nach Schlaganfall und TIA überlegen. // *Deutsche Apotheker Zeitung*, 160, 2020, № 41, art. no. 32. ISSN 0011-9857.
1937. **Wiśniewski, A.** Multifactorial background for a low biological response to antiplatelet agents used in stroke prevention. // *Medicina (Lithuania)*, 57, 2021, № 1, art. no. 59, p. 1-10. ISSN 1010-660X.
1938. **Xiong, Y., P.M. Bath.** Antiplatelet therapy for transient ischemic attack and minor stroke. // *Stroke*, 51, 2020, № 11, p. 3472-3474. ISSN 0039-2499.
1939. **Zeitouni, M., P. Guedeney.** Aspirin-Free Strategies in ACS: Is It the Drug or the Stent? // *JACC: Cardiovascular Interventions*, 14, 2021, № 4, p. 441-443. ISSN 1936-8798.

Vossler, D.G., S. Knake, T.J O'Brien, M. Watanabe, M. Brock, B. Steiniger-Brach, P. Williams, R. Roebeling On behalf of the SP0982 trial investigators ...**Dimitar Maslarov.** Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. // *Journal of Neurology, Neurosurgery & Psychiatry*, 91, 2020, № 10, p. 1067-1075. ISSN 0022-3050; E-ISSN 1468-330X.

#### Cited by:

1940. **Bosak, M., K. Węzyk, A. Słowik.** Lacosamide and myoclonic seizures: what is the risk of aggravation? // *Neurologia i Neurochirurgia Polska*, 55, 2021, № 1, p. 107-109. ISSN 0028-3843.



1941. **Carona, A., J. Bicker, R. Silva** et al. Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. // *Life Sciences*, 275, 2021, art. no. 119342. ISSN 0024-3205.
1942. **Dibek, D.M., I. Oztura, B. Baklan.** Our reasons for converting to valproic acid treatment in female patients with genetic generalized epilepsy: a retrospective, single-centre study. // *Neurological Sciences*, 2021. ISSN 1590-1874.
1943. **Mostacci, B., F. Ranzato, L. Giuliano** et al. Alternatives to valproate in girls and women of childbearing potential with Idiopathic Generalized Epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE). // *Seizure*, 85, 2021, p. 26-38. ISSN 1059-1311.
1944. **Rahim, F., R. Azizimalamiri, M. Sayyah** et al. Experimental therapeutic strategies in epilepsies using anti-seizure medications. // *Journal of Experimental Pharmacology*, 13, 2021, p. 265-290. ISSN 1179-1454.

Trinka E., Rocamora R., Chaves J., Moreira J., Ikedo F., Soares-da-Silva P. Estol C., Newton M., Carne R., Kowacs P., Petrova D., Syankov D., **Maslarov. D.** et al. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study, *Epilepsia, Open Access* 2020.

#### **Cited by:**

1945. **Hernández-Rubio, L., M. Asensio-Asensio, D. Tortosa-Conesa** et al. Alzemon: A prospective follow-up study of eslicarbazepine acetate monotherapy in patients with newly diagnosed epilepsy = Alzemon: Estudio de seguimiento prospectivo del acetato de eslicarbacepina en monoterapia en pacientes con epilepsia de diagnóstico reciente. // *Revista de Neurologia*, 72, 2021, № 8, p. 263-268. ISSN 0210-0010.

**h-индекс – 16** (изчислен на базата на тази справка)